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The effects of environmental conditions of Sudan on 
 the stability of drug products  
Abstract 
Drug stability is greatly affected by the environmental conditions especially 
temperature and humidity. WHO classified Sudan as zone III and recently in 2006 it 
had been classified by EMRO as zone III and zone IVA.  
As the climatic conditions in Sudan varies from one region to another, the study 
aimed at comparing these conditions with the internationally adopted conditions, to 
investigate the true transportation and storage conditions and their effects on the 
stability of justifiably selected drug products.  
The methodology was based on selecting six stations representing different 
climatic regions and six baskets of nine products together with Dataloggers were 
delivered to each station. Dataloggers measured and recorded temperature and 
humidity every 90 minutes during transportation and storage. The products had been 
tested initially, after transportation, after six months and lastly after 12 months using 
validated pharmacopoeial methods. The MKT for each station was calculated using 
data from Dataloggers, data from the adopted meteorological records and 
meteorological records for the same period of the study by the aid of stability system 
II, Scienteck  MKT program.  
The resulted MKT for Sudan using the past adopted meteorological records is 
31°C and 34°C when using the meteorological records for the same period of the 
study but the MKT of the controlled room temperature was 26°C to 29°C. The RH 
was higher in Portsudan, Damazin and Juba while the other parts of the country were 
very dry. The transportation MKTs for all stations were above 30°C. Almost all 
utilized products showed significant alternation in the concentrations of the active 
ingredients. The results had been analyzed using SPSS, Statistica and Excel software 
programs to compare the MKTs and to estimate the shelf lives of the products and the 
following findings were concluded: 
1- WHO used the mean of the past adopted meteorological records on calculating the 
MKT for Sudan and it was significantly different from the past and parallel 
meteorological records of four stations and it did not reflect the true picture of the 
actual storage conditions because of man interventions to improve the storage 
conditions. The mean temperature recorded by meteorological authority for the same 
period of the study was 3.89 °C above that recorded by Dataloggers, and the room 
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average RH was 6-7% lower than that of the open air. The most drastic and severe 
conditions for drugs were the transportation conditions which were almost above 40 
C° contradicting EMRO recommendation which specified 30 C° as maximum 
temperature for transportation.  
2- All products were labeled to be stored below 25 C°, none of the storage facilities 
could maintain this MKT resulting in a significant decrease in their shelf-lives. 
3- With exception of metronidazole I.V in glass containers, all drug products utilized 
showed marked stability problems losing fraction of their shelf lives, which is 
attributed to the drastic transportation conditions, inappropriate storage conditions and 
some of them was due to quality of the products. 
4- Plastic containers for parenteral aqueous fluids and tablets in hospital packs may not 
withstand the environmental conditions of Sudan.  
It was recommended that the conditions pointed out by EMRO could be acceptable as 
an in-house MKT and the RH could be accepted with exclusion of liquid preparation 
in plastic container. DRA should take immediate actions regarding transportation 
conditions and it should instruct the reference laboratory to perform such stability 
studies for all registered products on the basis of EMRO guidelines especially for 
calculations of the shelf lives. 
It was also recommended to use the Dataloggers in-house MKT as a global method to 
determine the storage condition all over the world and if only the meteorological 
records would have adopted, the MKT for Sudan might be 34 C°.  
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   ﺍﻷﺩﻭﻳﺔ ﻣﺴﺘﺤﻀﺮﺍﺕﻴﻪ ﻋﻠﻰ ﺛﺒﺎﺗﻴﺔﺌ ﺍﻟﺒﻴ ﺍﻟﺴﻮﺩﺍﻥﺗﺎﺛﲑ ﻇﺮﻭﻑ
  (ﺑﻜﺎﻟﺮﻳﻮﺱ ﺻﻴﺪﻟﻪ؛ ﻣﺎﺟﺴﺘﲑ ﺻﻴﺪﻟﻪ ) ﻋﺒﺪﺍﻟﺮﲪﻦ ﳏﻤﻮﺩ ﲨﻴﻞ 
   ﻣﺴﺘﺨﻠﺺ
ﺗﻌﺘﱪ ﺍﻟﺜﺒﺎﺗﻴﻪ ﺍﻟﺪﻭﺍﻧﻴﺔ ﻣﻦ ﺃﻫﻢ ﺍﳌﻮﺿﻮﻋﺎﺕ ﰲ ﳎﺎﻝ  ﺗﻜﻨﻮﻟﻮﺟﻴﺎ ﺍﻟﺼﻴﺪﻟﺔ ﻭﻫﻲ ﺗﺘﺎﺛﺮ ﻣﺒﺎﺷﺮﺓ ﺑﺎﻟﻈﺮﻭﻑ  ﺍﻟﺒﻴﺌﻴﺔ ﺧﺎﺻـﺔ 
ﻣﻨﻈﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﳌﻴﺔ ﺍﻟﻌﺎﱂ ﺍﱄ ﺃﺭﺑﻌﺔ ﺩﻭﺍﺋﺮ ﻣﻨﺎﺧﻴﺔ ﻭﻭﺿﻊ ﺍﻟـﺴﻮﺩﺍﻥ ﰲ ﺍﻟـﺪﺍﺋﺮﺓ ﺍﳊﺮﺍﺭﺓ ﻭﺍﻟﺮﻃﻮﺑﺔ ﻭﻟﺬﺍ ﻓﻘﺪ ﻭﺯﻋﺖ 
ﻡ ﺍﱄ ﺍﻟـﺪﺍﺋﺮﺓ 6002ﺍﻟﺜﺎﻟﺜﺔ ﺇﻻ ﺃﻧﻪ ﰎ ﺃﺧﲑﺍﹰ ﺗﻌﺪﻳﻞ  ﻣﻮﻗﻌﻪ ﺑﻮﺍﺳﻄﺔ ﺍﳌﻜﺘﺐ  ﺍﻷﻗﻠﻴﻤﻲ ﳌﻨﻈﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﳌﻴﺔ ﰲ ﺍﻟﻌﺎﻡ 
  .(ﺃ)ﺍﻟﺜﺎﻟﺜﺔ ﻭﺍﻟﺮﺍﺑﻌﺔ 
 ﻫﺪﻓﺖ ﺍﻟﺪﺍﺭﺳﺔ ﺍﱄ ﻣﻘﺎﺭﻧﺔ ﻫـﺬﻩ ﻘﻪ ﺍﱃ ﺃﺧﺮﻯ ﻓﻘﺪ ﲣﺘﻠﻒ ﻣﻦ ﻣﻨﻄ  ﻇﺮﻭﻑ ﺍﻟﺴﻮﺩﺍﻥ ﺍﳌﻨﺎﺧﻴﻪ   ﻭ ﳌﺎ ﻛﺎﻧﺖ 
ﺍﻟﻈﺮﻭﻑ  ﺍﳌﺘﻌﺪﺩﺓ ﺑﺎﻟﻈﺮﻭﻑ  ﺍﻟﻌﺎﳌﻴﺔ ﺍﳌﻌﺘﻤﺪﺓ ﻟﻠﺴﻮﺩﺍﻥ  ﻭﻛﺬﻟﻚ ﳌﻌﺮﻓﺔ ﻇﺮﻭﻑ  ﺍﻟﺘﺮﺣﻴﻞ ﻭﺍﻟﺘﺨﺰﻳﻦ ﻭﻣﺪﻱ ﺗﺎﺛﲑﻫـﺎ 
  .ﻭ ﻣﺪﻯ ﻣﻼﺀﻣﺔ ﻋﺒﻮﺍﺎ ﺍﻷﺩﻭﻳﺔ ﺍﻟﱵ ﰎ ﺃﺧﺘﻴﺎﺭﻫﺎ ﲟﱪﺭﺍﺕ ﻣﻌﻘﻮﻟﺔ ﻣﺴﺘﺤﻀﺮﺍﺕﻋﻠﻲ ﺛﺒﺎﺗﻴﻪ 
  9 ﻣـﻦ ﺕ ﺳﻼ ﺳﺘﻪ ﲡﻬﻴﺰﰎ ﺳﺘﺔ ﳏﻄﺎﺕ ﲤﺜﻞ  ﻛﻞ  ﺍﻟﻘﻄﺎﻋﺎﺕ ﺍﳌﻨﺎﺧﻴﺔ ﻭﻴﺎﺭ ﺍﺭﺗﻜﺰ ﻣﻨﻬﺞ ﺍﻟﺪﺭﺍﺳﻪ ﻋﻠﻰ ﺍﺧﺘ 
ﺃﺻﻨﺎﻑ  ﻣﻦ ﺍﳌﺴﺘﺤﻀﺮﺍﺕ ﺍﻟﺼﻴﺪﻻﻧﻴﺔ ﻭﺟﻬﺰﺕ ﻛﻞ ﺳﻠﺔ ﺑﺄﺟﻬﺰﺓ ﻗﻴﺎﺱ  ﻭﺗﺴﺠﻴﻞ ﺍﻟﻜﺘﺮﻭﻧﻴﺔ ﻟﺘﺴﺠﻴﻞ ﺩﺭﺟﺔ ﺍﳊـﺮﺍﺭﺓ 
  6ﰒ ﺑﻌـﺪ ﻛﻤﺎ ﰎ ﲢﻠﻴﻞ ﺍﳌﺴﺘﺤﻀﺮﺍﺕ ﺑﺪﺍﻳﺔ ﰒ ﺑﻌﺪ ﺍﻟﺘﺮﺣﻴـﻞ .    ﺩﻗﻴﻘﺔ ﺃﺛﻨﺎﺀ ﺍﻟﺘﺮﺣﻴﻞ ﻭﺍﻟﺘﺨﺰﻳﻦ 09ﻭﺍﻟﺮﻃﻮﺑﺔ ﻛﻞ 
ﻭﻓﻘﺎ ﻟﺪﺳﺎﺗﲑﺍﻷﺩﻭﻳﻪ ﺍﻟﱪﻳﻄﺎﱏ ﻭﺍﻷﻣﺮﻳﻜـﻰ ﻣﻦ ﺍﻟﺘﺨﺰﻳﻦ ﰲ ﺍﶈﻄﺎﺕ ﺍﳌﺨﺘﻠﻔﺔ "   ﺷﻬﺮﺍ 21ﰒ  ﺑﻌﺪ  ﺃﺷﻬﺮ  ﻣﻦ ﺍﻟﺘﺨﺰﻳﻦ 
  :ﻠﺖ ﺍﻟﺪﺭﺍﺳﻪ ﻟﻠﻨﺘﺎﺋﺞ ﺍﻟﺘﺎﻟﻴﻪﺻ ﻭ ﻗﺪ ﺗﻮ.ﻭﺍﻟﺪﻭﱃ
ﻛﻴـﻪ ﺮﺍﺭﻩ ﺍﳊﺮ ﳊ  ـﲝﺴﺎﺏ ﺑﻴﺎﻧﺎﺕ ﺗﻘﺮﻳﺮ ﺍﻻﺭﺻﺎﺩ ﺍﳉﻮﻯ ﻟﺪﺭﺟﺎﺕ ﺍﳊﺮﺍﺭﻩ ﻟﺜﻼﺛﲔ ﻋﺎﻣﺎ ﻧﺘﺞ ﺃﻥ ﻣﺘﻮﺳﻂ ﺩﺭﺟﺔ ﺍ  -ﺃ 
ﻭ ﲝﺴﺎﺏ ﺑﻴﺎﻧﺎﺕ ﺗﻘﺮﻳﺮ ﺍﻻﺭﺻﺎﺩ ﺍﳉﻮﻯ ﻟﺪﺭﺟﺎﺕ ﺍﳊﺮﺍﺭﻩ ﻟﻔﺘﺮﺓ ﺍﻟﺪﺭﺍﺳﻪ ﻧـﺘﺞ ﺃﻥ .  ﺩﺭﺟﻪ ﻣﺌﻮﻳﻪ 13ﻟﻠﺴﻮﺩﺍﻥ ﻫﻰ 
ﻭ ﲝﺴﺎﺏ ﺑﻴﺎﻧﺎﺕ ﺍﻷﺟﻬﺰﻩ ﻧﺘﺞ ﺃﻥ ﻣﺘﻮﺳﻂ ﺩﺭﺟـﺔ .  ﺩﺭﺟﻪ ﻣﺌﻮﻳﻪ 43ﺮﺍﺭﻩ ﺍﳊﺮﻛﻴﻪ ﻟﻠﺴﻮﺩﺍﻥ ﻫﻰ ﻣﺘﻮﺳﻂ ﺩﺭﺟﺔ ﺍﳊ 
  . ﺩﺭﺟﻪ ﻣﺌﻮﻳﻪ92- 62ﺮﺍﺭﻩ ﺍﳊﺮﻛﻴﻪ ﻟﻠﻐﺮﻓﻪ ﻫﻰ ﺍﳊ
 ﺃﺛﻨﺎﺀ ﺍﻟﺘﺨﺰﻳﻦ ﺍﻷﻣـﺮ  ﺍﻟﺘﺄﺛﲑ ﺍﳌﺎﺩﻩ ﺍﻟﻔﻌﺎﻟﻪ ﰱ ﻛﻞ ﺍﳌﺴﺘﺤﻀﺮﺍﺕ ﺗﺄﺛﲑﺍ ﻣﻠﺤﻮﻇﺎ ﺑﺎﻟﺘﺮﺣﻴﻞ ﻭ ﺗﻮﺍﺻﻞ ﺗﺄﺛﺮ ﺗﺮﻛﻴﺰ  -ﺏ 
  .ﺍﻟﺬﻯ ﻧﺘﺞ ﻋﻨﻪ ﺗﺮﺍﺟﻌﺎ ﻣﻌﺘﱪﺍ ﰱ ﺗﺄﺭﻳﺦ ﺍﻧﺘﻬﺎﺀ ﺍﻟﺼﻼﺣﻴﻪ ﺍﳌﻨﺼﻮﺹ ﻋﻠﻴﻪ ﺑﺎﻟﺪﻳﺒﺎﺟﻪ
  :  ﺧﻠﺼﺖ ﺍﻟﺪﺭﺍﺳﺔ ﻟﻶﰐ  ﻭ ﻣﻦ ﰒ 
ﺳﻂ ﺩﺭﺟﺎﺕ ﺍﳊﺮﺍﺭﺓ  ﻟﻠﺴﻮﺩﺍﻥ ﻛﻜـﻞ ﺍﻋﺘﻤﺪﺕ ﻣﻨﻈﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﳌﻴﺔ ﰲ ﺣﺴﺎﺏ  ﻇﺮﻭﻑ ﺍﻟﺴﻮﺩﺍﻥ ﻋﻠﻲ ﻣﺘﻮ  .1
ﺣﺴﺐ  ﺍﻟﺴﺠﻼﺕ ﺍﳌﻌﺘﻤﺪﺓ ﺑﺎﳍﻴﺌﻪ ﺍﻟﻌﺎﻣﺔ ﻟﻸﺭﺻﺎﺩ ﺍﳉﻮﻱ ﻭﻟﺬﻟﻚ ﻓﻬﻲ ﻻ ﲣﺘﻠﻒ   ﻣﻊ ﺍﳌﺘﻮﺳﻂ ﻭﻟﻜﻨﻬﺎ ﲣﺘﻠﻒ  ﻣﻊ 
ﻤﻴـﻊ ﳉ ﻛﻤﺎ ﺃﺎ ﲣﺘﻠﻒ ﻣﻊ ﺳﺠﻼﺕ ﺍﻻﺭﺻﺎﺩ ﺍﳉﻮﻯ – ﲔﻔﻖ  ﻣﻊ ﺃﺛﻨ ﺘﺍﳌﻨﺎﻃﻖ ﻛﻞ  ﻋﻠﻲ  ﺣﺪﺓ ﻷﺭﺑﻌﺔ ﻣﻨﺎﻃﻖ  ﻭﺗ 
 .  ﺔ ﻟﻔﺘﺮﺓ ﺍﻟﺪﺭﺍﺳﺔ ﻳﻡ ﻭﻫﻲ ﺍﳌﺪﺓ ﺍﳌﻮﺍﺯ8002 ﺣﱴ ﻣﺎﺭﺱ ﻡ7002ﺍﳌﻨﺎﻃﻖ ﻟﻠﻔﺘﺮﻩ ﻣﻦ ﺃﺑﺮﻳﻞ 
ﺔ ﺣﺴﺐ  ﺳﺠﻼﺕ ﺍﳍﻴﻨﺔ ﺍﻟﻌﺎﻣﺔ ﻟﻸﺭﺻﺎﺩ ﺍﳉﻮﻱ  ﻻ ﺗﻌﻄﻲ  ﺻﻮﺭﺓ ﺣﻘﻴﻘﻴﺔ ﻭﺻﺤﻴﺤﺔ ﻟﻈـﺮﻭﻑ  ﻴﺍﻟﻈﺮﻭﻑ ﺍﻟﺒﻴﺌ  .2
 ﺍﻟﺘﺨﺰﻳﻦ ﻭﺫﻟﻚ ﻟﻠﺘﺪﺧﻞ  ﺍﻟﺒﺸﺮﻱ ﻟﺘﺤﺴﲔ ﻇﺮﻭﻑ  ﺍﻟﺘﺨﺰﻳﻦ ﻓﻘﺪ ﻭﺟﺪ ﺃﻥ ﻣﺘﻮﺳﻂ ﺩﺭﺟﺎﺕ ﺍﳊﺮﺍﺭﺓ ﺣﺴﺐ ﺍﻷﺭﺻﺎﺩ 
 ﻭﻣﺘﻮﺳﻂ ﺍﻟﺮﻃﻮﺑﻪ ﺍﻟﻨﺴﺒﻴﻪ ﺧﺎﺭﺝ ﺍﻟﻐﺮﻓـﺔ    ﺩﺭﺟﺔ ﻣﺌﻮﻳﺔ 98.3ﺗﺰﻳﺪ ﻋﻦ ﺩﺍﺧﻞ  ﺍﻟﻐﺮﻓﺔ ﺑـ ( ﺧﺎﺭﺝ ﺍﻟﻐﺮﻓﺔ  )ﺍﳉﻮﻯ
 . (7% – 6 % )ﺗﺰﻳﺪ ﻋﻦ ﺩﺍﺧﻞ  ﺍﻟﻐﺮﻓﺔ ﺑﺴﺘﻪ ﺍﱃ ﺳﺒﻌﻪ ﺑﺎﳌﺎﺋﻪ
 ﺩﺭﺟﺔ ﻣﺌﻮﻳﺔ ﳐﺎﻟﻔـﺔ 04  ﻻ ﺗﻘﻞ ﰲ ﻣﻌﻈﻢ ﺍﻷﺣﻴﺎﻥ ﻋﻦ  ﻓﻬﻰ ﻭﻃﺄﺓ ﻋﻠﻰ ﺍﻷﺩﻭﻳﺔ ﻫﻲ ﺍﻷﺷﺪ ﻇﺮﻭﻑ  ﺍﻟﺘﺮﺣﻴﻞ   .3
 03ﻲ  ﳌﻨﻈﻤﺔ  ﺍﻟﺼﺤﺔ ﻟﺪﻭﻝ ﺷﺮﻕ ﺍﳌﺘﻮﺳﻂ ﺑﺎﻷ  ﺗﺰﻳﺪ ﺩﺭﺟﺎﺕ ﺍﻟﺘﺮﺣﻴﻞ  ﻋـﻦ ﰲ ﺫﻟﻚ ﺗﻮﺟﻴﻬﺎﺕ ﺍﳌﻜﺘﺐ  ﺍﻻﻗﻠﻴﻤ 
 .  ﺩﺭﺟﺔ ﻣﺌﻮﻳﺔ ﻭﻟﺬﻟﻚ ﻓﺈﻥ ﻣﻌﻈﻢ ﺍﳌﻨﺘﺠﺎﺕ ﺍﻟﱵ ﰎ ﺗﺮﺣﻠﻴﻬﺎ ﺗﺎﺛﺮﺕ ﺳﻠﺒﺎﹰ ﺬﻩ ﺍﻟﻈﺮﻭﻑ 
iiv 
ﻱ  ﱂ ﺬ  ﺩﺭﺟﺔ ﻣﺌﻮﻳﺔ ﺍﻷﻣﺮ ﺍﻟ 52ﻣﻌﻈﻢ ﺍﻷﺩﻭﻳﺔ ﻣﻨﺼﻮﺹ ﰲ ﺩﻳﺒﺎﺟﺎﺎ ﻋﻠﻲ ﺍﻟﺘﺨﺰﻳﻦ ﰲ ﺩﺭﺟﺔ ﺣﺮﺍﺭﺓ ﺃﻗﻞ ﻣﻦ  .4
 .  ﳝﻜﻦ ﲢﻘﻴﻘﻪ 
ﻓﺎﻥ ﻛﻞ ﺍﳌﺴﺘﺤﻀﺮﺍﺕ ﳍﺎ ﺍﺷﻜﺎﻻﺕ ﰱ ﻣﺴﺘﺤﻀﺮ  ﻣﻴﺘﺮﻭﻧﺪﺍﺯﻭﻝ ﻟﻠﺰﺭﻕ  ﺍﻟﻮﺭﻳﺪﻱ ﰲ ﻭﻋﺎﺀ  ﺯﺟﺎﺟﻲ ﺑﺎﺳﺘﺜﻨﺎﺀ  .5
ﺪﺓ ﺟﺰﺀﺍ ﻣﻘﺪﺭﺍ ﻣﻦ ﻣﺪﺓ ﺻﻼﺣﻴﺘﻬﺎ ﻭﻗﺪ ﻋﺰﻯ ﺫﻟﻚ ﻟﻈﺮﻭﻑ ﺍﻟﺘﺮﺣﻴﻞ ﺍﻟﻘﺎﺳﻴﻪ ﻭ ﻇـﺮﻭﻑ ﻓﺎﻗﺛﺒﺎﺗﻴﺘﻬﺎ ﰱ ﺑﻴﺌﺔ ﺍﻟﺴﻮﺩﺍﻥ 
  .ﺛﺒﺘﺖ ﰱ ﺑﻌﺾ ﺍﳌﺴﺘﺤﻀﺮﺍﺕﺃﺪ  ﻗﻩ ﻟﻌﺒﻮ ﻭﻋﺪﻡ ﻣﻼﺋﻤﺔ ﺍﺍﻟﺘﺨﺰﻳﻦ ﺍﻟﻐﲑ ﻣﻼﺋﻤﻪ ﻛﻤﺎ ﺃﻥ ﻋﺪﻡ ﺟﻮﺩﺓ ﺍﳌﻨﺘﺞ
  ﺃﺗﻀﺢ ﻣﻦ ﺧﻼﻝ ﺍﻟﺪﺭﺍﺳﺔ ﻋﺪﻡ ﺍﻟﺘﻘﻴﻴﺪ ﺑﱪﺗﻮﻛﻮﻝ  ﺍﳌﻜﺘﺐ  ﺍﻻﻗﻠﻴﻤﻲ ﳌﻨﻈﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﳌﻴﺔ ﻓﻴﻤﺎ ﳜﺺ ﺣﺴﺎﺏ  .6
 . ﻓﺘﺮﺓ ﺍﻟﺼﻼﺣﻴﻪ ﻭ ﺗﻮﺍﺭﻳﺦ ﺍﻷﻧﺘﻬﺎﺀ 
ﻌﺎﳌﻴـﺔ ﻭﻗﺪ ﺃﻭﺻﺖ ﺍﻟﺪﺭﺍﺳﺔ ﺑﺄﻥ ﺗﻘﺒﻞ  ﻇﺮﻭﻑ  ﺍﻟﺘﺨﺰﻳﻦ ﻟﻠﺴﻮﺩﺍﻥ ﺍﳌﺸﺎﺭ  ﺇﻟﻴﻬﺎ ﻣﻦ ﻗﺒﻞ ﺍﳌﻜﺘﺐ  ﺍﻷﻗﻠﻴﻤﻲ ﳌﻨﻈﻤﺔ ﺍﻟ 
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ﻡ ﺍﳌﻌﻤﻞ ﺍﳌﺮﺟﻌـﻲ ﺑﻌﻤـﻞ ﺣﺴﺐ ﻣﻮﺟﻬﺎﺕ ﺍﳌﻜﺘﺐ  ﺍﻻﻗﻠﻴﻤﻲ ﳌﻨﻈﻤﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﳌﻴﺔ ﻛﻤﺎ ﺍﻭﺻﺖ ﺍﻟﺪﺭﺍﺳﺔ ﺑﺄﻥ ﻳﻘﻮ 
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1. Introduction 
1.1 Concept of pharmaceuticals stability: 
1.1.1 Drug stability: 
 Stability is the ability of a pharmaceutical product to retain its properties 
within specified limits throughout its shelf-life. Aspects of chemical, physical, and 
microbiological and biopharmaceutical stability should be considered. (WHO/94) 
USP defines stability as the extent to which a product retains, with specified limits, 
and throughout its period of storage and use (shelf-life), the same properties and 
characteristics that it possessed at the time of manufacture (USP-30-8/2007). Stability 
with respect to drug dosage form is referred to the physical, chemical integrity of the 
dosage unit and to maintain protection against microbiological contamination (USP-
30-8/2007). The stability of a product relates to its resistance to various chemical, 
physical and microbiological reactions that may change the original properties of the 
preparation during transport storage and use (B.P.C. 1994).  The stability parameter of 
a drug can be influenced by environmental conditions of storage (temperature, 
humidity, light and air). Pharmaceutical articles should include required storage 
conditions on their labelling. These are the conditions under which expiration date 
shall apply. Label temperature and warning will both reflect the results of the real 
time storage tests and allow for expected seasonal excursions of temperature (USP-
30-8/2007). Any changes that occurs in a pharmaceutical product subsequent to its 
preparation, that adversely affects any attribute of the quality of the product in terms 
of its fitness for use by a patient is a matter of concern of stability. 
In terms of efficacy, the most obvious effect is the loss of potency of a drug, so loss of 
potency is the key factor in determination of the shelf life of the drug product 
(Kommanaboyina and Rhodes, 1999) usually 90% of the label claim as the lowest 
acceptable value of potency. Stability of a pharmaceutical product may be defined as 
the capability of particular formulation in specific container/closure system to remain 
within its physical, chemical, microbiological, therapeutic, toxicological, protective 
and informational specifications. Although there are exceptions, 90% of labelled 
potency is generally recognized as the minimum acceptable potency level (O Donnel 
P. and Bokser A., 2005). If the product is not stored in accordance with manufacturer 
instruction, then the product may expected to degrade more rapidly. Strict adherence 
to the storage conditions specified by the manufacturer on the product label will help 
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to ensure the product stability to manufacturer’s labelled expiration date (USP-30-
8/2007). Storage conditions should be according to the container label (USP 1079). 
 1.1.2 Shelf-life: Shelf-life is the period time during which a pharmaceutical 
product is expected, if stored correctly, to comply with the specification as determined 
by stability studies on a number of batches of the product. The shelf-life is used to 
establish the expiry date of each batch (WHO,1996). It is the time interval that a drug 
product is expected to remain within the approved shelf-life specification provided 
that it is stored under the conditions defined on the label in the proposed containers 
and closure, (FDA,ICH,2003). The shelf life of a medicinal product kept close in its 
container under specified conditions is the time from manufacturing or preparation 
until the original potency or concentration of the active ingredient has been reduced 
by 10%. It is known as t90 (BPC, 1994). 
1.1.3 Expiry date: 
 The expiry date given on the individual container (usually on the label) of a 
drug product designates the date up to and including which the product is expected to 
remain within specifications, if stored correctly. It is established for every batch by 
adding the shelf-life period to the manufacturing date (WHO,1996). It is the date 
placed on the container/labels of a drug product designating the time during which a 
batch of the product is expected to remain within the approved shelf-life specification 
if stored under defined conditions, and after which it must not to be used. (FDA, ICH 
Q1A,2003) 
1.1.2. Importance of stability studying: 
Stability studies are necessary for the following reasons: 
1. Degradation may lead to under-medication especially for life-saving drugs. 
2. Decomposition may result in toxic products. 
3. Physical changes may result in improper unacceptable dosage form. 
4. Stability studies assure the quality and guarantee for the patient.  
5. Patient welfare, relief discomfort, inconvenience and cost associated with use 
of product that is sub-potent or exhibits unacceptable serious potentialities. In 
some cases instability problems may cost patient life. 
6. Saving heavy expenditure of marketing unstable products. 
7. Legal aspects in providing application dossier for the regulatory authority        
( Subrahmanyam, 2000). To fill the requirements of regulatory authorities for a 
drug product to be marketed. 
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8. To protect the reputation of procedures and assures the product will retain 
fitness for use with all functionally attributes as long as it is on the market. 
9. To provide a data base that may be of value in other formulations in the 
research and development activities (Rhodes, 2000). 
10. Results are used in determining the appropriate storage conditions and 
expiration date (Connors et.al 1979) 
Stability study is also necessary for establishing the storage conditions. 
Drug quality is affected by the manufacturing processes, packaging, transportation 
and storage conditions. Chemical degradation and physical degradation of drug 
substances may alter their pharmacological effects, resulting in altered efficacy, 
therapeutic and toxicological consequences. 
The quality should be maintained under the various conditions that pharmaceuticals 
encounter, during production, storage in warehouses, transportation and storage in 
hospital and community pharmacies as well as in the home. 
Therefore, understanding the factors that alter the stability of pharmaceuticals and 
identifying ways guarantee their stability was critical (Yoshioka 2000). 
1.1.3 Impacts of instability of pharmaceuticals: 
If the drug product does not meet the established quality standards the possible 
sequences are: 
• Lack of therapeutic effect leading prolonged illness and death. 
• Toxic and adverse reactions. 
• Waste of limited financial resources. 
• Loss of creditability of health services and systems. 
• Resistance of microorganism in case of anti-infectious drugs. 
A drug that passes all laboratory tests,  may be useless after few months upon entry to 
a tropical country if the packaging, storage and transportation conditions have been 
substandard (Quick et al., 1997). 
1.1.4 Chemical stability: 
Chemical reactions proceed more readily in the liquid state than in the solid state, so 
that serious stability problems are more commonly encountered in liquid medicines; 
the stability of suspension of solid drugs in water or other liquid is usually greater 
than that of solution. Degradation reaction is commonly oxidation, hydrolysis, 
dehydration, polymerization, isomerization and photochemical reactions. 
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 1- Loss or increase of active ingredient: 
Loss of potency is not only a decisive variable but it is of major importance. Increase 
of active ingredients may occur due to loss of solvent. 
2- Formation of toxic degradation products: 
The classical example is epianhydroteracylcine from tetracycline. Also proteins drug 
may result in serous toxic potentials or generating allergic reactions. 
1.1.5 Physical Stability: 
With time, the drug may change from one state, usually unstable or metastable, to a 
more thermodynamically stable state (BPC,1994). The rate of conversion will depend 
on the chemical potential corresponding to the free-energy difference between the 
states and the energy barrier that must be overcome for the conversion to take place 
(Yoshioka and Stella, 2000). The followings are sorts of physical degradation:  
1.1.5.1 Loss of pharmaceutical elegance and patient acceptability: 
Attributes such as appearance, smell and taste may show unacceptable changes. 
Analysis of speckled tablets might reveal no loss of potency or change in dissolution, 
but of course, reputable manufacturer will not market and the patient will not accept 
tablets suffering from measles. Changes in the skin drag of topical preparation, 
ruptures or loss of adhesion of label it may engender doubts in the patient mind about 
the quality and thus affect patient compliance. 
1.1.5.2 Volatility of constituents: 
Some drugs may lose their use due to volatilization. Some drugs lose their potency at 
elevated temperature due to volatilization and sublimation, loss of water by 
evaporation from the aqueous solution in a permeable container in warm dry 
conditions may result in crystallization of the drug or excipients or increase in the 
concentration of drug. Creams may form skin on their surfaces. 
1.1.5.3 Change in water content of solids: 
Water can be sorbed in many drugs, excipients and medicinal products. Many 
materials are hygroscopic that gain or lose water depending on the relative humidity. 
Transfer of water from the capsules shell to the drug inside may enhance its 
degradation and render it hard cement-like which alters its bioavailability. Soft gelatin 
capsules are sensitive to humidity over 60% which softens them and they become 
tacky and bloated. Uptake of moisture may result in undesirable changes in tablets 
such changes in hardness, disintegration time, dissolution rate, bioavailability and 
efficacy. Dry powder may become aggregated to form a cake. 
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1.1.5.4 Changes in crystal properties: 
Changes in crystal form, habits and size of a solid can affect physical properties and 
bioavailability of drugs. 
Different forms of crystals may be chemically identical but differ in the physical 
properties due to differences in the free energy. 
In suspensions, change in the crystal form may lead to caking. Large fluctuations of 
temperature lead to changes in crystal habit. 
Polymorphic forms changes can occur during mechanical treatment of solid drugs. 
1.1.5.5 Physical changes in suspensions: 
 1- Loss of content uniformity: 
Suspensions are most likely to show loss of content uniformity as a function of time 
due to changes in sedimentation volume and sedimentation time. If the attraction 
between the particles due to relatively weak London-Van der Waals forces is greater 
than the repulsion forces which are due to the electrical double layer that surrounds 
each particle, the particles come together to form loose floccules that settle rapidly to 
produce a readily dispersed sediment. If the repulsion is greater than attraction, the 
suspension deflocculated, that each article settles slowly and individually to form 
sediment and the particles may aggregate to form indispersible sediment. Crystals 
may grow in some drug suspension due to temperature fluctuation. Dissolution of 
small crystals occur when the temperature is raised followed by deposition on the 
surface of large crystals during cooling. Even at constant temperature crystal growth 
may occur due to deposition of small particles on large crystals. Crystal growth may 
be followed by polymorphic changes. 
1.1.5.6 Physical changes in tablets: 
Uncoated tablets may crumble or break during packaging or transport to produce 
powder or pieces, cracks or chips may be evident on tablet surfaces. Changes in 
hardness, disintegration or dissolution, mottled appearance of coloured tablets may 
occur. Coated tablets changes include clumping of tablets, the coat may crack under 
tropical conditions or by abrasion during transport. 
1.1.5.6.1Changes in mechanical strength of tablets: 
Storage of solid dosage form under humid conditions may bring about absorption of 
moisture and lead to changes in the mechanical strength of tablets. Adsorption of 
moisture by tablet in blister package increases with increasing humidity and resulted 
in decreased mechanical strength. The change in the mechanical strength is the 
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function of moisture sensitivity of the tablet, moisture permeability of the package 
and the humidity conditions. 
 In wet granulation method of tablet manufacturing, the binder forms soft bridges 
between particles, and wet granules when dried it becomes hard. They form the bond 
during compression. The bonds must be exposed to pressure that exceed the elastic 
limit of the material. In the dry compression, the material has low elastic limit and 
flows well. If the drug is less than 20% of the tablet, the tablet will process the 
properties of the compressible ingredient, if it is more than 20%, the drug itself should 
have low elastic limit in order to be directly compressed. 
Hardness of a tablet is a function of the strength and the number of bonds. If the 
pressure is more than the critical limit, the tablet will laminate or cap. The laminated 
tablets contain strata of air and hence become thicker and weaker. If the applied 
pressure exceeds the number of bond and strength, the tablet will laminate within the 
die before the tablet is ejected or after ejection when the tablet expands. 
On storage this expansion can continue and the tablet becomes softer on standing. 
Frequently, tablets become softer or harder on storage due to crystallization of the 
soluble compound by the sorbed moisture which firstly softens the bond then when 
redried it becomes harder (Carestensen–2000). 
1.1.5.6.2 Disintegration: 
There is often a correlation between disintegration and dissolution. The disintegration 
of a tablet is a function of: 
1. Disintegrant, which expands once it is wetted. 
2. The rate at which the disintegrating liquid penetrate the tablet. 
3. The contact angle between the solid and liquid. 
There was a direct correlation between porosity and dissolution. The porosity changes 
as a function of time, resulting in change in disintegration (Carestensen–2000). 
• The longer the disintegration time, the more disintegrating particles must swell 
to make tablet disintegrate. 
• The longer the disintegration time, the smaller the pores. 
• The smaller the disintegration time, the larger the concentration of 
disintegrant. 
• The smaller the disintegration time, the smaller the angle of contact and 
interfacial tension. 
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1.1.5.6.3 Changes in dissolution on storage, effect of formulation: 
Excipients affect characteristics of a dosage form over time. Water content of the 
dosage form can also cause larger changes in the dissolution behaviour of tablets. 
• Gelatin as a binder, decreases dissolution rate at high humidity  
• Acacia, increases dissolution rate at high temperature 
• Carbomer, decrease dissolution rate and bioavailability at high humidity 
• Alginic acid as disintegrant, decreases disintegration at various conditions  
• Calcium sulphate, dissolution rate increased with storage time. 
• Lactose , decrease dissolution rate 
• Microcrystalline cellulose, decrease dissolution rate on storage at high 
humidity. 
• Polyvinylpyrrolidone as disintegrant, its water content evaporate at high 
temperatures leading to stabilization of drug release characteristics  
Moisture permeable package also affects dissolution (Yashioka and Stella).Tablets 
may change the dissolution profile due to decomposition or change in compression. 
Tablet that expands during storage may change the density so that tablet can change 
from sinking to floating which results in slowing down of the dissolution rate. 
Dissolution is the domin of quality assurance and tested as part of the specification 
and reflects the bioavailability. The particle size changes as a function of storage time 
so changing the dissolution profile. 
1.1.5.6.4 Changes in release of drug from coated dosage forms: 
Drug release from enteric-coated and sugar-coated tablets changes the disintegration 
time leading to decrease in dissolution rate due to humidity. Although drug release 
from film-coated is more stable than enteric coated however, it exhibits a change on 
fluctuating temperatures. 
1.1.5.7 Physical changes in powder for reconstitution: 
 The main physical concern of this aspect is appearance, organoleptic properties and 
ease of reconstitution. The most common reasons for powder changes during storage 
time are cohesion, crystal growth and moisture sorption causing lumping up of 
powders. The cohesional force is directly proportional to the square of the distance 
between the particles, so that, on storage where vibration may consolidate the powder 
bed, these forces become larger and the powder cake up, which may give rise to 
problems in reconstitution. (Carestensen–2000) 
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1.1.5.8 Crystal growth: 
There are two reasons for crystal growth: 
A. Polymorphism: 
If the original product is in polymorph or amorphous state, conversion from one type 
to another may occur during storage. This may be due to some stress on the powder 
by moisture or other stress. 
B. Fluctuation in temperature in the presence of moisture: 
The most common reason for increase in reconstitution time upon product storage is 
that the powder becomes lumpier through cohesion developing overtime or becomes 
coarser due to crystal growth. Both are associated with moisture content. 
1.1.5.9 Physical stability of parenteral solutions: 
Physical stability of parenteral solutions may be due to action of the container or due 
to chemical decomposition. One of the manifestation is the slight discolouration, 
which is often either photochemical or oxidational reactions (Carestensen–2000). 
1.   Swirly precipitates: 
Often a parenteral solution will develop swirly precipitates upon storage. It is usually 
due to interaction with either glass or stopper. It could be tested visually by expert 
inspector or coulter-counter. 
2.  Whiskers: 
This may be due to a pin-hole in the glass ampoule which wicks out part of the 
solution, then crystallizes due to evaporation and then becomes a nucleus for more 
solution along the ampoule to the solution inside. This may be due to an undetectable 
pinhole or glass did not have the time to anneal properly on sealing line, and the strain 
caused by the crack during storage not immediately after manufacture. 
3.  Clouds: 
Clouds may appear sometimes during storage due to the following reasons: 
1. The hydrolysis product is poorly soluble. 
2. Precipitate may occur as a result of solubility product being exceeded. 
3. Solution has a tendency to precipitate on the long standing at room 
temperature. 
4. Use of metastable commercial forms of the drug substance (Carestensen–
2000). 
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1.1.6 Microbiological stability:  
Contamination of products with bacteria, yeast and molds may occur during 
manufacture, dispensing or use. It may be derived from the drug substance, or 
excipients that contain water especially those of natural origin. Other sources include 
packaging materials, premises, equipments, clothes, workers and atmosphere. 
Contamination is unacceptable due to hazards to patient and the spoilage of the drug 
product (BPC,1994). 
1.1.6.1 Effects of pathogenic microorganism growth: 
There are two possible ways for microbiological contamination. 
• Microorganisms may be present at the time of manufacture and reproduce 
during storage by time due to appropriate conditions for its replication. 
• Package integrity is compromised during distribution or storage. 
Pathogenic bacteria include: Pseuomonas aeruginosa, Staphylococcus aureus, 
Escherichia coli, various species of Salmonella, Candida albicans and Aspergillus. 
Death may occur due to contamination of I.V preparations or local infection may 
occur near the site of injection. Endotoxins may cause rise in temperature, pain, 
discomfort and erythema at the site of infusion. Contaminated ophthalmic preparation 
is hazardous to eye particularly after surgery. Pseudomonas aeruginosa may 
contaminate dermatological preparation resulting in serious skin diseases. Oral 
contaminated product by Salmonella may give rise to severe infection. 
1.1.6.2 Spoilage due to growth of microorganism: 
Evidence of growth may be manifested as turbidity, discolouration, gas formation, 
unpleasant odour, loss of viscosity and ropiness. 
Emulsified preparations may be separated into oil and water. Degradation of drug 
may occur because of microbial growth. Fungi growing on the surface may cause 
damage of the drug substance and excipients. 
Polymers such as starches, carmellose sodium, tragacanth, pectin and dextrin are 
subjected to depolymerization by extracellular enzymes in microorganisms. 
Oils and fats may be attacked by lipolytic fungi. Preservatives if are in low 
concentration may be metabolized by bacteria such as Pseudomonas. 
During storage gram negative bacteria can multiply in distilled water. Generally 
bacteria grow best in solution of pH 6-8, mould and yeast proliferate in pH 4-6. 
Bacteria optimum growth at temperature 36-40 °C while fungi 20-30 °C. 
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Microorganism during storage can be minimized by avoiding storage in warm places 
(BPC). Care should be taken during dispensing to confirm the integrity of the seal of 
the container. Storage under artificially controlled tropical conditions, tablet made of 
lactose and starch undergo microbiological contamination by Asperigllus niger which 
has been prevented when incorporate preservative. This finding led to 
recommendation the preservatives should be added to tablets destined to be stored 
under tropical countries (BPC). Microbiological contamination could be minimized 
by the use of preservatives such as sodium benzoate which in turn should be assayed.  
1.1.6.3 Loss of Package integrity: 
Changes in package integrity during transformation and distribution or even during 
storage especially for plastic closure system may raise the possibility of 
microorganism contamination and increase the chemical degradation reaction by 
exposure to moisture and oxygen. 
          Loss of the label information or loss of label quality and legibility, disqualify the 
pharmaceutical product.. 
1.1.7 Factors influencing drug stability: 
Many factors affect drug stability. The intrinsic solubility of the active ingredient, the 
interaction between the active ingredient and additives, the manufacturing process; 
the dosage form; the container/closure system and packaging; the environmental 
conditions encountered during shipment, storage and handling, the length of time 
between manufacture and use.  
Environmental conditions such as temperature, light humidity and air. Chemical 
factors as oxidation, hydrolysis, racemisation, pH, ionic strength, radiation, catalyst, 
temperature can all affect drug stability. Of the many environmental factors that can 
be involved in drug degradation, temperature is the most important one that cannot be 
controlled by package (Kommanoboyina and Rhodes – 1999). 
The stability of a drug product depends on the raw materials used, warehouse and 
transport facilities. 
1.1.7.1 Effects of Humidity on stability of drugs: 
Solid dosage form may sorbs water on high relative humidity, which may lead to 
dissolution of the drug and to degradation. Water sorbed as a monolayer or multilayer 
on the surface of the drug particles; drugs dissolve in this layer and hydrolyze. This 
hydrolysis under these conditions follows zero order reaction. When the drug 
becomes only 20-30%, particles tend to stick together so that the physical state 
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changes and the simple mechanism no longer operates. Water vapour may gain access 
to medicinal products through poorly-fitted closures as a result of failure to reapply 
closures or by direct permeation within the container’s wall. Low moisture content 
could be maintained within the container by inclusion of desiccants. 
Chemical reactions may be initiated during storage under moist conditions. Drugs 
prone to hydrolysis may degrade. 
Exposure to excess moisture may change the visible physical properties. In capsules, 
moisture may be transferred to the inside content causing degradation and formation 
of hydrates or production of hard-cement like mass which decreases the 
bioavailability of drug (B.PC, 1994). Storage of hard gelatin capsules at high relative 
humidity may result in capsule becoming sticky and distorted due to loss of its 
mechanical strength. In very dry conditions water desorbs from the capsule shells and 
so, shrinks and become brittle. Soft gelatin capsules may become soft and tacky. 
Tablets may alter hardness, disintegration and dissolution. Aqueous solutions and 
creams lose its water content and plastic container may also develop increase in 
electrostatic charge which encourages particulate contamination. Efflorescent 
compounds lose its water content while deliquescents gain water easily. 
Increase in the amount of moisture generally increases the rate of decomposition. In 
all cases it is important to minimize the access to moisture. 
However, tablets containing a water labile drug were found to be more stable in water 
permeable blister package at 50 °C than in glass container at room temperature. This 
was suggested to be attributed to the loss of water content through the blister leading 
to stabilization of the product (Florence and Attwood, 1998). 
Moisture plays two primary roles in catalyzing degradation rate: 
1. Water participates as a reactant: Hydrolysis, hydration, isomerization 
2. Providing a favourable environment for degradation: 
Drugs that form hydrates, water of crystallization is trapped in the crystals and 
generally cannot participate in the drug degradation when it is released from the 
crystal by actions such as grinding. The same occurs when dehydration due to storage 
under inappropriate humidity (Youshioka and Stella,2000). 
1.1.7.2 Effects of Temperature on drug stability: 
Temperature remains as the most important factor influencing drug degradation, 
which the product cannot be protected from. For many reactions an increase in 
temperature enhances the rate constant and the effect can often be described by 
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Arrhenius equation. Information on the effect of temperature is important in 
prediction of the shelf life. 
Despite the possible complication that may arise by the presence of excipients, many 
authors have found that the effect of temperature on decomposition rate can be 
described by Arrhenius equation. 
Log K = 
RT
EaA
303.2
log −  
Log K versus 1/T, linear plot will be obtained. Then Ea which is the activation energy 
could be calculated because the intercept of plot with 1/T = 0 is log A. 
Ea usually between 50-96 KJ/mol. Temperature is in Kelvin where the equilibrium is 
obtained. Van’t Hoff equation is used  
          ln K =  ∆H/RT + constant 
K here is the equilibrium constant. ln K versus 1/T could be plotted (Florence and 
Attwood, 1998). Stability testing methods based on the Arrhenius equation are valid 
only when the break down is a thermal phenomenon with an activation energy of 
about 10-30 kcal/mol. 
If the reaction is determined by diffusion or photochemical reaction or if the 
decomposition is due to freezing, contamination by microorganisms or excessive 
agitation during transport and so on, an elevated temperature study is obviously of 
little use in predicting the shelf-life (Sinko.2006). 
1.1.7.3 Effect of containers and packaging: 
The British pharmacopoeia defines, the following terms for containers: 
Well-closed container: as one that protects the content from contamination with 
extraneous solids and liquids and from loss of contents under ordinary conditions of 
handling, storage and transport. 
Air-tight container: as one that is impermeable to solids, liquids or gases under 
ordinary conditions of handling, storage and transport. 
Light-resistant container: Containers which protect the content from the effect of 
radiations of wavelength between 290-450 nm (BPC, 1994). 
Loss of solvent can occur through permeable containers of polyethylene, through an 
inadequate sealing or through leakage. Leach can develop through rough handling or 
from inadequate contact between the container and closure due to building up of 
pressure during storage. Leak may be due to failure of the crimp seal in ampoules. So, 
stability of a drug product need to be evaluated over time in the same container-
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closure system in which it is marketed (Sinko.2006). Water vapour or gases may 
penetrate a container closure system either by passing through the permeable 
container walls or by diffusion past a seal. Plastic containers are susceptible to both. 
Although glass containers seem to offer better protection because glass is 
impermeable, glass containers are more effective if there is a good seal between the 
container and closure (Sinko.2006). 
Packaging: 
Factors through which packaging affect the stability, of medicinal product lie on the 
following: 
Sorption on packaging: 
Generally macromolecular drug such as proteins adsorb on the surface of glass 
container even small molecules such as chloroquine adsorb on the surface of soda 
glass containers (BPC, 1994). Adsorption is followed by absorption into the plastic 
matrix. The primary mechanism is interfacial partitioning of preservative between the 
rubber and the solution followed by diffusion into the matrix of the rubber and finally 
volatilization into the atmosphere. Losses of drug from aqueous solution by sorption 
occur commonly on PVC. Sorption is much less in polyethylene or polypropylene. 
Polymers such as nylon 6 (polycoprolactam) were known to adsorb drug substances. 
Glass surfaces are known to adsorb drug substances. Adsorption of volatile 
component of rubber onto drug substances was known. Rubber closures were also 
known to adsorb materials, including drug (Yoshioka. and Stella, 2000) . At the same 
time degradation of the containers material affect the content e.g. alkylesterification 
of polypropylene. 
Leaching from packaging: 
Leaching means the migration of a substance from the packaging material into a 
medicine e.g. leaching of alkali from type III soda-glass bottles and the leaching of 
zinc salts used as activators, from rubber closures. Barium ion leaches from 
borosilicate glass and may react with sulphates of drug or the antioxidants contained 
and results in a formation of crystals. Di-2-ethylhydroxyl phethalate DEHP leaches 
from  PVC. 
Interactions with metals in packaging: 
Traces of metals and metal salts in the container greatly enhance the oxidation and 
degradation of medicinal products. Glass of ampoule is specified by USP as type I 
(borosilicate) for parenterals. 
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Type II glass is sulphur dioxide-treated soda lime glass. It is suitable for products that 
remain below pH 7 for their shelf-life. Type III glass is used for alkali insensitive 
products. Also metals interact directly with many products. 
Permeation through packaging: 
Packaging may permeate gases, liquids, and vapours. Water vapour permeates 
through silicone rubber, through plastic particularly polystyrene and PVC. 
Adsorption of moisture by tablets contained in polypropylene films was successfully 
modeled from storage temperature when the difference in vapour pressure between 
the inside and outside the packaging is significant. Desiccants are often used to 
eliminate moisture in the packaging when the moisture resistance of the packaging 
itself is not sufficient to prevent moisture (Yoshiokia. and Stella, 2000). 
• The primary role of packaging, often than its esthetic one is to protect the 
dosage form from moisture, oxygen present in the atmosphere, light and other 
types of exposure. 
  Protection from light can be obtained by using primary and secondary light 
resistant materials. Incorporating oxygen adsorbant such as iron powder in 
packaging unit can reduce the effect of oxygen. 
• Strips may be aluminum/aluminum. 
• Aluminum/cellulose film; cellulose film is of bright appearance but is subject to 
high moisture permeation. 
• Aluminum is light-proof, good moisture protection but in thin films it is fragile. 
• Paper has good mechanical strength. 
• The use of PVDC is more protective from moisture than PVC. 
• The use of PVC/ polymonochlorotrifluoroethylene (Aclar) provides more 
moisture resistance than PVC/PVDC in blister packaging materials. 
• Tropical packs: are blister packs that have an additional aluminum membrane 
sealed over the polymer membrane to provide protection against high humidity. 
• The disadvantages of glass as packaging material are, Fragility, Weight and the 
ability to release alkali to aqueous content, especially during heating. 
Type I borosilicate, it is neutral 
Type II soda-glass treated by sulphur dioxide (it is acidic) at high temperature to 
impart hydrolytic resistance. 
Type III: soda-glass it is only used for nonaqueous parentral preparations.  
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Closures: 
While the closure must form an effective seal for the container, the closure must not 
react chemically or physically with the product. It must not absorb materials from the 
formulation or leach its ingredient into the content. The integrity of the seal depends 
on the material of the closure and the tightness with which the cap had been applied. 
The circular force applied to open a closed container is measured by torque. Rubber is 
a common component of stoppers, cap liners so sorption and leaching are common 
problems. 
The application of epoxy lining to the rubber closure reduces the amount of leached 
extractions but has no effect on sorption. Teflon-coated rubber may prevent most of 
the sorption and leaching (Rabinow and Roseman, 2005). 
1.1.8 Formulation strategies to improve shelf-life:  
Addition of antioxidants, preservative, control pH, protect from light, control of 
humidity and temperature control of oxygen content, use of polymers. 
Addition of overage: 
Excess amount of drug is added to the preparation to maintain at least 100% of 
labeled amount during the expected shelf-life. If 10% decomposition is permitted, 
another 10% is added over during manufacturing. The international Pharmaceutical 
Federation (IFP) allow overage of maximum 30% over the labeled amount. Safety 
and toxicity should be considered, it requires another shelf-life definition rather than 
90%. Thus the addition of overage may double the shelf-life. (Subrahmannyam 2000). 
Overage are of three types: 
1. Container overage: Overage is added to allow for the fact that it is not possible 
in the same cases to remove all the contents from the container so addition of 
volume or weight is added. 
2. Manufacturing overage: Overage is added when it is known that relatively 
small and reproducible amount of the active substances are always lost during 
manufacturing process. 
3. Stability overage: This is to compensate the degradation. 
Reluctance to overage: 
1. Possible increase in toxicity: if compendial limit is 90-110% is release for the 
market as 100% on the label, if the degradation up to the expiry date is 10% 
and the product released as 110%, so the degradation will be out of 120%, if 
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the degradation product is toxic this will double the toxicity and the potential 
hazards to which the patient exposed. 
2. Stability overage provides the patient with different concentrations and this 
reflect different variation in patient's blood levels and may need patient's 
titration if it is a more severe drug of a narrow therapeutic index and 
antibiotics. 
3. It may be as bond-aid approach to formulation problem which is unacceptable 
in modern pharmaceutical technology (Carestensen 2000). 
1.2 Chemical Kinetics: 
The order of a chemical reaction determines the concentration time profile of a drug 
or drug product while the rate constant determines its slope. The most frequently 
encountered kinetics in pharmacy are the overall zero-, first-, and second-order 
reaction. More complex reactions are also observed. However, for the shelf life 
calculation in which the concentrations change is generally not more than 20%. The 
distinction between orders is relatively unimportant (Connor et al. 1979). If the 
variance is small and the concentrations measured are in a narrow range ( as might 
occur in a short term stability study to 10% decomposition), the log transformation 
will result in data that are close to normal with homogeneous variance( Bolton, 2004). 
The expiration dates are usually based on assumed zero- or first-order kinetics  
According to the law of mass action, the rate of a chemical reaction is proportional to 
the product of the molar concentration of the reactants each raised to a power equal to 
the number of molecules of the substance undergoing reaction. 
nm
nm BAKrate ][][)( +=  
1.2.1 Zero-order reaction: 
The reaction proceeds independent of the concentration. The rate constant is given by 
the equation. 
C0 is the initial concentration. 
C is the concentration at time t. 
t
CCK −= 00  
K0 is the zero order constant 
The half-life will be 
0
0
50
5.0
K
C
t =  The shelf life is given by 
0
0
90
1.0
K
Ct =  
So, the shelf-life could be enhanced by overage. 
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There are not many reactions that are truly zero order in pharmacy. Most of those that 
appear to be zero order are, in fact, pseudo-zero order. 
ICH stated that the nature of any degradation relationship will determine the need for 
transformation of the data for linear regression analysis. Usually the relationship can 
be represented by a linear, quadratic or cubic function on arithmetic or logarithmic 
scales. Prediction for stability during the short term based on the least square fit will 
be approximately correct (Bolton and Bon, 2004).  
1.2.2 First-order reaction: 
First order reaction is defined as a reaction in which the rate reaction depends on the 
concentration of one reactant. 
The rate constant is given by the following equation: 
C
C
t
K 01 log
303.2= . Plotting log concentration versus time slope = 
303.2
1K−  
303.2
loglog 10
tKCC −=  
The exponential form of the equation 
tKeCC 10
−=  
Or 303..2/0 110
tKCC −= .   
Thus decrease in concentration of the reactant is mono-exponential with time. The 
concentration begins at C0 and decreases slowly as the reaction becomes 
progressively slower. The concentration approaches a final C∝ as the time proceed 
towards infinity. 
1
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693.0
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1.2.3 Second order reaction: 
The rate of reaction depends on the concentration of two reactants each raised to the 
power one. 
)(
)(log
)(
303.2
2 xba
xab
bat
K −
−
−=  
Where: a = initial concentration of A 
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     b = initial concentration of B 
              x = the product of reaction 
aK
t
2
50
1=  
On plotting 
)(
)(log
xb
xa
−
−  a linear line is obtained of slope 2303.2
)( Kba −  
Second order reaction is not common in pharmaceuticals (BPC,1994, 
Subrahamanyam,2000). 
1.2.4 Pseudo zero order: 
Pseudo zero order is a reaction which may be a first order, but behaves like a zero 
order. The rate of degradation of suspensions depends on the solubility of the 
suspended particles in the liquid. As the drug decomposes in the solutes, more drug 
released from the suspended particles so that the concentration in the solution remains 
constant. The reservoir of solid drug in suspension is responsible for this constancy. 
Thus the system follows a zero order. Once the entire solid is exhausted the system 
follows first order. 
When tablets are exposed to high humidity, moisture precipitates on the surface, part 
of the drug goes into solution and develops saturated aqueous drug layer. Thus this 
system behaves like suspension and hence follows zero order. When the 
decomposition occur in small amounts, it is difficult to distinguish between zero and 
first order reaction. Thus the first order reactions may appear as zero order in 
processing the data. Such reactions are referred to pseudo zero order. 
1.2.5 Pseudo-first order reaction: 
Even in case of reaction involving more than one reacting species, the rate may still 
follow first-order kinetics. The most common example when one of reactants is in 
large excess that any change in its concentration is negligible compared with the 
changes in concentration of other reactants. This type of reaction is termed as pseudo-
first-order.  
Most hydrolysis reactions are of this type (Sinko.2006) 
1.2.6 Determination of reaction order: 
Many methods could be used, of them are the graphic method and the half-life 
method and the most important is the substitution method. 
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Substitution method: 
1. Obtaining the concentration of reactants at different time intervals.  
2. Substitution of data in the equation of different orders for K value. 
3. The substitution is repeated for each time interval. 
4. The order at which K remains constant is the related order. 
 Zero order      first order      second order 
         
t
CCK t−= 00             
tC
C
t
K 01 log
303.2=          
)(
.12 xa
x
at
K −=  
1.2.7 Calculation of rate constant by fitting to kinetic models: 
A rate equation for drug degradation can be obtained by fitting an observed 
degradation curve to a suitable kinetic model chosen on the basis of proposed 
mechanism. Since any experimental data include errors, the least-squares regression 
analysis is usually carried out to test the validity of the model and to calculate the 
apparent rate constant. 
The concentration of the drug remaining is generally represented by linear equation 
for zero order kinetic or linearized forms of various equations. 
1.2.8. Effect of moisture on stability of solid dosage form: 
Primarily moisture in the dosage form that causes its instability, and hence there is a 
link between solution and solid state stability. Decomposition in solution is usually 
hydrolysis. It behaves as pseudo-first order. It is obvious that the solid dosage form 
always contain water. This water acts as a solution medium and all decomposition 
usually takes place in this layer. Thus concentration in this layer is the saturation 
concentration (Solubility S). Each molecule being decomposed in this layer is 
replaced by another molecule from the solid, so that the aqueous layer is always 
saturated. So the rate will be dC/dt = -KlS. The reaction will be zero order. So that, the 
more water there is in the dosage form, the more unstable it is going to be. 
K0 = K1SV    V  is the volume of  water. If the apparent rate constant is plotted versus 
moisture content, straight line through the origin will result (Carestensen,2005 ). 
Strength is plotted versus time at certain RH and the rate is investigated. 
R
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Water soluble drugs in solid dosage forms will dissolve in any moisture which is 
adsorbed on the solid surface. Then the drug behaves as solution. Increase in the 
amount of moisture associated with the drug, greatly increases the decomposition rate.  
The prevention of moisture permeation through the packaging is not always 
absolutely enhance stabilization, because  the drug in the enclosed excipients contains 
water, it will lose this moisture at high temperatures through the permeable packaging 
leading to stability of product (Florence and Attwood, 1998). Moisture plays two 
primary roles in catalyzing chemical degradation: 
1. Water participates in the drug degradation process as a reactant, leading to 
hydrolysis, hydration, and isomerization. In this case the rate of reaction is 
directly affected by concentration of water. 
2. Water adsorbed may change the physical state of drugs, thus providing 
favorable environment for degradation. 
The effect of water depends on the physical state of water in the molecules. 
For drugs that form hydrates, water of crystallization is trapped in the crystal and 
hence cannot participate in the chemical reactions, unless it is released from 
crystalline state by grinding. Decomposition increases by increasing grinding time. A 
rapid degradation was seen when its crystalline structure was disordered by 
dehydration upon storage under conditions of low relative humidity , X is the ratio of 
drug degraded at time t. X0 is the ratio of drug degraded at 25 °C and 100% RH (p = 
23.756 mm Hg) when t = 50 days. 
`
0 50756.23
.1
298
1exp.
nS tP
TR
Eaxx ⎟⎠
⎞⎜⎝
⎛⎟⎠
⎞⎜⎝
⎛⎥⎦
⎤⎢⎣
⎡ ⎟⎠
⎞⎜⎝
⎛ −=  
Where, S and n are constants (Yoshioka and Stella, 2000). 
Kinetics in the dry versus moist state: 
Solids behave as pseudo-zero order with segmoidal behavior at the anhydrous state( 
Carestensen, 2000).The Leeson-Mattocks model is the most frequently applicable 
model. It assumes that the sorbed water produces a layer about the particles. 
Degradation follows pseudo-zero order with rate constant linearly related to the 
relative humidity. 
Very low moisture content: 
In these cases decomposition is pseudo-first order. The active sites in a Prout-
Tompkins disappear by dissolution. The molecules adjacent to the intact drug 
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molecules take part in the reaction, and then the first order kinetic should prevail. The 
reaction profile takes sigmoid nature and can be explained by surface-interaction-
model. 
The equation is           )(
1
ln 2/1ttKx
x −=⎥⎦
⎤⎢⎣
⎡
−  
In great majority of cases, the decomposition follows zero order  
M = M0 (M0K)t = M0 K0t 
This means that the amount of decomposition is linear in time. 
1.2.9 Effects of Temperature on reaction rate: 
Among the many factors affecting the reactions rate, temperature is the most 
important one. 
As the temperature increase, the number of collisions increases. The reaction rate is 
proportional to the number of collisions per unit time. So, the reaction rate increases 
as the temperature increases. In fact, the speed of many reactions increases about two 
or three times with each 10 °C rise in temperature. 
1.2.9.1 Collision theory: 
As the reaction proceeds from reactants to products, the system passes through a state 
whose energy is greater than the initial reactants. Thin barrier that prevents the 
reactants to be products immediately. The activation energy is the measure of this 
barrier Ea. 
Arrhenius suggested the equation for that: 
   RTEaAek /−=   Or    e
RT
EaAk lnlnln −=   Or 
RT
EaAk
303.2
loglog −=  
K : Specific rate constant 
A : Frequency factor or Arrhenius factor 
Ea : Energy of activation 
R: Ideal gas constant (1.987 cal/mol.deg) 
T : Absolute temperature in Kelvin  
log A
Lo
g 
K
1
T
Slope = 
-Ea
2.303R
 
Energy of activation is defined as the minimum energy that a molecule should possess 
so that molecular collisions produce the product. 
Arrhenius factor is defined as the frequency of collisions which can occur between 
molecules. A is the multiplication of the number of molecules and probability factor 
of collisions which give a reaction product. (Martin’s 2006). 
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1.2.9.2 Estimation of energy of activation: 
• On plotting log K at different temperatures against 1/T a straight line will be 
obtained the slope of which is
R
Ea
303.2
− . 
R is gas constant (1.987 cal/mol.deg). the intercept of the line with the vertical 
axis is log A. 
So Ea could be calculated. 
• Ea can also be obtained by the equation 
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
12
12
1
2
.303.2
log
TT
TT
R
Ea
K
K
 
Ea is generally between 12-24 Kcal/mol (Martin’s 2006). Usual range of Ea is about 
12-24  K cal/mol with typical value 19-20 K cal/mol (Connor’s 1979). Ea values 
within the range 50-96 K J mol-1. For rough estimation in calculations use Ea say 75 
KJ mol-1 (Florence and Atwood, 1998). It is noted that, activation energy of about 20 
K cal/mol is quite common activation energy for many reactions (Carstensen, 2000). 
Ea values 10-30 K cal/mol (40-130 KJ mol-1) are generally observed in degradation of 
drug substances (1 K cal/mol = 4.18 KJ mol-1) (Yoshioka, 2000). 
1.2.10 Prediction of shelf life from kinetic data: 
Knowledge of activation energy and the rate constant at a particular temperature 
enables the shelf-life of the product at another temperature to be predicted by 
application of Arrhenius equation ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
12
12
1
2
.303.2
log
TT
TT
R
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K
K
 
• The assumption of first order kinetic for drug decomposition provides 
minimum error (Florence and Atwood, 1998). 
• There is a liner relationship between t90 and 1/T independent of reaction order 
(Sinko., 2006). 
Arrhenius equation could be used to predict stability in the solid state even though the 
kinetic breakdown are different to those in solution except when equilibrium is 
present at room temperature Van’t Hoff equation is valuable 
                             ln K= ∆H/RT + constant               (Van’t Hoff equation). 
Equilibrium concentrations of products and reactants are determined at different 
temperatures. Then plot log K against 1/T. 
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1.2.11 Storage of medicinal products at temperatures other than specified: 
1.2.11.1 Q10 concept:  
Q10 is the factor by which the rate constant increases for a 10 °C temperature increase. 
It is used as a rough approximation. It is often 2 as optimistic estimate and 4 as 
pessimistic estimate (BPC, 1994). It is justifiable to use pessimistic estimate value. 
⎥⎦
⎤⎢⎣
⎡ ⎟⎠
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It is possible to define Q10 in terms of shelf-life: 
)10(10 += T
s
s
t
TtQ      where tsT is the shelf life at temperature T. 
                          tsT+10 is the shelf life for temperature T+10 
The equations are generalized for instances when prediction of shelf life is required 
for changes in temperature ∆T of more than 10 °C. 
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In practice the value of Ea range between 50-125 KJ/mol (BPC) and so the value of 
Q10 near room temperature will be between the extreme values of 2, 3, 4, 5. For most 
conservative estimates of the shelf-life using Q10 concept, a value of 2 would be used 
to predict the increase of shelf-life by decreasing temperature. And value of 5 for the 
prediction the decrease of shelf-life by increase in temperature (BPC,1994). Q10 
concept could not be applied for physical changes (Connor’s 1979). 
There are three values 1, 2, 3 for Q10 if the activation energy 12.2, 19.4 and 24.5 K 
cal/mole respectively for increase in temperature from 20 to 30 °C (Sinko.,2006). 
1.2.11.2 Products stored under unspecified conditions of temperature: 
Having the conditions specified and the expiry date designated and the product being 
stored in other conditions of temperature, the shelf-life will change accordingly. 
Assuming that the exact Ea values available, so, Q10 values of 2, 3 and 4 would be 
used to estimate the change in the shelf-life (Connor’s, 1979). 
For estimation purposes, all reactions might be either apparent zero or first order (it 
makes no practical differences) 
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∆  
So that t90(T2) is independent of the order, that there is no need to know the order to 
make this estimate. 
The value of Q10 = 3 gives the most likely estimate than 2 and 4 
In decreasing temperature use Q10 = 2. 
In increasing temperature use Q10 = 4. 
1.2.11.3 Relation between energy of activation and the relative rate constant: 
Increase of 10 °C from 20-30 °C raises the degradation rate 1.76 folds using Ea 10 K 
cal/mol. and 5.5 folds using Ea K cal/mol. 
Relative rate for drugs “20 °C - 30 °C” having different Ea values 
Ea KT2/KT1 
10 K cal/mol 1.76 
15  ,,,,,, 2.34 
20 ,,,,,, 3.11 
25  ,,,,, 4.12 
30 ,,,,, 5.48 
Arrhenius plot has been used to describe temperature dependency for various 
chemical reactions by regarding A and Ea as temperature independent. Increase in 10 
°C form 20 to 30 °C increases the degradation 1.76 folds. If the rate constant be 
estimated by fitting the Arrhenius equation, it is possible to estimate the time required 
for 10% degradation (t90) where reciprocal of t90 is related to temperature. Arrhenius 
equation is valid at the range of temperature at which Ea and A are regarded as 
constant. Ea of Rifampicin is 19.2 K cal/mol at pH acidic (Yoshioka, 2000). 
 1.2.11.4 Bracket tables: 
Data are completed assuming the Ea 10 and 20 K cal/mol for a table to be 
constructed. Both bracket tables and Q10 provides useful information although they 
are not official in ICH or FDA (B. Kommandaboyina & Rodes). 
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1.2.11.5 Prediction of degradation rate constant by linear regression analysis of 
the Arrhenius equation: 
The regression analysis using different rate constanst at different temperatures is the 
classical Arrhenius analysis and still used as a basic method for prediction of drug 
stability. The Arrhenius regression analysis can be performed by using multiple rate 
constants calculated from drug concentration/time data points observed at a single 
temperature level. 
For the first-order: 
First-order: 
[ ]
[ ] tKD
D
1
0
ln −=                   [D] concentration at t,   [D]0 initial 
concentration 
 Arrhenius equation:   K = ⎥⎦
⎤⎢⎣
⎡−
RT
EaAexp                                                        
Replacing the K in first equation  
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This is the modified Arrhenius equation. 
1.2.11.6 Prediction of degradation rate by non-linear regression analysis of 
Arrhenius equation: 
Although linear regression analysis provides biased results and weighed least-squares 
analysis is required to improve the estimates, non-linear regression analysis does not 
form the same problem. 
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Monte Carlo simulation performed by king et al.(Yoshioka, 2000) suggested that non-
linear regression analysis could provide more reliable estimates with smaller 
deviations and biases than in the linear regression. 
1.2.11.7 Estimation of shelf-life from real time data (Yoshioka, 2000): 
The Woolfe equation has been used to estimate the shelf-life of a product from data 
obtained at the same temperature conditions as those expected for the final product. 
The time at which drug content diverges from its specifications is estimated by 
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extrapolating the time course of degradation at specific temperature when the time 
course of drug content C is represented by: 
b
cctt −==  ,  
t = the time course;   t  = average of t,  c = drug content, c  = Average of c, b = 
constant 
The confidence interval of the time at which the drug diverges from specification, 
determined by regression analysis of n sets of time-content data is given by: 
Woolf’s equation given by Bolton: 
]²)x¯-x(∑/²)x¯-X+(N)/g-1(√] [ b)/Syx(t[gx¯ ±-X  
1-g 
  ² )x¯-x(∑² b-N /²)∑y (-² ∑y√ =Syx , Where         
                                                 N- 2 
 g =   t²( S²yx) /     b²∑(x-x¯) ² ,      ( Bolton and Bon,2004) 
The shelf-life (the lower confidence limit of the time at the drug content diverges 
from the specification range) can be estimated. When the lower limit of content 
specification is 90%, the shelf-life corresponds to tL at C of C90%. If Syx is large or b 
is small, shelf-life cannot be estimated because the value of g must not be less than 1 
because the confidence interval becomes narrowest at ¯x, a more precise estimate of 
shelf-life can be obtained by extrapolating the regression curve determined from a 
larger number of time content data points at larger x. Carstensen derived equation to 
calculate the confidence limit of c at specific t( Carstensen,2000). 
1.2.11.9 Estimation of shelf-life from temperature accelerated studies: 
Shelf-life at a storage temperature T1 is estimated from the shelf-life at an elevated 
temperature T2. 
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A shelf-life of 6 months at 40 °C corresponds to a shelf-life of 3 years at 25 °C when 
activation energy of 22.1 K cal/mol is assumed. 
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The distribution of the true value of the shelf-life is shown as a function of the 
observed value for degradation percentage. 
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1.3 Mean kinetic temperature: 
Mean kinetic temperature is defined as the single calculated temperature at which the 
total amount of degradation over a particular period is equal to the sum of individual 
degradation that would occur at various temperatures (USP, 8/2007). It is the 
temperature at which isothermal storage at MKT would have caused the same drop in 
potency (Carstensen 2000). The mean kinetic temperature is a single derived 
temperature that, if maintained over a defined period of time, affords the same 
thermal challenge to a drug substance or drug product as would be experienced over a 
range of both higher and lower temperature and takes into account the Arrhenius 
equation. When establishing the mean kinetic temperature for a defined period, 
Haynes formula could be used (ICH QAIR2, 2003). 
If the temperature fluctuates between 20 and 35 °C during the year as it is generally 
observed during winter and summer, the average or the arithmetic mean is 27.5. The 
following graph will be obtained on plotting the concentration over the initial 
concentration against months. So that, at the end of the year, the total degradation as a 
result of various fluctuating temperatures equal to the degradation due to one 
isothermal temperature if it was maintained all over the year. 
The temperature dependency is not linear but logarithmic according to Arrhenius 
equation. 
12
C/C0
100
Months
C/C0 MKT
C/C0 in variable temp.
C/C0 average temp.
 
The temperature for calculating MKT can be conveniently collected using electronic 
devices that measure temperature at frequent intervals. For dispensing sites such as 
pharmacies and hospitals where the use of these devices may not be feasible, devices 
such as high-low temperatures are capable of indicating weekly high and low 
temperatures over 52 weeks period may be employed MKT is calculated from records 
of one year with a minimum twelve equally spaced average temperature observations 
(USP,2007). 
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The USP mean kinetic temperature given by Haynes: 
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∆H is the heat of activation = 83.144 KJ.mol-1, (unless accurate information is 
available) 
R is the gas constant     = 8.3144x10-3 KJ.mol-1.degree-1  
T is the temperature in Kelvin, n is the number of entries, minimum of 52 week 
entries. PDMA requires that all warehouses, distribution centers, transportation chains 
and pharmacies retain MKT less than 25 °C that the average measured temperature 
should be below 25 °C, and only spurious excursions to 30 °C are allowed. 
The regulations governing drug distributors state that all drugs shall be stored at 
appropriate temperature and under conditions in accordance with requirements in the 
labeling of such drugs or that in an official compendium (FDA, 1998). CGMP 
regulations state that written procedures describing the warehousing of drug products 
shall be established and followed. These regulations also state that such procedures 
shall include instructions for the storage of drugs under appropriate conditions of 
temperature, humidity and light. So, the identity, strength, quality, purity of the drug 
product are not affected (Willig, 2005). The FDA states that any time the yearly MKT 
of a facility approaches 25 °C, the occurrence should be documented, the cause 
should be investigated and corrective actions should be taken to ensure that the 
facility is maintained within the established conditions for drug product storage. FDA 
recognizes that when the MKT exceed 25 °C, it may not have an impact on product 
being stored less than one year at a time, but warning that the facility itself may not be 
under adequate control. However, depending on the duration and extent of such 
excursions and the dosage form, it may be necessary to determine if the product 
quality has been adversely affected. 
Section 501 @(2)(B) of the Federal Food, Drug and Cosmetic Act states that a drug 
shall be deemed to be adulterated if the facilities or control used for holding drugs do 
not conform to GMP to assure that such drugs meet the requirements of the act as to 
safety and have identity and strength and meet the quality and purity characteristics, 
which they purport or are represented to possess. This applies to all persons engaged 
in manufacturing, holding and storage of drugs. 
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MKT calculations gives the higher temperatures a greater weight.( USP,2007). 
1.3.1 USP method of calculation: (USP, 2007). 
 The method uses the mean of highest and lowest temperature for 52 weeks. 
1.3.2 FDA method of calculation: 
FDA recommends that, for manufacturers, repackagers and warehouses, all data 
points obtained by inserting directly into MKT equation. A minimum weekly highest 
and lowest temperature is recommended, and rigorous approximation using daily 
higher and lower or even frequent reading would be acceptable. 
That means 104 entries are entered. 
1.3.3 Devices used to measure temperature and humidity: 
The shelf-life is a function of the temperature and humidity conditions under which it 
stored and transported as well as the chemical and physical properties of drug 
substances (USP 8/2007). 
Thermistor Type: This is a semiconductor whose resistance varies with temperature. 
Thermistors are able to detect very small changes in temperature (USP 8/2007). 
Electronic time-temperature history recorders: 
Data loggers: A more capable device records the temperature at very short intervals 
and is able to download the temperature history record to a personal computer. It may 
record the humidity also. It may be fixed or mobile. Data loggers may be preferred 
when it would be useful to demonstrate the exposure to the highest temperature was 
very brief. Recent studies reported significant departure from ambient temperature on 
summer days for mailboxes, truck and warehouses (USP 8/2007). Although there is a 
general recognition in North America, European Union, Japan and WHO for the 
utility of MKT concept, there is still some debate about the exact method of 
calculation. USP advised to enter the frequent records for pharmaceuticals in the 
doctor’s cars, sales representatives cars and  patients,… etc. If the temperatures are 
electronically recorded at many times during a day and all the values are used in the 
calculation of MKT, then there is no difference between the USP and FDA method 
The USP method of calculation of the MKT gives lower values than the FDA method 
because of the use of an arithmetic average that is incorrect for an Arrhenius-type 
equation (.Kommonobiona and Rhodes, 1999). The FDA method is therefore referred. 
Grimm and Schepky used 83 KJ mol-1 as the energy of activation after a survey of 
literature reports of energy of activation of variety of drugs. Later this value had been 
adopted by ICH, FDA, USP and WHO (Kommanaboyina and Rhodes,1999). 
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1. Drugs that have energy of activation lower than 83 Kgmol-1 will be less 
sensitive to temperature stress than the average of Grimm and Schephy (e.g. 
oxidation where the Ea is 20-50 KJmole-1). 
2. Drugs degraded with the energy of activation more 83 KJmol-1 will be more 
sensitive than Grimm and Schephy average. 
3. The assigned shelf-life is slightly smaller than the conformance period. The 
difference can safeguard against smaller excursions. 
4. MKT is dependent on the activation energy, the effect is quite small. 
5. As the length of excursion is increased, the effect on the MKT values 
especially for the systems with short lives becomes increasing significantly. 
6. Even at low temperatures, longer excursions adversely affect drugs especially 
those of short lives and where there is no safety margin from the conformance 
period. 
In mail box across USA calculations of MKT, 32.1% of the packages had MKT 
values above 25 °C for periods 19 and 21 days, and 40% above 26 °C. 
It is assumed that all the time intervals are of equal length, although this assumption is 
not truly necessary (USP,2007) and where the temperature is held thermostatically 
constant, the entire temperature equal the MKT. Software to complete the MKT is 
available commercially e.g.: http://www.stabilitysystem.com. Software assumes 
activation energy of 83.14472 KJ/mol for its calculation. In fact, any value between 
60 and 100 KJ/mol, which covers most solid and liquids, will have only a small effect 
on the final value (Madgetech). However, the software of stability system is capable 
to compute different value of energy of activation. Minimal and maximal values of 
the temperature excursion should be specified by the authority because labile 
substances can degrade on very short exposure to higher temperatures. The constants 
are obtained from the CODATA/NIST at http://physics.nist.gov/cuu/constant. 
1.3.4 Reference Thermal Exposure (RTE): 
This process was proposed by PMA-1980, which is a characteristic condition for a 
particular warehouse. The times in hours for each range of temperature were obtained, 
K for each temperature was calculated and hence the potency of drug at each 
temperature is obtained and using different orders of reaction and different activation 
energy: The defect of Haynes calculations is due to the fact that it is based on the 
weather data which do not necessarily reflect the temperatures in a warehouse (Yang, 
2007). 
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1.4 Sudan climatic profile: 
1.4.1 Sudan location: 
Sudan is an African country bounded by latitude 2°-3°N from the south and 22°N 
from the North, and 22°E longitude from the east and 36-37°E from the west. It is 
surrounded by the Ethiopian plateaus at the east to the south east and the equatorial 
forest belt at the south to the south west, the Red Sea at the east and the Western 
Desert at the west and to the north. Due to these conditions Sudan is characterized by 
a wide range of climatic variations which vary from the desert climate in the northern 
part which is hot and dry to the poor savannah through rich savannah to the equatorial 
climate at the southern part which is hot and humid, and the characteristic Red Sea 
climate. 
1.4.2 Temperature: 
Sudan is a tropical country with a mean annual temperature varying between 26 °C 
and 32 °C (Sudan metrological Authority Report,2007). The hottest area lies within 
the northern parts and the highest temperature being reported is 49.1 °C in June 1978 
at Dongolla at latitude 18°N. Hottest and coldest months vary according to the 
latitude. 
1.4.3 Humidity: 
The Eastern part of Sudan climate is greatly influenced by the red sea, providing a 
humid climate which in turn was influenced by temperature. The rain or monsoon 
season is 2-3 months in the north and increases southwards. Rain fall is influenced by 
the behaviour and the nature of the inter-tropical convergence zone (ITCZ) which is 
controlled by the atmospheric pressure over and near the African continent. The ITCZ 
is the zone that separates the dry northerly wind from the south moist wind. It 
oscillates north and south following apparent movement of the sun. South to this zone 
is humid with occasional rainfall. 
1.4.4 International records on Sudan climate: 
USP classified Sudan as zone III in the, together with Iraq and Iran as hot, dry 
climate. The calculated data were as follows: 
Calculated data Derived data 
measured 
MKT RH mbar Temp. RH mbar 
26.4 °C 27.9 35% 11.9 30 °C 35% 15 
(USP 30, 1/8/2007). 
 32
The oldest stability testing guidelines for the Arab countries (Pre-WHO guidelines) 
define the conditions for Sudan for the long-term stability testing as 35-40 °C. 
(Kopp-Kubel and Zahn, 1998). WHO defined Sudan as a member of Zone III. The 
Sudanese governmental laboratory and the regulatory authority use these guidelines 
using the conditions for long-term stability testing as 30°C/35%RH. 
The climate of Sudan provided by the world metrological organization WMO, Geneva 
was presented as Khartoum weather. Data are derived as a mean of 30 years from 
1961-1990 (www.worldweather.or/085/coo249) 
During the argument for globalization of stability testing conditions for long-term 
stability testing, Sudan was classified as zone III hot/dry and so most of the African 
countries (Grimm, 1998). According to this study Khartoum represented Sudan. It has 
been reported as the hottest city in the world having the highest MKT 32.5°C, 
followed by Aswan 30°C and New Delhi 27.9°C. 
The climatic conditions of Zone III and zone IV: 
Grimm had calculated 27.8 °C as MKT for zone IV and the energy of activation is 83 
KJ.mol-1. Both temperatures are fixed to 30 °C providing 2.2 °C and 2.4 °C as margin 
of safety (Grimm W, 1998). 
measured calculated Derived 
Zone 
Temp. P.V.P MKT RH% Temp. RH% 
III 24.4 °C 11.9 27.8 °C 35% 30 35% 
IV 26.5 °C 26.6 27.4 °C 75.8% 30 30 
Using meteorological data from Shambat station, a study calculated that the mean 
kinetic temperature using one program is 29.7 °C and it is 32.4 °C when using a 
program giving the higher temperatures more weight than the lower ones as the 
relation of Arrhenius equation is exponential to temperature (Carstensen and. 
ElBadawi, 1995). This temperature was pointed out by Brahamaiah and Rhodes as 
greater than that stipulated for the dry hot climatic zone (Kommanaboyina and 
Rhodes, 1999). Recently Sudan was classified as zone III and Zone IVA.  Conditions 
were defined for Sudan as 30 °C/65% RH with a notice, that the aqueous preparations 
in semipermeable containers and dosage forms sensitive to humidity may require 
testing at low humidity according to the procedure described in the guideline (EMRO 
– 9/ 2006). 
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1.4.5 The adopted National Meteorological records: 30 years records: 
Table ( 1 ) Adopted Meteorological Records for the Six Stations 
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1.4.6 Transportation across Sudan: 
Most medicinal products are imported via Portsudan. They are exposed to high 
temperatures and humidity at the port waiting for clearance. Usually they are 
contained in metal containers which in turn elevate the temperature and worsen the 
conditions. These drastic conditions continue during transportation to Khartoum by 
trucks as they are exposed to direct sun and open air on the back of the trucks. 
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All medicines are then stored in Khartoum at the distributor's warehouses and then 
distributed to all cities at all parts of the country. They are transported via passenger 
buses, trucks and Lorries, being exposed to the blazzy sun, open air, dust and rains. 
Transportation took many days to some cities from Khartoum.  
Table (2) Distances between Stations and Khartoum and Route of Transportation. 
Centre City Distance Route Media 
Khartoum Wadi Halfa 930 km Land Railways 
Khartoum Port Sudan 1200 km Land Trucks 
Khartoum Juba 1440 km Air Air 
Khartoum Alfashir 1355 km Land Lorries 
Khartoum Al Damazin 780 km Land Lorries, buses 
Khartoum Wawo 1600 km Land Lorries 
Khartoum Neyala 1355 km Land Lorries 
(Military Trucks Directorate Records,2006) 
Medicinal products will be exposed to temperature exceeding 30 °C and up to 45 °C 
in summer. The stability of several medicinal products had been investigated during 
their transportation by sea from Europe to Sudan and during subsequent storage and 
transportation within Sudan. 
No significant degradation of tested products was reported during transportation to 
Sudan, but significant degradation of three aqueous injections of lignocaine with 
adrenaline, suxamethonium chloride and ergometine maleate occurred rapidly during 
storage and transportation in tropical climate (BPC, 1994). This is the only field study 
that took place in Sudan and was done by IDA and WHO Action Programme on 
Essential Drugs in 1989-1990 (Hogerzil et al., 1990). The freshly manufactured 
basket of medicinal products are sampled and transported to Sudan from Netherlands: 
Netherlands - Portsudan, 2 months; Wait at the sea port for clearance, 8 months; At 
the CMS warehouses, 2 months; 3 Hospitals at the Nile province, 4 months 
Then the samples were returned back to IDA laboratories by air. The study resulted in 
that, three products were instable. One of them, ergometrine, is already instable at 
room temperature, (Hogenzil et al., 1991). 
The Suxomethonium chloride was not pointed to be stored in a cool place, but it is 
well known that it should be stored in a refrigerator. 
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The study did not consider or calculate the storage conditions of the country or  of the 
Nile Province. Also staying 8 months at Port Sudan is not a familiar case. The study 
did not point recommendations to correct the instability of medicinal products in 
tropical climates. 
1.5 The utilized Medicinal Products: 
1.5.1 Amoxicillin for oral suspension: 
Amoxicillin for oral suspension contains the equivalent of not less than 90% and not 
more than 120% of the labelled amount of amoxicillin (C16H19N3O5S). It contains one 
or more suitable buffers, colours, preservatives, stabilizers, sweeteners, and 
suspending agents (USP 2007). When freshly constituents not more than 120% of the 
stated amount. When stored at the temperature and for the period stated on the label 
during which the oral suspension may be expected to be satisfactory for use, not less 
than 80% of the stated amount (BPC 2007). 
1.5.1.1 Packaging and storage: 
Preserve in tight containers and stored at controlled room temperature (USP,2007). 
The oral suspension should be kept at a temperature and used within the period stated 
on the label (BP, 2007). 
1.5.1.2 Structural formula: 
H
NH2
CO.NH
N
S
H
COOH
CH3
CH3H
H
O
HO365.4
3H2O
 
(6R)-6(α-D-P-hydroxyphenylglucylamino) penicillanic acid 
As tri hydrate C16H19N3O5S.3H2O = 419.4  
Amoxicillin Trihydrate should be stored at a temperature not exceeding 30° C in air 
tight container. The Dry ingredients of the oral suspension should be stored at a 
temperature not exceeding 25°C (B.P.C. PP-728-731). 
1.5.1.3 PH: Between 5- 7.5, in the suspension constituted as directed in the label USP. 
B.P. stated it as 4-7  
1.5.1.4 Water: 
Water contents limits, is not more than 3% except where it is labelled as containing 
80mg amoxicillin per ml after constitution, the limit is not more than 4%. 
(USP,2007). 
1.5.1.5 Deliverable volume: meets the requirement. 
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The B.P specifies that after constitution as directed by the label and stored under 
specified conditions and for the period stated in the label it should contain not less 
than 80% of the stated amount. 
1.5.1.6 Stability consideration: 
Amoxicillin is subject, in common with all pencillins, to hydrolytic degradation of the 
β- Lactam ring to produce under alkaline conditions, the penicilloic acid which 
subsequently decomposes to penilloic acid by decarboxylation. The reaction is first 
order (B.P.C,94). Under acidic conditions, amoxicillin hydrolyses to penicillenic acid. 
At the same time, base-catalysed self-aminolysis, dimerisation occurs, by nucleophilic 
attack of β-lactam carbonyl moiety of one molecule by the free side chain amino 
group of a neighbouring molecule. Concentrations of amoxicillin and the pH of the 
solution determine the corresponding input of the hydrolysis and aminolysis to the 
overall degradation reaction. 
The degradation of amoxicillin trihydrate over pH 3-10.5 at 35°C, follows first order 
kinetic. The activation energy was 90.75 KJ/mol (Tsuji et al,1978).  
T90 for amoxicillin trihydrate is 3.2 years at 20°C (Sylvestri et al ,1988) recommended 
that suspension stored in original container at room temperature will have expiration 
date of 7 days after reconstitution. Polymerization occurs during storage of 
concentrated solutions. The reactive β-.lactam bond of one molecule is opened by 
reaction with side-chain of another molecule and a dimer is formed. The process can 
continue to form higher polymers such polymers shown to be highly antigenic in 
animal and considered to play part in eliciting pencilloyl Specific reaction in man. 
The hydrolysis rate constant of amoxicillin at PH 8.2 is 1.1x10-6 at 35 °C 
(Yoshioka,2000). The electron withdrawing group NH2 played the significant role in 
the initial rupture of the β-.lactom ring which was responsible for the overall 
degradation (Kessler et al 1983). Amoxicillin, β-lactam ring is more susceptible to 
hydrolytic degradation when the pH deviated from the isoelectric point (pH 4.8) 
(Tsuji et al., 1978) and the zwitter ionic form of the drug was the most stable species 
(Mendez et al., 1989). In strong acid medium the main degradation products are 
amoxicillin penamaldic and amoxicillin penicilloic acid. As the pH increases, the 
formation of penicamaldic acid decreases and penicilolic acid increases. In the neutral 
and basic region, the degradation products are amoxicillin penicilloic acid and 2-(6`-
phenylpiperazine-2,5-dione-3`-yl)5,5`-dimethylthiazolidone-4-carboxylic acid 
(Mondez et al., 1989). At pH 6 amoxicillin present as the zwitter ionic form degraded 
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to give amoxicillin penicilloic acid. Then at pH 12 it gives penicilloic acid. In aqueous 
solution in acidic pH, the activation energy is 59.79 KJ mol-1 and in pH 5-7 the 
activation energy is 70.56 KJmol-1, it is the zwitter ionic form which is the most stable 
form. Above pH 8 the activation energy is 54.98 KJmol-1 (Chadha et.al., 2003).  At 
pH 5 the Ea is 72.59 KJmol-1, Arrhenius factor A is 9.47 ±0.01. Amoxicillin 
trihydrate 1.15 gm is equivalent to 1 gm amoxicillin. Elevated temperature and 
humidity may sufficiently free the intrinsic water molecule of crystallization to 
participate in amoxicillin hydrolysis. The oral suspension is stable for 14 days at room 
temperature; however, refrigeration is the recommended condition. The drug also 
undergoes dimerisation, the dimerisation assures important role in the concentrated 
preparations (Trissel., 2005). 
1.5.2 Rifampicin + INH tablets: 
Rifampicin and isoniazid is an effective combination in primary treatment of 
pulmonary tuberculosis. It is effective against Gram-positive bacteria, some 
Mycobacteria specially Mycobacterium tuberculosis and some Gram-negative 
bacteria. It is a bactericidal agent. 
The compendial preparation in USP is Rifampin and isoniazind capsule and Rifampin, 
isoniazid, and pyrazinamide tablets. In the BP 2007, rifampicin capsules alone and 
isoniazid tablets alone. 
1.5.2.1 Official preparations: 
Rifampicin and isoniazid capsules USP: 
It contains not less than 90% and not more than 130% of the labelled amount of 
rifampicin and not less than 90% and not more than 110% of the labelled amount of 
isoniazid. 
1.5.2.2 Packaging and storage: 
Preserve in tight light-resistant containers and avoid exposure to excessive heat (more 
than 40 °C) (USP 2007). It should be prescribed in tight, light-resistant container and 
not exposed to excessive heat. It should be stored below 25 °C (BPC). 
Rifampicin should be protected from exposure to air, moisture and excessive heat. 
Rifampicin should be stored at controlled room temperature (15-30 °C) and protected 
from heat of 40 °C and higher (Trissel., 2005).Strips packs are preferred over blister 
packs, because strip packs showed a low moisture gain (Bhutani, et.al ,2003). 
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1.5.2.3 Rifampicin: C43H58N4O12 
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C H 3
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3-{[(4-methyl-1-piperazinyl)imino]methyl}-rifamycin. 
Rifampicin is odourless, brick-red to reddish-brown crystalline powder. 
1% w/v suspension has a pH 4.5-6.5. 
It is slightly soluble in water, soluble in methanol. 
1.5.2.4 Stability considerations: 
Rifampicin is stable in the solid state for 5 years if stored below 25 °C (BPC). 
Rifampicin is reported to exhibit potential bioavailability problems in conventional 
oral dosage form (WHO/Eur., 1986). Rifampicin decomposes by oxidation (BPC), 
and undergo hydrolysis of the imine-like structure (Yoshioka,2000). 
O H
N H
N−C H 3C H=N−N
O H
N−CH 3H 2N−N
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N H
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In aqueous solution it decomposes by hydrolysis in acidic medium (pH 2.3) to 1-
amino-4-methyl piprazine and to 3-formylrifampicin S.V. 
The activation energy is found to be 80.3 KJ/mol (BPC). In basic medium (pH 8) and 
in presence of air or oxygen, rifampicin oxidizes to quinine derivative at 20-22 °C. 
Maximum stability was demonstrated at pH 5 (Trissel, 2005)., Ea is 19.2 Kcal/mol 
(Yoshioka,2000). Suspension of 10 mg/ml (1%) stored at 25 °C and 4 °C was found 
to be stable for six weeks (Krukenberg et al.,1986) and it was stable for four weeks 
(Trissel, 2005).in another study by (Nahata et al.1994) It was stable for 56 days the 
potency drop to 83% after 70 days. Nahata reported that rifampicin suspension 
prepared from rifampicin injection retains 95% potency for eight weeks if stored at 22 
°C, while study by Allen and Erickson indicated that 10% loss after 28 days at 25  °C 
and 5 °C in dark. 
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1.5.2.5 Isoniazid: C6H7N3O                              = 37.1 
N
C O − N H − N H 2  
Isonicotinyl hydrazide. It is soluble in 1 in 8 water. 1% solution has been reported to 
have a pH of 5.5-6.5. 5% solution has a pH 6-8. 10% solution has a pH 6-7.5. 
1.5.2.6 Stability consideration: 
Isoniazid undergoes hydrolysis or oxidation depending on the conditions. 
Hydrolysis: Isoniazid undergoes hydrolysis or oxidation in alkaline medium under 
aerobic conditions to produce, isoniconitic acid, isonictinamide and 1,2-
diisonicotinolyl hydrazine. The predominant product is isonicotinic acid and 1,2-
diisonicotinolyl hydrazine. In acidic medium under anaerobic conditions, the initial 
product of pseudo-first order hydrolysis was isonicontinic acid. 
Oxidation: the oxidation and complexation of isoniazid in aqueous solution that 
catalyzed by CUII ion, were isonicotinic acid, isonicotinamide and 1,2-
diisonicotinolyl hydrazine, isonicotine –carboxyaldehyde and isonicotinolyl 
hydrazine. The reaction follows first order reaction (BPC,1994). Potentially 
carcinogenic levels of hydrazine were found in isoniazid syrup as result of INH 
decomposition at room temperature (25°C) for four months. The formation of 
hydrazine increased six folds if stored at temperature 40°C (Carlin et al.1998,) 
(Trissel., 2005). 
Isoniazid tablets (100 mg) stored for 5 months at 60 °C and 70% RH, were found to 
contain 1.5% hydrazine which is found to have carcinogenic and mutagenic properties 
(Matsui et.al, 1983). Pulverized tablets in B.P. syrup contains 95% after 28 days if 
stored at 24 °C (Seifart et al,1991). 
1.2.5.7 Combined dosage form: 
WHO and International Union against Tuberculosis and lung disease recommend the 
use of a fixed-dose combination formulation of the essential antituberculosis drugs to 
ensure adequate treatment of patient (WHO, 2001). Mixed suspensions of isoniazid 
and rifampicin, which are separately stable, stored at 4 °C, both drugs lost 10-12% of 
its potency in two days (Seifart et al., 1991), commented that the browning reaction 
during wet granulation of INH with lactose may become significant under tropical or 
subtropical conditions. INH also reacts rapidly with lactose degradation product, 
hydroxymethyl furdural. Primary and secondary amine groups undergo Millard 
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reaction (addition/rearrangement reaction) with lactose resulting in discolouration and 
so called browning reaction (Yoshioka, 2000). In commercial INH tablets that 
contained lactose, between 10-22% isoniazid was present as lactose isonicotinolyl 
hydrazone. The reaction of isoniazid with lactose at pH 1-6 to form isonnicotinoyl 
hydrazine was pseudo-first order and further to form hydrazone was second order 
reaction (Devan’s et al, 1985). The increase in rifampicin degradation in the presence 
of isoniazid in acidic medium is due to the formation hydrazone (Singh et al.,2000). 
The minimization of contact between rifampicin and isoniazid can alleviate the 
degradation of rifampicin to certain extent, a novel dosage form was developed 
containing sustained release rifampicin and isoniazid. (Gohel and Sarviaya, 2007) 
1.5.3 Metronidazole I.V. Infusion: 
1.5.3.1 Contents: 
Metronidazole injection is sterile, isotonic, buffered solution of metronidazole in 
water for injection. It contains not less than 90% and not more than 110% of the 
labelled amount of metronidazole (C6H9N3O3) (USP 2007). 
Metronidazole intravenous infusion is sterile solution of metronidazole in water for 
injection. It contains 95% to 110% of stated amount of C6H9N3O3 (BP 2007). It is 
almost colourless to pale yellow solution. 
1.5.3.2 pH: 4.5 to 6. 
1.5.3.3 Storage:  
The BP states that it should be stored protected from light. It also stated that the label 
states that solutions containing visible solid particles must not be used. 
The USP stated that it should be preserved in single-dose container of type I or II 
glass, or in suitable plastic containers, protected from light. 
The requirement of USP for pH is 4.5-7 
C 6H 9N 3O 3  =   17 1 .1 5
N
NO 2N
C H 2  C H 2O H
C H 3
 
1-(2-hydroxymethyl)-2-methyl-5-nitroimidazol. It contains not more than 0.35 USP 
Endotoxin units per mg of metronidazole, and it meets the requirement of particulate 
matter under small volume injections (USP,2007). 
1.5.3.4 Stability consideration: Metronidazole undergoes hydrolysis in aqueous 
solutions, maximum stability is reported to occur at pH 5 under alkaline conditions, 
and hydrolysis took place to yield ammonia, acetic acid and unidentified compound. 
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Photodegradation of metronidazole solution exposed to light for 18 months yield two 
colourless products. The order of the decomposition reaction appeared to be 
dependent on temperature. The pseudo-first order photodegradation was claimed to 
increase with temperature, pH and intensity of radiation (BPC 1994). Solutions in 
contact with plastic containers can leach out components in up to 5 ppm within the 
expiration date. 
Degradation of metronidazole aqueous solution followed pseudo-first order 
degradation kinetic. There is no acid/base catalysis imposed by the buffer. The 
Arrhenius plot indicates the temperature dependence of the degradation and indicates 
the estimate of activation energy of 15.35 Kcal/mol. 
Shelf-life is 963 hours at room temperature at pH 3.1, ionic strength = 0.5 and UV 
radiations 254 nm (Wang and Yeh,.2006). Metronidazole infusion should be stored at 
controlled room temperature and protected from exposure to light. Solid state of drug 
is stable in dry conditions (Trissel, 2005). Metronidazole degrades extensively in 
oxidative conditions, mildly in acid and neutral conditions and it is stable to thermal 
stress (Bakashi and Singh 2003). The Arrhenius plot showing the temperature 
dependence of metronidazole degradation indicates estimates of metronidazole 
activation energy of 15.35 Kcal/mol (Wang and Yeh,.2006).  
1.5.4 Artemether Injection: 
Artemether injection is a sterile solution of artemether in suitable oil for injection. It is 
a clear colourless or almost colourless oily solution. It is an antimalarial drug (Int  Ph,  
2003 ). It contains not less than 95% and not more than 105% of the amount of 
C16H26O5 stated on the label. It is the drug of choice for the severe malaria in 
Sudanese protocol (Sudanese protocol for the treatment of malaria 6/2004). 
1.5.4.1 Arthemether Structural formula: 
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Dihydroartemesinin methyl ether, (3R, 5aS, 6R, 8aS, 9R, 105, 12aR)-decahydroxhlor-
10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[6,3-;]-1,2-benzodioxypin  
“12-b-dihydroartemesinin methyl ether”. 
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Artemether is the methyl ether of dihydroartemsinin, which is derived from artesinin 
the isolate substance from the extract of leafy portion of Artemisia annua (Ging Hao) 
family asteraccae. 
It acts through the endoperoxides group as schizontocidal destroying the asexual 
erythrocytes form of Plasmodium filciparum and P. vivax (Ch. ph1995). 
1.5.4.2 Storage: 
Artemether injection should be protected from light, stored in a cool place and the oil 
used in the formulation should be indicated on the label (Int.Ph.). The Indian sample 
used in the study indicates that it should be stored below 25 °C, do not freeze. Protect 
from light and the Chinese sample indicates closed storage in cold place. 
1.5.4.3 Stability consideration: 
Artemether is known to be thermally stable. It is stable in tropical environment 
(IPCA- India). The Int. Ph specifies that any of the related substances should not be 
more than 0.5% and not more than one related substance should be more than 0.25% 
and the total of all the related substances should not be more than 1% calculated from 
peak obtained from the HPLC chromatogram, disregarding any peaks less than 
0.05%. For tablets the Int. Ph specifies that it should contain not less than 90% and 
not more than 110% of the labelled amount of C16H26O5. 
1. Dihydroartemisinin  2. α-artemether and unknown related substance. 
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The Indian sample from the market has the shelf-life of 24 months when stored below 
25 °C protected from light. The Chinese sample from the CMS has the labelled shelf-
life of 36 months, when stored in cold place light-protected. Novartis stability study 
for long-term storage at 35 °C and 30 °C RH 60% indicates a decrease in the content 
after 24 months but without dropping below 90% and increase in the related 
substances dihydroartmesinin and other related substances. At 40 °C and 50 °C for 12 
and 6 months, an increase of unknown decomposition products is observed, which is 
not correlated to pronounced decrease in drug content. 
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At elevated temperatures a higher decrease in content is observed. The loss is 
attributed to sublimation of artemether rather than to degradation. After xenon light 
exposure and elevated temperature the colour of the tablets changes to dark yellow. 
The dissolution of artemether decreases slightly after storage at 25 °C and 30 °C. 
Higher decrease in dissolution at 40°C storage conditions is attributed to the 
decreasing artemether content. The results of the study were that, artemether stability 
is good at ambient temperature. The product need to be protected from light and 
protected from temperature above 30°C to avoid loss and degradation of artemether. 
The packaging in PVC/PVDC blister packs or HDPE bottles with tight screw-cap 
closure, and storage conditions not above 30 °C. The product has a shelf-life of 24 
months (Novartis 1998). Artemisinin and its semisynthetic artemether degrade with 
activation energy 13.54 Kcal/mol. Artemether shows a remarkable thermal stability 
(Hanna, 2000). Artemisinin compounds are sensitive to moisture. The shelf-life of 
most products is around two years and this is contingent on high standards of blister 
packaging and storage conditions ( WHO, Geneva  - 7/2003). It also recommended 
that, appropriate transportation and storage facility must be ensured to maintain 
product stability and integrity. 
1.5.5 Lumefantrine: 
Lumefantrine is a synthetic racemic fluorine mixture. It is an antimalarial drug, it is 
also named Benflumetol. Lumefantrine 120 mg is combined with 20 mg artemether in 
Coartem tablets. It is a yellow crystalline powder, insoluble in water, freely soluble in 
dimethylformamide and ethyl acetate, soluble in dichloromethane, slightly soluble in 
ethanol ® and methanol. It is non-hygroscopic. 
Lumefantrine should be kept in a well-closed container. Lumefantrine contains not 
less than 98.5% and not more than 101% of C30H32Cl3NO calculated on the anhydrous 
(Int Ph, 2006)). 
1.5.5.1 Lumefantrine structure: C30H32Cl3NO, Molecular weight:  528.94 
N
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When dried it looses weight not more than 0.2% (Ch. ph 2005). 
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α-(dibutylaminomethyl)-2,7-dichloro-9-(p-chlorobenzenemethylene)-4-fluorene 
methanol. The absorption of lumefantrine in the fasting state, the normal condition 
actually in ill patient, is relatively poor (Walther 4/2004).  
1.5.5.2 Storage: 
Lumefantrine should be kept in a well-closed container (Chinese Ph and Int Ph.). 
1.5.5.3 Stability consideration: 
Stability testing in the active ingredient, in the following conditions: 
25 °C / 60% RH in amber glass bottle with screw cap closures for 36 months. 
30 °C / 30% RH in amber glass bottle with screw cap closures for 36 months. 
25 °C / 60% RH in amber glass bottle with screw cap closures for 24 months. 
30 °C / 60% RH in amber glass bottle with screw cap closures for 12 months. 
40 °C / 75% RH in amber glass bottle with screw cap closures for 6 months. 
Using HPLC method of assay, the results indicated that no degradation of the drug 
substance was observed. In the long-term stability in solid state, lumefantrine was 
found to be stable and no increase in the content of the related substances. So, 
lumefantrine is solid state stored below 30 °C in polyethylene in steel drums will have 
a re-test period of 3 years (Novartis-1998). In the finished product, the tablets dosage 
form in combination with artemether in study of 40°C/12 months, 50°C/6 months, 
25°C/75%RH, 30°C/80%RH 6 months, there was no degradation for lumefantrine. 
The shelf-life had been stated as two years. The impurities should be not more than 4 
and every spot is not darker than that of 50 µg/ml of the solution (Ch ph, 2005). 
Lumefantrine/artemether dry suspension in a vial is stable for 3 years at a temperature 
not exceeding 30°C. After reconstitution and stored at 30°C, artemether content fall to 
92% after one month and to 96% after 4 days. Lumefantrine is 97% after one month 
and 96 after 14 days (Co-artesiane suspension; WHO Int. - application). 
The related substances are: 
1. CGP 71876 of empirical formula C30H32Cl3NO of molecular weight 529. 
2. CGP 71878 a mixture of steroisomers A and B. of empirical formula 
C44H24Cl6O2 of molecular weight 529. 
Bioavailability of lumefantrine increased markedly by taking a normal good meal. 
( Ezzet et al.2000) 
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1.6 Stability testing and protocols: 
1.6.1 Stability Testing: 
Stability testing is the process aiming at assessing the physical, chemical and 
microbiological properties of a drug product or drug substance at appropriate intervals 
1.6.1.1 Purpose of stability testing: 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light to establish a retest 
period for drug substance or a shelf-life for the drug product and recommend storage 
conditions (QIA (R2), FDA ).  
1.6.1.2. Objectives of stability testing: 
a- Main objectives of stability testing: 
Objective Type of the study 
To select adequate formulation and container-closure system Accelerated 
To determine shelf-life and storage conditions Accelerated / real time 
To substantiate the claimed shelf-life Real time 
To verify that no changes have been introduced in the 
formulation or manufacturing process 
Accelerated and real 
time 
 
For the global market, WHO recommended testing for product intended to be 
marketed in zone I and II, the manufacturer is advised to carryout the test according to 
conditions of zone II, and conditions of zone IV to both zone III and IV. 
1.6.1.3 Types of stability testing: 
There are many types of stability testing according to the objectives of the study: 
1.6.1.3.1 Long-term stability testing: 
It is conducted in the laboratory under controlled condition similar to that encountered 
during storage. The BPC 1994 defines 25°C/75% RH to represent the temperature 
conditions and 38/90% RH to represent tropical conditions. However, these had been 
organized by recent guidelines. When a drug loses m% at 25°C, it will be considered 
1.1 m% provided the Arrhenius plot is linear and the activation energy is 60-120 
KJ/mol usually for liquids (Carstensen and Rhodes 1986). 
Long term stability testing provides the reliable evaluation of chemical, physical, 
biological and microbiological characteristics of the drug product and drug substances 
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when stored for a period covering the expected duration of the shelf-life and retest 
period which are claimed in the submission and will appear on the labeling (Yoshioka 
and Valentino, 2000). 
The reliability of data interpretation can be increased by including in each assay a 
single lot of reference material with established stability characteristics. One lot of 
reagents should be used to increase precision. The time at which 90% two sided 
confidence bound intersects 90% potency level on the stability plot is best termed the 
conformance period. This should be greater than the labelled shelf-life e.g. 21.3 
months = 18 months, 38.7 months = 3 years, 69.5 months = 5 years. The shelf-life 
may be rounded down from the conformance period ( Kommanabyina and Rhodes, 
1999). Most of international guidelines specify the storage conditions, the duration of 
study and the frequency of tests. 
1.6.1.3.2 Accelerated stability testing: 
The product is challenged by controlled exaggerated stress over a short time to 
enhance the rate of reaction. The stress conditions are temperature, moisture, 
agitation, gravity, pH, packaging and method of manufacture. Accelerated method is 
used to provide an early indication of the product shelf-life which may permit the 
prediction of the stability of drug at ordinary conditions. Four stress temperatures are 
required to apply Arrhenius equation RTEaAeK /−= . This needs two sequential steps 
of linear regression involving potency% versus time to obtain the rate constant for 
every temperature. Then plot K versus 1/T to predict the rate constant at room 
temperature and hence the shelf-life, applying 95% confidence bound. ICH assumes 
the energy of activation about 83 KJ/mol ( Kommanbayina B and Rhodes, 1999). In 
the past Q10 was used, however, both methods are non-official in ICH and FDA. 
Accelerated stability testing provides a rapid detection of stability of one product in 
different formulations during R&D trials and prediction of shelf-life and the 
degradation profile. However, no absolute conclusion can be drawn about predicted 
stability under normal conditions (Pugh J- 2002). Accelerated stability studies can be 
used to support tentative expiration dates in the event that full shelf-life studies are not 
available. Data from these studies, in addition to long term studies can be used to 
assess long term chemical effects at non accelerated conditions and to evaluate the 
effects of short term excursions outside the label conditions (Martin’s 2006). 
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Limitations of accelerated stability testing: 
1. Valid only when the break down is temperature dependent. 
2. Valid only when the energy of activation is 10-30 Kcal/mole. If it is less, when 
10 Kcal/mole the rate would be faster at normal conditions and elevated 
temperature has little influence and if it is higher, very high temperature is 
required. 
3. Shelf-life obtained for one set of conditions for a preparation cannot be applied 
to another preparation of the same drug. 
4. Whenever slight change in the formula is made, kinetic study at one elevated 
temperature will be sufficient to predict stability. Ea can be obtained from the 
literature. 
5. Stability prediction at elevated temperatures was of little use when the 
degradation is due to diffusion, microbial contamination, photochemical or 
excessive agitation stress. 
6. Stability studies are meaningless when the product loses its physical integrity 
at higher temperatures. 
7. Order of reaction may change at elevated temperature. 
However, temperature is still considered as an important factor in predicting 
shelf-life but excessively higher temperatures should be avoided 
(Subrahmanyam, 2000). 
8. Extrapolation of results is risky even from a purely statistical stand point. 
9. It did not regard loss of oxygen during elevated temperature and difference in 
solubility on rise of temperature (Lachman et,al,1987). It is not always true to 
assume that the same changes that occur at elevated temperature will happen 
later at room temperature (Linter, 1986). 
1.6.1.3.3 Field stability study: 
The packed medicinal product is sent by various means of transport to the countries 
where it will be sold; it is stored in a warehouse, transported to a typical pharmacy 
and then returned back to the manufacturer's laboratory for examination and analysis. 
Such realistic tests provide information of value since the conditions are those 
encountered when the product is marketed (BPC 1994). 
It is normal to retain samples in the manufacturer's storage area, but these samples are 
not dropped of the back of a truck, they are not left on loading dock in the blazing 
sun, nor were they subjected to rains or dusty weather. Thus it is somewhat unrealistic 
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to expect retained samples to reflect accurately the stability of the products in the 
distribution channels. 
There is now increasing concern about the stability of products in the distribution 
channels. A level of additional sophistication can be added to test distribution by 
using computer chip recorders, which will record temperature/time profile, the 
information is downloaded, a hardcopy is obtained when the chip is returned to 
manufacturer laboratory (Cartennsen , Rhodes, 2000). Re-estimating the shelf-life 
may be valuable when unwanted storage conditions occur.The committee of the WHO 
agreed that when special transportation and storage conditions are not complying with 
the real time conditions, additional study data supporting these conditions may be 
needed (WHO,2001). In 1989-1990 an inland stability testing was performed in 
Sudan, in 3 hospitals, in the Nile province where samples from IDA were transported 
for Sudan in 8 months and stored for 4 months and returned back to IDA laboratories, 
of 15 samples, 3 showed serious loss of potency (Hogerzeil et al., 1991). 
Stability of products in the channels of distribution: 
The evaluation of samples that had been stored at the manufacture warehouses under 
utopian conditions are of limited value. Samples retained for stability testing are not 
dropped off the back of the truck; they are not left on a blazing sun on a loading dock; 
nor exposed to dusty weather. Thus it is somewhat unrealistic to expect retained 
samples to reflect accurately the stability status range of products those in channels of 
distribution (Rhodes, 2000). The manufacture can generate the quality of a product up 
to the time designated as its expiration date only if the product has been stored in the 
original container under recommended storage conditions usually stated on the label 
(USP,2007). Storage conditions should be according to the container label. 
Observation of the temperature variations in the warehouse should be made over a 
period of time to establish a temperature profile. Mean kinetic temperature should be 
calculated for any separate area. Validated, available temperature and humidity-
monitoring technologies can be used to monitor the overall environmental effects on 
articles during shipment and distribution (USP,2007).  
Mail order distribution across USA showed that only 8.4% of the packages 
experienced temperature variations with the excursions allowable under the CRT 
(Kommanoboyina and Rohds, 1999). 
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1.6.1.3.4   Retained samples stability testing: 
For each marketed product stability data is required, the manufacturer selects stability 
samples for retained storage for at least one batch a year. Stability samples are tested 
at predetermined intervals. However, Carstensen pointed out some disadvantages of 
this method and proposes the method of stability testing by evaluation of the market 
samples. This method involves taking samples already in the market place and 
evaluating stability attributes. This method is inherently more realistic since it 
challenges the product not just in the idealized retained samples storage conditions, 
but also in the actual market place (Carstensen and Rhodes, 1993). 
E.  Cyclic temperature stress testing: 
This method is used to mimic likely conditions in the market place storage. The 
period of cycle is 24 hours; it was recommended that the test should have about 20 
cycles( Kommanaboyina and Rhodes 1999). Most drug products of solid dosage form 
are not affected by short-term temperature excursions encountered during shipment 
and distribution conditions (Valvani, 2000). 
1.6.1.3.5 Stress testing: 
Stress testing is to elucidate the intrinsic stability data of the drug substance is part of 
the development strategy and is usually carried out in more severe conditions than 
those used for accelerated testing. The testing typically includes the effects of 
temperature in 10 °C increments above that for accelerated testing, 75% RH is 
appropriate. Oxidation and photolysis on the drug substance are induced . 
1.6.1.3.6 The USP mailbox study: 
The USP subcommittee on packaging, storage and distribution implementation in 
1996 a study of temperature and humidity conditions that may be experienced in main 
transit mailing from Rockville was performed between June and August, with 
destination in various parts of USA. The rather worrying result of this survey showed 
that 84% of the packages recorded temperature within USP specifications. The 
remainders were subjected to temperature above 30 °C and 21% experienced 
excessive heat over 40 °C (Rhodes, 2000). 
• HPLC is the method of choice for stability testing used by the pharmaceutical 
industry to assay the intact drug and its degradation products (Jeffs, 1998). 
• A major factor in the improvement of pharmaceutical stability testing has been 
the development of analytical methods that are suitable for use in stability-
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indicating assay. In particular, the availability of HPLC has been a real boon to 
stability testing. It is noteworthy that our definition of stability-indicating 
assay has evolved from method that would allow quantification of a drug in 
the presence of its degradation product and excipients to a method that allow 
quantification not only of the drug, but also of major degradation products. 
1.6.2 Stability Testing Protocols: 
The stability of drug substances and drug products has been a concern of both 
pharmaceutical industry and regulatory agencies for many years. Although all 
pharmaceutical products have to satisfy the government regulatory authorities, 
surprisingly there is no one international standardized storage conditions (Pugh, 
2002). Both parties want to ensure that the patient receives safe and effective drug 
product throughout its claimed shelf-life. Today, HPLC is the method of choice used 
to assay intact drug and its degradation product. Before the introduction of stability 
guidelines, the pharmaceutical companies used various conditions for long-term 
testing, and different procedures for selection of batches, different test parameters, 
and different intervals lead to a huge and numerous analytical data. This is 
complicated by different requirements between regulatory agencies in different 
countries. Therefore, that the development of common set of stability requirements 
for international filings was a high priority. The stability testing required in 1993 by 
the Arab countries, pre-WHO guidelines was established and was taken by the WHO 
as an example necessitating the development of the stability testing guidelines (abine 
Kopp-Kubel S. and Zahn-1998). The final version of WHO guidelines was published 
in 10/1996 and approved by WHO Assembly in Jan. 1997. Later EMRO organize 
workshop in Amman in 1993 which resulted in a recommendation of acceptance of 
WHO draft. These include 30 °C/70%RH for long term stability testing for zone IV. 
ICH was established between Japan, European Union and USA, the regulatory 
agencies and pharmaceutical industry select the first topic for discussion by EWC was 
stability testing. The first guideline enclosed by ICH steering committee in 10/1993 
(Jeffs et, al 1999). Stability is the corner stone for development of specifications, test 
parameter, establishment of limits, development of analytical methods, formulations, 
methods of manufacture, selection of packaging, labeling and storage conditions. 
1.6.2.1 International climatic zones and Harmonization:  
The world has been divided into four climatic zones according to the international 
meteorological data, measured in the open air (Grimm, 1998).   
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1.6.2.1.1 WHO Climatic Zones: 
Table (2): definition and storage conditions of the four zones: 
Climatic zone Definition Storage conditions 
I Temperate climate 21 °C/ 45% RH 
II Subtropical and Mediterranean  25 °C/ 60% RH 
III Hot, dry climate 30 °C/ 35% RH 
IV Hot, humid climate 30 °C/ 70% RH 
Table (3) Mean climatic conditions, measured data in open air and storage room 
Climatic zone Measured in the open air Measured in the storage room 
I 10.9 °C/ 75% RH 18.7 °C/ 45% RH 
II 17 °C/ 70% RH 21.1 °C/ 52% RH 
III 24.4 °C/ 39% RH 26.0 °C/ 54% RH 
IV 26.5 °C/ 77% RH 28.4 °C/ 70% RH 
Then amendment on the 37th report of expert committee in October 2001 zone IV had 
been changed to be 30 °C ±2/65% RH. 
For countries where certain regions situated in zone III and IV and also with the view 
to the global market, it is recommended that stability testing program should be based 
on the conditions corresponding to climatic zone IV (WHO, 1996). 
Table (4): Mean climatic conditions; calculated and derived storage conditions: 
Calculated data Derived storage conditions Climatic 
zone Measured MKT RH °C %RH 
I 20 °C 20 °C 42% 21 45 
II 21.6 °C 22 °C 52% 25 60 
III 26.4 °C 27.9 °C 35% 30 35 
IV 26.7 °C 27.4 °C 76% 30 ± 2 65 ± 5 
USP adopted the same conditions for the above zones (USP. 2007). 
1.6.2.1.2 Harmonizing stability testing requirements on global basis:  
ICH specified for the study of zone IV, the following criteria: (Turner – 2000),- 
1- A Mean annual (temperature measured in the open air of greater than 22c°. 
2- A Mean annual temperature of greater than 24c°. 
3- A Mean annual water vapour pressure of greater than 15 mbar.  
All data from Met.O.1617 meteorological office tables of temperature, relative 
humidity and precipitation for the world (Volume I-VI) of 23 cities were chosen, the 
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data was in good agreement with Grimm original data. This validates its 
representation. The mean described by Grimm was 26.5/ 76% RH. The originally 
calculated humidity 76% is derived from the measured temperature but if it is 
calculated from MKT it will yield 73% (MKT is 27.4 °C). In turn the temperature is 
rounded up to 30 °C, the humidity dynamic with 30 mbar is assigned giving rise to 
relative humidity 71% RH which is modified to 70% RH. (Turner and Zahn, 2003). 
The study concluded that 30/65% is sufficient for zone IV countries. ICH and WHO 
agreed to state the conditions for zone IV as 30c° ± 2 / 65 ± 5% RH (WHO, 2002). 
1.6.2.1.3 Extension of ICH guideline for stability testing to zone III and IV:- 
Storage conditions were derived with 30c°/ 35% RH for climatic zone III and 
30c°/70% RH for climatic zone IV. Both conditions contain a margin of safety 
compared to calculated and measured data in warehouse. (Grimm-1998) Six months 
at 40c°/75% RH was fixed as storage conditions for accelerated testing to cover the 
extreme temperatures above 30c°and 40c° the predictive factor is 3.3 for 30c° (6 
months at 40c° corresponds to 20 months at 30c°). Extreme temperature during 
shipment could be covered by stress testing at 50c° for 3 months. In the evaluation the 
temperature difference of 10°C (40 – 30) instead of 15°C has to be considered , which 
limits shelf-life in critical cases to 18 months instead of 24 month (Grimm – 1998). 
Then ICH delivered Q1F which stated that special transportation and climatic 
conditions outside the stated store conditions should be supported by additional data, 
as for example, data obtained from one batch conducted up to 3 months  at 50 °c/ 
ambient humidity to cover the extreme hot / dry, and 25c°/80%RH to cover extreme 
humidity. Stability testing at higher humidity (80%) is recommended for solid dosage 
form in water-vapour permeable packaging e.g. tablets in PVC/ Aluminum blisters. 
Although tablets in primary container that make barrier to water –vapour (aluminum 
/Aluminum blisters) humidity is unnecessary. More protective packaging, additional 
cautionary label statement and reduction of the proposed shelf life (safety margin) 
were essential parameters to assure stability maintenance. In harmonization with 
WHO the storage conditions for long-term are agreed to be 30c° ± 2/ 65% ± 5% RH 
for zone IV. The ICH in it's QIF describes 30 ± 2c°/ 35% ± 5% for zone III which is 
already conforms to the WHO guidelines. 
WHO previously described zone IV to be 30 ± 2c°/ 70% ± 5% RH. 
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 1.6.2.1.4 ASEAN Countries Resonance:- 
Asian countries oppose this approach and Expert committee held the task and  use the 
same data used by Turner and Zahn with the check up at the WHO and used Wexler's 
equation and the dew point provided by the European Centre for medium – range 
weather forecasts. These calculations obtain the RH at 27°C as 79% RH with absolute 
humidity 0.0178kg water/kg dry air. The committee requested meteorological data 
from Asian countries and concluded that 30/75% is satisfactory condition for long 
term stability testing in zone IV, providing that 5% was the safety margin (Santoso, 
2004). On discussing Asians claims by WHO expert committee with experts from 
ICH and IPFMA, that, vast areas of climatic zone IV with climatic conditions that are 
above the average RH and temperature of QIF. The 23 chosen cities, the mean value 
is less stressful than the conditions of more than half of the selected cities. 
The climatic conditions of the cities did not represent large area of the country 
sampled. Badly conditioned storage facilities may mitigate the lower extremes of 
humidity and temperature, but not the lower ones. Storage facilities are less protective 
in developing countries especially outside cities (Dr. Lucky et, al, 2004). 
The stress conditions of Q1F, 25°C/ 80% was also opposed declaring that 40°C/75% 
is better. Substances in impermeable containers do not require testing at any specific 
conditions of humidity. The ICH in it's guidance QIF describes 30 ± 2c°/ 35% ± 5% 
for zone III which already conforms to the WHO guidelines. In 1996 WHO adopted 
the guidelines for stability testing, stating 30°C/ 70%RH as the conditions for long-
term stability testing for zone IV. In 2000 ICH proposed modifications for these 
conditions and then adopted 30°C/ 65%RH±5%RH.  Transportation conditions did 
not comply with those conditions. On the basis of these considerations, as a matter of 
principle, testing conditions should be biased towards more stressful conditions so as 
to provide a margin of safety in the favour of patient and quality. The activation 
energy Ea, WHO and ICH guidelines refer to average value of Ea is 19.8 kcal/mol 
(82.8KJ.mol -1) for calculating the MKT. The average value for ASEAN countries is 
27.7°C/ 78.99% RH while it had been calculated by WHO 26.7°C / 76% so the 
proposed conditions are:- 
Product in containers permeable to water vapour  30c°±2c°/ 78%±5%RH 
Product in containers impermeable water vapour  30c°±2c°/ unspecified RH 
Accelerated studies 40c°±2c°/ 75%±5%RH 
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Stress testing is unnecessary when accelerated studies are available. 
Real time testing will continue for at least 12 months. In October 2005, the WHO 
Expert Committee in specifications of pharmaceutical preparations recommended the 
amendment to WHO stability guidelines to split zone IV into IVa 30 °C ± 2/ 35% RH 
and IVb 30 °C/65% RH (WHO report series, 937/2000). WHO requests the members' 
states to declare applicability of conditions in their territory (IVa or IVb). (WHO, 
June 2006).  
The result is the divergence of global stability testing requirement and the initial idea 
was not supported and the harmonization conditions is not supported because the 
safety margin for medicinal products considered not adequately. (Copenhagen 
30.10.2006) 
1.6.2.1.5 EMRO Resolution: 
Testing conditions where the stability of product has 
been shown 
Recommended labeling statement 
Climatic zone I and II: long term 25c°/60%RH 
accelerated 40c°/75%RH 
Store below 30c° 
Climatic zone III and IVA: long term 30c°/ 65% RH 
accelerated 40c°/75%RH 
Store below 30c° 
Climatic zone III and IVA: long term 30c°/ 65% RH  Store and transport below 30c° 
Climatic zone I and II: long term 25c°/ 60% RH 
intermediate 30c°/65%RH 
Store below 30c° 
Climatic zone I and II: long term 25c°/ 60% RH 
accelerated 40c°/75%RH 
Store below 25c° 
5c°±3c° Store and transport in a refrigerator (2-8c°)  
-20c° ± 5c° Store in a freezer and transport frozen 
* Precautionary statement maybe added. 
Data ERA – 40 reanalysis conducted by ECMWF is a process in which global 
weather observations are assembled to form a regular mesh covering the earth with a 
resolution of about 125km. Measurements take place every 6 hours, reanalyzed 
temperatures and dew points from 1979 – 2002 were averaged into monthly means at 
00.00 UTC, 06:00 UTC, 12:00UTC and 18:00UTC (coordinated universal time). 
In this way Sudan falls into 2 zones, Zone III and zone IVA. The recommended long 
term testing condition is 30c°/65%RH. With a note that the aqueous – based solutions 
in semi-permeable packaging, and dosage form sensitive to low humidity, e.g. hard 
gelatin capsules may require testing at low humidity according to the procedure 
described in this guidance ( WHO –EMRO, 2006) 
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1.6.2.1.6 Withdrawal of ICH QIF:  
This document of ICH had been withdrawn on June 2006. It describe the stability data 
package for registration applications in climatic zone III and IV, the withdrawal was a 
consequence to the split of zone IV into IVa and IVb. However, it considered that all 
requirements for QIAR are applicable except the storage conditions. The withdrawal 
results in divergence in the global stability testing and thinking and ICH retained the 
condition for long term study as 30c°/65% as an option and more stress condition 
30c° /70% is acceptable also. (ICH, June 2006).  
1.6.2.1.7 European guidelines on stability testing of medicinal substance or 
product manufactured in zone III and IV:- 
-  Stability studies should be provided based on the length of time the product is 
at the country of manufacture, conditions 30°C / 65%. And conditions of zone 
II 25°C/ 60% based in the length of time in Europe.  
-  Temperature and humidity during transport to Europe should be accounted  
( EMEA,2004). 
1.6.2.1.8 Multinational Companies Resonance:- 
Prior to the concept of globalization of stability testing storage conditions, terms as 
22°C, 20°C , 25 °C , 30 °C were used by the pharmaceuticals manufactures, with 
variable humidity. International companies generally select the most stringent 
conditions for testing, then incurring financial penalties of shorter shelf lives or more 
expansive packaging when these were not needed for local markets. The WHO efforts 
were unnecessary duplication of the ICH efforts. This leads to divergence rather than 
convergence of requirements.  Both guidelines refer to climatic zone and MKT 
approaches. For the global market it is recommended that stability testing programs 
be based on the conditions corresponding to WHO climatic zone IV, it is relevant to 
revisit the basic premises on which the constant conditions are based. 
The meteorological data obtained from external measures, and the pharmaceuticals 
are retained and stored internally. Usually assumption is made that warehouses and 
pharmacies have some degree of heating, hence an up-ward adjustment is made. But 
never consider the impact of air conditioning within these facilities. The factor of the 
absolute humidity increases as the temperature decreases was not considered in the 
ASEAN guideline. 
The ICH recommended 30°C/ 60% - changed to 65%, to be used as intermediate 
conditions if significant changes occur, accelerated conditions of 40°C/75%. Why 
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data generated at 30°C/ 65% are unacceptable as a measure of impacts of storage 
conditions in hot and humid countries in a localized environment offering no 
protection measures from the external climate? Would unsatisfactory storage 
conditions at 30°C/ 65% result in the product not being approved as medicine being 
denied to patient population? (Terry,1998). Would storage below 25 °C be required? 
If so, how could this be ensured? If labeling to store below25 °C is required what is 
the relevance of having requirement to test long term at 30 °C? 
1.6.2.2 Testing conditions: 
1.6.2.2.1 WHO Testing Conditions 
Zone I and II Zone III and IV 
Study 
Condition Duration Condition Duration 
Accelerated 40 °C ± 2 / 75% RH ± 5% 3 months 
40 °C ± 2 / 75% RH ± 
5% 
6 months 
Intermediate 30 °C ± 2 / 65% RH ± 5% 6 months   
Long term 25 °C ± 2 / 60% RH ± 5% Shelf-life 
30 °C ± 2 / 65% RH ± 
5% 
Shelf-life 
Store at 15 °C above the storage temperature for 6 months is accepted. 
45-50 °C / 75% for 3 months may also be recommended 
Zone Conditions Duration 
IVA 30c° ± 2/ 65% ± 5% RH 12 months 
IVB 30c° ± 2/ 75% ± 5% RH 12 months 
1.6.2.2.2 Asian Testing conditions: 
a- New Entity:-  
Study Storage conditions Duration Number of batches 
Real time 30c°±2c°/ 75%±5%RH 12 months 3 batches 
Accelerated 40c°±2c°/ 75%±5%RH 6 months 3 batches 
b- Generics and variations:- 
Study Storage conditions Duration Number of batches 
Real time 30c°±2c°/ 
75%±5%RH 
12 months 2 batches for stable product 
3 batches for critical or unstable product 
Accelerated 40c°±2c°/ 
75%±5%RH 
6 months  2 batches 
No specification for humidity for product in impermeable container. 
Adopt matrixing and bracketing. 
Freezing conditions, real time is – 20c°±5c° for 12 months. 
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1.6.2.2.3 ICH Testing Conditions: 
 a- General case: 
Storage condition Study 
Temperature C° RH% 
Duration 
Long-term 25C°±2C° 
or 
30C°±2C° 
60%±5% 
or 
65%±5% 
12 months 
Intermediate 30C°±2C° 65%±5% 6 months 
Accelerated 40C°±2C° 75%±5% 6 months 
• Stability testing of the drug product after reconstitution or dilution should be 
conducted, to provide the in-use period; this could be done initially and at the end 
of the study. 
• Intermediate testing maybe conducted if using 25C°/60% RH and the accelerated 
testing show significant changes at any time during 6 months. 
• For drugs intended to be used in zone III and IV, an intermediate testing is 
required (QIF), and long term conducted at 30C°±2/65%±5%. 
1.6.2.2.4 ICH Significant Changes: 
1- A 5% change in assay from its initial value; or failure to meet the acceptance 
criteria for potency. 
2- Any degradation products exceeding the acceptance criteria. 
3- Failure to meet the acceptance criterion for appearance, physical attributes and 
functionality test (colour, phase separation, resuspendability, caking, hardness, and 
dose delivery). 
4- Failure to meet the acceptance criteria for PH. 
5- Failure to meet the acceptance criteria for dissolution of 12 units.  
b- Drug product in impermeable container: 
Stability study could be conducted at ambient humidity. 
c- Drug product packed in semi-permeable container:   
Aqueous-based products should be evaluated for water loss. 
Condition Study 
Temperature °C RH% 
Minimum period 
Long term 25C°±2 °C 
(QIF) 30 °C ± 2 °C 
40%±5% 
35%±5% 
12 months 
Accelerated 40C°±2C° Not more than 25%±5% 6 months 
If 30 °C ± 2/35% ± 5%, no intermediate testing is required because intermediate is 30 
°C ± 2/65% ± 5%. 
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• Significant change in water loss in accelerated storage condition does not 
necessitate intermediate testing. 
• 5% water loss from an initial value is considered a significant change in a product 
in a semi permeable container after 3 months storage at 40c°/NMT 25% unless the 
container is 1ml or less. 
d-  Drug products intended for storage in a refrigerator:- 
Study Conditions Duration 
Long term 5 °C ± 3 °C 12 months 
Accelerated 25 °C ± 2 °C/60% ± 5% RH 6 months 
• If significant changes occur between 3- 6 months at the accelerated study the 
proposed shelf life should be based on the real time data. 
e-  Drugs products intended to be stored in a freezer:- 
Only long term study in storage condition – 20c°±5c° for 12 months. 
f-  Drug products intended for storage below - 20c°:- 
 This should be treated in a case- by- case basis. 
1.6.2.3 Frequencies of testing:  
1.6.2.3.1 WHO Frequencies of testing: 
Study Frequencies in months 
Accelerated 0,   1,   2,   3,   6 
Real time 0,   6,   12,   24,   36,   48,   60 
On-going Every 6 months for confirmation of shelf-life 
Highly stable 12 months, and then after the end of shelf-life 
Less stable 0,   3,  9,   12,   18,   24,   36,   46,   60 
1.6.2.3.2 ICH Frequencies of testing: 
 Study  Testing frequency in months 
Long term 0,3,6,12,18,24 then every 12 month throughout the shelf-life 
Intermediate 0,6,9,12 
Accelerated 0,3,6 
1.6.2.3 Sampling: 
1.6.2.3.1 WHO Sampling: 
1. For products containing fairly stable substances, samples should be taken from 
two production batches. 
2. For products containing substances unknown stability substances, samples 
were taken from three production batches. 
3. Batches may be from pilot scale or full production scale. 
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4. It is better that batches were manufactured from different batches of API. 
5.      For on-going studies, one batch every other year for stable substances, otherwise 
one batch yearly. One batch every 2-3 years for products of well established stability. 
1.6. 2.3.2 ICH Selection of Batches: 
i- Data should be provided from 3 primary batches one of them may be smaller. 
Formulation in the same closure- container as proposed for the market. When 
possible, manufactured from three different batches of drug substance. Matrixing and 
Bracketing can be applied. 
ii- Container- closure- system should be that intended for marketing including any 
secondary packaging and label.  
1.6.2.4 Labelling: WHO guidelines stated that, storage conditions should be stated on 
the label and other precautionary statements. 
ICH Statement/ labeling:  Specific instructions should be provided. Terms such as 
"ambient condition" or room temperature should be avoided. There should be direct 
link between the label storage conditions and demonstrated stability of the product. 
Statements for precautions could be added. 
-  Store below 30c°: normal storage conditions. 
-  Store below 25c°: controlled air conditioning. 
-  Store between 2 – 8c°: refrigeration without freezing. 
-  Store below 8c°: refrigeration. 
-  Store between -5c° - 0c°: freezer. 
-  Store below -18c°: deep freezer 
1.6.2.5 Testing Attributes: 
1.6.2.5.1 WHO analytical parameters: 
 Information should include physical, chemical, biological and microbiological test 
characteristics. Assay value, degradation content, hardness, and disintegration, 
particulate matter should be determined. For solids and semisolids oral dosage form, 
dissolution tests should be carried out. Preservative should be assayed. Appropriate 
validation and precision of reasonable standard deviation should be recorded. The 
assay should be indicative. 
1.6.2.5.2 ICH Q6A Specifications for New Drug Product: The ICH established the 
Q6A document for specification at 6/10/99; describing the test procedures and 
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acceptance criteria for new drug substance and new drug products for chemical 
substances. The ICH document stated that; references to certain procedures are found 
in the pharmacopoeias, where ever they are appropriate, pharmacopoeial procedures 
should be utilized. Impurities test on drug substance is not necessary to be tested on 
the drug product only those proposed to generate on degradation. (Q6A - ICH/1999). 
A specific stability – indicating procedure should be induced to determine the content. 
In many cases it is possible to employ the same procedure (e.g. HPLC) for both assay 
and quantification of impurities. Method used for content uniformity is also 
appropriate as assays (Q6A – ICH). 
 1.6.2.5.2.1 Universal tests;- 
1- Description: includes a- definition b- shape c- colour d- size. 
2- Identification. 
3-  Assay.        4-  Impurities, which should be specified. 
1.6.2.5.2.2 Tests for Tablets:- 
1- Dissolution: It could be replaced by disintegration in some cases. 
2- Disintegration: For rapidly dissolving products (dissolution > 80% in 15 minutes at 
pH 1.2-4-6.8) containing drugs which are highly soluble throughout the physiological 
range (dose / solubility volume < 250ml at PH 1.2-6.8) 
3-  Hardness/ Friability. 
4-  Test for Uniformity of dosage units, this includes both: mass of the dosage form 
and content of the active ingredient. The specification should include one of them. 
5-  Water content: Karl Fisher titration is performed. 
6-  Microbial test: microbial test is seen as an attribute of good manufacturing 
practice as well as quality assurance. Pharmacopoeial procedures should be used, 
with acceptable scientific justification; it should be possible to propose no 
microbial limit testing for solid oral dosage forms. 
1.6.2.5.2.3 Oral liquids and powders intended to be reconstituted:- 
1- Uniformity of dosage units: Mass or content, one of them should be 
performed. The dose used should be typical to that used by the patients. 
2- PH. 
3- Microbial limit; with acceptable scientific justification, maybe proposed to 
provide no microbial limit testing for powders intended for reconstitution as 
oral liquid. 
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4- Test for Antimicrobial preservative content:  This could be through chemical 
determination or by the antimicrobial effectiveness. 
5-  Antioxidant and preservative content may be unnecessary in stability testing if 
justified. 
6-  Extractables. 
7-  Alcohol content: if stated. 
8-  Dissolution for oral suspension. 
9-  Particle size distribution: it maybe performed as in process test. 
10-  Redispersibility:-shaking maybe appropriate procedure "time required to 
achieve suspension (for really suspension). 
11-  Rheological properties: elimination of this attribute maybe proposed. 
12-  Water content: for powders for suspension. 
13-  Reconstitution time: for dry powder which is required to be reconstituted. 
1.6.2.5.2.4 Parenteral drug product: 
1-  Uniformity of dosage units. 
2-  PH. 
3-  Sterility. 
4-  Endotoxin/ pyrogens: it specifics (LAL) test pyrogencity. 
5-  Particulate matter. 
6-  Antimicrobial preservative content.  
7- Antioxidant preservative content 
8- Water content 
9- Extractables  
10- Functionality testing for delivery systems 
 - Syringeability, pressure, leakage, tip-cap removal force. 
 - Piston release force, piston travel force, injector function force. 
11- Osmolarity: the tonicity should be specified. 
12- Particle size distribution 
13- Redispersibility 
14- Reconstitution time 
The other dosage forms are included such as inhalation and nasal aerosols, nasal 
sprays, topical, ophthalmic and otic preparations. Suppositories and drug admixtures, 
transdermal preparations and freeze dried products. 
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1.6.2.6 Evaluation of Results:  
1.6.2.6.1 WHO Evaluation of results: 
Results are considered to be positive if none of the following significant changes took 
place: 
1. The assay value shows 5% decrease as compared with the initial value. 
2. Product exceeds the specified limits. 
3. The pH limit is no longer met. 
4. The specification of dissolution of 12 capsules or tablets is no longer met. 
5. The specifications for appearance and physical properties, colour, phase 
separations, caking, hardness are no longer met. 
As a rule accelerated studies are not suitable for semisolid and heterogeneous 
preparations.  
1.6.2.6.2 ICH QIE Evaluation: 
 The purpose of stability testing based on 3 batches is to establish the shelf life and 
label instructions for the product. Where the data show so little degradation and so 
little variability between batches, the requested shelf-life will be granted. An approach 
for analyzing data of quantitative attribute that change with time, is to determine the 
time at which 95% one-sided confidence limit for the mean curve intersected the 
acceptance criterion. June 2004 "Evaluation of Data" 
I- The parent guidance states that regression analysis is an appropriate approach to 
analyzing quantitative stability data for retest period or shelf life. It recommends that 
statistical test for batch poolability should be performed using level of significance of 
0.25. 
*If the assay values of the batches used to support the registration are higher than 
100% of label claim, the shelf life can be over estimated than the proposed in the 
application and vice versa for values below 100%. 
* In general, certain quantitative chemical attributes can be assumed to follow zero- 
order kinetics during long term storage – ( Carstensen, 1977 ). 
II- Data evaluation for retest or shelf life estimation for drug substance or drug 
product intended for room temperature storage conditions:- 
* Long- term and accelerated data showing little or no changes over time and little or 
no variability between batches, in this case no statistical analysis is required. The 
shelf life can be up to twice as long, but not more than 12 months, the period covered 
by long term data. 
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* Long – term data change overtime and/or variability took place, and when long term 
data are not amendable to statistical analysis, the shelf life can be the period covered 
by long term data but not more 6 months.            
1.6.2.6.3 Asian Evaluation:- 
* In general, quantitative chemical attributes (assay) of drug product can be assumed 
to follow zero-order of kinetic during long term storage. 
* Regression analysis is considered to be an appropriate approach to evaluating 
stability data for quantitative attribute and establishing a shelf –life. 
* Analyze quantitative attribute by determining the earliest time at which 95% 
confidence limit for the mean around the regression curve intersects the proposed 
criteriona. If it is inappropriate to combine data from several batches, the overall 
shelf-life should be based on the minimum time. 
* This approach can be used to estimate shelf-life for a single batch. 
* In order to firmly establish the shelf-life, the long term study should be conducted to 
at least the minimum production batches and covering the proposed shelf-life. Asian 
Significant changes are those of the ICH. It is unnecessary to continue accelerated 
stability if significant changes occur within 3 months. 
1.6.2.7  WHO Shelf-life and recommended storage conditions: 
*Shelf-life is always determined in relation to storage conditions. 
*The shelf-life proposed should not exceed twice the period covered by the real time 
studies. 
*A tentative shelf-life of 24 months may be established if the product known to be 
stable or other similar preparations are given 24 months and no significant changes 
during accelerated study, provided that manufacturer will continue real test studies. 
1.6.2.8 Stability of drug substances and drug product; FDA: 
The FDA guidelines are the same as ICH in all aspects. It states in section 5-B-250; 
the storage condition of high humidity applies only to solid dosage forms, for drug 
product in solutions or suspensions contained in packs designed to provide permanent 
barrier to water loss, specific storage conditions of high humidity is unnecessary, but 
the same range of temperature should be applied. Low relative humidity 10-20%RH 
can adversely affect products packed in semi permeable containers. 
Section (B-6-a-320-343) stability storage conditions for drug product in semi 
permeable or permeable containers: this includes large and small volume parenterals, 
ophthalmic, otic and nasal preparations packed in plastic bags, semi-rigid plastic 
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containers, ampoules, vials and bottles which may be susceptible to water loss, the 
recommended storage conditions are: Accelerated: 40c°±2c° /15%±5%RH, 
Intermediate: 30c°± / 40%RH, 
 and for the long term: 25c°±2c°/ 40%±5%RH. 
For liquid in glass containers, vials, ampoules which provide barrier to water loss, the 
ambient humidity could be used, temperatures is as above. It states in section VIII. 
Page 80- line 2554 considerations for specific dosage form: 
 
Dosage form Tests 
A- Tablets Appearance/ odour/ colour/ assay/ degradation products/ dissolution/ moisture 
/friability> 
B- Capsules Appearance/ odour/ colour/ assay/ degradation products/ dissolution/ moisture / 
microbial limits. 
E- Oral powder for 
reconstitution 
Appearance/ odour/ colour/ assay/ degradation products/ moisture 
reconstitution and redispersibility. 
L. Small volume 
parenterals 
Appearance/ odour/ colour/ assay/ degradation products/ PH Preservative/ 
particulate matter/ sterility and pyrogensity. 
 
1.6.2.9 Stability testing for Australia: 
 Australia adopted the guidelines of EU, and in turn this lead to adoption of 
ICH guidelines. It adopts the MKT approach defining it as best method available for 
taking account of temperature variations in a given environment, such as warehouse. 
The continent of Australia should not be considered as one zone because the four 
zones fall into different part of Australia (Walters, 1999). The argument is the WHO 
statement for countries where certain regions are situated in zone III and IV, (1996-
WHO) and also with a view of global market, it is recommended that stability testing 
programs should be based on the conditions corresponding to zone IV. In the case of 
Australia currently acceptable storage conditions for labeling include. "Store below 
25c°" for air conditioned premises and "store below 30c°" for non-air-conditioned 
ones but 30c° is more practical, because not all premises have air-conditions (Walters, 
1999). 
1.6.2.10 WHO – Eastern Mediterranean Regional Office EMRO: 
 The Regional Guideline (Stability testing of active substance and 
pharmaceutical products – draft 2.0, 19 April 2006)  was adopted by Regional 
Committee on the resolution EM/RC 53/ R, 12 dated September 2006, and requesting 
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the members state to revise their registration guidelines to be consistent with this 
guidelines. The resolution also requested the director – general to revise the global 
WHO stability guideline taking into consideration the regional guideline. It also 
requested the regional director to continue efforts in the area of harmonization in the 
technical registration. 
• The scope of the guideline is to be submitted to new entities as well as for the 
existing products and substances. 
• The purpose of stability testing is to provide evidence on how the quality of an 
active substance or pharmaceutical product varies with time under the influence of 
a variety of environmental factors such as temperature, humidity and light. In 
addition, product related factors influence the stability. 
• The climatic data of the member states is extracted from ERA – 40 reanalysis of 
ECMWF. 
• MKT was adopted and being obtained from the data above. 
The guideline was divided into two sections, for drug substance and pharmaceutical 
product, with glossary and Annexes. 
1.6.2.10.1 Pharmaceutical Product: 
• Selection of batches, Container closure system, Specifications, Testing Frequency, 
Storage conditions, General case storage conditions, Significant changes, 
Pharmaceutical products packed in impermeable containers, Pharmaceutical 
products packed in semipermeable containers, Commitment, Evaluation were all 
the same as ICH. 
Test the thermal stability, sensitivity to moisture and solvent loss.  Conditions should 
cover the storage, shipment and use with regard to climatic zone which the product is 
intended to be marketed. 
As a part of development the stability conducted in one batch for up to 3 months at 
50c° / ambient humidity maybe useful. 
• Photostability should be conducted on one primary batch. 
• Reconstituted product should be tested at the initial and the end points. 
• Statement/ labeling: ambient conditions or room temperature should be avoided. 
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1.6.2.10.2 EMRO Testing Parameters:- 
Dosage form Parameters 
Tablets Dissolution and if justified disintegration, water content, 
hardness/friability. 
Powder for suspension Water content, reconstitution time. 
Small value parentrals Colour, clarity, particulate mater, PH, sterility, Endotoxins.  
Large value parentrals  Colour, particulate matter, clarity, PH, sterility, Endotoxins. 
For all dosage forms:- 
• Appearance, assay and degradation product. 
• Preservative content and antioxidant if applicable. 
• Listed testing may be conducted at the beginning and at the end of study 
particularly sterility together with the microbiological contamination for liquid in 
plastic container. 
1.6.3 Pharmacopoeial Requirements for the specified tests:   
1.6.3.1 Requirements for tablets: –  
1.6.3.1.1 B.P. 2007 Requirements for tablets: 
Volume III, formulated preparations, general monograph, defines the tablets 
requirements according to PhEu monograph 0478. The tests are: 
1. Friability: For uncoated tablets. 
 (BP 2007, volume IV, Appendix XVIIG, PhEur. 2.9.8): 
This test is for uncoated tablets. 
2- Resistance to crushing (BP 2007, volume IV, Appendix XVIIH, PhEu. Method 2.9.7) 
It is the force required to when applied diametrically causes tablet fracture. Apply the 
test for 10 tablets, express the results as minimum, maximum and mean for forces 
measured in Newtons. Erweaka was described in BPC. 
3- Uniformity of mass: The test is not required if the uniformity of content is 
indicated (BP 2007, volume IV, Appendix XIIG, PhEu. Method 2.9.5) as the BPC 
requirements, table (2.9-5-1). 
When the average mass is 40 mg or less, the preparation is submitted to uniformity of 
content but not uniformity of mass 
20 tablets are weighed, the mean is obtained, and not more than two tablets are 
permitted to deviate from the mean by more than the percentage below and no tablet 
deviate from the mean by double this percentage. 
Table (2.9.5-1): For uncoated and film coated tablets  
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Average weight of tablet Percentage deviation 
80 mg or less 
More than80 mg and less than250 mg 
250 mg or more 
10 
7.5 
5 
4- Uniformity of content (BP 2007, volume IV, App. XIIH, PhEu method 2.9.6) 
The test may not be required in justified or authorized circumstances. 10 tablets are 
assayed individually, the average is obtained. 
• All tablets should be 85-115% of the average to comply the test. 
• The test failed if more than one tablet is outside this limit or if one tablet is 
outside 125-75%. 
If one tablet falls within 127-75% but outside 85-115, another 20 tablets are assayed, 
no more are outside 85-115% to comply the test  
• When the active substance constitutes the bulk of the tablet the uniformity of weight 
replace this test and when the drug is not that potent and did not require dilution 
before taking, the uniformity of weight can replace this test; otherwise, 10 tablets are 
assayed individually. 
• Not more than one tablet fall outside the range of 85%-115% of the average value or 
if no tablet outside 75%-125%. 
• If one tablet is outside 85%-115%, another 20 tablets will be assayed and no more 
tablets outside this range should be found. 
• The test should be applied to all tablets having drug content of less than 2 mg or when 
the active ingredient comprises less than2% of the tablet total weight. 
• Other criteria, 30 tablets are sampled, 10 tablets are assayed, if one tablet outside 85-
115% but within 125-75 and the relative standard deviation is more the 6%, the 
remaining 20 tablets are assayed and no more tablet should fall outside 85-115% and 
the standard deviation 7.8% is now permitted. 
5- Disintegration: (BP 2007, volume IV, Appendix XIIA, PhEu. Method 2.9.1): For 
film coated tablets, place a tablet in each tube, use water or 0.1M HCl, operate the 
apparatus for 30 minutes if any of the tablets did not disintegrated, repeat for another 
6 tablets, replacing water by 0.1M HCl. 
If 1 or 2 tablets fail to disintegrate, repeat the test on another 12 tablets, the 
requirements is met if not less than16 of the 18 tablets, have disintegrated. 
6- Dissolution (BP 2007, volume IV, Appendix XIID, PhEu. Method 2.9.3): 
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The test describes four types of apparatus 
1. Basket apparatus 
2. Paddle apparatus 
3. Reciprocating cylinder 
4. Flow through cell. 
For apparatus 1 and 2 apparatus, used, one tablet is placed in the defined medium at 
37 °C ± 0.5°C. The requirements were met if the quantities of the active substance 
conform to table 2.9.3-1 (Q: is the amount of substance dissolved specified in the 
individual monograph. 
Level Number 
tested 
Acceptance criteria 
S1 6 Each unit is not less than Q + 5% 
S2 6 Average of 12 units (S1+S2) is equal or greater than Q, and no unit is less than 
Q+15% 
S3 12 Average of 24 units (S1+S2+S3) is equal to or greater than Q. not more than 2 
units are less than Q-15%, and No is less than Q-25% 
 
The BP specified the time as 45 minutes, the amount of the active substance is not 
less than 70% of the labelled amount if one failed, another 6 tablets should comply. 
Medium: In general an aqueous medium is used. The composition of the medium 
should be chosen on the basis of the physiochemical characteristics of the substances 
within the range of conditions to which the dosage form is likely to be exposed after 
administration. This applied in particular to pH and ionic strength. 
In specific cases the dissolution medium may contain enzyme, surfactants further 
organic or inorganic substance. 
The volume of media is 500-1000 ml. the stirring speed is 50-100 r/min. it must not 
exceed 150 r/min. 
Recommended dissolution media: 
- Hydrochloric acid media 
- Acetate buffer solutions 
- Phosphate buffer solutions 
- Orthophosphate buffer fluid pH 6.8 
- Artificial gastric juice 
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7- Microbiological quality (BP 2007, volume IV, Appendix XVID, PhEu. General text 5.1.4): 
1. Total viable aerobic count: Not more than 103 bacteria and not more than 102 
fungi/gm. 
2. Absence of E. coli 
Preparations for oral administration, Preparations containing materials of natural 
origin should contain not more than 104 bacteria and not more than 102 fungi and not 
more than10² Enterobactericeae and other gram-negative bacteria. 
- Absence of Salmonella,  E. coli and absence of Staphylococcus aureus 
 Content of the active ingredient: 
20 tablets are crushed and the content is determined and then obtains the mean. The 
variation is controlled by uniformity of weight. 
The BP provides an allowance table for the content of the active ingredient (Tablets of 
the BP volume IV) for limit of 90-110% 
Subtract from the lower limit for 
samples of 
Add to the upper limit for 
samples of 
Weight of active ingredient in 
each tablet 
15 10 5 15 10 5 
120 mg or less 0.2 0.7 1.6 0.3 0.8 1.8 
More than120 mg and less 
than 300 mg 
0.2 0.5 1.2 0.3 0.6 1.5 
300 mg and more 0.1 0.2 0.8 0.2 0.4 1 
1.6.3.1.2 USP 8/2007 Requirements for tablets:  (General chapter <1151>)  
1- Uniformity of dosage unit: weight variation is applied where the active ingredient 
comprises a major portion of the tablet and where control of weight may be presumed 
to be an adequate control of drug contents uniformity. Weight variation is not an 
adequate indication of content uniformity where the drug substance comprises a 
minor part of the tablet is sugar-coated. Coated tablets or tablets containing less than 
50 mg or less of active ingredient, comprising less than 50% by weight of dosage unit 
passes a content uniformity. <905> uniformity of dosage form may be through weight 
variation or content uniformity. 
Application of content uniformity CU and weight variation WV for dosage forms 
Dose and ratio of drug substance Dosage 
form 
Type Subtype ≥ 25 mg and ≥ 25% < 25 mg or < 25% 
uncoated  WV CU 
Film WV CU Tablets 
coated 
others CU CU 
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2- Disintegration (USP 8/2007,General chapters <701>): 
It is harmonized with the Ph.Eur. 
3- Dissolution (USP 8/2007) General chapter <711>): 
This test was harmonized with Ph.Eur. 
4- Microbiological examination of non-sterile products: Acceptance criteria for 
pharmaceutical preparations (USP 8.2007, General chapters <1111>): 
The acceptance criteria for microbiological quality for preparations nonaqueous for 
oral use were as follows: 
• Total aerobic microbial count 103 cfu = 2000 cfu/ml or gm. 
• Total yeast and mould count 102 cfu = 200 cfu/ml or gm 
• Absence of E. coli (1 gm or 1 ml). 
1.6.3.2 Requirements for Oral powder intended to be reconstituted: 
1.6.3.2.1 BP 2007 Requirements: volume III, formulated preparations, general 
chapters, Ph.Eur (0672) requirements: 
• During development of oral powders intended for oral suspension that 
containing preservative, the effect of antimicrobial preservation is evaluated. 
• During development, manufacturing, packaging, storage and distribution, it is 
recommended on this aspect to consider microbiological quality of the 
pharmaceutical preparations which pointed out that the total viable count of 
less than 103 cfu/gm for bacterial and less than 102 cfu/gm for fungi and 
absence of E. coli. 
• Uniformity of content and uniformity of mass are nominated for single dose. 
• Powders for suspension should comply with the requirements for oral powders 
(BP 2007, oral powders, general Notice Ph.Eur monograph 1165) which 
specify the tests of uniformity of mass of delivered dose from multidose 
container (Monograph 2.9.27), App. XIIL: Weigh individually 20 doses taken 
at random from one or two containers with the measuring device and 
determine the average mass from the individual masses. Not more than 2 of 
the individual masses deviate from the average by more than 10% and non-
deviates by 20% from the average. 
Labelling:  
1. The label states the method of preparation of suspension. 
2. The label states the conditions and duration of storage after constitution. 
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1.6.3.2.2 USP requirements:  
USP also requires uniformity of dosage form test for single dose containers. 
USP: 8/2007, general chapters <698>. Deliverable volume: 
The deliverable volume from multidose container was not indicated for article packed 
in a single unit container when the monograph indicates uniformity of dosage unit 
test. Take 10 containers, add the accurately measured volume of the diluents indicated 
in the label, shake each container well. Pour the content of each container into 
calibrated measuring cylinder and allow to drain for 30 minutes, measure the volume 
of each and obtain the average volume (AV). 
Acceptance criteria: 
1- If AV is less than 100% of the labelled volume and one container is less than 95% 
of the AV, the product failed the test. 
2- If the AV is less than 100% and no container less than 95%, another 20 bottles 
should be tested and take the AV of 30 bottles, if it is less than100%, it failed. 
3- If the AV of 30 containers is not less than 100% and the volume of not more than 
one container is less than 95% but not less than 90%, it passes the test but 
otherwise failed. 
4- If the AV of 10 containers is not less 100% and no container less than 95%, it 
passes the test. 
5- If the AV of 10 containers is not less than 100% and volume of one or more 
containers are not less than 95%, if the volume of more than one container were 
less than 95%, it failed the test, but, if only one container is less than 95% and not 
less than 90%, take an other 20 containers and proceed as before.  
Stability of the resultant suspension: 
The stability of suspension is a balance between flocculation and deflocculation, 
disturbed by small change in pH, temperature, electrolyte and polymer concentration 
and the additives. Suspensions are adversely affected by both high and low 
temperature. Cold environment can cause aggregation and crystal formation. 
Fluctuation in temperature causes crystal growth that the soluble small quantities will 
recrystallize on larger particles (Oswald Ripening). 
Evaluation of suspension stability: 
Measurement of sedimentation volume is preformed by placing the thoroughly mixed 
suspension in a cylinder and measuring the sediment volume at appropriate intervals 
V. The initial volume is V0; on plotting V/V0 against time. Zero slopes indicate the 
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sedimentation is zero and the system is very stable, while large negative slope 
indicates that the sedimentation is rapid and hence it is not possible to measure 
accurate dose. On other approach it is to apply standard shakes and take the number of 
shakes required for reconstitution. 
1.6.3.3 Requirements for Parenterals: 
• Stability testing for parenterals containing preservatives it is recommended to evaluate 
the antimicrobial efficacy initially and at the end of the study. 
• Test for particulate matter is necessary to ensure that particles are not generated 
during storage or precipitation. Sterility testing and particulate matter tests are applied 
specifically to parenteral product stability testing (BPC parameters pp. 107-113). 
Other chemical and physical tests are included in the protocol. 
• PH, chemical assay, degrade assay, test like fill volume, specific gravity, excipient 
concentration other than preservative and antioxidants are not needed to be performed 
as a part of stability study. 
• The BPC specifies 0.5% as a normal limit for individual degrade and 2% for the total 
degrades and this varies from one product to another according to toxicity. 
1.6.3.3.1 BP 2007 requirements: (volume III, formulated preparations, general 
monograph, parenteral product, Ph.Eur. (0521)).  
1- Particulate contamination: (Appendix XVIA, Ph.Eur. 2.9.1.9) sub-visible 
particles. The BP adopts two methods for determination of particulate matter, light 
obstruction count test and the microscopic count test. Preparation of reduced clarity 
and increased viscosity should be tested by microscopic method. For preparations 
supplied in 100 ml or less when applying the microscopic method, it should comply 
with criteria 2B which stated that the average number of particles in the limit tested 
should not exceed 3000 particulate matter per container equal to or greater than 10 
µm and does not exceed 300 particulate matter per container equal to or greater than 
25 µm. 
2- Sterility test: (Appendix XVI A, Ph.Eur 2.6.1): 
The requirement specifies the conditions of performing the test and specifies fluid 
thioglycolate medium to be used for anaerobic bacteria and Soya bean Casein 
Medium for aerobic bacteria and fungi. The period of incubation is 14 days. The test 
is validated by growth promotion test by incubation of small number of viable 
microorganism not more than (100 cfu) added to the final portion of the sterile diluent 
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to rinse the filter, using the technique of membrane filtration of 0.45 µm. No growth 
should occur. 
3- Uniformity of content: 
This test is applied for single-dose suspensions of active constituent less than 2 mg or 
less than 2% of the total mass. 
4-Bacterial Endotoxins  (Ap. XIV C LAL test; Ph.Eur. 2.6.14.)  
Harmonised with USP and Japanese: 
It is used to detect or quantify Endotoxins of gram-negative bacterial origin using 
Amoebocyte lysate from horse crab. There are three techniques, Gel-clot technique, 
turbimetric technique and the chromogenic technique. Six methods using these three 
techniques are defined of which is the gel-clot method, limit test. The BP indicates 
that the final decision is based on this method. 
A-Gel-clot techniques: (App. XIVC: LAL Test collaborated with the Japanese 
pharmacopoeia and USP). 
The test is used to detect or quantify the endotoxins of gram-negative bacteria using 
ameobocyte lysate from horse crab. The glassware and all tubes and apparatus should 
be endotoxin free by exposing on hot-air oven at 250 °C for 60 minutes. One 
international unit equals one endotoxin unit. The sensitivity of LAL reagent is 
confirmed by preparing 4 dilutions 2λ, 0.5 λ , λ, 0.25λ. where λ is the labelled 
sensitivity. Prepare a series of two fold standard endotoxin reference standard. 
On carrying out the test, the tested preparation is diluted with water for bacterial 
endotoxin test (BET)) to prepare the maximum valid dilution (MVD). MVD = 
Endotoxin limit X concentration of test solution/ λ. Where λ is the labelled sensitivity. 
The endotoxin limit is specified in the monograph and it is equal K/M where K is the 
threshold pyrogenic dose of endotoxin per kg body weight and M is the maximum 
dose of product per kg body weight. 
B- Limit test: 
Prepare the following solutions, to which the reagent is added: 
(Table 2.6.14-2) 
Solution Endotoxin concn/solution to which End is added replicate 
A None/diluted sample solution 2 
B 2 λ /diluted sample solution 2 
C 2 λ /LAl reagent water 2 
D None/LAl reagent water 2 
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A and B are not more than MVD. They are product positive controls. B, C are 
positive controls, D is negative control. 
C-Interpretation: 
• The test is not valid unless B and C are positive and D is negative. 
• The preparation being examined complies with the test when a negative result 
is found for both replicates of A. 
• When positive results is found for both replicates of A 
If the preparation is diluted to MVD, it did not pass the test. 
If the preparation is diluted to less than MVD, the test is repeated at a dilution 
not greater than MVD. 
1.6.3.3.2 USP: 8/2007 Requirements: (Injection, General Chapter <1> ) 
 1-Particulate matter: microscopic method 
  ≥ 10 µm ≥ 25 µm 
100 ml or less Small volume parenterals 3000 300 per container 
More than 100 ml Large volume parenterals 12 2 per ml 
 
2- Bacterial Endotoxin test: Harmonized with Eur and paper. 
The USP adopted either pyrogen test or the bacterial endotoxin test. 
 
3- Sterility testing: 
Media used are fluid thioglycolate media for anaerobic bacteria, Soya bean-Casein 
digest media for fungi and aerobic bacteria and fungi. Incubation for 14 days, no 
growth should be observed and the validation that had been inculcated by specific 
organism, growth should occur. 
Minimum quantity to be used for each media is, 1 ml the whole container should be 
used, and if not greater than 100 ml use 20 ml, use membrane filters 0.45 µm. 
For oily solution the USP specify that it may be filtered undiluted through dry 
membrane. 
Recommended added volume to injections: 
For 1 ml, for viscous liquids, recommended to add 0.15 ml 
For more than 50 ml add 2% of the volume. 
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3. Objectives: 
 
Various drug products in various packaging materials are imported from many 
sources to the Sudan, where different climatic conditions existing. 
Medicines are distributed centrally to all parts of the country in indefinite 
transportation conditions and stored in unknown conditions. 
What are the transportation conditions of medicines in Sudan? What are the storage 
conditions? Are these conditions similar to those internationally reported? To what 
extend can medicines withstand these conditions? What is the role container closure 
system in the stability of the selected drug products? 
The study is focusing on the following objectives:  
 
2.1 To measure and calculate the transportation and storage conditions of 
Sudan and to design an appropriate transportation and storage 
conditions to facilitate the stability of drugs to preserve safety and 
efficacy. 
2.2 To investigate the stability of the selected drugs on the real 
transportation and storage conditions of Sudan. 
2.3 To measure the compliance of the real storage condition with that of 
the international ones, comparing the mean kinetic temperature and 
estimating the shelf-lives according to the obtained data. 
2.4     To recommend an appropriate packaging material for the different drug 
products utilized in this study to withstand the real conditions of 
Sudan. 
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3. Materials and Methods 
3.1 Materials:  
3.1.1. Samples:  
The nominated medicinal products are selected according the prevalence of diseases, 
suspected instability and new products of unavailable practical stability information. 
 Samples are randomly selected and could be described as follows:  
1-Amoxicillin trihydrate powder for 125mg/5ml oral suspension.  
Manufactured and donated by ……., lot no. 0906317, date of manufacture 6/06, 
expiration date 6/08, contained in amber glass bottle with aluminum cap and packed 
in a carton of 50 bottles. 
2- Amoxicillin trihydrate powder for 125mg/5ml oral suspension.  
Manufactured by ……., India donated by CMS lot. No.1620526 manufactured in 
6.05, expiration at 9/07, contained in amber glass bottles with plastic closure cap and 
packed in carton of 50 bottles.  
3-Metronidazole I.V infusion 500mg/ 100ml. Manufactured by ……. - India 
donated by scientific office–Sudan, lot. no. U 6020, manufactured 12/05, expiration at 
11/08, in plastic bottles, each bottle was wrapped by cellophane sheet and packed in 
carton boxes, 40 bottles are used.   
4- Metronidazole I.V infusion 500 mg/ 100 ml. Manufactured by ……., Saudi 
Arabia donated by CMS, lot. no. LM111206, manufactured in 12/05, expiration at 
12/08, contained in coluorless glass bottles, without carton boxes, and total of 40 
bottles in a hard carton. 
5-Artemether 80 mg/ ml ampoules.  
Manufactured by ……., China, donated by CMS, lot no. 060116, manufactured in 
1/06, expiration at 1/09. It is an oily solution in1 ml glass ampoule. Each 8 ampoules 
are contained in carton box. Total of 36 boxes. 
6- Artemether 80 mg/ ml ampoules.  
Manufactured by ……., India, donated by the Scientific office–Sudan, lot. 
no.7000312, mfg, 4 /06, exp 3/08. It is an oily solution in 1 ml glass ampoules. Each 8 
ampoules in carton box. Total of 36 boxes.  
7- Rifampicin 300mg+150mg INH tablets.  
Manufactured by …. Sudan, lot. no. 350, mfg. 10/05, exp.10/07, each 10 film coated 
tablets in PVC/Al blister, each 10 blisters are contained in carton boxes. 40 boxes had 
been donated by CMS. 
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8- Rifampicin 150mg+100 mg INH tablets. 
 Manufactured by... … India, mfg.12/04, exp.11/07. Each 1000 tablets contained in 
Cellophane bag packed in a plastic bottle. 3bottles had been donated by T.B 
protection National program-Sudan. 
9- Artemether+lumefantrine 20/120mg tablets.  
Manufactured by ….. Switzerland lot. no.0283, mfg. 2/06, exp. 1/08, each 8 film 
coated tablets are blistered in PVC/AL blister, each 3 blisters are packed in carton 
box. 110 boxes had been donated by …. Scientific Office, Dubai. 
3.1.2 Reagents: 
3.1.2.1 HPLC grade reagents:  
1.Acetonitrile from Sotex pharmaceuticals -UK.  
2.Potassium Dihydrogen orthophosphate - UK.  
3.Dilute acetic acid. Merck- Germany.  
4.Dibasic sodium phosphate. Merck- Germany.  
5.Phosphoric acid. Merck- Germany.  
6.Methanol - Merck- Germany.  
7.Hexane sulphonic acid sodium salt. Sotex. U.K.  
8.Ethanol Merck- Germany.  
9.1- Propanol – Sotex- U.K., Treated water, Eurowater.  
3.1.2.2 Analytical reagents: 
1. Sulphanilic acid solution – Sotex, U.K.  
2.Aminonaphthalenesulponic acid – Sotex U.K.  
3.  0.1 Hydrochloric acid - Merck- Germany.  
4. Nitrite standard solution 20 PPm - Merck- Germany. 
5. Sodium Dihydrogen phosphate Monohydrate- Merck- Germany. 
3.1.2.3 Microbiological reagents:  
1. Absolute Ethanol.  
2. Polysorbate 80.  
3. Endosafe:  
LAL reagent water code: WHO, Lot: 99732053 Exp. 4/0009, Charles River, 
Charleston, Sc. 29407. Control standard endotoxin, E. coli b: 055 NG , Loy EM 
61792, Exp. 7/2010. Limulus Amoebocyte Laysate endosafe single test 0.2 ml U.S  
license No. 1197 Charles River Endosafe. Lot: W 28425, λ sensitivity: 0.25 , Expiry: 
12/2009.    
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3.1.3 Reference standards:  
1. Amoxicillin Trihydrate Reference Standard, batch No.:53 –1006 –1326 A. Mfg. 
date, 10/2006. Exp. Date, 10/2010. Antibioticus ltd.–Spain. It Contains amoxicillin 
trihydrate 100%.  
2. Metronidazole Reference Standard: Batch No., 2007010105. Mf date, 1/2007. Exp. 
Date, 10/2011. Concentration of metronidazole is 100%, each 100 grams powder 
contains 100 grams metronidazole. Source Von Valtier Ltd. Germany. 
3. Rifampicin Reference Standard: Lot No., 200502080. Q.C.no.,R-05040. Mfg. date, 
31/5/2005. Retest date, April 2009. GMC, Shin Pong Pharma- Korea. Concentration 
of rifampicin is 99.2%, each 100 grams of powder contains 99.2 grams of rifampicin. 
4. Isoniazid Reference Standard: G.M. C. Shin Pong Pharma – Korea. Lot No., T 
2005240. Q.C. No. ,R 06027. Mf. Date, 10/2005. Exp. Date, 9/2009. Concentration of 
isoniazid is 99.7%, each 100 grams of powder contains 99.7 gram of isoniazid.  
5. Artemether Reference Standard: (Chinese Ph. 2005). Lot No., 060600050.  Mf. 
Date, 06/2006. Exp. Date, 06/2010. Source, Herbstars Co. – China.  
Concentration is 99.7%; each 100 grams powder contains 99.7 grams artemether 
based on dried substance.  
6. Lumefantrine Reference Standard: (Chinese Ph. 2005). Lot No., 060701.  
Mfg. date , 7/2006 . Exp. date , 7/2008.  Source, Herbstars Co. – China .  
Concentration , each 100 grams powder contains 99.69 grams lumefantrine.   
 7. 2-Methyl-5- nitroimidazole Reference Standard: Mfg. date, 7/2006. Exp.date, 
7/2011. Source, Park Scientific ltd -U.K. Concentration is 99%. 
 8. Limulus Amebocyte lysate (LAL). Lot No., W 28425. Exp.date ,12/2009.  License 
, US 1197. Charles River Charleston, Sc 29407.  Sensitivity, λ = 0.25 Units / 0.2ml.  
 9. Control Standard Endotoxins. Lot ,EM 61792. Exp. date , 7/2010. Source,  Charles 
River Endosaf. E. Coli , 055 : B 5 500 NG.  
10. Staphylococcus Aureus specimen  
11. Candida albicans specimen.  
12. E. coli specimen. 
13.  Penase E. C 35- 2.6 SRO/ 29/3, 3.300 I.U. Lot. no.556048.   
Exp. Date, 6/2009. Source, Oxiod. – England. Concentration: I.U activity will 
hydrolyze 1.0 U of benzyl penicillin per minute 250C at pH 7.   
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3.1.4 Culture Media:  
1.Medium A, B.P 2007, Fluid  Soya bean- Casein Digest medium. 
2.Medium B, B.P 2007, Soya bean. Casein Digest Agar Media. Source, HIMEDIA – 
India M- 290 , 500 gram. Expiry date 2/2012.  
3.Medium C, B.P 2007, Sabouraud –Glucose Agar Medium. HIMEDIA – India. 
4.Buffered Sodium Chloride – peptone solution pH 7: B.P 2007  
5.Medium D (Lactose monohydrate broth) B.P 2007.  
6.Medium E Enrichment broth  B.P 2007, (Entrobacteria enrichment broth – Mossel)  
7.Agar Medium F, (Crystal violet, neutral red, bile agar with glucose)  
8.Broth Medium G ( Mac Conkey Broth) 
9.Agar Medium H ( Mac Conkey Agar) 
10.  Broth Medium I (Tetrathionate bile brilliant green broth) 
11. Agar Medium J (Deoxycholate citrate agar)  
12. Agar Medium K ( xylose, lysine, deoxycholate agar) 
13. Agar medium M (Triple sugar – iron agar).  
14. Agar Medium N ( Cetrimide agar) 
15. Agar Medium O ( Baird Parker agar)  
16. Fluid thioglylcolate Medium .  (Oxoid CM 173)  
17. Soy Bean Casein Digest Medium (Oxiod CM 129) 
18.  Peptone (oxiod)  
19. Mannitol – salt Agar medium USP 2007  
3.2 Instruments: 
3.2.1 Temperature and humidity data logging devices: Total of six electronic 
devices are used, from  SATO KEIRYOKI MFG. CO. LTD.  
TOKYO 101 – 0037 JAPAN SK- L 200II series dataloggers No. 8171 – 00 model SK 
– L 200 TH II. With Probes  sensitive for temperature of thermistor type and a high 
polymeric resistance change humidity sensor.  
Measuring range , from – 100C to 600C for temperature and from  20% RH to 98 % 
RH at 23 0C. and accuracy, temperature : ± 0.50C  from 20 – 30 0C - 10C at other 
ranges. Humidity : ± 3% from 30 – 90% at 30 0C - 20 0C and  
   ± 5% for the other ranges. Accompanied by Software deriver : SK – L 200 / L 200 
II series software, SK Sato Data logger for windows, version 5.11 E. 
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 Serial number of the devices with the calibration test number.   
Data logger Serial number  Calibration test  
10152 H  35 06 0000 17  
10153 H  35 06 0000 18 
10154 H  35 06 0000 19 
10155 H  35 06 0000 20 
10156 H  35 06 0000 21 
10158 H  35 06 0000 23 
3.2.2 Chromatographic Instruments:  
3.2.2.1 Gradient HPLC with U.V detector apparatus: Manufactured by Knavery 
advanced scientific Instruments .Germany. Model,  Smart line HPLC consists of 
degasser S.N , 92382 – Smart line manger 5000. Pump S.N. 92603 – Smart line pump 
100 stainless steel. Injection valve S.N 91157, stainless steel. Chamber S.N 92379. 
Programmable detector S.N. 90662- U.V detector 2500. Column thermostat test 
stream 2 –plus. With software and PCL, Dell computer system with hp 1280 printer 
and 4 Schott- one liter bottles.  
3.2.2.2 Isocratic HPLC with UV detector manufactured by Knauer advanced 
scientific Instruments-Germany. It consists of degasser S.N 62349. Pump S.N 60996 
– 60997. Solvent organizer S.N. 62081. Dynamic Mixing Chamber S.N.  60527. 
Column thermostat, jet stream 2 plus, S.N. 61884. UV detector K 2501 S.N. 60369 
Knauer. Compaq computer system with hp printer 1280 and software Eurochorm 
HPLC version 2.05.  
3.2.2.3 Columns: 
1.Lichro cart 250 mm – 4 lichorospher 100 RP -18 (5 micrometer) HPLC cartridge. 
Packed with silica gel bounded to octadecylsilyl Groups.   
2. Lichrocart 125-4, 125mm length and 4mm internal diameter, PUROSPHER RP–18 
(5micrometer) HPLC cartridge packed with octadecylislane.  
3.Lichrocart 125 -4, of length 125 mm and internal diameter of 4 mm, Nucleosil 5 C 
18 HPLC cartridge.  
4.Lichrocart 250 – 4.6. Purospher star RP – 18 endcapped 5 micrometer, deactivated 
base. Packed with octadecylsilane bonded to porous silica micro particles of 5 
micrometer.  
5.Manu. Cart NT cartridge holder for lichrocart .  
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6.Lichrocart 4-4 Purosher RP-18 ( 5- micrometer) HPLC guard column.  
All columns are from Merck K GaA – D 64271, Frankfurter- Germany. 
3.2.3 Spectrophotometer UV/ VIS Lambda 2. Manufactured by  Perkin – Elmer 
USA. S.N. 4505 I.D. 166351 with Perkin Elmer Ex- 80 printer. Detection range: both 
UV and visible spectra.   
3.2.4  Grant Ultrasonic bath, type,  MXB 6. S.N. : CG0709004. – England.  
3.2.5 pH meter, manufactured by HNNA Instruments – Portugal. Type, pH 302 
S.N.560882. Measuring range, 0.01 pH Unit With programmable printing. Calibrated 
at pH 7 and pH 4 solutions and  it is in current use.  
• 3.2.6 Weight Balance: Type :  AB 204 Metter Toledo in a weighting cabinet. With 
a measuring range 0.01- 210grams and sensitivity 0.001 gm for 200 gm and 0.0001 
gm for 100 gram and 0.002 for 50 gram.  
3.2.7 Hardness Tester: Manufactured by ERWEKA – Apparatuses BAU GHBH – 
Germany. Type,  TB 24. S.N. : 54389. Precision : I Newton.  
3.2.8 Disintegration Tester; ERWEKA Disintegrator – Germany. Type, ZT41. S.N : 
105297 . 05 dc. – rack type of B.P.  
3.2.9 Dryer ;  Mettler LP 16 Dryer. Toledo – Switzerland, S.No. : 114490150 ,
With Mettler PM 600 Balance S.N.  114490149.  
3.2.10 Mixers : Fisher Scientific Mixer with Magnetic Stirrer, Stuart ( Auto vortex 
Mixer)–UK. Stirrer, Scientific Industrial incorporation, Bohemia N.Y- USA.  
3.2.11 Stop watch:  
 Q & Q – indicate the date and 0.01 of the second water resist with alarm.  
3.2.12 Laminar Flow Cabinets:  
1.Laminar Flow  Cabinet with U.V lamp, Labconco ® Class II Safety Cabinet. USA.  
2.Laminar Sterile air flow: BS – 57  26 Class I, Model, ROBINAIR – 
VACUMASTER.  
3.2.13 Pipettes: Micro pipette :10,20, 50, 100 ml. Pipettes  : 2, 5, 10 ml. 
3.2.14 Ovens :  Incubator  33 C0 Nǚve , EN 400. Incubator  25C0 VVWR   1520. 
Oven Glassware sterilizer, Fisher model S.N 501 –137.  Isotemp  oven (35 C0 - 250 
C0). block Incubator - 37 C0.  
3.215 Autoclaves: GCA 67013 – 12 AR – 3  
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3.2.16 Glassware: Test tube and racks for test tubes, petri dishes of a 9 cm diameter, 
beakers, conical flasks, measuring cylinders, funnels and glass bottles with screw cap 
closure. 
3.2.17 Miscellaneous: Water bath; SB 410, Nǚe, Turkey S.N 01 .311, Leonard 
refrigerator, Bunsen flame, porcelain mortar and pastille, aluminum foil and sterile 
cotton Swab. Membrane filter nominal pore size 0.45nm, cellulose Nitrate 50 mm 
diameter Membrane filter 0.8 m Panasonic video camera with Panasonic tape. hp 
computer system. 
3.2.18 Kits: Sterility Test Kit ,SM16826–8, Sartorius Goettingen– Germany, 
Entrobacteriaces Identification kit, HIMEDIA – India  
3.2.19 Microscope: Olympic Binocular microscope – 25 v lamp with one eye piece 
with reticle to measure objects of 10 m or larger. The magnifying power is 10, with 
object micrometer to calibrate eye piece reticle. 
3.3 Methods:  
3.3.1 Study Design  
It is a field stability study, designed to evaluate the distribution, transportation and 
storage of a selected pharmaceuticals across Sudan which lies between 30 -40 N and 
21 -220 N latitude. Sudan climate differs from one region to another, and the 
warehouses mean kinetic temperature for any region had not been determined before. 
The international reports were based on Khartoum only using the meteorological 
international data. So, the study was focused on determining the mean kinetic 
temperature of the country. The country is divided into six climatic zones according to 
the climatic profile considering the latitude and the nature of each region. The main 
city was selected as a representative station for such smaller zones 
3.3.1.1 Stations:  
1. Juba: Juba, the capital city of the south of Sudan. It represents the equatorial 
climate. It lies at latitude 3.540N.  
2.  Damazin : It is the main city of the Eastern South of the country where the climate 
is influenced by the Ethiopian Plateau. It lies at 110 N latitude.  
3. AL-Fashir : It is the main city in Darfour district representing the Western region. 
It lies at 140 N latitude. The climate of which is greatly influenced by the western 
desert.  
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4. Khartoum : It is the central station at the middle of the country. It lies at 160 N 
latitude. It represents the central region.  
5. Dungola: It represents the Northern region. It lies at 180 N latitude.  
6.  Port sudan: It represents the Red Sea region of which climate is greatly 
influenced by the Red Sea. It lies at 210 N latitude. (Fig.1) 
  
3.3.1.2 Distribution and Transportation:  
Six sets were prepared and coded , each set contains the followings:  
1.Amoxicillin for oral suspension I              : 8 bottles  
2.Amoxicillin for oral suspension II              : 8 bottles  
3.Artemether 80 mg injection I   : 4 boxes of 8 ampoules   
4.Artemether 80 mg injection II   : 4 boxes of 8 ampoules   
5.Metronidazole I.V infusion I     : 8 bottles  
6.Metronidazole I.V infusion II  : 8 bottles  
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7.Rifampicin + NH tablets I              : 300 tablets  
8.Rifampicin + NH tablets II               : 4 boxes of 100 tablets  
9.lumfanterine + Artemether Tablets    : 20 box of 24 hours  
Each set was accompanied by one datalogger and packed in a hard carton and sealed. 
A label instructing that these samples are not for use but for study was fixed.  
Then the sets were transported to the designated city via the usual route of 
transportation of the hospital drugs.  
1.To Omdurman by hand                              Distance  
2.To Dungola by passenger buses   520 km  
3.To Al- Fashir by airplane    1355 km  
4.To Juba by air plane               1440 km  
5.To Damazin by trucks    780 km  
6.To Port Sudan by Trucks                        1200 Km (Fig.  )   
3.3.1.3 Devices:  
   Six electronic devices; data loggers were imported from SATO – JAPAN.  
They are readily calibrated and tested, each with software CD, USB, and calibration 
certificate. They are thermistor type which is recommended by USP 2007. The model 
used is LTH 200- model which is sensitive to both temperature and humidity.  
They had been adjusted to log data every 90 minutes intervals, up- to more than 5000 
points in 52 weeks. The readings had been barred by adjusting the screen not to 
display the recorded data. The software had been installed in hp computer system and 
the graph and records were printed using hp 1280 printer. The date is adjusted on 15th 
of April 2007, at 12.30pm.  
3.3.1.4 Selected pharmaceutical products: 
1. Amoxicillin 125mg/5ml dry suspension: It is widely used antibiotic for children 
in cases of wider range of infections which are the most prevalent cases. It is widely 
used in rural areas as well as the formal areas. It had been reported to show instability 
problem in tropical climates (Hogerzil et al, 1987).  
2. Metronidazole I.V infusion: It had been selected to compare between the effects 
of the environmental condition on glass container metronidazole and in plastic 
container. 
 3. Rifampicin +INH Tablets: It is antitubercluosis combination therapy. It had been 
selected because it affects the poorer population, the tuberculosis patients. The 
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mycobacterium mostly acquire resistance even against good quality drugs and due to 
the directive of Federal Pharmacy Directorate.  
4. Artemether Injection:  It is an oily solution small volume parenteral, 80 mg/1 ml 
ampoules were used. It had been recently defined as the first choice therapy for severe 
complicated malaria. (National Protocol for Treatment of Malaria). 
5. Lumefantrine + Artemether Tablets:  
It is a brand named antimalarial combined therapy products of 120 mg lumefantrine 
and 20 mg artemether tablets. It is defined in the recent National Protocol of Malaria 
Treatment in Sudan as the second line of treatment for malaria.  
3.3.1.5  Storage at the sites:  
The sets are stored in the normal storage conditions at the hospital pharmacies among 
the stored medicinal products intended to be dispensed to patients. The usual actual 
conditions are not altered and the samples were stored with the current stock without 
any extra measures or special conditions. The dataloggers are placed side by side with 
the samples on the shelves. 
3.3.1.6 Duration of the study:  
A period of 52 weeks is the duration of the study complying with the USP method for 
calculating the mean kinetic temperature. 
3.3.1.7 Frequencies of testing:  
1.Initial testing or zero-time: Tests were carried out in April2007 for the chemical 
assays for the active ingredients,  physical tests for the dosage form and 
microbiological examinations. 
2.After transportation: Samples from each set were returned back after being 
transported to designated site and then they were analyzed for potency In June 2007.  
3.Mid – point testing: Chemical assay for the active ingredients were performed after 
6 months In November 2007. 
4. Final testing: The final testing was in April 2008.  
All the samples from each set were subjected to chemical, physical and 
microbiological evaluation.  
3.3.2 Chemical Analysis:  
3.3.2.1 Amoxicillin for oral suspension 125mg/ 5ml: 
A- Principle: Isocratic HPLC with UV detector. B.P -2007, USP 2007.  
B- Reagents: Use HPLC grade materials to prepare the following solutions: 
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1.  Mobile phase A: A mixture of 50 ml acetonitrile, 50 ml of 0.2M  potassium 
dihydrogen orthophosphate, adjust with 0.5ml dilute acetic acid to pH 5. Dilute to 
1000 ml with purified water. 
2. Mobile phase B: A mixture of 50 ml of 0.2M potassium dihydrogen orthophosphate 
with 400 ml acetonitrile, adjust pH to 5 using 0.5 ml acetic acid. Dilute to 1000 ml.  
3. Mobile phase ratio: 850 ml of mobile phase A and 150 ml of mobile phase B. Mix 
for 15 minutes and degas. 
C- Chromatographic conditions:  
1. Columns:  Stainless steel column 125 mm 4mm Nucleosil C 18 packed with 
octodecysilane 5  m, Merck.   
2. Flow rate:  Flow rate of 1 ml/ min  
 3. Detection: Detection at wave length of 254 nm.  
 4. Injection volume:  20 l volume.  
D. Assay preparation: 
1) Setting of the apparatus:  
1.Place the mentioned column.  
2.Place the mobile phase and insert the pump tubes.  
3.Switch power on, wait to complete initialization and self – calibration.  
4.Calibration the detector by pressing Hold Key ▲ and switch on the detection and 
then press ▼quickly.  
5.Select wavelength 254 nm and press enter.  
6.Click pump on and run for 12 hours for the first time.  
7.At the beginning of test, run the mobile phase for 30 minutes.  
8.Inject the sample and click start – Enter.  
9.Turn on the loading valve.     
2) Preparation of the reference standard: 
Take 143.6 mg of amoxicillin trihydrate internal reference standard which is 
equivalent to 125mg amoxicillin in anhydrous state to 100 ml volumetric flask, 
complete to 100 ml with mobile phase. Stir in a magnetic stirrer for 15 minutes. Filter 
and discard the first 10 ml filtrate.  
3)  Preparation of sample:  
1.Reconstitute the domestic sample by adding water to 75ml and shake well, the 
Indian sample by adding 43 ml of water.  
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2.Take 5 ml of the suspension to 100 ml volumetric flask.  
3.Complete to volume with the mobile phase and stir for 15 minutes and then filter. 
Discard the first 10 ml of filtrate.   
E. Procedure:  
1.Separately inject 20 L of the standard preparation and the sample into the 
chromatographic system.  
2.Read and print the chromatograph, record the retention time and the area under the 
main peak.  
3.Wash the column by running the mobile phase for 15 minutes and reinject the 
reference standard and the tested sample, each for three times.  
4.Obtain the standard deviations for the replicates of not more than 2%. Tailing factor. 
not more than 2.5.  
F- Calculation:  
Determine the weight content per 5 ml as follows:  
(L/D) CP/100) (ru/rs)  Where: 
 L :is labeled concentration per ml.  
D: is the concentration of the test preparation.  
C: is concentration of the reference standard in its preparation  
P : is the declared potency  of reference standard 
ru : is the peak area of the tested sample 
rs : is the peak area of the reference standard.  
This will give the content per ml of suspension, when multiplied by 5 ml the content 
per 5 ml will be obtained. Then the percentage of the content to the labeled quantity is 
obtained.  
G- Repeat the same for the second sample and after 7 days for both samples 
suspension after constitution and storage at room temperature for 7 days.  
3.3.2.2 Rifampicin + INH Tablets:  
A.  Principle: Gradient HPLC with programmed UV detector  (USP 2007) 
 B. Reagents:    
(1) Buffer solution:  
Dissolve 1.4 gram of dibasic sodium phosphate in one litre of purified water and 
adjust with phosphoric acid to pH 6.8.  
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(2)  Solution A:  Prepared a mixture of buffer solution and acetonitrile  (96 : 4), 
filter and degas.  
(3)  Solution B:  Prepare a mixture of buffer and acetonitrile ( 45 : 55)  
(4)  Mobile phase program:  
Linear  gradient and isocratic  
Time (min)  Solution A %  Solution B %  Elevation  
0 100 0 Equilibrium  
0-5 100 0 Isocratic  
5-6  100 ? 0 0 ? 100 Linear gradient  
6- 15  0 100 Isocratic  
 
C.  Chromatographic conditions:  
(1) Columns:  
4.6 mm x 25cm column packed with octadecylsilane bounded to 5-  base 
deactivated packing - Merck.  
(2) Flow Rate: 1.5 ml/ min  
(3) Detection limits:  Set the detector at 238 nm wavelength.  
(4) Injection volume:  20  
D.  Assay preparation:  
(1) Standard preparation: Dissolve accurately weighed 16 mg of Rifampicin 
Reference Standard and 8 mg isoniazid reference standard in 100 ml volumetric flask, 
add a mixture of buffer and methanol (96 :4) to volume.  
(2) Sample preparation:  Weigh and finely powder 20 tablets, transfer a powder 
equivalent to 8 mg isoniazid to 100 ml volumetric flask, add 90 ml of buffer solution 
and sonicate for 10 minutes and allow to equilibrates to room temperature. Dilute with 
buffer to volume and mix. 
E- Procedure: 
1.Set the apparatus and standby.  
2.Inject separately three replicates of 20  of the reference standard and three 
replicates of 20  of the test sample.  
3.Use both solutions immediately; not more than two hours.  
4.Record the retention time, the area under the peak. 
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F. Calculations:  
Calculate the quantities of Rifampicin and INH in the portion of tablets taken by the 
formula: 100 C (ru/ rs) , where C is the concentration in mg/ ml of reference standard 
in the standard preparation, ru  and rs are the peak responses of the preparation and 
the standard respectively.     
3.3.2.3 Metronidazole intravenous infusion:  
A. Principle: Spectrophotometric method and HPLC method B.P. 2007.  
1.Assay for the active ingredient by spectrometer.  
2. Assay for 2- methyl–5-nitroimidazole by HPLC method.  
3.Assay for Nitrite contents by spectrophotometer.  
B. Reagents:  
1.2- methyl-5nitroimidazole reference standard.  
2. Methanol HPLC grade.  
3.Potassium dihydrogen orthophosphate HPLC grade.  
4.Sulphanilic acid solution.  
5.Aminonaphtlalene sulphonic acid solution.  
6. 0.1 M hydrochloric acid.  
3.3.2.3.1 Assay for 2- methyl – 5-nitroimidazole:  
(1) Solution I :  Contains 0.0050% W/V of 2-Methyl-5-nitroimidazole R.S. in mobile 
phase.  
(2) Solution II:  Dilute I.V metronidazole solution with mobile phase. 
(3) Solution III: Contains 0.00050% W/V of 2-meth–5-nitroimidazole in solution II.  
(4) Mobile phase:  (30: 70) volumes of methanol and 0.1M potassium dihydrogen 
orthophosphate.  
(5) Column:  Stainless steel column 20 cm x 4.6mm packed with 10 m-C-18 Merck. 
(6) Flow rate:  1 ml per minute.  
(7) Detection: Detection of wavelength 315 nm.  
(8) Procedure:  
1.Perform the three injections.  
2.The highet of the peak obtained by solution III is about 50% of the full scale 
chromatogram.  
3.Record the peaks highet and area.  
(9) Comment:  
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The area of any secondary peak in the chromatogram obtained by solution (II) is not 
greater than the peak obtained by solution (I ). 
3.3.32.3.2 Assay for the nitrite contents: 
(1) Principle : Spectrophotometeric method at wave length  524 nm using 1 cm 
Quartz cell.  
(2) Reagents: 2 ml sulphanilic acid solution,  2 ml aminonaphthalen sulphonic acid. 
(3) Procedure:  
1.To a volume containing 2.5mg of metronidazole, (0.5 ml) add 40 ml of water.  
2. Add 2 ml sulphanilic acid solution and 2 ml aminonaphthalene sulphonic acid 
solution.  
3. Add sufficient water to produce 50 ml.  
4.Allow to stand at room temperature for 1 hour.  
5.Measure the absorbance at 524 nm, using in the reference cell a solution prepared 
by 1 ml off water in the same manner.  
6.Treat 1 ml nitrite standard solution by the same manner.  
(4)  Calculation:  
The absorbance is not greater than that obtained by the nitrite standard solution.  
3.3.2.3.3 Assay for Metronidazole content:  
(1) Principle: Spectrophotometer at the wavelength 277 nm. 
(2) Procedure:  
1.Dilute a volume of infusion containing 50 mg of metronidazole (10 ml) to 100 ml 
with 0.1 M Hcl.  
2.Dilute 10 ml of the resulting solution to 250 ml with 0.1 M Hcl.  
3.Measure the absorbance of this solution at 277 nm.  
(3)Calculation: 
Calculate the content of metronidazole taking 375 as the value of A (1%, 1 cm) at the 
maximum at 277 nm. 
3.3.2.4 Artemether Injection:  
A. Principle:  HLPC with U.V detector according to the international pharmacopeia- 
volume 5 – 2003. 
B. Reagents: Acetonitrile HPLC grade, Artemether reference standard, Ethanol 
HPLC grade and Hcl.  
(1)  Mobile phase:  
It is a mixture of 62 volumes of acetonitrile and 38 volume Of water. 
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C. Chromatographic conditions 
(1) Column: Stainless steel column 25cmx4mm packed with 5 m octadecylsilane- 
Merck.  
(2) Flow rate:  1.5 ml per minute.  
(3) Detection: Set the U.V detector at a wavelength of 216 nm. 
(4) Injection volume: 20 L. 
D. Assay Preparation: Prepare the following solutions: 
1.Solution A: Dilute a volume of injection with mobile phase to obtain a 
concentration of  10mg/ml. (1 ml compete to 8 ml).  
2.  Solution B: Dilute a quantity of reference standard to obtain a concentration of 10 
mg/ml of mobile phase. ( 1 g in 100 ml) or (100 mg in 10 ml).  
3.Solution C: Dilute a volume of solution A with mobile phase to obtain a 
concentration of 0.05mg/ml. (1 ml A to 200 ml mobile phase).  
E. Procedure:  
- Inject 20 L of each of solution A and B.  
- Inject 20 L of solution C.  
- Measure the areas of the peak responses.  
F. Calculations: 
1. Calculate the percentage of contents of artemether in the sample using peak area 
obtained from solution A and B.  
2. Calculate the content of the related substances as a percentage.  
The area of any peak other than the principle peak, is not greater than that obtained by 
solution C. And not more than one peak is greater than half area of the principle peak 
solution of solution C.  
The sum of all areas of all peaks, other than the principle peak. Is greater than twice 
the area of the main peak of solution C.  
Ignore any peak with an area of less than 0.1 times the area of the principle peak in 
chromatogram obtained with solution C. 
3.3.2.5  Artemether + lumefanterine 20/120 tablets 
A. Principle : Gradient HPLC, programmed U.V detection. (Novartis method. )  
Smart line knauer HPLC chromatographic system with automatic programmable 
pump and detector.  
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B. Reagents: HPLC grade reagents, Hexane sulphonic acid sodium salt. Sodium 
dihydrogen phosphate monohydrate. Phosphoric acid. Acetonitrile. 1- propanol 
C. Chromatographic conditions: 
1. Ion- pair reagent: dissolve  (5.65 gm) of hexanesulphonic acid sodium salt 
and 20 mmol (2.75 gm) of sodium dihydrogen phosphate monohydrate in 800 ml 
water. Adjust the pH to 2.3 using phosphoric acid. Dilute to 100 ml with water and 
filter through 0.5 m Millipore membrane filter.  
2. Solvent:  
Mix 100 ml of ion pair reagent with 30 ml of water, add 100 ml of propanol and dilute 
with acetonitrile to 500 ml.  
3.  Mobile Phase: 
Solution A:  700 ion pair + 300 acetonitrile  
Solution B:   300 ion pair + 700 acetonitrile.  
4.  Column:  Neucleosil C 18, 15 cm x 4.6 mm – Merck. Packed with 5 m 
octadecylsilane 
3. Flow rate: 1.3 ml per minute.  
4. Detection: UV 210 nm and 380 nm. Set the detector for the first 30 minutes to 210 
nm, then switch to 380 nm.  
5. Temperature :  Ambient temperature.  
6.  Injection volume: 20 L  
7.  Pump program: From the pump menu set the program as follows:  
Time min Phase A% Phase B % 
0 60 40 
28 60 40 
29 0 100 
45 0 100 
46 60 40 
65 60 40 
D. Assay preparation: 
(1) Standard Reference Solution: Weigh 20 mg of artemether reference standard 
powder and 120 mg of lumefantrine reference standard in 100 ml volumetric flask.  
Dissolve and dilute to volume with solvent.   
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(2)  Test solution: Disintegrate 10 tablets, equivalent to 200 mg of artemether and 
1200 mg of lumefantrine, with 60 ml of water in 100 ml volumetric flask. Add 200 ml 
of 1- propanol and sonicate for 15 min.  
Add 200 ml of ion pair reagent and 400 ml of acetonitrile and sonicate again for 30 
minutes. Dilute to volume with acetonitrile. Withdraw 10 ml of the suspension and 
centrifuge for 5 minutes. Use the clear solution for the assay.   
 E. Procedure: Set the gradient program. Set the detector as described. Inject each of 
the standard preparation for three replicates between each replicate 15 minutes 
running of mobile phase and do the same for the samples tested. Record the results 
and print out the chromatograph. 
F. Calculations:  Calculate the content of artemether from the formula: 
 
  : Percent content of artemether,  : Mass in mg of artemether 
Reference Standard.  : Peak area of artemether in test assay.  : Peak area 
for artemether in Reference Standard. Calculate the content of lumefantrine from the 
following formula:  
  : Percent content of lumefantrine,  : Peak area of 
lumefantrine  in test assay. : Mass in mg of lumefantrine  Reference Standard. 
 : Peak area for lumefantrine  in Reference Standard. 
3.3.2.6 Validation of Methods  
3.3.2.6.1 For chemical analysis  
As all methods used are pharmacopoeial and validated methods and the limits 
required to be covered are governed by the concentration of active ingredients in each 
sample, so the methods are partially validated for the required range by testing for 
linearity ( Huber 2003). 
Testing for linearity:  
Procedures described in the methods were repeated for each method using five 
dilution for each sample and three replicate injections for each dilution.  
The following concentrations were used, Table (5)  
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Table ( 5)  Validation of Methods 
Rifampicin  + I N H Artemether+ Lumefantrine  Con Amoxicillin  
mg/ 100 ml  
Metronidazole 
mg/250 ml  
Rifampin 
mg/100ml  
I NH 
mg/100ml 
Artemether 
Mg/100ml  
Artemether 
Mg/100ml  
Lumefant
mg/100ml 
1 15.62 1.25mg/ 250ml  10 10 10 1.25 7.5 
2 31.25 2.5 25 25 20 2.5 15 
3 62.5 5 50 50 30 5 5 
3 125 7.5 75 75 40 10 60 
5 250 10 100 100 50 20 120 
 
3.3.2.6.2 Treatment of data:  
The mean of the three replicates is obtained, the standard deviation is calculated.  The 
mean under the peak is used for each dilution.  
3.3,2,6.3 Statistical analysis:  
Statistica ( statsoft version 8) is used to analyze the data obtained. 
 Regression analysis is used to plot the peak area against the concentration. The 
correlation coefficient, the regression equation, the slope and intercept were obtained. 
For metronidazole, the absorbance is used instead of the peak area P. value and results 
of the positive linearity were obtained. 
3.3.3 Methods for Physical Tests:  
The following physical tests are carried out for different dosage forms of the sample 
twice during the study; initially and at the end of the study after storage of 52 weeks.  
3.3.3.1 Appearance:  All the products are described after visual examination for: 
Shape, colour, inspection of the surface for tablets, odour and taste for suspensions . 
3.3.3.2 pH:  (B.P 2007 appendix VL – ph Eur method 2.2.3)  
The test is performed for Amoxicillin suspension and Metronidazole I.V. infusion 
 General procedure: Switch power on. Calibrate the instrument as follows:  
Dip the electrode in a buffer pH 7 solution the reading should be 0.05 wait for 30 
seconds and then press CFM. Dip the electrode in a solution of pH , wait for 30 
seconds and then press CFM. The reading should be 0.05.   
Wash the electrode using distilled water. Dip the electrode in the sample,  
(Amoxicillin suspension 20 ml or Metronidazole I.V infusion).  
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3.3.3.3 Moisture content:  
The test was applied for tablets only. Rifampicin + INH tablets and Artemether + 
Lumfantrine tablets.  
General Procedure: By Infra Red dryer. 
Finely powder 20 tablets and take accurately weight 1 gram of powder. Press the 
control of instrument 180.000  
1. Place it in the oven of Mettler LP 16 Dryer. Toledo, spread the powder and press 
start key.  
2.Determine the loss of weight as percentage after flashing of the starting knob read 
the moisture content of the sample.  
3.Switch off the dryer.   
3.3.3.4 Weight Variations: (B.P 2007, ph. Eur method 2- 9.5)  
Balance: AB 204 Mettler Toledo in weighing cabinet being calibrated as 
follows:  
Theoretical Weight   Actual Weight  
200 gram  199.99 
100 gram  99.999 
50 gram  49.998 
Procedure:  
1.Weigh every tablet individually for twenty tablets taken randomly.  
2.Calculate the average.  
3.Calculate the deviation of each tablet from the mean.   
4. Apply ICH specifications.  
3.3.3.5 Disintegration: The test was applied for: Rifampicin + 1NH tablets - Sudan. 
Rifampicin + 1 NH tablets – India. Artemether + lumefantrine 20/120. The test was 
performed in accordance with the (B.P 2007, Eur ph method 2.9.1). 
A. Apparatus:  
• The disintegrator used was basket -rack type of B.P. It is Erweka Disintegrator type 
ZT41 with water bath. SB 401, NUVE, and six tubes moving vertically up and down. 
 B. Procedure:  
1.Use water as a medium for disintegration.  
2.Maintain the temperature at 370C 0. 20C for the medium.  
3.Place one tablet in each of the six cylinders.  
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4.Operate the apparatus and start the stop watch.  
5.Record the time when all tablets disappear completely from the rack of the tube.  
6.Turn off the apparatus and water bath.  
3.3.3.6 Hardness (Resistance to Crushing of Tablets)  
The test was applied to tablets of :  
Rifampicin + 1 NH 300/150 – Sudan. Rifampicin + 1 NH 150/100 - India. Artemether 
+ Lumefantrine 20/120.  
The test was performed in accordance with the B. P 2007, Appendix XVIIG – ph. Eur 
method 2.9.7 and USP 80 – 2007 < 1151>.  
A- Apparatus:  
Hardness tester of Erweka type TB 24 with precision of I newton.  
B- Procedure:  
1.Place tablet, selected randomly, between the Jaws diametrically on the fixed Jaw.  
2.Move the movable Jaw smoothly towards the tablet surface.  
3.Record the force when the tablet breaks.  
4.Repeat the procedure for other 10 tablets.  
5.Express the results as mean, max and minimum.  
3.3.3.7 Deliverable volume:  
The test for the total deliverable volume is a USP test for multidose containers and 
was applied to Amoxicillin suspensions.  
Procedure:  
1.Prepare the Indian product by adding 43 ml water as labeled.  
2.Prepare the domestic preparation by completing the volume . 
3.Both preparation were labeled as 75 volume and Shake well.  
4.Pour the content of preparation in a separate measuring cylinder.  
5.Allow to drain for 30 minutes.  
6.Measure the volume of each.  
7.Repeat the test for the remaining five stations. 
3.3.3.8 Reconstitution time and Sedimentation volume:  
These tests are applied to the suspension. It is directed to evaluate the stability of the 
suspendibility function of the resulting suspension.  
It is applied to amoxicillin trihydrate dry suspension for the six stations.  
The method was described by the (B.P.C – 1994).  
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A. Reconstitution time: Add the labeled amount of water to prepare the 
suspension and shake well till complete suspension of the powder.   
Allow to stand for 24 hours. By fixed shaking force; resuspend the preparation. Start 
the stop watch at the beginning shakes.  
Count the shakes and time when complete resuspendability. 
B. Sedimentation volume:  
Place the thoroughly mixed suspension in a measuring cylinder Vo.  
Measure the sediment immediately. Measure the sediment at 0, 4, 8, 24 hours. Plot V/ 
Vo against time. Calculate the slope of the curve. 
3.3.3.9 Particulate contamination:  
(B. P 2007, Appendix XIIIA, particulate contamination subdivide particles. Ph. Eur. 
Method 2.9.19)  Microscopic particle count test method:  
The test is carried out in laminar sterile air flow cabinet.  
1.Wash the glassware and filtration equipment except membrane filters with warm 
detergent solution. Then rinse with abundant amount of water to remove the 
detergent.  
2. Rinse the equipment from top to bottom, outside and inside with particle free water.  
Preparation of instruments for use:  
Prepare the glass vacuum - filtration system and free it from particles. Use 0.8  m 
membrane filter. Prepare the binocular microscope, by aid of an object calibrate the 
eye piece reticle, micrometer.  
Procedure:  
1.Rinse the funnel and filter holder with particle free water.  
2.Pick up the dried membrane with forceps that had been previously washed and freed 
from particle.  
3. Rinse both sides with particle free water top to bottom.  
4.Place the rinsed filter on the funnel and install it.  
5.Invert and rinse the whole apparatus.  
6.Place the unit on the filter flask.  
Filtration of the sample:  
Mix the solution by inverting the container many times. Transfer 25 ml of the 
homogenized apparatus and allow to stand for one minute. Apply a vacuum and filter. 
Release vacuum gently and rinse the inner walls with particles free water. Maintain 
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the vacuum for a moment to dry the filter and then release the vacuum. Carefully 
remove the funnel, pick up the filter with forceps and place it in a cleaner Petri dish to 
allow to dry. 
Examinations:  
1.Examine the surface of the membrane filter at magnification of 100 ml using 
reflecting light.  
2.Count and classify dimension equal or larger than 10  m and equal or larger than 
25  m.  
Limits:  25  m, not more than 02 particles / ml.  
 10  m, not more than 12 particles / ml. 
3.3.4 Methods for Microbiological Examinations:  
Microbiological examinations were performed at the beginning and at the end of the 
study; before and after storing of samples at all stations.  
The tests were performed in accordance with the (B.P 2007, appendix XVID 
Microbiological quality of pharmaceutical preparation- ph. Eur. General tests 5.1.4 )  
Sterility testing, total endotoxin and particulate material tests were performed to 
parenteral preparations. Total viable count and absence of specific organism were 
performed to tablets and oral suspensions.   
3.3.4.1 Sterility Testing:  
(B.P 2007, Appendix XVIA, ph Eur method (2.6.2 )( membrane filtration method).   
3.3.4.1.1 Preparation of Reagents:  
A. Fluid thioglycolate medium (oxioid CM 137).  
1.Suspend 29.5 gram of oxid medium in 1 liter of distilled water.  
2.Boil to allow complete dissolution.  
3.Adjust the pH to 7.1   0.2  
4.Distribute 90 ml into screw capped Borosilicate glass bottle.  
5.Sterilize by autoclaving at 1200C for 20 minutes.  
B. Soya bean casein digest Medium (Oxiod CM 129). 
1.Dissolve 30 gram of powder into 1 liter of distilled water.  
2.Mix well and adjust the pH to 7.3  0.2.  
3.Distribute 90 ml into screw capped borosilicate glass bottle sterilize by autoclaving 
at 1200C for 20 minutes.  
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C. Peptone (Oxid).  
D. Sodium chloride – analytical reagent.  
0.1% peptone water 
Dissolve 9 grams of sodium chloride and 1 gram of peptone and add water to 1 liter. 
Fill a screw – capped borosilicate glass bottle with 250 ml and sterilize by autoclaving 
at 1200C for 20 minutes.  
3.3.4.1.2 Membrane filtration: 
The test was carried out aseptically in a laminar sterile air flow class I cabinet.   
1.Transfer the content of the product to be tested to the membrane filter apparatus in 
the laminar sterile air flow class I.  
2.Use membrane filter of nominal pore 0.45  m. cellulose nitrate filter.  
3.Apply a negative pressure and pour the content of the sample in the filter .  Transfer 
the whole membrane and cut it into two parts using sterile conditions. Incubate one 
part in the Thioglycolate medium at 33 0C for 14 days. Incubate the other part in Soya 
bean casein digest medium at 25 0 C for 14 days.  
4.Quantity of sample: Use 20 ml of metronidazole I.V infusion. Use the whole content 
of artemether injection.  
5.Report on the observation at the last date of incubation.  
3.3.4.2 Bacterial Endotoxin (L.A.L) Test:  
(B.P 2007, appendix XIVC. Ph. Eur methods 2.6.14 Harmonized Gel – clot method A 
limit Test:  
The test is conducted by mixing LAL reagent and test specimen and promptly 
incubating the mixture undisturbed for 60 minutes at 37 0 C. A positive response on 
the gel clot test indicates there is an amount of endotoxin in the sample equals or 
exceeding the reagents labeled sensitivity. 
The LAL reaction requires a neutral pH and it is time and concentration dependent.  
1.Preparation of instruments:  
- Depyrogenate all glass ware and other heat stable apparatus in a hot air oven at 250 
0 C for 30 minutes.  
- Use sterile endotoxin-free, capped tubes and calibrated mechanical pipettes with 
sterile, disposable plastic tips.   
- Perform the test in a tested laminar air flow class I.   
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2.Preparation of Reagents:  Charles River Endosafe: It is composed of LAL reagent 
water and control standard endotoxin which was obtained from E. Coli 055 B5 and 
limulus Amoebocyte lysate single test (0.2 ml) with senstivity ג 0.25 .  
The control standard contains 5 EU/ ng and after constitution with 2.5 ml LAL 
reagent it contains 1000 EU/ ml.  
   Preparation of the control positive and negative tests:  
1.Reconstitute the lyophilized material with 2.5 ml of LAL reagent water to obtain 
100 Eu/ ml.  
2.In a vortex mixture, mix vigorously for 5 minute after rehydration and for one 
minute immediately before each test.  
3.Take 0.5 ml of the solution, add 9.5 ml lal water, this will obtain concentration of 50 
Eu/ ml.  
4.Take 0.5 ml and add 4.5 LAL water, this will give concentration 5 EU /ml. again 
take 0.5 ml and add 4.5 ml LAL water, this will give a concentration of 0.5 Eu/ ml, 
this is for a positive control.  
5. Dilute metronidazole I.V infusion which has a limit of 3.5 EU/ ml by the same 
manner to obtain a concentration of 0.25 Eu/ ml.  the sensitivity of the lysate.  
6.Use 0.2 ml of the solutions and add them to each of the two tubes containing the 
lysate specimen.  
7.Mix the content and immediately incubate at 37 0 C   10 C for 1 hour block 
thermolylyne incubator.  
Reading of Result:  
- Take each tube gently and turn it 1800.  
- An intact gel remaining upon inversion, the result is positive.  
- Runny or semi- solid response, the result is negative.  
- The sample passes the test when both results are negative. 
3.3.4.3 Total viable count and absence of specific organism:  
3.3.4.3.1  Total viable count:  
A. Preparation of culture Media:  
1. Preparation of buffered sodium chloride – peptone:  
Solution pH 7 (Neutral solution) B.P 2007 
Dissolve the constituents in a volume of water and mix well then complete to 1000 
ml. Sterilize by autoclaving at 1210 C for 15 minutes.  
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2.  Preparation of agar Medium B (Casein Soya bean digest Agar) 
Preparation:  
Suspend 40 gram of powder in purified water 1000 ml, Heat to boiling till dissolving 
the powder completely. Sterilize in an autoclave at 1210 C for 15 minutes.  
3.Preparation of Agar Medium C ( Sobauraud – glucose agar): B.P 2007 
HIMEDIA, India M 063, Purified water to1000 ml, adjust the pH to 5.6  0.2  
Suspend 65 gm of the powder in 1000 ml purified water. Boil to dissolve the medium 
completely. Sterilize by autoclaving at 1210 C for 15 minutes.  
4.Preparation of Broth Medium A ( Casein soya bean digest broth) B.P 2007 
Adjust pH at 7.3  0.2, Mix the ingredients till dissolution- and sterilize by 
autoclaving at 1210 C for 15 minutes. 
5.Preparation of Broth Medium D (Lactose monohydrate broth) B.P 2007. 
Merck. Adjust the pH to that after sterilization it is 6.9  0.2 Sterilize by autoclaving 
at 1210 C for 15 minutes and cool immediately.   
6.Enrichment broth Medium E ( Entrobacteria enrichment broth Mossel) B.P 
2007.  
7. Agar Medium F (Crystal violet, neutral red, bile agar with glucose) B.P 
2007 
Adjust the pH to is 7.2  0.2 after boiling  
8. Broth Medium G (Mac Conkey broth)  
Mix and dissolve the ingredient in 100 ml of water sterilize by autoclaving at 1210 C 
for 15 minutes the pH is 7.3  0.2 
9. Agar Medium H (Mac Conkey Agar)HIMEDIA – M 081  
- Suspend 51.5 gm in 1000 ml purified water.  
- Heat boiling with gentle stirring to dissolve the medium.  
- Sterilize by autoclaving at 1210C for 15 minutes, avoid over heating. PH 7.3  0.2 
10. Broth medium I; Tetrathionate – Aureicherungs. Bowillon (Basis) – Merck. 
Suspend 46 grams of powder in 1000 ml of purified water, add 20 m/L Iodine 
potassium iodide solution ( 6 gm iodine + 5 gm potassium iodide 20 l purified water) 
add 10 ml brilliant gram solution.  
Adjust pH 7.0    0.2 , heat just to boiling.   
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11.  Agar Medium J (Deoxycholate citrate agar) B.P 2007 – HIMEDIA M 065  
- Suspend 70.52 gm in 1000 ml distilled water. Heat to boiling to dissolve the 
medium completely, boiling only for 1 min, cool to 500 C.  
12. Xylose – lysine, deoxycholate agan Medium K  
B.P  2007, HIMEDIA M 031  
- Suspend 56.68 gm in 1000 ml distilled water.  
- Heat gently with frequent agitation until the medium boils.  
- Transfer immediately to a water bath at 500 C.  
- After cooling, pour into sterile petri plates.   
13. Agar Medium M (Triple Sugar Iron Agar)  
B.P 2007, HIMEDIA – M 0215  
- Suspend 65 gm in 1000 ml distilled water.  
- Heat to boiling to dissolve the medium completely .  
- Mix well and distribute into test tubes.  
- Sterilize by autoclaving at 1210 C for 15 minutes.  
14. Mannitol – Salt Agar Medium USP 2007   HIMEDIA M 118  
- Suspend 111 gm in 1000 ml distilled water.  
- Heat to boiling to dissolve the medium completely.  
- Sterilize by autoclaving at 1210C for 15 minutes.  
15. Agar Medium N ( Cetrimide agar) B.P 2007 HIMEDIA  M 024  
- Suspend 46.7 in 1000 ml distilled water containing 10 ml glycerol, heat to boiling to 
dissolve the medium completely.  
- Sterilize by autoclaving at 1210 C for 15 minutes.  
C. Evaluation of Media and Neutralizing Solution:  
1.Prepare the following solutions:  
Solution I : 100 ml buffered sodium chloride peptone solution pH 7 in a conical flask.    
Solution II: Place 4 grams polysorbate 80 in 100 ml conical flask and complete to 
volume by buffered sodium chloride peptone solution. Mix well by magnetic stirrer  
2.Place 7 test tubes in a rack;  
a. Place 10 ml of solution II in the first test tube.  
b.Place 7.5 ml of solution II and 1.25 ml solution I and mix.  
c. Place 6.25 ml  of solution II and 2.5 ml solution I and mix.  
d.Place 6.25 ml of solution II and 3.75 ml solution I and mix.  
e. Place 5 ml of solution II and 5 ml solution I and mix.  
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f. Place 3.75 ml of solution II and 6.25 ml solution I and mix.  
g.Place 2.5 ml of solution II and 7.5 ml solution I and mix.  
3.  Take one ml from each of the seven tubes and place it in each of 4 petri dishes and 
leave other 4 petri dishes. (32 petri dishes).  
4.Prepare 500 ml of medium B in a conical flask; melted and liquefied medium. And 
prepare 50 ml of liquefied medium C.  
5.At 450 C, pour 20 ml of liquefied medium B in two of the pour empty petri dishes 
and the other two medium C.  
6. Pour 20 ml medium B in two petri dishes of each dilution.  
7.Pour 20 ml medium C in two of each dilution.  
8.Agitate gently allow media to solidify.  
9.     Inoculate the first 16 petri dishes ( of medium B) by swab of staphylococcus 
aureus specimen and incubate at 330C for 5 days.  
10. Inocubale the second 16 petri dishes ( of medium C) by swab of Candida 
albicans specimen and incubate at 250C for 5day.  
The following diagram summarize the experiment  
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Observations:  
1.Growth is positive in all the 32 plates.  
2.In 24 plates a separate distinctive clear colonies are observed.  
3.In 8 plates those of concentration of polysorbate 80  3.5% and 4% in both media B 
and C, growth occur but no distinctive separate colonies but diffused and emulsified 
appearance and saponified. 
Comment:  
The concentration of 3% of polysorbate 80 could be used without injuring the growth 
of microorganism as inactivating agent in the serial dilutions in the diluents.  
C.  Preparation of the sample:  
(1) Sterilize a mortar and a pestle by washing carefully with a sufficient quantity 
of absolute ethanol.  
(2)  Sterilize all the glass ware in fisher isotemp oven at 1700 C for 2 hours.  
(3) Place 3 grams of polysorbate 80 in 100 volumetric flask and complete to 
volume by buffered sodium chloride peptone solution pH 7.  
(4) Place 10 ml of this solution in one test tube and 9 ml in each of the 9 test 
tubes. Close by cotton and aluminum foil and sterilize at a hot air oven at 1210 C for 
15 minutes.  
(5) In the sterile mortar finely powder 10 tablets of the tested tablets and 
accurately weigh 1 gram of the powder of tablets and dry suspension powder. 
(6) Suspend the weighed 1 gm powder in 10 ml buffered sodium chloride peptone 
solution – polysorbate 80, mix well and stir in vortex vibrator.  
(7) Prepare 10 fold dilutions from this suspension by taking 1 ml to the next 9 ml 
tube and from the resulting 10 ml to the next tube as so on. 
D- Examination of the sample  
Plate count method B.P 2007 (Appendix XVID Microbiological quality of 
pharmaceutical preparations ph. Eur method 2.6.12)  
Pour – Plate Method:  
(1) Prepare 8 sterile dishes for each dilution:  
a- In each add 1 ml of the specific dilution.  
b- In 4 petri dishes add 20 ml of liquefied medium B at 450 C, and inoculate by 
one swab of Staphylococcus aureues specimen to two of them.  
c- To the other 4 petri dishes, add liquefied medium C at 450 C and inoculate two 
of them by candida albicans specimen 
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d- Incubate the first four petri dishes of , media B in on oven at 330 C for 5 days 
and examine the culture.  
e- Incubate the other four petri dishes of medium C in an oven at 250 for 5days 
and examine the culture.  
(2)  Repeat the same procedure for each dilution 
E- Calculations:  
1.Select the plates corresponding to one dilution showing the highest number of 
colonies less than 300 CFU for medium B and 100 C.F. U for medium C.  
2.Record the dilution where the inoculated plate show C.F.U.  
3.Take the arithmetic average of the count for each two plate of one situation.   
4.Calculate the number of colony – forming units per gm of substance.  
5.Record the observation by video camera.  
6.Not move than 103 bacteria and not more than 102 fungi per gram of substance.  
F- Alternative Method for amoxicillin powder for suspension:  
Using penase enzyme:  
1.Add 5 ml sterile water to the vial of penase SRO 129 B (oxoid) with gentle mixing.  
2.Add 0.1 ml of the resulting solution to the buffered sodium chloride peptone 
solution pH 7 immediately before adding 1 gm of the sample to the first tube.  
3.Repeat the same procedure as mentioned in the plate method.  
3.3.4.3.2 Absence of specific organism:  
(B.P 2007, Appendix XVID, Microbiological quality of pharmaceutical preparation, 
ph. Eur general text 5.1.4, category 3, A) 
Preparation for oral and rectal administration, the required tests are the following: 
Absence of salmonella. Absence of E. coli. Absence of Staphylococcus aureus. Not 
more than 102 Enterobacteria.  
A. Test for E. coli  
1.Take 1 gm of the powder and add 10 ml of neutralizing solution. Shake well in 
sterile test tube.  
2.Add the whole quantity 10 ml to 100 ml broth medium A and homogenize in sterile 
conical flask. Incubate at 370 C for 48 hours.  
3.Shake the content and transfer 1 ml to 100 ml of broth medium G and incubate at 
450C for 24 hours.  
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4.Subculture on each of two sterile petri dishes of medium H at 370C for 72 hours. 
Growth of red, non-mucoid colonies of gram- negative rods indicates the possible 
presence of E. coli.  
B. Test for Salmonella Species:  
1.Take one gm of the finely powder sample to 10 ml broth medium A in sterile test 
tube shake well. Incubate at 370 C for 24 hours.  
2.Homogenize and take 1 ml to 10 ml broth medium and incubate at 430 C for 24 
hours.  
3.Subculture in two plates of agar medium J and two plates for agar medium K and 
incubate at370 C  for 72 hours.  
4.Observe the following colonies:  
Medium K : well – developed , red colonies with or without black center.  
Medium J : well developed, colourles colonies.  
5.Transfer separately a few of the colonies to agar medium M into two sterile test 
tubes. Inoculate at the surface, and deep in the medium. The presence of Salmonella is 
confirmed by the deep inoculation, but not the surface, the red colour changed to 
yellow, usually with the formation of gas.  
C- Test for Staphylococcus aureus: 
1.Take 1 gm of the powder and add it to 100 ml broth medium A. homogenize and 
incubate at 370 C for 48 hours. Subculture in two sterile plates of medium O and 
incubate at 370 C for 72 hours.  
2.Black colonies of gram – positive cocci, surrounded by a clear zone indicates the 
presence of Staphylococcus aureus.  
D- Test for Pseudomonas aeroginosa:  
1.Take 1 gm of the powder, place it in 100 ml of broth medium A and incubate at 37 
0C for 48 hours.  
2.Subculture in two sterile plates of mannitol – salt medium and cetrimide agar 
medium.  
3.Invert the dishes and incubate at 370 C for 72 hours.  
4.If no growth the samples passes the test.  
D- Detection of Entrobacteriacae species:  
E- The detective of Enterobacteriacae using HIMEDIA Ref: K B 003, kits, 
strip I Hi 25 TM Enterobacternacia  identification kit. It is a combination of 12 test for 
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identification of enterobacteriacae species. Strip II refer colon inoculate and observe 
the change of colour.  
F- Pharmacopoeial method for detection of Enterobacriacae:  
1.Take 1 gm of the powder and place it in sterile test tube and add 10 ml of broth 
medium D and incubate at 370C for 2 hours.  
2.Shake the content and transfer to 100 ml of medium E and incubate at 370C for 48 
hours.  
3.Subculture in two sterile plates of medium F and incubate passes the test if no 
growth.  
F- Quantification of enterobacteria and other gram-negative bacteria:  
1.Place 0.1 gm, 0.01 gm and 0.001 gm of the powder in broth medium A in 3 test 
tubes. 
2.Incubate 1 ml in broth medium E and incubate at 370C for 48 hours.  
3.Subculture each of the cultures on a plate of agar medium F and incubate at 370C 
for 24 hours.  
4.Growth of well developed colonies, red to reddish, constitutes a positive result.  
5.Note the smallest concentration of the product which gives a positive result and the 
largest quantity that gives negative result determine the probable from the table :  
0.1 gm  0.01 gm  0.001 gm  Probable No per gm  
+ + +  More than 103  
+ +  -  More than 102 
+  +  -  Less than 102 
- - -  Less than 10 
3.4 Treatment of Data:  
3.4.1 Mean kinetic temperature:  
Mean kinetic temperature for every month of the year and for each of the six stations 
and had been calculated. 
1. Using SK-SATO LH III 200 software, data had been downloaded in hp computer. 
2. Then it had been transferred to CVS spread sheet and to note pad program.  
3. Using both methods of USP and FDA, the MKT had been calculated.  
4. The software used was Scien Teck stability system II software for calculating mean 
kinetic temperature by Dr. Yang using and activation energy 83.114 KJ Moe -1 
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5.Results of both methods of USP and FDA are compared and final result is compared 
to the international mean kinetic temperature of Sudan.  
6.The mean kinetic temperature had been calculated for the six stations according to 
the meteorological data, and the international data of WMO also used to calculate the 
MKT. Then the results were compared.  
7.Estimation of the MKT for the worst condition is used to locate the country in the 
international  zones.     
3.4.2 Reference Thermal exposure:  
R. thermal exposure is an unofficial approach for calculating the total exposure 
temperature as a function of temperature and period of exposure. The approach was 
proposed by pharmaceutical manufacturing association in USA – 1980.  
The time in hours for each range of temperature emphasis to compare there results 
with those of the mean kinetic temperature with the potency of drugs, had been made.  
Using not less than 5000 readings for each of the six stations for temperature, 
humidity, date and time were used in the calculation.  
SPSS software  and Excel statistical packages were used in this field.      
3.4.3 Meteorological Recorded Data:  
Data of the temperature and the relative humidity of the six stations were obtained 
from the National Meteorological Authority for the last 30 years and compared with 
the experimental data.    
3.4.4 Stability testing:  
- Stability testing was carried out using WHO and ICH guidelines.  
- Evaluation of the results according to QE, ICH guideline.  
- Regression analysis for the potency versus time for every station was performed 
taking 5% lower level of confidence and the p of replicates 0.05. Using Statistica 
software version 16 and/ or SPSS version 14 statistical packages and Microsoft Excel 
spread sheet.  
- The shelf life of each product at each station was calculated and compared to that of 
the product label.  
- The effect of storage conditions on the expiration date was obtained.  
- The storage conditions being measured was compared with that stated on the label 
and with those described by WHO and ICH guidelines and other international 
publications. 
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4. Results 
4.1 The Mean kinetic Temperature and the Relative Humidity: 
The MKT and the average RH for transportation and storage facilities for the different 
stations were calculated using data from different sources and different methods of 
calculation. Stability System II Software version 1.7 was used. The monthly average 
RH and Reference Thermal Exposure were obtained for each station. 
4.1.1 Damazin Station: 
4.1.1.1 Transportation conditions: The following data was recorded by the 
 datalogger during transportation from Khartoum to Damazin via usual goods loading 
truck.                   Table (6) Transportation conditions to Damazin 
=No                        °C %RH No                   °C %RH 
1 30.8 17.3 15 39.1 15.3 
2 31.4 16.5 16 40.8 15.1 
3 30.6 16.2 17 41.2 14 
4 30 16.2 18 37.2 15 
5 29.1 16.1 19 36.1 15.1 
6 28.2 16.1 20 35.3 15.1 
7 27.1 16.2 21 34.7 15.3 
8 26.1 16.3 22 34.1 15.3 
9 25.1 16.4 23 33.6 15.3 
10 26.3 16.3 24 33.1 15.4 
11 28.4 16.2 25 31.9 15.6 
12 30.3 16.2 26 30.7 15.9 
13 32.6 15.8 27 30.3 15.9 
14 35.9 15.6 28 30.8 15.8 
Using the pooled data method the MKT is 33.1 °C and the average RH is 15.7%. 
4.1.1.2 The Past Meteorological Records for Damazin: 
The monthly mean of the minimum and maximum temperature and the monthly 
average RH % for the years 1962 to 1991 were used to calculate the MKT and the 
monthly average RH % as in table (7) 
 Table (7) Damzin Monthly Maximum and Minimum Temperature &RH%  
month Mean max °C Mean min °C Av RH% month Mean max °C Mean min °C Av RH% 
Jan 35.2 16.6 30 July 32.1 21.4 74 
Feb 36.9 18.3 23 August 31.3 21 79 
March 39.5 21.7 20 Sept 32.5 20.9 76 
April 40.6 24.2 25 Oct 34.9 21.3 67 
May 38.5 24.8 44 Nov 36.8 19 40 
June 35.3 22.6 61 Dec  35.6 16.9 33 
From the above table, the storage conditions of Damazin is 28.5 °C/ 47.7 % RH.  
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4.1.1.3 Recent Meteorological Records: 
Meteorological records for the period from April 2007 to March 2008 which is the 
same period of the study was obtained as 10 days mean of daily maximum and 
minimum temperature together with the monthly average RH.  
Table (8) Meteorological records (4.2007- 3.2008) 
Dekad  Max °C Min °C  RH % Dekad  Max°C  Min°C  RH % 
4.07-1 41.9 26.1 24.4 9.07-1 31.3 20.8 76 % 
4.07-2 39.3 21.6  9.07-2 32.6 21.7  
4.07-3 40.5 27.6  9.07-3 33.5 21.7  
5.07-1 39.7 26.4 40 % 10.07-1 33.6 21.9 70 % 
5.07-2 40 27.1  10.07-2 34.9 22.2  
5.07-3 38.1 26.2  10.07-3 35.5 22  
6.07-1 35.7 23 62 % 11.07-1 35.7 21.3 54 % 
6.07-2 34.5 22.7  11.07-2 36.5 21.8  
6.07-3 33.1 23.6  11.07-3 37.6 18.2  
7.07-1 31.1 21.9 77 % 12.07-1 37.9 18.2 35 % 
7.07-2 30.5 21.8  12.07-2 36.8 18.2  
7.07-3 32 22.1  12.07-3 36.1 18  
8.07-1 30.8 22 80 % 1.08-1 37.3 17.5 43 % 
8.07-2 31.6 22  1.08-2 35.8 18.2  
8.07-3 31.3 21.6  1.08-3 33.1 18.4  
2.08-1 36.9 17.5 25 % 3.08-1 40.9 20.7 20 % 
2.08-2 35.9 19.3  3.08-2 40.2 22.5  
2.08-3 37.5 20.8  3.08-3 41.7 24.1  
 
Inserting the 72 readings into the Stability System program, the mean kinetic 
temperature was found to be 31.7 °C, the monthly average RH is 50.4 %.  
4.1.1.4 In-house datalogger readings from April 2007 to March 2008: 
Total of 5967 readings for each of temperature and relative humidity were recorded 
and used to calculate the ambient conditions for the hospital pharmacy. (app.3). The 
MKT is 25.4 °C. The monthly average RH is 41.3%, ( App. 1). 
4.1.1.5 The MKT using USP method of calculation:  
Using the date column of datalogger records, data was split into weeks excluding 
transportation period. Total of 112 readings for every week of the 52 weeks were then 
sorted out as maximum and minimum, then the average for every week was obtained.  
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Table (9 ) weekly max, min and average temperature for Damazin 
week Min  °C Max°C average week Min °C Max°C average 
1 24.6 28.1 26.35 27 25.6 27.3 26.45 
2 23.1 26.7 24.9 28 25.6 26.3 25.95 
3 23.1 28.4 25.75 29 25.1 26.4 25.75 
4 22.1 27.8 24.95 30 25.1 26.6 25.85 
5 23.3 26.9 25.1 31 22.7 26.6 24.65 
6 23.9 25.9 24.9 32 22.3 23.6 22.95 
7 24.1 26.6 25.35 33 22.3 23.6 22.95 
8 24.5 26.8 25.65 34 21.7 24 22.85 
9 25.1 26.8 25.95 35 22.4 26.2 24.3 
10 26.6 27.6 27.1 36 21 26.6 23.8 
11 26.4 27.9 27.15 37 21.3 26 23.65 
12 25.8 27.7 26.75 38 21.8 26.5 24.15 
13 25.8 26.5 26.15 39 21.9 26.3 24.1 
14 25.9 27.1 26.5 40 22.3 28.2 25.25 
15 26.3 26.9 26.6 41 25.3 27.3 26.3 
16 26.2 26.9 26.55 42 22.7 27.1 24.9 
17 26.3 26.9 26.6 43 21.9 27.9 24.9 
18 25.9 26.8 26.35 44 22.1 27.4 24.75 
19 25.7 27.1 26.4 45 26.6 28.1 27.35 
20 26.3 26.8 26.55 46 24.8 28.4 26.6 
21 25.8 26.8 26.3 47 24.4 26.1 25.25 
22 26 27.1 26.55 48 23.2 28.4 25.8 
23 25.8 26.8 26.3 49 22.8 28.8 25.8 
24 25.4 26.9 26.15 50 24 27.3 25.65 
25 26.3 27.1 26.7 51 24.4 25.8 25.1 
26 26.2 27.2 26.7 52 24.3 26.1 25.2 
The MKT for Damazin using USP method of calculation is 25.6 °C.  
4.1.1.6 MKT calculation using the minimum required data for the FDA:  
The weekly high and low readings were inserted into the Stability System II program, 
total of 104 readings ( table  9   ), and MKT was 25.6 °C. 
4.1.1.7 Reference Thermal Exposure: 
Using statistica statsoft version 6, data was analyzed to obtain the frequencies of 
temperature at five degrees intervals, then multiplied by the fixed duration of time 
intervals. 
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Table ( 10   ) Reference Thermal Exposure 
 interval frequency duration RTE in hours 
1 15 °C - < 20 °C 30 90 min 45 hours 
2 20 °C - < 25 °C 2070 90 min 3105 hours 
3 25 °C - < 30 °C 3876 90 min 5814 hours 
4 30 °C - < 35 °C 14 90 min 21 hours 
5 35 °C - < 40 °C 9 90 min 13.5 hours 
6 40 °C -  45 °C 3 90 min 4.5 hours 
 
4.1.2 Dongola Station: 
4.1.2.1 Transportation conditions:  The following data was recorded by the 
datalogger during transportation from Khartoum to Dongola via usual passenger's bus.  
Table (11) Transportation conditions to Dongola 
Using the pooled data method the MKT is 34 °C and the average RH is 16.6%. 
4.1.2.2 The Past Meteorological Records for Dongola: 
The monthly average of the minimum and maximum temperature and the monthly 
average RH for the years 1962 to 1991 were used to calculate the MKT /RH%. 
Table (12 ) Dongola Monthly Maximum and Minimum Temperature:  
month Mean Max. Mean Min Month Mean Max. Mean Min 
Jan 26.5 8.7 July 42.6 25.5 
Feb 29.3 10.1 August 42.2 25.7 
March 33.7 14 Sept 41.8 25.4 
April 38.9 18.9 Oct 39 21.8 
May 42.2 23.2 Nov 32.1 14.9 
June 43.1 24.9 Dec  28.2 10.3 
No C %RH No C %RH 
1 27.5 23.9 10 29.6 16.3 
2 39.4 24.1 11 28.8 16.4 
3 42.1 15.2 12 28.2 16.7 
4 40.3 14 13 26.9 16.9 
5 38.6 14 14 27.6 16.8 
6 36.3 14 15 33.3 15.6 
7 34.5 15.2 16 34.5 15.2 
8 32.1 15.7 17 30.0 16.2 
9 31.1 15.9    
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According to the above data the MKT for Dongola is 29.4 °C.   
4.1.2.3 Recent Meteorological Records: 
Meteorological records for the period from April 2007 to March 2008 which is the 
same period of the study was obtained as 10 days mean of daily maximum and 
minimum temperature together with the monthly average RH. ( App. 3). 
          Table ( 13   ).  Meteorological records (4.2007- 3.2008) 
Dekad  Max°C  Min°C  RH % Dekad  Max°C  Min°C  RH % 
4.07-1 41.1 22.5 15 % 10.07-1 39.1 23 20 % 
4.07-2 36.3 17.1  10.07-2 39.7 23.4  
4.07-3 43.3 23  10.07-3 40.2 22.8  
5.07-1 44.4 26.9 15 % 11.07-1 38.3 21.8 24 % 
5.07-2 40.4 22.2  11.07-2 35.5 18.5  
5.07-3 43.8 24.5  11.07-3 31.6 13.8  
6.07-1 44 25.7 17 % 12.07-1 30.7 14.5 31 % 
6.07-2 43.2 25.2  12.07-2 29.1 11.8  
6.07-3 43.8 26.3  12.07-3 28.2 10.4  
7.07-1 42.6 27.1 29 % 1.08-1 29.6 12.3 31 % 
7.07-2 41.2 27.7  1.08-2 24.9 9.6  
7.07-3 43.8 28.2  1.08-3 22.3 8.9  
8.07-1 43.9 29.8 26 % 2.08-1 28.2 10.2 29 % 
8.07-2 43.4 28.9  2.08-2 25.3 8.6  
8.07-3 42.5 28.8  2.08-3 29.7 11.4  
9.07-1 42.1 26.7 21 % 3.08-1 36.7 16.5 19 % 
9.07-2 39.8 24.6  3.08-2 33.5 16.1  
9.07-3 39.3 23.8  3.08-3 39 18.6  
 
Using the pooled data method, 72 readings were inserted into the Stability System 
program the MKT was found to be 33.8 °C. The monthly average RH is 23.1 %.  
4.1.2.4 In-house Datalogger readings from April 2007 to March 2008: 
Total of 3901 readings for each of temperature and relative humidity were recorded 
and used to calculate the ambient conditions for the hospital pharmacy. ( app 2  ). The 
MKT is 27.1 °C. The monthly average RH is 22.9 %. 
4.1.2.5 The MKT using USP method of calculation:  
Using the date column of datalogger records, data was split into weeks excluding 
transportation period. Total of 112 readings for every week of the 52 weeks were then 
sorted out as maximum and minimum, then the average for every week was obtained. 
(Table 14    ).   
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Table ( 14 ) Weekly max, min and average temperature for Dongola 
   week Min  °C Max°C average week Min °C Max°C average 
1 19.7 26.9 23.3 27 21.3 23 22.15 
2 21.1 34.5 27.8 28 21.8 24.9 23.35 
3 23.4 41.3 32.35 29 22.2 25.1 23.65 
4 28.5 32.4 30.45 30 23.6 24.2 23.9 
5 29.2 32.3 30.75 31 21.9 24.1 23 
6 26.6 32.8 29.7 32 21.6 22.2 21.9 
7 28.8 32.6 30.7 33 21.3 22.3 21.8 
8 28.7 32.8 30.75 34 20.7 21.3 21 
9 28.6 33.8 31.2 35 19.4 20.8 20.1 
10 29.2 34 31.6 36 20.7 22.2 21.45 
11 28.6 32.6 30.6 37 20.4 22.5 21.45 
12 28.7 33.2 30.95 38 19.8 21.9 20.85 
13 28.1 32.8 30.45 39 20.3 21.4 20.85 
14 25.4 37.3 31.35 40 21.6 22.9 22.25 
15 28.8 29.6 29.2 41 22.1 26.9 24.5 
16 28.9 29.6 29.25 42 23.3 28.2 25.75 
17 28.8 29.6 29.2 43 25.1 27.1 26.1 
18 28.1 29.5 28.8 44 24.9 26.9 25.9 
19 27.5 28.3 27.9 45 25.6 28.4 27 
20 23.6 28.3 25.95 46 27.7 29 28.35 
21 21.3 26.3 23.8 47 27.5 28.6 28.05 
22 21.4 24.9 23.15 48 27.6 28.4 28 
23 21.3 24.3 22.8 49 27.3 28.6 27.95 
24 21.8 24.2 23 50 28.3 30.4 29.35 
25 22.4 24 23.2 51 29.6 42.1 35.85 
26 21.1 23.9 22.5 52 28.1 30 29.05 
The MKT for Dongola using USP method of calculation is 27.2 °C.  
4.1.2.6 MKT calculation using the minimum required data for the FDA:  
The weekly high and low readings were inserted into the Stability System II program, 
total of 104 readings ( table 14 ), and it was 27.6 °C. 
4.1.2.7 Reference Thermal Exposure: 
Using statistica statsoft version 6, data was analyzed to obtain the frequencies of 
temperature at five degrees intervals then multiplied by the fixed duration of time 
interval.                   Table ( 15 ) Reference Thermal Exposure  
 interval frequency duration RTE in hours 
1 15 °C - < 20 °C 36 90 min 54 hours 
2 20 °C - < 25 °C 1733 90 min 2600 hours 
3 25 °C - < 30 °C 1382 90 min 2073 hours 
4 30 °C - < 35 °C 717 90 min 1075 hours 
5 35 °C - < 40 °C 35 90 min 52.5 hours 
6 40 °C -  45 °C 10 90 min 15 hours 
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4.1.3 Fashir Station: 
4.1.3.1 Transportation conditions: The following data was recorded by the 
datalogger during transportation from Khartoum to Fashir  by plane via Khartoum 
airport. 48 readings were recorded. 
Using the pooled data method the MKT is 30.6 °C and the average humidity is 15.8%. 
4.1.3.2 The Past Meteorological Records for Fashir: 
The monthly average of the minimum and maximum temperature and the monthly 
average RH for the years 1962 to 1991 were used to calculate the MKT and the 
monthly average RH as follows:  
Table ( 16  ) Fashir Monthly Maximum and Minimum Temperature &RH% 
Month Mean max °C Mean min °C Month Mean max °C Mean min °C 
Jan 29.4 9.9 July 35.8 22.9 
Feb 31.8 11.9 August 34.6 22.3 
March 35.2 15.9 Sept 35.8 21.8 
April 37.9 19 Oct 36 19.5 
May 38.9 22.1 Nov 32.7 13.7 
June 38.5 23.3 July 35.8 22.9 
According to the above data the MKT for Fashir is: 26.9 °C.  
4.1.3.3 Recent Meteorological Records for Fashir: 
Meteorological records for the period from April 2007 to March 2008 which is the 
same period of the study was obtained as 10 days mean of daily maximum and 
minimum temperature together with the monthly average RH.  
          Table ( 17 )  Meteorological records (4.2007- 3.2008) 
Dekad  Max°C  Min°C  RH % Dekad  Max°C  Min°C  RH % 
4.07-1 39.4 21.9 13 10.07-1 36.6 20.6 19 
4.07-2 36 18.9  10.07-2 36.5 22.5  
4.07-3 39.8 23  10.07-3 36.8 19.7  
5.07-1 40.4 26 22 11.07-1 35.3 19.3 17 
5.07-2 38.2 26.1  11.07-2 34 196.8  
5.07-3 40.1 23.8  11.07-3 31.8 13.9  
6.07-1 39.5 25.7 31 12.07-1 31.4 13.9 20 
6.07-2 38.6 26  12.07-2 30.4 10.1  
6.07-3 37.9 25  12.07-3 28.8 10.4  
7.07-1 37 24.6 50 1.08-1 32.2 13.1 18 
7.07-2 33.4 23.3  1.08-2 29.6 12.6  
7.07-3 34.7 23.5  1.08-3 26.4 12.9  
8.07-1 32.7 22.7 59 2.08-1 31.3 11.4 15 
8.07-2 33.2 23.2  2.08-2 28.7 11.6  
8.07-3 31.6 21.6  2.08-3 31.8 12.6  
9.07-1 33.9 22.5 37 3.08-1 36.3 15.4 13 
9.07-2 35.3 22.5  3.08-2 33.3 18.7  
9.07-3 36.8 22.1  3.08-3 38.2 18.9  
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Using the pooled data method, 72 readings were inserted into the Stability System 
program, the MKT was found to be 27.8 °C. The annual average RH is 26.2 %.  
4.1.3.4 In-house datalogger readings from April 2007 to March 2008: 
Total of 5025 readings for each of temperature and relative humidity were recorded 
and used to calculate the ambient conditions for the hospital pharmacy. (app 4, 5). 
The MKT is 28.8 °C. The monthly average RH is 19.4 %. 
4.1.3.5 The MKT of Fashir using USP method of calculation:  
Using the date column of datalogger records, data was split into weeks excluding 
transportation period. Total of 112 readings for every week of the 52 weeks were then 
sorted out as maximum and minimum, then the average for every week was obtained. 
(Table 18 ).   
Table ( 18  ) Weekly max, min and average temperature for Fashir 
week Min  °C Max°C average week Min °C Max°C average 
1 21.6 36.9 29.25 27 21.9 28.7 25.3 
2 31.1 37.3 34.2 28 21.7 24.5 23.1 
3 31.3 38.2 34.75 29 20.4 24.5 22.45 
4 33.5 38.4 35.95 30 20.3 27.4 23.85 
5 33.2 38.6 35.9 31 21 28.7 24.85 
6 32.1 38.4 35.25 32 20.5 27.7 24.1 
7 32.4 37.5 34.95 33 21.2 27.3 24.25 
8 33.6 38.3 35.95 34 19 25.1 22.05 
9 33 37.9 35.45 35 21.5 28.7 25.1 
10 33.3 37.4 35.35 36 22.2 27.1 24.65 
11 32.4 37.6 35 37 21.6 28.4 25 
12 29.5 36.9 33.2 38 20.1 29.1 24.6 
13 25.7 35.9 30.8 39 19.9 25.8 22.85 
14 24.5 35.6 30.05 40 17.8 25.4 21.6 
15 20.8 32 26.4 41 22.8 29.8 26.3 
16 22.1 28.4 25.25 42 19.9 29.5 24.7 
17 20.1 26.3 23.2 43 20.1 26.6 23.35 
18 22.1 31.4 26.75 44 21.6 28.8 25.2 
19 22.8 30.9 26.85 45 22.6 30.6 26.6 
20 22.8 33.1 27.95 46 23.3 31.2 27.25 
21 22.7 27.6 25.15 47 22.8 29.6 26.2 
22 23 29.6 26.3 48 23.8 31.3 27.55 
23 23.2 29.4 26.3 49 23.7 30.2 26.95 
24 23 30.9 26.95 50 23.1 30.3 26.7 
25 22.6 28 25.3 51 24.3 30.1 27.2 
26 20.8 29.8 25.3 52 25.5 36.4 30.95 
 
The MKT for Fashir using USP method of calculation is 28.8 °C.  
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4.1.3.6 MKT calculation using the minimum required data for the FDA:  
The weekly high and low readings were inserted into the Stability System II program, 
total of 104 readings ( table 18 ), and MKT was 28.8 °C. 
4.1.3.7 Reference Thermal Exposure: 
Using statistica statsoft version 6, data was analyzed to obtain the frequencies of 
temperature at five degrees intervals then multiplied by the fixed duration of time 
intervals. 
        Table (19    ) Reference Thermal Exposure temperature 
 Interval frequency duration RTE in hours 
1 15 °C - < 20 °C 28 90 min 42 hours 
2 20 °C - < 25 °C 2064 90 min 3096 hours 
3 25 °C - < 30 °C 1889 90 min 2833.5 hours 
4 30 °C - < 35 °C 616 90 min 924 hours 
5 35 °C - < 40 °C 714 90 min 1071 hours 
6 40 °C -  45 °C 2 90 min 3 hours 
4.1.3.4 Variations of temperature as a function of daily time: 
Using SPSS software to split data as function of time then the mean temperature for 
the given time was obtained, and then the mean temperature of the given period of 
time was determined. (table 20     ) 
Table ( 20  ) The average temperature at each taken period 
 Time Mean temperature in °C 
1 08 : 00 AM  to   03 : 30 PM 28.7 °C 
2 04 : 00 PM  to   11 : 00 PM 29.3 °C 
3 12 : 00 AM  to  07 : 30 AM 27.7 °C 
 
4.1.4 Juba Station: 
4.1.4.1 Transportation conditions: The following data was recorded by the 
Datalogger during transportation from Khartoum by airfreight to Juba accompanying 
hospital drugs consignment. Table (21) Transportation conditions to Juba 
 
No   °C % RH 
 
No 
                                 
°C 
                        
   %       RH 
1 45.3 16.7 5 27.5 43.4 
2 27.8 50.6 6 28 40.4 
3 27.1 51.3 7 29.5 38.8 
4 27.3 47.6 8 30.9 38.8 
Using the pooled data method the MKT is 32.7 °C and the average RH% is 41%. 
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4.1.4.2 The Past Meteorological Records for Juba: 
The monthly average of the minimum and maximum temperature and the monthly 
average RH for the years 1962 to 1991 were used to calculate the MKT and the 
average RH as follows:  
Table (22 ) Juba Monthly  Maximum and Minimum Temperature:  
month Mean 
max °C 
Mean min 
°C 
RH % month Mean 
max °C 
Mean min 
°C 
RH % 
Jan 46.8 20.1 39 July 31.1 21.1 77 
Feb 37.9 21.7 37 August 31.6 21 76 
March 37.7 23.6 45 Sept 33.1 21.1 72 
April 35.4 23.4 60 Oct 34 21.3 69 
May 33.5 22.6 70 Nov 34.7 20.9 64 
June 32.4 21.9 73 Dec  35.9 20 48 
From the above data the MKT and the RH for Juba are 28.8 °C / 60.8 % respectively.    
4.1.4.3 Recent Meteorological Records: 
Meteorological records for the period from April 2007 to March 2008 which is the 
same period of the study was obtained as 10 days mean of daily maximum and 
minimum temperature together with the monthly average RH. (Table23).  
Table (23) Meteorological records (4.2007- 3.2008) 
Dekad  Max°C  Min°C  RH % Dekad  Max°C  Min°C  RH % 
4.07-1   35.7  23.7 54.4 10.07-1 33.5 21.2 57 
4.07-2 34.0 23.4  10.07-2 35.6 20.4  
4.07-3 34.9 23.0  10.07-3 34.5 20.6  
5.07-1 35.5 23.5 59.7 11.07-1 34.7 20.5 55 
5.07-2 33.4 22.2  11.07-2 34.7 21.3  
5.07-3 33.7 23.0  11.07-3 35.3 21  
6.07-1 30.9 21.9 71.3 12.07-1 35.6 20.8 39 
6.07-2 31.6 21.8  12.07-2 36.1 20.7  
6.07-3 30.8 21.4  12.07-3 36.4 19.4  
7.07-1 29.6 21.3 72.2 1.08-1 37.9 20.8 35 
7.07-2 30.7 20.7  1.08-2 36 21.7  
7.07-3 30.8 20.9  1.08-3 35.7 21.2  
8.07-1 30.4 20.7 73.3 2.08-1 36.2 22.3 27 
8.07-2 31.0 20.7  2.08-2 37.4 21.9  
8.07-3 30.6 20.7  2.08-3 37.9 22.7  
9.07-1 30.5 21.0 74.4 3.08-1 38.6 24.1 41 
9.07-2 30.8 20.3  3.08-2 37.4 24.4  
9.07-3 29.1 19.8  3.08-3 35.7 23.8  
 
Using the pooled data method, 72 readings were inserted into the Stability System 
program the MKT was found to be 28 °C. The annual average RH is 55 %.  
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4.1.4.4 In-house Datalogger readings from April 2007 to March 2008: 
Total of 5285 readings for each of temperature and relative humidity were recorded 
and used to calculate the ambient conditions for the pharmacy. ( app 6). The mean 
kinetic temperature is 29.2 °C. The monthly average RH is 44 %. 
4.1.4.5 The MKT using USP method of calculation:  
Using the date column of datalogger records, data was split into weeks excluding 
transportation period. Total of 112 readings for every week of the 52 weeks were then 
sorted out as maximum and minimum, then the average for every week was obtained.  
Table (  24 ) Weekly max, min and average temperature for Juba 
week Min  °C Max°C average week Min °C Max°C average 
1 21.0 37.5 29.25 27 18.5 25.8 22.15 
2 21.0 38 29.5 28 20.1 26.6 23.35 
3 22.0 36.5 29.25 29 19.6 25.9 22.75 
4 22.0 36.5 29.25 30 19.9 22.6 21.25 
5 20.5 34.0 27.25 31 19.8 26.6 23.2 
6 21.5 36.5 29 32 22.4 27.9 25.15 
7 21.5 34.5 28 33 23.1 28.7 25.9 
8 19.5 33.5 26.5 34 20.5 27.9 24.2 
9 21.0 32.0 26.5 35 20.3 27.2 23.75 
10 20.0 32.5 26.25 36 19.3 25.4 22.35 
11 20.0 33.5 26.75 37 21.3 27.6 24.45 
12 21.0 31.0 26 38 24.9 29.2 27.05 
13 20.1 32.2 26.15 39 27.0 30.3 28.65 
14 19.5 32.8 26.15 40 26.6 30.6 28.6 
15 19.5 32.6 26.05 41 28.3 31.1 29.7 
16 19.5 33.2 26.35 42 28.8 31.1 29.95 
17 19.5 32.7 26.1 43 28.9 30.8 29.85 
18 20.2 32.5 26.35 44 19.4 30.9 25.15 
19 19.5 33.5 26.5 45 19.6 24.9 22.25 
20 19.5 31.5 25.5 46 19.8 25.8 22.8 
21 19.0 33.0 26 47 20.6 29.7 25.15 
22 21.4 33.5 27.45 48 21.2 29.5 25.35 
23 21.4 33.5 27.45 49 20.4 31.6 26 
24 19.3 23.7 21.5 50 20.6 29.5 25.05 
25 18.8 22.4 20.6 51 20.6 29.5 25.05 
26 19.3 23.1 21.2 52 20.6 29.5 25.05 
The MKT for Juba using USP method of calculation is 26.1 °C, (App. 7). 
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4.1.4.6 MKT calculation using the minimum required data for the FDA:  
The weekly high and low readings were inserted into the Stability System II program, 
total of 104 readings ( table  24   ), and so MKT was 26.1 °C. 
4.1.4.7 Reference Thermal Exposure: 
Using statistica statsoft version 6, data was analyzed to obtain the frequencies of 
temperature at five degrees intervals then multiplied by the fixed duration of time. 
Table ( 25   ) Reference Thermal Exposure temperature 
 interval frequency duration RTE in hours 
1 15 °C - < 20 °C 294 90 min 36 hours 
2 20 °C - < 25 °C 1426 90 min 2139 hours 
3 25 °C - < 30 °C 1139 90 min 1708.5 hours 
4 30 °C - < 35 °C 2047 90 min 3111 hours 
5 35 °C - < 40 °C 378 90 min 567 hours 
6 40 °C -  45 °C 1 90 min 1.5 hours 
 
4.1.4.9 Relative Humidity Time Exposure: 
The annual room relative humidity is analyzed using Statistica Statsoft version 6 
package, (table 26    ) 
Table (  26  ) Exposure Time of Relative Humidity 
 RH%  range Count Time interval Exposure hours 
1 10 -< 20  1 90 minutes 1.5 
2 20 -< 30 1329 90 minutes 1993.5 
3 30 -< 40 1214 90 minutes 1821 
4 40 -< 50 333 90 minutes 499.5 
5 50 -< 60 363 90 minutes 544.5 
6 60 -< 70 924 90 minutes 1386 
7 70 -< 80 767 90 minutes 1105.5 
8 80 -< 90 336 90 minutes 504 
9 90 --100 18 90 minutes 27 
 
4.1.5 Khartoum Station: 
4.1.5.1 Transportation conditions:  
The Datalogger recorded 50 °C and 45.9 °C as a car cabinet temperature for three 
hours at Khartoum traffics.  
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4.1.5.2 The Past Meteorological Records for Khartoum: 
The monthly average of the minimum and maximum temperature and the monthly 
average RH for the years 1962 to 1991 (app. 10) were used to calculate the MKT and 
the annual average RH as follows:  
Table (27   ) Khartoum Monthly  Maxi-Minimum Temperature and RH 
month Mean max°C Mean 
min°C 
RH % month Mean 
max°C 
Mean 
min°C 
RH % 
Jan 30.7 15.6 26 July 38.5 26.2 42 
Feb 32.6 16.8 21 August 37.6 25.6 48 
March 36.5 20.3 16 Sept 38.7 26.3 41 
April 40.4 24.1 15 Oct 39.3 25.9 29 
May 41.9 27.3 20 Nov 35.2 21 26 
June 41.3 27.6 26 Dec  31.7 17 29 
From the above data the MKT for Khartoum and the average RH is 30.6 °C / 28 %.   
4.1.5.3 MKT Using WMO Data: The International data for Sudan climate was 
presented by WMO. (table 28 ) shows the monthly data for the daily mean of max and 
min temperature. ( App. 9).          
     Table ( 28 ) WMO Khartoum Temperature Profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to the above data, the MKT for Khartoum is 33 °C. 
Mean Temperature oC 
Month Daily 
Minimum 
Daily 
Maximum 
Jan 15.6 30.8 
Feb 17.0 33.0 
Mar 20.5 36.8 
Apr 23.6 40.1 
May 27.1 41.9 
Jun 27.3 41.3 
Jul 25.9 38.4 
Aug 25.3 37.3 
Sep 26.0 39.1 
Oct 25.5 39.3 
Nov 21.0 35.2 
Dec 17.1 31.8 
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4.1.5.4 Recent Meteorological Records: Meteorological records for the period from 
April 2007 to March 2008 which is the same period of the study was obtained as 10 
days mean of daily maximum and minimum temperature together with the monthly 
average RH. ( App. 11). 
          Table (29 ). Recent Meteorological records (4.2007- 3.2008) 
Dekad  Max°C  Min°C  RH % Dekad  Max°C  Min°C  RH % 
4.07-1 41.8 28.3 15 10.07-1 41.9 27.5 29 
4.07-2 37.7 27.8  10.07-2 40.7 26.6  
4.07-3 43.2 28.5  10.07-3 40.3 26.3  
5.07-1 44.3 28.3 14 11.07-1 39.4 25.2 30 
5.07-2 42.2 27.8  11.07-2 38 24.8  
5.07-3 44 28.7  11.07-3 35.8 20.5  
6.07-1 42.9 29.2 33 12.07-1 35.7 21.5 36 
6.07-2 41.7 27.3  12.07-2 34.4 19.5  
6.07-3 40.2 28.2  12.07-3 32.4 17.1  
7.07-1 36.6 25.6 69 1.08-1 33.4 18 35 
7.07-2 34.2 24.8  1.08-2 33.3 16.4  
7.07-3 37.1 26.3  1.08-3 27.6 15.5  
8.07-1 34.9 24.8 72 2.08-1 33.7 16.4 27 
8.07-2 36.6 25.8  2.08-2 31.6 15.6  
8.07-3 35.3 25.3  2.08-3 33.9 18.2  
9.07-1 36.5 24.6 80 3.08-1 39.5 21.6 14 
9.07-2 39.3 26.8  3.08-2 38.6 22.4  
9.07-3 41 26.7  3.08-3 42.2 23.4  
 
Using the pooled data method, 72 readings were inserted into the Stability System 
program, the MKT was found to be 31.6 °C. The annual average RH is 37.8 %.  
4.1.5.5 In-house Datalogger readings from April 2007 to March 2008: 
Total of 5173 readings for each of temperature and relative humidity were recorded 
and used to calculate the ambient conditions for the pharmacy. ( app 8 ). The mean 
kinetic temperature is 26.2 °C. The monthly average RH is 28.2 %. 
4.1.5.6 The MKT using USP method of calculation:  
Using the date column of datalogger records, data were split into weeks excluding 
transportation period. Total of 112 readings for every week of the 52 weeks were then 
sorted out as maximum and minimum then the average for every week was obtained.  
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Table (  30 ) Weekly max, min and average temperature for Khartoum 
week Min  °C Max°C average week Min °C Max°C Average 
1 17.4 27.3 22.35 27 22.4 31.8 27.1 
2 20.1 29.4 24.75 28 23.1 32.6 27.85 
3 21.1 30.4 25.75 29 23.2 32.1 27.65 
4 20.1 30.6 25.35 30 23.3 33.3 28.3 
5 19.4 29.5 24.45 31 23.7 34.3 29 
6 20.8 29.1 24.95 32 23.4 36.8 30.1 
7 21.9 31.2 26.55 33 16.9 34.9 25.9 
8 21.7 30.2 25.95 34 16.6 24.3 20.45 
9 21.7 30.6 26.15 35 17.4 26.7 22.05 
10 21.6 28.6 25.1 36 18.8 28.4 23.6 
11 21.3 28.8 25.05 37 19.1 25.1 22.1 
12 22.1 28.8 25.45 38 19.8 26.7 23.25 
13 21.6 27.7 24.65 39 19.0 26.8 22.9 
14 21.5 27.7 24.6 40 20.7 28.4 24.55 
15 21.3 26.8 24.05 41 20.1 31.1 25.6 
16 21.8 28.3 25.05 42 19.6 28.6 24.1 
17 22.3 29.5 25.9 43 19.7 27.8 23.75 
18 20.3 29.1 24.7 44 18.9 34.3 26.6 
19 21.4 26.5 23.95 45 21.6 37.0 29.3 
20 21.5 29.8 25.65 46 23.2 37.9 30.55 
21 21.8 28.9 25.35 47 23.5 35.9 29.7 
22 22.4 30.8 26.6 48 23.3 38.9 31.1 
23 22.6 28.8 25.7 49 24.9 38.4 31.65 
24 24.0 31.1 27.55 50 26.1 38.6 32.35 
25 23.4 31.3 27.35 51 24.0 36.9 30.45 
26 23.6 30.9 27.25 52 28.4 50.6 39.5 
The MKT for Khartoum using USP method of calculation is 27 °C.  
4.1.5.7 MKT calculation using the minimum required data for the FDA:  
The weekly high and low readings were inserted into the Stability System II program, 
total of 104 readings ( table 30), and MKT is 27°C. 
 4.1.5.8 Reference Thermal Exposure: 
Using statistica statsoft version 6, data was analyzed to obtain the frequencies of 
temperature at five degrees intervals then multiplied by the fixed duration of time 
interval. 
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Table ( 31 ) Reference Thermal Exposure 
 interval Frequency duration RTE in hours 
1 15 °C - < 20 °C 244 90 min 366 
2 20 °C - < 25 °C 2289 90 min 3433.5 
3 25 °C - < 30 °C 2119 90 min 3178.5 
4 30 °C - < 35 °C 397 90 min 595.5 
5 35 °C - < 40 °C 118 90 min 177 
6 40 °C -  45 °C 2 90 min 3 
 
4.1.6 Portsudan Station: 
4.1.6.1 Transportation conditions: The following data was recorded by the 
datalogger during transportation from Khartoum to Portsudan via drug distribution 
truck. Total of 104 readings were recorded. Table (32  ) shows recorded temperature 
and relative humidity during six days transportation (24/4/2007-30/4/2007). 
Table ( 32  ) Transportation conditions to Portsudan 
 °C RH% °C RH% °C RH% °C RH% °C RH% 
1 28.5 18 32.2 15.1 34.1 15.8 35.9 14 38.9 14 
2 28.6 15.5 32.3 15.2 34.3 15.8 36.0 14 38.9 16.9 
3 29.6 15.6 32.3 15.3 34.3 15.8 36.1 14 39.1 25.6 
4 29.7 14 32.5 15.4 34.4 15.8 36.1 14 39.4 31.8 
5 30.2 14 32.6 15.6 34.4 15.6 36.5 14 39.5 31.1 
6 30.3 15 32.6 15.6 34.4 15.2 36.6 14 39.6 31.2 
7 30.6 15.1 32.8 15.7 34.5 14 36.9 14 39.8 31.4 
8 30.7 15.1 33.0 15.8 34.6 14 36.9 15.3 40.1 31.3 
9 30.8 15.3 33.0 15.6 34.6 14 37.0 16.4 40.4 32.2 
10 30.9 15.4 33.0 15.6 34.7 14 37.3 18.4 40.4 31.1 
11 30.9 15.6 33.1 15.5 34.7 14 37.4 20.5 40.5 31.3 
12 31.0 15.8 33.2 15.4 35.2 14 37.6 19.9 40.6 21.8 
13 31.0 16.1 33.3 15.1 35.2 15.3 37.6 20.1 40.7 18.6 
14 31.1 16 33.5 14 35.3 15.4 37.8 23.6 40.8 20.3 
15 31.4 15.4 33.6 14 35.4 15.5 37.9 22.9 41.7 32.8 
16 31.4 14 33.7 14 35.4 15.6 38.0 22.8 42.1 39.5 
17 31.5 14 33.7 14 35.5 15.9 38.4 20 42.3 43.6 
18 31.7 14 33.8 14 35.8 16.3 38.5 18.2 42.3 48.6 
19 31.8 14 33.8 15.1 35.8 16.4 38.7 17.4 42.8 53.4 
20 31.8 15 33.9 15.4 35.8 18.4 38.7 15.6 42.9 61.8 
21 31.8 15.1 34.0 15.6 35.9 18.3 38.8 15.3   
Using the pooled data method the MKT is 35.9 °C and the average RH  is 18.9% 
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Then the products had been transported back to Khartoum at 20/4/2008 via 
passenger's bus and the following table shows the recorded data. 
Table ( 33  ) Conditions of  Portsudan passengers buses. 
 °C RH% °C RH% 
1 43.3 32.8 44.6 24.5 
2 43.6 33.1 44.6 23.7 
3 43.6 33.7 46.1 22.3 
4 43.7 33.8 46.6 19.9 
5 43.9 33.2 47.3 17.4 
6 44.1 31.2 47.6 17.3 
7 44.4 27.9 47.8 18.5 
 The transportation conditions are, MKT is 45.2 °C/ RH% is 26.3%. 
4.1.6.2 The Past Meteorological Records for Portsudan: 
The monthly average of the minimum and maximum temperature and the monthly 
average RH for the years 1962 to 1991 were used to calculate the MKT and the 
annual average RH as follows:  
Table (34   ) Portsudan Monthly  Maxim and Minimum Temperature  
month Mean max°C Mean min°C RH% 
Jan 26.6 19.4 65 
Feb 26.9 18.7 65 
March 28.5 19.5 63 
April 31.8 21.7 59 
May 35.4 24.2 53 
June 38.4 26.3 44 
July 40.7 28.5 44 
August 40.4 29 46 
Sept 37.9 27.1 55 
Oct 33.8 25.3 67 
Nov 30.9 23.7 69 
Dec  28.3 21.1 68 
According to this the conditions for Portsudan is 29.4 °C / 58.2 RH % .   
4.1.2.3 Recent Meteorological Records: 
Meteorological records for the period from April 07 to March  08 which is the same 
period of the study was obtained as 10 days mean of daily maximum and minimum 
temperature together with the monthly average  
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RH. Table ( 35   ).  Meteorological records (4.2007- 3.2008) 
Dekad  Max Min  RH % Dekad  Max  Min  RH % 
4.07-1 33.0 21.0 35 10.07-1 36.3 25.2 35 
4.07-2 31.5 19.5  10.07-2 35.7 26.1  
4.07-3 24.4 24.7  10.07-3 33.1 25.1  
5.07-1 37.1 26.0 27 11.07-1 33.4 24.6 27 
5.07-2 38.8 26.3  11.07-2 31.2 23.9  
5.07-3 39.6 25.9  11.07-3 29.4 22.9  
6.07-1 38.4 26.4 35 12.07-1 30.4 22.9 35 
6.07-2 40.0 26.3  12.07-2 28.5 22.5  
6.07-3 44.1 29.9  12.07-3 27.9 20.4  
7.07-1 42.8 31.2 27 1.08-1 28.0 19.9 61 
7.07-2 41.9 30.8  1.08-2 26.4 19.9  
7.07-3 44.7 31.8  1.08-3 25.2 17.7  
8.07-1 43.4 29.5 35 2.08-1 27.9 19.7 62 
8.07-2 41.7 29.5  2.08-2 26.1 19.2  
8.07-3 43.3 31.0  2.08-3 28.0 19.2  
9.07-1 40.7 29.1 27 3.08-1 29.6 19.9 63 
9.07-2 24.6 40.6  3.08-2 30.3 20.2  
9.07-3 23.8 36.9  3.08-3 33.1 20.6  
 
Using the pooled data method, 72 readings were inserted into the Stability System 
program, the MKT was found to be 30.8 °C. The monthly average RH is 39.1 %.  
4.1.6.4 In-house Datalogger readings from April 2007 to March 2008: 
Total of 5647 readings for each of temperature and relative humidity were recorded 
and used to calculate the ambient conditions for the pharmacy. ( app 12,13 ). The 
MKT is 24.3 °C. The monthly average RH is 52.2%. 
4.1.6.5 Datalogger readings and Meteorological data for Humidity: 
 The average monthly humidity for datalogger readings and meteorological records 
for the same period (April07-March 08) using Microsoft Excel 2003 could be 
represented in the following table.  
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Table (36  ) Average relative humidity 
 Month Datalogger readings Meteorological records 
  min      max      mean  
1 April 2007 31.9     75.7     49.6 35 % 
2 May 2007 30.4      92.8     48.4 27 % 
3 June 2007 26.1     66.9      40.7 35 % 
4 July 2007 28.2     82.1      46.2 27 % 
5 August 2007  30.2     71.5      42.5 35 % 
6 September 2007 33.0     74         47.5 27 % 
7 October 2007 19.3     80.6      66.3 35 % 
8 November 2007 25.0     79         60.5 27 % 
9 December 2007 35.4    76.6      58.2 35 % 
10 January 2008 25.2     76.7      51.7 61 % 
11 February 2008  27.5     80.3      55.5 62 % 
12 March 2008 29.1     76         59.3  63 % 
13  Annual average                          52.2 39.1 % 
 
4.1.6.6 The MKT using USP method of calculation:  
Using the date column of datalogger records, data was split into weeks excluding 
transportation period. Total of 112 readings for every week of the 52 weeks were then 
sorted out as maximum and minimum then the average for every week was obtained. 
(Table 37 ). Then 52 readings were inserted into the stability system II program and 
the MKT was determined.   
Table ( 37 ) Weekly max, min and average temperature for Portsudan 
week Min  °C Max°C average week Min °C Max °C average 
1 31.7 37.0 34.4 27 26.1 37.3 31.7 
2 23.1 42.1 32.6 28 25.7 27.6 26.7 
3 22.0 25.8 23.9 29 25.6 27.4 26.5 
4 20.1 24.8 22.5 30 22.6 26.8 24.7 
5 19.7 23.8 21.8 31 22.2 26.9 24.6 
6 22.9 27.4 25.2 32 22.1 26.0 24.1 
7 24.6 28.4 26.5 33 22.3 26.1 24.2 
8 21.6 27.2 24.4 34 23.7 26.2 25.0 
9 20.8 25.6 23.2 35 23.7 26.5 25.1 
10 23.3 29.5 26.4 36 23.4 25.3 24.4 
11 29.0 31.9 30.5 37 21.8 25.2 23.5 
12 25.9 29.9 27.9 38 21.0 24.1 22.6 
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13 26.1 30.6 28.4 39 21.9 24.1 23.0 
14 20.6 30.3 25.5 40 22.3 24.3 23.3 
15 20.9 30.2 25.6 41 21.3 26.1 23.7 
16 20.2 30.6 25.4 42 22.3 25.8 24.1 
17 19.9 28.5 24.2 43 24.9 26.5 25.7 
18 20.8 29.6 25.2 44 23.4 25.8 24.6 
19 20.3 30.6 25.5 45 22.8 25.3 24.1 
20 19.7 27.2 23.5 46 23.0 25.3 24.2 
21 19.6 27.7 23.7 47 21.9 25.6 23.8 
22 19.1 28.3 23.7 48 21.8 25.6 23.7 
23 18.2 27.1 22.7 49 22.2 26.5 24.4 
24 25.8 27.6 26.7 50 22.4 27.0 24.7 
25 26.4 27.7 27.1 51 18.5 27.4 23.0 
26 26.4 28.1 27.3 52 18.6 25.9 22.3 
 
The MKT for Portsudan using USP method of calculation is 25.6 °C.  
4.1.6.7 MKT calculation using the minimum required data for the FDA:  
The weekly high and low readings were inserted into the Stability System II program, 
total of 104 readings ( table 37 ), and it was 25.6 °C. 
4.1.6.8 Reference Thermal Exposure: 
Using statistica statsoft version 6, data was analyzed to obtain the frequencies of 
temperature at five degrees intervals then multiplied by the fixed duration of time 
interval. 
Table ( 38   ) Reference Thermal Exposure 
 interval frequency duration RTE in hours 
1 15 °C - < 20 °C 342 90 min 513 
2 20 °C - < 25 °C 3220 90 min 4830 
3 25 °C - < 30 °C 2058 90 min 3087 
4 30 °C - < 35 °C 114 90 min 171 
5 35 °C - < 40 °C 39 90 min 58.5 
6 40 °C -  50 °C 27 90 min 40.5 
 
 
4.1.6.10 Total relative humidity exposure: 
The total period of exposure to different intervals of relative humidity was tabulated 
using SPSS version 13. 
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Table (39   ) Relative Humidity Exposure 
 RH Range Frequency Duration Total exposure 
1 15- < 20 % 92 1.5 hour 138 hours 
2 20 - < 25 % 21 1.5 hour 31.5 hours 
3 25 - < 30 % 42 1.5 hour 63 hours 
4 30 - < 35 % 356 1.5 hour 534 hours 
5 35 - < 40 % 833 1.5 hour 129.5 hours 
6 40 - < 45 % 783 1.5 hour 1174.5 hours 
7 45 - < 50 % 633 1.5 hour 949.5 hours 
8 50 - < 55 % 635 1.5 hour 952.5 hours 
9 55 - < 60 % 664 1.5 hour 996 hours 
10 60 - < 65 % 608 1.5 hour 912 hours 
11 65 - < 70 % 579 1.5 hour 868.5 hours 
12 70 - < 75 % 382 1.5 hour 573 hours 
13 75 - < 80 %  120 1.5 hour 180 hours 
14 80 - < 85 % 17 1.5 hour 25.5 hours 
15 85 - < 90 % 4 1.5 hour 6 hours 
16 90 - < 95 % 7 1.5 hour 10.5 hours 
 
4.1.6.11 Variation of relative humidity during the day: 
Data obtained from the datalogger was analyzed using SPSS software to determine 
min, max, and mean relative humidity for a given time. 
Table (40   ) Variation of RH during the day 
 Time  Min % Max % Mean % SD 
1 0 : 30  29.6 91.4 51.05 13.05 
2 2 : 00 27.8 90.1 50.75 13.27 
3 3 : 30 27.5 90.7 50.42 13.56 
4 5 : 00 27.9 89.9 50.15 13.75 
5 6 : 30 25 88.6 49.9 13.69 
6 8 : 00 25.8 88.8 50.48 13.39 
7 9 : 30 25.2 80.3 50.87 12.03 
8 11 : 00 26.6 78.4 51.29 11.5 
9 12 : 30 27.9 78.8 52.72 11.35 
10 14 : 00 29.1 80.1 54.54 10.8 
11 15 : 30 28.2 84.3 55.93 11.1 
12 17 : 00 26.1 87.9 56.14 11.2 
13 18 : 30 27.8 90.6 54.82 11.63 
14 20 : 00 30.5 92.4 53.25 12.03 
15 21 : 30 31.1 92.8 52.3 11.6 
16 23 : 00 29.7 92.6 52.67 12.99 
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4.2. Stability Testing for the Selected Products: 
4.2.1 Metronidazole I.V infusion 500 mg/100 ml contained in glass container 
denoted as sample 4:  
Tests were performed for metronidazole contents in 500mg/100 ml infusion in glass 
container manufactured by ……., lot number: LM 111206, manufactured at 12/2005 
and the labeled expiration date is 12/2008. 
4.2.1.1 Physical tests: 
4.2.1.1.1 Appearance:  
It is a colourless aqueous solution in a colourless glass container, closed by a rubber 
cap sealed by aluminum foil cap closure system around the rubber stopper down to 
the neck of the bottle.  
4.2.1.1.2 PH: 
The initial pH of metronidazole I.V infusion in glass container was 4.98. 
Then after storage at different stations for 52 weeks. 
 Fashir  Damazin Khartoum Dongola Juba Portsudan 
5.02 5.03 5.03 5.02 5.03 5.02 
4.2.1.1.3 Volume: 
The initial volume is 103 ml, then after storage at different stations, volumes were 
Table (41) volumes of metronidazole of glass container from different stations. 
    Fashir  Damazin Khartoum Dongola Juba Portsudan 
102.5 102 104 103 105 104 
4.2.1.1.4 Particulate matter testing before distribution and after the storage 
period: Using filtration method, 20 mls of the fluid were utilized; results are 
presented in the following table. 
Table (45   )  Particulate matter testing for Product 4 
Station 25 µm 10 µm  
Initial blank 00 00 
Sample product 4 00 p/ ml 0.03 p/ml 
Final blank 00 00 
4 N  0/20 ml                            1/20 ml 
4 Th 0/20 ml                              0/20 ml                              
4 K 0/20 ml                             0/20 ml                             
4 G 0/20 ml                             0/20 ml                             
4 J 0/20 ml                              0/20 ml                              
4 B 0/20 ml                              0/20 ml                              
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4.2.1.2 Chemical assay for metronidazole content: ( App. 14). 
4.2.1.2.1  Table (42) Contents % of Metronidazole in Product 4 during 52 weeks: 
Time  4 N 4 TH 4 K 4 G 4 J 4 B 
Initial  101.6  101.6 101.6 101.6 101.6 101.6 
Initial 101.6 101.6 101.6 101.6 101.6 101.6 
Initial  101.6  101.6 101.6 101.6 101.6 101.6 
Initial  101.2 101.2 101.2 101.2 101.2 101.2 
Initial  101.2 101.2 101.2 101.2 101.2 101.2 
Initial  101.333 101.333 101.333 101.333 101.333 101.333 
Mean 101.422 101.422 101.422 101.422 101.422 101.422 
St.d 0.20074 0.20074 0.20074 0.20074 0.20074 0.20074 
Transportation  101.867 101.733 101.867 102.4 101.333 101.867 
Transportation 101.867 101.733 102 102.4 101.333 101.733 
Transportation 102 101.733 101.733 102.267 101.467 101.733 
Mean  101.9111 101.7333 101.8667 102.3556 101.3778 101.7778 
St.d 0.07698 0 0.133333 0.07698 0.07698 0.07698 
6 months 99.0667 100.4 99.8667 100.533 99.8667 100 
6 months 99.3333 100.267 99.8667 100.667 99.8667 100 
6 months 99.3333 100.533 99.6 100.8 99.6 100 
Mean 99.24444 100.4 99.77778 100.6667 99.77778 100 
St.d 0.15396 0.13333 0.15396 0.13333 0.15396 0 
12 months 99.6 100.267 100.133 99.8667 99.6 100.933 
12 months 99.6 100.267 100.133 99.8667 99.6 100.933 
12 months 99.6 100.267 100.267 99.8667 99.6 101.067 
12 months 99.6 100.267 100.267 99.8667 99.6 100.933 
12 months 99.6 100.267 100.267 99.8667 99.6 100.933 
12 months 99.6 100.267 100.267 99.8667 99.6 100.933 
12 months 99.6 100.267 100.267 99.8667 99.6 100.933 
12 months 99.6 100.267 100.267 99.8667 99.6 100.8 
Mean 99.6 100.267 100.233 99.8667 99.6 100.933 
St.d  0 0 0.06172 0 0 0.07127 
4.2.1.2.2 Assay for 2-methyl-5- nitroimidazole: 
4.2.1.2..1 Initial testing: 
The height and area of the main peak obtained by injection of solution I which 
contains 0.0050% W/V of 2-methyl-5-nitroimidazole in mobile phase and those for 
the secondary peak obtained by injection of solution II which contains 0.1% W/V of 
metronidazole could be presented in table (43   ).   
Table ( 43  ) Assay results of 2-methyl-5- nitroimidazole assessment. 
 
 
Peak area height 
0.1% metronidazole 18.4477 96.777 
Secondary peak No second. peak No second. peak 
0.5% 2-methyl-5-nitroimidazole 6.52414 49.3169 
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4.2.1.2.6.2 Final testing: 
Samples were retested at the end of the storage period at different stations. The peak 
area of 0.5% 2-methyl-5-nitroimidazole was 8.240 and no secondary peaks were 
detected in all stations chromatograms.  
Table ( 44  ) Peak area and height of 0.1% metronidazole for different stations 
 4 N 4 Th 4 K 4 G 4 J 4 B 
Peak area 797.598 797.285 795.932 793.956 795.463 800.516 
Peak height 2279.36 2277.47 2280.91 2281.88 2279.41 2289.54 
4.2.1.2.7 Assay for Nitrite contents: 
4.2.1.2.7.1 Initial testing: The absorbance of nitrite reference solution ( 20 ppm) at 
524nm is 0.266 while that of the test sample is .0.039. 
 4.2.1.2.7.2 Final testing: 
The absorbance obtained from samples being stored at different stations could be 
tabulated as follows: 
Station 4 N 4 Th 4 K 4 G 4 J 4 B 
absorbance 0.051 0.047 0.048 0.052 0.045 0.045 
4.2.1.3 Microbiological tests: 
Particulate matter, assay for total endotoxins and sterility testing were performed 
initially before distribution, and then finally at the end of the storage period. 
4.2.1.3.1 Total Endotoxins testing before distribution: 
Samples were tested initially before distribution and results are reported as follows: 
Number of samples: one bottle., Incubation temperature: 37 °C, Lysate labeled 
sensitivity: 0.25 EU/ml, Dilution: No dilution. 
Table ( 46   ) Gel formation test for product 4 
No Sample  Observation  Set 1 Set 2 
1 L.S.E (positive test) Gel formation + + 
2 L.R.W(negative test) No gel formation _ _ 
3 Product 4 No gel formation _ _ 
Limit: Endotoxins in product 4 is< 0.25 EU/ml. 
4.2.1.3.2 Total Endotoxins testing after storage at different stations for 52 weeks: 
The test was repeated for samples from different stations at the end of the storage 
period and none of the samples showed a clot formation and the total endotoxins were 
below 0.25 EU/ml. 
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4.2.1.3.3 Sterility testing before distribution: 
Using membrane filtration method, 20 mls of the product were utilized. Then dipping 
the membrane filter in a thioglycolate medium (Oxoid) and Soya bean Casein medium 
and incubate at 33 °C and 35°C respectively for 14 days. Observations: no change in 
the reddish-brown colour of thioglycolate medium and no turbidity or change in 
colour of Soya bean casein medium. The Results: No evidence of microbial growth 
during entire 14 days of incubation. 
Comment: Product 4 is complying with the requirements and passes sterility testing. 
4.2.1.3.4 Sterility testing at the end of the storage period for all stations:      
The test was repeated for samples from different stations at the end of the storage 
period and none of the samples showed a change in the reddish-brown colour of 
neither thioglycolate medium nor turbidity or change in colour of Soya bean casein 
medium. This indicates that no evidence of disturbance in sterility of product 4 during 
storage at the stations of the study. 
4.2.2 Metronidazole I.V infusion 500 mg/100 ml contained in plastic container 
denoted as sample 3:  
Tests were performed for metronidazole contents in 500mg/100 ml infusion in plastic 
container manufactured by …..,India lot number: U6018, manufactured at 12/2005 
and the labeled expiration date is 11/2008. 
4.2.2.1 Physical tests: 
4.2.2.1.1 Appearance:  
It is a colourless aqueous solution in a PPG plastic container, without mouth, the 
bottle is one unit. Each bottle was wrapped by cellophane sheet and packed in a light 
carton box.  
4.2.2.1.2 PH: The pH at the beginning of the study was 5.48. 
The pH after storage at different sites was as follows. 
Fashir  Damazin Khartoum Dongola Juba Portsudan 
5.27 5.32 5.36 5.33 5.30 5.26 
4.2.2.1.3 Volume: 
The initial volume is 100.1 ml, then after storage at different stations, volumes were 
as follows: 
    Fashir  Damazin Khartoum Dongola Juba Portsudan 
94 ml 97.5 ml 101 ml 100 ml 96 ml 100.5 ml 
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4.2.2.1.4 Particulate matter testing before and after distribution: 
Using filtration method, 20 ml of the fluid were utilized; results are presented below:  
Table (50   ) Initial and final Particulate matter testing for Product 3 
Station 25 µm 10 µm  
Initial blank 00 00 
Sample product 4    0.01  p/ ml 0.02 p/ ml 
Final blank 00 00 
4 N  1/20 ml                            1/20 ml 
4 Th 0/20 ml                              0/20 ml                              
4 K 1/20 ml                             1/20 ml                             
4 G 1/20 ml                             1/20 ml                             
4 J 0/20 ml                              0/20 ml                              
4 B 0/20 ml                              1/20 ml                              
4.2.2.2 Chemical assay for metronidazole contents: ( App. 15). 
Table ( 47) Content of Metronidazole in Product 3 during 52 weeks 
Time  4 N 4 TH 4 K 4 G 4 J 4 B 
Initial  102.133 102.133 102.133 102.133 102.133 102.133 
Initial 102 102 102 102 102 102 
Initial  102 102 102 102 102 102 
Initial 103.6 103.6 103.6 103.6 103.6 103.6 
Initial 103.6 103.6 103.6 103.6 103.6 103.6 
Initial 103.6 103.6 103.6 103.6 103.6 103.6 
Mean 102.822 102.822 102.822 102.822 102.822 102.822 
St.d 0.8534 0.8534 0.8534 0.8534 0.8534 0.8534 
Transportation  106.4 106.267 104.4 106.933 106.4 107.333 
Transportation 106.4 106.533 104.4 106.933 106.4 107.467 
Transportation 106.4 106.267 104.4 107.067 106.4 107.467 
Mean  106.4 106.3556 104.4 106.9778 106.4 107.4222 
St.d 0 0.15396 0 0.07698 0 0.07698 
6 months 104.4 103.733 104.267 104.267 104.933 104.533 
6 months 104.4 103.867 104.133 104.4 105.067 104.533 
6 months 104.267 103.733 104.133 104.267 105.067 104.533 
Mean 104.3556 103.7778 104.1778 104.3111 105.0222 104.5333 
St.d 0.07698 0.07698 0.07698 0.07698 0.07698 0 
12 months 105.2 104.667 104.133 104.933 105.467 106.267 
12 months 105.2 104.667 104.133 105.067 105.467 106.267 
12 months 105.2 104.667 104.267 105.067 105.467 106.267 
12 months 105.2 104.8 104.133 105.067 105.467 106.4 
12 months 105.2 104.667 104.267 104.933 105.333 106.4 
12 months 105.2 104.667 104.267 104.933 105.333 106.4 
12 months 105.2 104.667 104.267 104.933 105.467 106.4 
12 months 105.2 104.667 104.267 104.933 105.467 106.4 
Mean 105.2 104.683 104.217 104.983 105.433 106.35 
St.d  0 0.04714 0.06901 0.06901 0.06172 0.06901 
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4.2.2.2.6 Assay for 2-methyl-5- nitroimidazole: 
4.2.2.2.6.1 Initial testing: 
The height and area of the main peak obtained by injection of solution I which 
contains 0.0050% W/V of 2-methyl-5-nitroimidazole in mobile phase and those for 
the secondary peak obtained by injection of solution II which contains 0.1% W/V of 
metronidazole are presented in table (48   ).   
 Table ( 48 ) Assay results of 2-methyl-5- nitroimidazole assessment. 
4.2.2.2.6.2 Final testing: 
Samples were retested at the end of the storage period at different stations. The peak 
area of 0.5% 2-methyl-5-nitroimidazole was 8.240 and negligible secondary peaks 
were detected in all stations chromatograms.  
Table ( 49  ) Peak area and height of 0.1% metronidazole for different stations 
 3 N 3 Th 3 K 3 G 3 J 3 B 
Peak area 817.064 811.197 813.654 810.232 811.936 811.663 
Peak height 2303.58 2304.25 2303.79 2307.94 2306.52 2310.41 
 
4.2.2.2.7 Assay for Nitrite contents: 
4.2.2.2.7.1 Initial testing for nitrite contents: 
The absorbance of nitrite reference solution ( 20 ppm) at 524nm is 0.266 while that of 
the test sample is .0.085. 
 4.2.2.2.7.2 Final testing for nitrite contents: 
The absorbance obtained from samples being stored at different stations could be 
tabulated as follows: 
Station 3 N 3 Th 3 K 3 G 3 J 3 B 
absorbance 0.090 0.094 0.094 0.098 0.091 0.087 
4.2.2.3 Microbiological testing: 
Particulate matter, assay for total endotoxins and sterility testing were performed 
initially before distribution, and then finally at the end of the storage period. 
 
Peak area height 
0.1% metronidazole 18.7763 99.9893 
Secondary peak No second. peak No second. peak 
0.5% 2-methyl-5-nitroimidazole 6.52414 49.3169 
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4.2.2.3.1 Total Endotoxins testing before distribution: 
Samples were tested initially before distribution and results are reported as follows: 
Number of samples : one bottle. 
Incubation temperature: 37 °C. 
Lysate labeled sensitivity: 0.25 EU/ml. 
Dilution: No dilution. Gel formation test for product 3 
No Sample  Observation  Set 1 Set 2 
1 L.S.E (positive test) Gel formation + + 
2 L.R.W(negative test) No gel formation _ _ 
3 Product 4 No gel formation _ _ 
 
Limit: Endotoxins in product 3 is< 0.25 EU/ml. 
4.2.2.3.2 Total Endotoxins testing at the end of the storage period at different 
stations: The test was repeated for samples from different stations at the end of the 
storage period and none of the samples showed a clot formation and the total 
endotoxins were below 0.25 EU/ml. 
4.2.2.3.3 Sterility testing before distribution: 
Using membrane filtration method, 20 mls of the product were utilized. Then dipping 
the membrane filter in a thioglycolate medium (Oxoid) and Soya bean Casein medium 
and incubate at 33 °C and 35°C respectively for 14 days. 
Observations: no change in the reddish-brown colour of thioglycolate medium and no 
turbidity or change in colour of Soya bean casein medium. 
Results: No evidence of microbial growth during entire 14 days of incubation. 
Comment: Product 3 is complying with the requirements and passes the test for 
sterility. 
4.2.2.3.4 Sterility testing for product 3 after storage at different stations:      
The test was repeated for samples from different stations at the end of the storage 
period and none of the samples showed a change in the reddish-brown colour of 
neither thioglycolate medium nor turbidity or change in colour of Soya bean casein 
medium. This indicates that no evidence of disturbance in sterility of product 3 during 
storage at the stations of the study. 
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4.2.3. Domestic Amoxicillin Trihydrate powder for 125mg/5ml oral suspension: 
Samples of amoxicillin125mg/5 ml for oral suspension from …..–Sudan 
manufactured at 06/2005, expiration date at 06/2008, batch number; 0906317 were 
subjected to stability testing and they were coded as product 6. 
4.2.3.1 Physical Tests: 
Physical tests include description and appearance, variation of weight of powder, 
deliverable volume, sedimentation volume and reconstitution time and pH. 
4.2.3.1.1 Description and appearance: It is a white amorphous powder with a 
lemon-banana flavour in an amber glass bottle closed by aluminum cap with 
aluminum ring fixed to the neck of the bottle. Each bottle contains about 31 grams 
powder intended to produce 75 ml suspension of 125 mg/ 5ml amoxicillin trihydrate 
when constituted by 46 ml water. 
 4.2.3.1.2 Variation of powder weight: The test was performed to the whole batch 
provided that the theoretical weight is 30.9707 grams and it yields the following 
results:         Table: ( 51 )    variation of powder weight in Product 6 
 Weight in grams Contents %   Weight in grams Contents %  
1 31.1 102 7 31.21 103 
2 31.16 103 8 29.51 99 
3 29.13 96 9 31.79 105 
4 31.84 105 10 29.89 98 
5 30.30 98 Mean 30.719 101.2 
6 31.26 103 St.d 0.95  3.19 
 
4.2.3.1.3 Deliverable volume, sedimentation volume and reconstitution time:   
Deliverable volume Sedimentation volume Reconstitution time 
76 ml 68/76 2-3 shakes 
 
4.2.3.1.4 Physical changes: 
No physical changes were detected at the end of the study. The product retained its 
physical characters.    
 6B 6J 6G 6k 6Th 6N 
pH 5.96 5.90 5.91 5.96 5.94 5.91 
volume 75.5 75 76 75.5 74.5 75 ml 
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4.2.3.2 Chemical assay for amoxicillin contents: 
Using HPLC method of analysis (USP method), samples were assayed for amoxicillin 
contents initially, after transportation, after 6 months of storage at ambient storage 
conditions at different stations and finally at the end of the storage period. ( App. 16). 
Table (52 ) Content of amoxicillin in product 6 during storage 
6 B 6 J 6 G 6 K 6 Th 6 N 
 
 
Time  
101.41 101.41 101.41 101.41 101.41 101.41 0 
101.56 101.56 101.56 101.56 101.56 101.56 0 
101.485 101.485 101.485 101.485 101.485 101.485 Mean  
93.10463 96.43445 102.7553 99.54323 97.32578 89.93472 transportation 
95.19149 94.4432 99.16002 91.20711 98.18868 90.38 6 months 
88.32 91.67 90.38 91.2 90.85 92.38 Final  
90.79 90.52 90.55 91.87 90.39 91.94 Final 
90.47 90.01 90.11 92.36 89.43 92.43 Final 
89.63 90.54 90.47 90.69 88.18 93.49 Final 
89.8025 90.685 90.3775 91.53 89.7125 92.56 Mean 
1.102765 0.700976 0.191377 0.73462 1.180575 0.657926 STD 
06/2008 
labeled expiration 
date 
06/2006 manufacture date :     
0906317  batch number            
4.2.3.3 Microbiological Tests: 
The microbiological tests took place were tests for the total viable count before and 
after distribution of samples on different stations of the study. 
4.2.3.3.1 Initial bacterial count: 
Initially polysorbate 80 and 9 serial dilutions were used to neutralize the antimicrobial 
activity of amoxicillin. Two sterile Petri dishes (plate I, plate II) and one Petri dish as 
control positive test (plate III) of Agar medium B were used as culture medium. The 
following results were obtained: 
Plate 10¯¹ 10¯² 10¯³ 10¯4 10¯5 10¯6 10¯7 10¯8 10¯9 
I - - - - - - - - - 
II - - - - - - - - - 
III - - - - many many many many many+ 
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Result: The product is either containing bacteria less than 10³ /gram of tablets or 
growth was inhibited by the antimicrobial activity of amoxicillin at higher 
concentration.    
 4.2.3.3.2 Initial fungal count: 
The same procedure was repeated using Medium C instead of Medium B and Candida 
alb. instead of Staph.aureous as a control positive test. 
Total fungi count for product 6 
Plate  10¯¹ 10¯² 10¯³ 10¯4 10¯5 
I 1 c.f.u - - - - 
II - - - - - 
III + + + + + 
Result: The product contains 0.5×10 fungi/ gram powder which is < I0² .  
4.2.3.3.3 Final bacterial count: 
At the end of the storage period of 52 weeks at the six stations, samples were 
subjected to total bacterial count. Positive and negative control tests were performed. 
Penase β-lactamase enzyme was used to inactivate the anti-microbial actions of 
amoxicillin. 0.2 ml of the reconstituted solution of the enzyme was added to each 
medium B culture of the five serial dilutions. 
Results: 
No c.f.u was developed in all dilutions for all stations. This indicates that no bacterial 
contamination took place. 
4.2.3.3.4 Final fungal count: 
Using medium C and five serial dilutions, and after incubation at 23 °C, the following 
results were obtained. 
Table ( 53  )  Fungal Count for product 6 at different stations 
Station initial 10¯¹ 10¯² Result 
Portsudan - 2 c.f.us - 2×10¹ 
Juba - - - - 
Dongola - 1 c.f.u - 10¹ 
Khartoum - 1 c.f.us - 10¹ 
Damazin - - - - 
Fashir - - 1 c.f.u 10² 
Therefore, fungal count for all stations was < 10². 
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4.2.4 Imported Amoxicillin 125 mg/5ml powder for suspension: 
Amoxicillin 125mg/5ml powder for oral suspension donated by CMS was imported 
from India. Samples were subjected to stability testing for the contents of the active 
ingredient, physical and microbiological properties of the product. The product was 
from batch 163, manufactured at 06/2005 and the labeled expiration date is 05/2007 
and for the purpose of the study, it was coded as number 7. 
4.2.4.1 Physical Tests: 
Physical tests include description and appearance, weight of powder, deliverable 
volume, sedimentation volume and reconstitution time and pH. 
4.2.4.1.1 Description and appearance: It is a yellowish white amorphous powder 
with a faint banana odour in an amber glass bottle closed by plastic cap with plastic 
ring fixed to the neck of the bottle. Each bottle contains about 48.4 grams powder 
intended to produce 75 ml suspension of 125 mg/ 5ml amoxicillin trihydrate when 
constituted by 43 ml water, labeled as to be stored below 25 °C in a dry place. 
4.2.4.1.2 Deliverable volume, sedimentation volume and reconstitution time:   
Sedimentation volume and reconstitution time for sample 7 
Sedimentation volume Reconstitution time 
9/74 4-5 shakes 
 
4.2.4.1.3 Physical changes: 
Complete loss of the flavour, nasty odour of amoxicillin was dominant and increased 
yellow colouration of the suspension was observed. Deliverable volume and pH 
shows no change. pH and deliverable volume for sample 6 from different stations 
 7B 7J 7 G 7k 7Th 7N 
pH 5.85 5.83 5.84 5.85 5.82 5.85 
volume 76 75 74.5 75.5 75.5 75.5 
 
4.2.3.2 Chemical assay for amoxicillin contents: 
Using HPLC method of analysis (USP method), samples were assayed for amoxicillin 
contents initially, after transportation, after 6 months of storage at ambient storage 
conditions at different stations and finally at the end of the study. ( App. 17). 
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 Table (54  ) Content of amoxicillin in product 7 during storage  
4.2.4.3 Microbiological Tests: 
The microbiological tests took place were tests for the total viable count before and 
after distribution of samples on different stations of the study. 
 4.2.4.3.1 Initial bacterial count: 
Initially polysorbate 80 and 9 serial dilutions were used to neutralize the antimicrobial 
activity of amoxicillin. Two sterile Petri dishes (plate I, plate II) and one Petri dish as 
control positive test (plate III) of Agar medium B were used as culture medium. The 
following results were obtained: 
Plate 10¯¹ 10¯² 10¯³ 10¯4 10¯5 10¯6 10¯7 10¯8 10¯9 
I - - - - - - - - - 
II - - - - - - - - - 
III - - - - + + + + + 
 
Result: The product contains bacteria less than 10³ /gram of tablets . 
  
 
S 7B 7 J 7 G 7 K 7 Th 7 N time 
79.4513 103.67% 103.67 % 103.67% 103.675 103.67% 103.67% 0 
79.5828 104.68 104.68 104.68 104.68 104.68 104.68 0 
79.4716 104.175 104.175 104.175 104.175 104.175 104.175 mean 
79.4458 105.3481 105.127851 106.5517 101.2206 99.05007 101.7337 transportation 
79.48788 100.9491 98.6891335 96.45735 94.21248 96.84068 102.5921 6 months 
0.064249 103.42 103.38 103.86 100.87 101.93 102.41   
  104.2 103.28 103.98 101.44 102.14 102.76   
  104.06 103.74 103.55 100.94 101.45 102.95   
  104.14 103.62 103.42 101.22 101.57 102.94   
  103.955 103.505 103.7025 101.1175 101.7725 102.765 Final mean 
  0.361248 0.2118962 0.261327 0.262853 0.318787 0.252256 std 
 05/2007 
labeled 
expiration date :  
 06/2005 
manufacture 
date:          
 1630526 batch no :             
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4.2.4.3.2 Initial fungal count: 
The same procedure was repeated using Medium C instead of Medium B and Candida 
alb. instead of Staph.aureous as a control positive test. 
Total fungi count for product 7 
Plate  10¯¹ 10¯² 10¯³ 10¯4 10¯5 
I - - - - - 
II - - - - - 
III + + + + + 
Result: The total fungi count is  < I0² per gram of powder.  
4.2.4.3.3 Final bacterial count: 
At the end of the storage period of 52 weeks at the six stations, samples were 
subjected to total bacterial count. Positive and negative control tests were performed. 
Penase was used to inactivate the anti-microbial actions of amoxicillin. 0.2 ml of the 
reconstituted solution of the enzyme was added to each medium B culture of the five 
serial dilutions. 
Results: 
No c.f.u was developed in all dilutions for all stations. This indicates that no bacterial 
contamination took place. 
4.2.4.3.4 Final fungal count: 
Using medium C and five serial dilutions, and after incubation at 23 °C for 5 days, the 
following results were obtained.  Fungal Count for product 7 at different stations 
Station initial 10¯¹ 10¯² Result 
Portsudan 2 c.f.us - - 0.2×10¹ 
Juba - - - - 
Dongola - - - - 
Khartoum - - - - 
Damazin - - - - 
Fashir - - - - 
Therefore, fungal count for product 7 at all stations was < 10². 
4.2.5 Rifampicin 300 mg + INH 150 mg Tablets: 
Samples of the products were supplied by CMS as domestically manufactured 
product, manufactured by ……-Sudan coded for the purpose of this study as product 
8. Samples from batch 350 manufactured at 10/2005 and labeled to be expired at 
10/2007 were subjected to physical, chemical and microbiological stability testing.  
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4.2.5.1 Physical tests: 
Description and general appearance, uniformity weight, hardness, loss on drying and 
disintegration tests were performed. 
4.2.5.1.1 Description and general appearance: 
Prickly reddish brown flatted film coated tablets, diameter of 12.6 mm with notched 
rounded edges and marker line across the tablet. Each 10 tablets were packed in PVC/ 
AL blister, each 10 blisters were packed in a white carton box. 
4.2.5.1.2 Uniformity of weight: 
Test was performed at the beginning of the study table (55   ).    
Table (  55 ) Initial weight uniformity of product 8 
tablet weight gm 
Content 
percentage tablet weight gm percentage 
1 0.6559 97.24024 11 0.6689 99.16755 
2 0.6602 97.87773 12 0.6833 101.3024 
3 0.6742 99.9533 13 0.6641 98.45593 
4 0.6728 99.74574 14 0.6762 100.2498 
5 0.6963 103.2297 15 0.679 100.6649 
6 0.7097 105.2163 16 0.6787 100.6204 
7 0.6796 100.7539 17 0.6628 98.2632 
8 0.6699 99.30098 18 0.6816 101.0504 
9 0.6719 99.61231 19 0.6714 99.53819 
10 0.6762 100.2498 20 0.6577 97.5071 
 
 
 
 
Then the test was carried out again at the end of the storage period for samples stored 
at different stations and the results are presented in the following table (  56     ). 
mean 0.67452 
STD 0.012694 
RSD 1.88 
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Table ( 56) Weight uniformity for product 8 after storage at different stations 
 
4.2.5.1.3 Resistance to crushing of tablets (Hardness): 
Tablets were subjected to hardness testing by Erweka Hardness Tester. The following 
table shows the results: 
Table ( 57  ) Hardness testing of product 8 tablets. 
Tablet   Hardness in Newton  Tablet  Hardness in Newton 
1 156 6 162 
2 124 7 142 
3 111 8 175 
4 160 9 114 
5 176 10 193 
station 8N 8 Th 8 K 8 G 8 J 8 B 
Mean 0.688445 0.677695 0.692575 0.680445 0.69199 0.69905 
STD 0.014679 0.012917 0.013507 0.011333 0.014629 0.011869 
 % % % % % % 
1 98.8016 98.55466 97.17359 101.1691 99.13438 97.43223 
2 99.00361 99.30721 98.05436 101.9921 100.0448 99.49217 
3 102.8564 99.15965 97.17359 98.90586 101.3165 101.2803 
4 97.95023 100.9156 100.2491 97.71547 102.9928 100.2646 
5 99.45094 97.49223 101.0432 100.978 103.094 97.33209 
6 100.4322 101.255 100.8122 101.2132 99.17773 100.236 
7 94.64578 103.3798 101.6352 100.6253 96.69215 103.0685 
8 95.26627 100.5172 100.1047 101.5365 102.3136 99.53508 
9 101.7164 100.5615 99.3683 98.94995 100.4494 100.5794 
10 99.00361 101.196 97.8089 97.40684 99.66907 102.8396 
11 100.6486 101.5354 101.7363 99.5525 99.92919 100.2503 
12 99.63853 99.74989 101.7074 97.80364 98.0072 101.1659 
13 101.2114 96.06091 99.52713 99.34675 99.4234 99.82119 
14 99.75397 98.65795 101.8518 101.9333 101.3309 98.76261 
15 98.0801 100.5615 100.509 97.99469 100.9408 98.49081 
16 98.59958 97.2709 95.20991 98.53846 100.4639 100.9656 
17 103.2171 101.9042 101.0288 100.8605 96.44648 102.0814 
18 99.50866 97.9054 101.1587 101.9627 99.04767 96.7885 
19 99.22006 102.1403 102.2561 98.90586 96.17191 100.0215 
20 97.83479 101.8747 101.5919 102.6093 103.3541 99.5923 
STD 2.118188 1.905996 1.950291 1.665483 2.114056 1.697863 
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Maximum: 193 Newton.                  STD  : 27.829 
Minimum : 111 Newton.                  RSD  : 18.39 
Mean        : 151.3 Newton. 
Then the test was carried out at the end of the storage period and yield the results 
shown in table (66   ). 
Table (58) Hardness testing for product 8 after storage at different stations 
 8N 8Th 8K 8 G 8 J 8 B 
Min 89 84 110 139 110 129 
Max 187 194 196 216 155 227 
Mean 31.70699 32.50573 22.85826 27.168 13.40647 30.62116 
STD 142 165.2 145.5 183.1 129.8 177.9 
 
4.2.5.1.4 Loss on drying:  
Before distribution the moisture contents was 1.67%. 
The moisture contents after the storage period at different stations could be tabulated 
as follows: 
Moisture contents after the storage period 
Station 8N 8Th 8K 8 G 8 J 8 B 
Moisture 
contents 
2.16% 2.06% 2.1% 2.09% 2.66% 2.93% 
 
4.2.5.1.5 Disintegration Time test: 
Six tablets were subjected to test on Erweka disintegration tester of paddle type. 
Disintegration time was 16 minutes and 29 seconds. 
Then the test was repeated after the storage period and the results are presented in 
table ( 59) 
Table (59   )  Disintegration time for product 8 after storage at different stations 
Station 8N 8Th 8K 8 G 8 J 8 B 
Disintegration time 
in min 
18.0 12.3 20.10 8.15 19.58 12.37 
 
4.2.5.2 Chemical tests for determination of Rifampicin and Isonazid ( App. 18). 
Contents in product 8 during storage at different stations: 
4.2.5.2.1 Rifampicin contents: 
 Results could be tabulated as follows: 
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Table(60) contents of rifampicin in product 8 during storage at different stations. 
4.2.5.2.2 Isoniazid contents: results could be presented in table( 61  ) 
Contents of isoniazid in product 8 at different sites and time. 
RS 8 B 8 J 8 G 8 K 8 Th 8 N time 
 95.1% 95.1% 95.1% 95.1% 95.1% 95.1% 0 
 118.7% 118.7% 118.7% 118.7% 118.7% 118.7% 0 
 99.9% 99.9% 99.9% 99.9% 99.9% 99.9% 0 
 104.6 % 104.6 % 104.6% 104.6% 104.6% 104.6 % mean 
 99.2 101.3 92.7 97.6 106.5 107.1 transportation 
 101 100.9 94.6 96.5 97.7 98.4 6 months 
55308 64.5 63.7 64.2 63.1 62 63.8  Final 1 
54832 63.3 63 63.2 64.1 63.7 62.5  Final 2 
55044 63.7 61.8 63.5 62.4 62.4 66.9  Final 3 
54516 63 61.6 64.3 60.8 63.6   Final  4 
54925 63.6 62.5 63.8 62.6 62.9 64.4 Final mean 
 0.63 0.98 0.52 1.3 0.83 2.2 std 
11/2007 labeled expiration date :  
10/2005 manufacture date:          
350 batch no :                     
RS 8 B 8 J 8 G 8 K 8 Th 8 N time 
 95.8 % 95.8 % 95.8 % 95.8 % 95.8 % 95.8 % 0 
 96.4 % 96.4 % 96.4 % 96.4 % 96.4 % 96.4 % 0 
 94.8 % 94.8 % 94.8 % 94.8 % 94.8 % 94.8 % 0 
 95.7 95.7 95.7 95.7 95.7    95.7 mean 
 99.4 102.4 95.8 97.6 97.5 97.4 transportation 
 97.7 99.2 92.1 99.9 95.5 97.4 6 months 
16582 63 65.5 65 64.4 63.1 66  Final 1 
16436 64.3 65.3 64.5 63.9 64.6 66  Final 2 
16686 64.4 63.2 64.7 65.2 65.7 67.2  Final 3 
1645 63.5 63.1 64.4 62.8 64.6   Final  4 
16540 63.8 64.3 64.6 64.1 64.5 66.4 Final mean 
 0.67 1.3 0.23 0.98 1.1 0.71 std 
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4.2.5.3 Microbiological Examination: 
One gram of powder was used to prepare 5 serial dilutions which were then used in 
the total viable counts for bacteria and fungi in the presence of 4% polysorbate 80 as 
inactivating agent. 
4.2.5.3.1 Initial count of bacteria: 
Two sets of sterile Agar Medium B culture were prepared, and after incubation at 33 
°C, the arithmetic mean of the two sets could be presented as in table ( 70)  
Control Test: 
Experiment Observation of set I Observation of set II Result 
Buffer + medium B No  c.f.u No  c.f.u Negative  
Buffer + Medium B + 
Staph. aureus 
Many c.f.u Many c.f.u Positive  
Table (  62 )  Bacterial growth in different dilutions: 
Dilution 1×10¯¹ 1×10¯² 1×10¯³ 1×10¯4 1×10¯5 Result  
Sample+ 
medium B 
No  c.f.u No  c.f.u No  c.f.u No  c.f.u No  c.f.u _ 
Sample + 
medium B + 
Staph.areus 
Many c.f.u Many c.f.u Many c.f.u Many c.f.u Many c.f.u + 
 
Result: Total viable aerobic count for bacteria is less than I0³/ gram of tablets  
4.2.5.3.2 Initial count for fungi: 
One gram powdered tablets we suspended in 10 ml sterile sodium chloride- peptone 
buffer solution B.P. Then 5 serial dilutions were made and used to prepare two sets of 
sterile Medium C. After incubation at 23 °C for five days, the results could be 
presented as in table (  63  ). Control Test: 
Experiment Observation of set I Observation of set II Result 
Buffer + medium C No  c.f.u No  c.f.u Negative  
Buffer + Medium C + 
Candida Alb. 
Many c.f.u Many c.f.u Positive  
Table ( 63   )  Initial  Fungi growth in different dilutions of product 8: 
Dilution 1×10¯¹ 1×10¯² 1×10¯³ 1×10¯4 1×10¯5 
Sample+ medium C No  c.f.u No  c.f.u No  c.f.u No  c.f.u No  c.f.u 
Sample + medium C + 
Candida 
Many c.f.u Many c.f.u Many c.f.u Many c.f.u Many c.f.u 
 Result: Total viable aerobic count for Fungi is < I0²/ gram of tablets. 
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4.2.5.3.3 Final Bacterial Count for Product 8 at Different Stations: 
3 % Polysorbate 80 was used in the neutralizing buffer. 5 serial dilutions were 
prepared to be incorporated in Medium B and incubated at 33 °C for 30 hours. The 
results could be concluded as follows: 
None of the six stations showed bacterial growth for each of the five  serial dilutions. 
Thus, the product was either free from bacterial contamination.  
4.2.5.3.4 Final Fungal Count for Product 8 at Different Stations: 
 Using medium C and five serial dilutions, and after incubation at 23 °C for 5 days, 
the following results were obtained. 
Table (64  )  Fungal Count for product 8 at different stations 
Station initial 10¯¹ 10¯² Result 
Portsudan - - - - 
Juba - - - - 
Dongola - - - - 
Khartoum - 1-0 c.f.u - 0.5×10¹ 
Damazin - - - - 
Fashir - - - - 
Therefore, fungal count for product 8 at all stations was < 10². 
4.2.6 Rifampicin 150 mg + INH 100 mg Tablets: 
Samples of the products were supplied by National Program for T.B Protection, 
manufactured by ……-India coded for the purpose of this study as product 9. Samples 
were manufactured at 12/2004 labeled to be expired at 11/2007 were subjected to 
physical, chemical and microbiological stability testing.  
4.2.6.1 Physical tests: 
Description and general appearance, uniformity weight, hardness, loss on drying and 
disintegration tests were performed. 
4.2.6.1.1 Description and general appearance: 
Pale pinkish, flatted film coated tablets, diameter of 9.1 mm with notched rounded 
edges and marker line across the tablet. The surfaces of the tablets were coarse on 
touch and black spots of different sizes were distinctly observed. Each 1000 tablets 
were in cellophane bag in a white plastic bottle. 
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Fig. ( 2 ) Black Spots and protrusion in the tablets coarse surface of product 9 
 
 
4.2.6.1.2 Uniformity of weight: 
Test was performed at the beginning of the study table ( 65 ).  
Table (65    ) Initial weight uniformity of product 9 
 
 
Then the test was carriedout again at the end of the storage period for product stored 
at different stations and the results could be presented in the following table (66 ). 
 
 
tablet percentage weight gm tablet percentage weight gm  
1 98.48448 0.3077 11 98.19642 0.3068 
2 101.013 0.3156 12 100.4689 0.3139 
3 96.6281 0.3019 13 102.8374 0.3213 
4 102.5493 0.3204 14 99.38067 0.3105 
5 99.9888 0.3124 15 102.1332 0.3191 
6 101.4931 0.3171 16 103.7656 0.3242 
7 98.74054 0.3085 17 99.18863 0.3099 
8 95.09178 0.2971 18 100.981 0.3155 
9 98.48448 0.3077 19 101.9732 0.3186 
10 98.03639 0.3063 20 100.5649 0.3142 
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Table (66) Weight uniformity for product 9 after storage at different stations 
 
4.2.6.1.3 Resistance to crushing of tablets (Hardness): 
Tablets were subjected to hardness testing by Erweka Hardness Tester. The following 
table shows the results: 
Table (67 ) Hardness testing of product 9 tablets. 
Tablet   Hardness in Newton  Tablet   Hardness in Newton 
1 79 6 75 
2 69 7 76 
3 90 8 72 
4 68 9 83 
5 99 10 112 
Maximum: 112 Newton.                  STD  : 14.18959 
Minimum : 68 Newton.                     RSD  : 17.2413 
Mean        : 82.3 Newton. 
station 9 N 9 Th 9 K 9 G 9 J 9 B 
Mean 0.315555 0.317025 0.31153 0.31434 0.313535 0.31284 
STD 0.006267 0.006044 0.005515 0.00492 0.005959 0.00981 
 % % % % % % 
1 97.51074 99.36125 100.7287 97.21957 100.6586 100.4987 
2 97.60581 103.2411 100.3756 100.4645 99.28716 100.4987 
3 102.5812 101.2538 99.34838 101.5779 98.77685 100.3069 
4 101.9791 100.0867 98.77058 98.93746 97.3416 95.41619 
5 101.1234 99.14045 99.44468 101.6415 101.8068 98.45288 
6 101.6622 102.3894 101.3707 97.91945 99.38284 99.95525 
7 100.553 99.07736 98.54589 99.73277 102.0301 102.5125 
8 98.74665 99.96057 99.82987 100.4963 100.4035 98.67664 
9 97.19383 97.65791 102.0447 101.9915 99.0639 103.6312 
10 101.9791 98.09952 99.86197 99.16015 98.45791 90.74926 
11 98.77834 95.79686 100.4077 100.7508 99.82937 102.5125 
12 99.76074 102.3894 102.0768 99.38283 98.29844 102.8641 
13 98.46144 98.6673 102.141 99.76459 104.167 103.9189 
14 100.7748 102.9887 98.73848 100.719 104.6135 97.87751 
15 100.141 97.84717 99.70147 101.8006 99.09579 101.5855 
16 99.00017 100.1498 99.70147 97.95126 100.3078 97.49393 
17 104.2924 100.623 96.49151 102.6277 99.44663 102.2248 
18 97.85933 100.1814 96.68411 101.0053 98.96822 102.5125 
19 98.23961 100.0867 103.7781 99.19196 97.97949 99.44381 
20 101.7572 101.0015 99.95827 97.66495 100.0845 98.86843 
STD 1.98589 1.906541 1.770406 1.565331 1.900616 3.135944 
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Then the test had been done at the end of the storage period and yield the results 
shown on table (68   ). 
Table ( 68) Hardness testing for product 9 after storage at different stations 
 9 N 9 Th 9 K 9 G 9 J 9 B 
Min 61.2 69.7 61.9 62.2 60.2 68 
Max 95.2 94.7 96 97 80.7 97.7 
Mean 78.31 81.13 76.99 80.71 74.96 76.61 
STD 11.96425 7.457591 10.31185 11.12819 5.791795 8.94706 
 
4.2.6.1.4 Loss on drying:  
Before distribution the moisture contents was 1.67%. 
The moisture contents after the storage period at different stations could be tabulated 
as follows: 
Moisture contents after the storage period 
Station 9 N 9 Th 9 K 9 G 9 J 9 B 
Moisture 
contents 
2.00% 2.81% 2.32% 2.01% 2.53% 2.66% 
 
4.2.6.1.5 Disintegration Time test: 
Six tablets were subjected to test on Erweka disintegration tester of paddle type. 
Disintegration time was 3 minutes and 13 seconds. 
Then the test was repeated after the storage period and the results could be presented 
in table (69   ) 
Table ( 69) disintegration time for product 9 after storage at different stations 
Station 9 N 9 Th 9 K 9 G 9 J 9 B 
Disintegration time 
in min 
2: 33 2: 42 2: 24 3: 01 2: 17 2: 37 
 
4.2.6.2 Chemical tests for determination of Rifampicin and Isonazid 
Contents in product 9 during storage at different stations: ( App. 19). 
 
4.2.6.2.1 Rifampicin contents: 
Results could be presented as in table ( 70   ). 
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Table ( 70  ) Contents of Rifampicin in product 9 during storage at different stations. 
4.2.6.2.2 Isoniazid contents: results could be presented in table( 71    )  
RS 9 B 9 J 9 G 9 K 9Th 9 N time 
 94.1 % 94.1 % 94.1 % 94.1 % 94.1 % 94.1 % 0 
 95.3 % 95.3 % 95.3 % 95.3 % 95.3 % 95.3 % 0 
 94.7 % 94.7 % 94.7 % 94.7 % 94.7 % 94.7 % mean 
 93.4 96 86.6 94.9 93.9 82.9 transportation 
 86 95.2 96.2 92.7 90.4 91.1 6 months 
66854 74.5 % 79.9 % 95.7 % 97.7 % 97.3 % 96.7 %  Final 1 
66525 73.3 % 76.7 % 97.0 % 96.1 % 94.3 % 91.5 %  Final 2 
65449 78.0 % 74.0 % 95.9 % 94.8 % 96.2 % 96.9 %  Final 3 
67176 77.4 % 74.9 % 96.1 % 95.3 % 97.5 % 96.4 %  Final  4 
66500 75.8 % 76.4 % 96.2 % 96.0 % 96.4 % 95.4 % Final mean 
 2.275308 2.609958 0.57399 1.288446 1.460373 2.587054 std 
11/2007 labeled expiration date :  
12/2004 manufacture date:          
RS 9 B 9 J 9 G 9 K 9 Th 9 N time 
 103.6 % 103.6 % 103.6 % 103.6 % 103.6 % 103.6 % 0 
 102.8 % 102.8 % 102.8 % 102.8 % 102.8 % 102.8 % 0 
 103.9 % 103.9 % 103.9 % 103.9 % 103.9 % 103.9 % 0 
 103.4 % 103.4 % 103.4 % 103.4 % 103.4 % 103.4 % mean 
 0.0056 0.0056 0.0056 0.0056 0.0056 0.0056 std 
 100.2 % 99.2 % 102.8 % 98 % 96.6 % 101.4 % transportation 
 100.5 % 99.7 % 98.6 % 96.9 % 94.4 % 95.3 % 6 months 
28171 65.8 % 67.3 % 99.8 % 99.4 % 98.6 % 101.9 %  Final 1 
28613 66.3 % 68.2 % 99.2 % 97.7 % 99.9 % 97.3 %  Final 2 
28428 67.4 % 67.8 % 99.0 % 98.8 % 99.0 % 100.8 %  Final 3 
29030 66.9 % 65.8 % 99.6 % 97.2 % 99.9 % 101.6 %  Final  4 
28560.5 66.6 % 67.3 % 99.4 % 98.3 % 99.3 % 100.4 % Final mean 
1.266412 0.698121 1.06416 0.369303 0.996153 0.67646 2.108865 Relative std 
11/2007 labeled expiration date :  
12/2004 manufacture date:          
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4.2.6.3 Microbiological Tests for product 9: 
One gram of powder was used to prepare 4 serial dilutions which were then used in 
the total viable counts for bacteria and fungi in the presence of 3 % polysorbate 80 as 
inactivating agent. 
4.2.6.3.1 Initial count of bacteria: 
Two sets of sterile Agar Medium B culture were prepared, and after incubation at 33 
°C, the arithmetic mean of the two sets could be presented as in table (  80    ). 
Control Test: 
Experiment Observation of set I Observation of set II Result 
Buffer + medium B No  c.f.u No  c.f.u Negative  
Buffer + Medium B + 
Staph. aureus 
Many c.f.u Many c.f.u Positive  
Table ( 72  )  Bacterial growth in different dilutions of product 9: 
Dilution 1×10¯¹ 1×10¯² 1×10¯³ 1×10¯4 
Sample+ medium B No  c.f.u No  c.f.u No  c.f.u 20  c.f.u 
Sample + medium B + 
Staph.areus 
Many c.f.u Many c.f.u Many c.f.u Many c.f.u 
Result: Total viable aerobic count for bacteria is 2× I0³/ gram of drugs. 
 4.2.6.3.2 Initial count for fungi: 
One gram powdered tablets we suspended in 10 ml sterile sodium chloride- peptone 
buffer solution B.P. Then 4 serial dilutions were made and used to prepare two sets of 
sterile Medium C. After incubation at 23 °C, Table (81) shows the results. 
Control Test: 
Experiment Observation of set I Observation of set II Result 
Buffer + medium C No  c.f.u No  c.f.u Negative  
Buffer + Medium C + 
Candida Alb. 
Many c.f.u Many c.f.u Positive  
Table ( 73  )  Fungi growth in different dilutions of Product 9: 
Dilution 1×10¯¹ 1×10¯² 1×10¯³ 1×10¯4 1×10¯5 
Sample+ 
medium C 
No  c.f.u No  c.f.u No  c.f.u No  c.f.u No  c.f.u 
Sample + 
medium C + 
Candida 
Many c.f.u Many c.f.u Many c.f.u Many c.f.u Many c.f.u 
Result: Total viable aerobic count for Fungi is < I0²/ gram of drugs. 
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4.2.6.3.3 Final Bacterial Count for Product 9 at Different Stations: 
3 % Polysorbate 80 was used in the neutralizing buffer. 5 serial dilutions were 
prepared to be incorporated in Medium B and incubated at 23 °C for 30 hours. The 
results could be concluded as follows: 
None of the six stations showed bacterial growth for each of the five serial dilutions. 
Thus, the product was either free from bacterial contamination or the anti-bacterial 
activity of the product was not affected by the neutralizing solution or the dilutions, so 
it is unlikely to be contaminated by bacteria. 
4.2.6.3.4 Final Fungal Count for Product 9 at Different Stations: 
 Using medium C and five serial dilutions, and after incubation at 23 °C for 5 days, 
the following results were obtained. 
Table (74  )  Fungal Count for product 9 at different stations 
Station initial 10¯¹ 10¯² 1×10¯³ Result 
Portsudan - - - - - 
Juba - - - - - 
Dongola - - - 0.5 c.f.u 0.5×10³ 
Khartoum - 0.5 c.f.u - - 0.5×10¹ 
Damazin - - - - - 
Fashir - - - - - 
Therefore, fungal count for product 9 at all stations was < 10² except for Dongola, 
which is above the limits ( App. 23).. 
4.2.7 Lumefantrine 120 mg + Artemether 20 mg Tablets: 
Samples of the products were supplied by ------ Scientific Office and coded for the 
purpose of this study as product 5. Samples were manufactured by ….-Switzerland 
lot. no.0283, mfg.date was 2/06, exp. date 1/08, each 8 film coated tablets were 
blistered in PVC/AL blister, and each 3 blisters are packed in carton box. Samples 
were subjected to physical, chemical and microbiological stability testing.  
4.2.7.1 Physical tests: 
Description and general appearance, uniformity weight, hardness, loss on drying and 
disintegration tests were performed. 
4.2.7.1.1 Description and general appearance: 
Yellow coloured, flatted film coated tablets, diameter of 8.5 mm with notched 
rounded edges and marker line across the tablet. The surfaces of the tablets were fine 
on touch. 
4.2.7.1.2 Uniformity of weight: 
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Table (75    ) Initial weight uniformity test of product 5 
tablet weight gm percentage tablet weight gm percentage 
1 0.2408 99.96471 11 0.2406 99.88169 
2 0.2399 99.59109 12 0.2405 99.84017 
3 0.2408 99.96471 13 0.2412 100.1308 
4 0.2401 99.67412 14 0.2411 100.0893 
5 0.2405 99.84017 15 0.2387 99.09293 
6 0.2392 99.3005 16 0.2424 100.6289 
7 0.2399 99.59109 17 0.2419 100.4214 
8 0.242 100.4629 18 0.2428 100.795 
9 0.2418 100.3798 19 0.2441 101.3347 
10 0.2393 99.34201 20 0.2401 99.67412 
 
 
Then the test was repeated again at the end of the storage period for samples stored at 
different stations and the results could be presented in the following table ( 76      ).      
Table (76)Weight uniformity for product 5 after storage at different stations 
 
 
mean 0.240885 
STD 0.001323 
station 5 N 5 Th 5 K 5 G 5 J 5 B 
Mean 0.241545 0.242525 0.24178 0.24127 0.242295 0.24321 
STD 0.000883 0.001066 0.001062 0.00088 0.001074 0.000874 
 % % % % % % 
1 99.93997 100.1959 100.2564 100.0539 99.83698 99.83142 
2 100.3126 100.8556 99.96691 99.47362 99.83698 100.5715 
3 99.98137 100.5257 99.05699 99.43217 100.291 100.0781 
4 100.3954 100.3196 99.42923 99.84664 100.3735 100.1192 
5 99.69157 100.6082 100.2978 100.2197 100.0433 99.83142 
6 100.6024 99.86599 99.71875 99.8052 100.6211 100.0781 
7 99.15337 100.1959 99.80147 100.3855 100.3735 99.2969 
8 99.31897 100.0722 100.0083 100.0124 100.3322 99.91365 
9 100.1884 99.70106 99.92555 100.1368 99.17662 100.5304 
10 99.89857 98.95887 99.55331 99.84664 100.5799 100.2015 
11 99.93997 100.3196 99.71875 99.59796 99.42426 99.70807 
12 99.81577 99.90723 100.3392 100.2197 99.91952 100.1604 
13 100.147 100.0722 100.9596 100.2197 100.3735 99.5436 
14 100.2712 99.3712 100.2564 100.5512 99.75443 99.66695 
15 100.0642 100.0309 100.7528 100.4684 99.58934 100.1192 
16 100.4368 99.53613 99.71875 100.6341 99.96079 99.99589 
17 99.89857 99.57736 100.2151 99.59796 100.3735 99.7903 
18 99.56737 99.90723 99.76011 99.47362 99.87825 100.4893 
19 100.1884 99.94846 100.1737 100.0124 99.05281 99.5436 
20 100.1884 100.0309 100.091 100.0124 100.2084 100.5304 
STD 0.365507 0.439611 0.439068 0.364593 0.443195 0.359166 
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4.2.7.1.3 Resistance to crushing of tablets (Hardness): 
Tablets were subjected to hardness testing by Erweka Hardness Tester. The following 
table shows the results:  
Table ( 77  ) Hardness testing of product 5 tablets. 
Tablet   Hardness in Newton  Tablet   Hardness in Newton 
1 69 6 88 
2 75 7 68 
3 67 8 72 
4 73 9 85 
5 76 10 92 
Maximum: 92 Newton.                  STD  : 8.8 
Minimum : 67 Newton.                  RSD  : 11.5 
Mean        : 76.5 Newton. 
Then the test was repeated again at the end of the storage period and yielded the 
results shown in table (78). 
Table ( 78    ) Hardness testing for product 5 after storage at different stations 
 5 N 5 Th 5 K 5 G 5 J 5 B 
Min 68 52 60 57 71 60 
Max 91 84 99 94 88 86 
Mean 76.7 71 75.5 79.3 81.5 72.3 
STD 8.192815 8.576454 11.04788 10.18768 4.836206 7.986795 
4.2.7.1.4 Loss on drying:  
Before distribution the moisture contents was 3.85 W/W %. 
The moisture contents after the storage period at different stations could be tabulated 
as follows: 
Table ( 79  ) Moisture contents after the storage period 
Station 5 N 5 Th 5 K 5 G 5 J 5 B 
Moisture 
contents 
1.65 1.65 1.67 1.67 2.17 2.87 
 
4.2.7.1.5 Disintegration Time test: 
Six tablets were subjected to test on Erweka disintegration tester of paddle type. 
Disintegration time was 4 minutes and 24 seconds. 
Then the test was repeated after the storage period and the results could be presented 
in table (80   ) 
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Table ( 80  )  Disintegration time for product 5 after storage at different stations 
Station 5 N 5 Th 5 K 5 G 5 J 5 B 
Disintegration time 
in min 
4: 55 4: 53 4: 55 4: 40 4: 10 4: 39 
4.2.7.2 Chemical tests for determination of Lumefantrine and Artemether 
Contents in product 5 during storage at different stations: ( App. 20). 
 Samples were assayed initially for lumefantrine and Artemether contents on February 
2007. Then they were reanalyzed after transportation to their storage site on July 
2007. Samples from Juba were recalled and tested on 02.12.2007 because of the 
political status at that time. Finally samples were tested at the end of the study on May 
2008.     
4.2.7.2.1 Lumefantrine contents: 
Samples were analyzed initially, then after transportation, after 6 months storage at 
the stations, then finally after 52 weeks. (table 81)  
Table (81) Contents of lumefantrine in Product 5 at different stations 
Time  Reference  5B 5J 5G 5K 5Th 5N 
0 
165.975 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
0 
163.957 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
Mean 166.492 100.2655 % 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
100.2655 
% 
St.d 165.4747 0 0 0 0 0 0 
R. st.d 1.339517 0 0 0 0 0 0 
Transport,A 10727 11022 10796 10763 10810 10718 10896 
Transp. C 100 102.7 100.6 100.3 100.8 99.9 101.5 
6 months,A 16991.25 17697.79 17310.01 18168.92 16973.67 17602.86 16935.48 
6 months, C 100 104.15% 101.8% 106.93% 99.89% 103.59% 99.67% 
52 weeks,A 21429.8 20729 22553 22104 21760 21878 22275 
52 weeks,A 21531.4 21345 21591 22149 22591 22226 21856 
52 weeks,A 21547.2 21761 22472 22401 22821 22206 22291 
Mean  21502.8 21278.33 22205.33 22218 22390.67 22103.33 22140.67 
R. St.d 
0.296294 
 
2.4 % 2.4 
 
0.072 
 
2.4 
 
0.88 
 
1.11 
52 weeks,C 
100 % 98.95 % 
 
103.26 
 
103.3 
 
104.1 
 
102.8 
 
102.9 
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4.2.7.2.2 Artemether contents in product 5: 
Initial testing for Artemether yielded the following results.  
Table (82 ) Initial contents percentage of Artemether in product 5 
 Area of the standard Area of the sample Content percent. 
1 18.386 18.7283 102.1618 
2 18.3229 18.7755 102.4193 
3 18.2871 18.7283 102.1618 
Mean  18.332 18.74403 102.2476 
St. d 0.050074 0.0272 0.148 
Relative St.d 0.27 0.145 % 0.144 % 
Samples were then transported to different stations and tested after 6 months and 
yielded the following results for Artemether: 
Table (83) Contents percentage of Artemether in product 5 after  transportation. 
Station RS 5B 5J 5G 5K 5Th 5N 
P. area 189.472 164.4 165.9 190 206 182 175.1 
Contents% 100 86.8 87.6 100.3 108.7 96.1 92.4 
Then, samples were collected from different stations after storage period of six 
months and the resultants contents were as follows: 
Table (84   ) concentration of Artemether in product 5 after storage period of six 
months at different stations 
RS Station 5B 5J 5G 5K 5Th 5N 
242.479 P. area  267.013 236.746 236.374 243.89 227.131 208.246 
240.148 Contents% 110.6498 98.10723 97.95308 101.0677 94.12279 86.29687 
241.3135 Mean  
Lastly, samples were analyzed for Artemether content at the end of the study in May 
2008 and the results obtained were presented in the following table. 
Table (85   ) Final contents of Artemether in product 5. 
station RS B J G K Th N 
1 342.187 311 371 330 327 326 297 
2 339.331 324 336 330 333 335 298 
3 358.5 336 354 336 315 327 304 
Mean  346.6727 323.6667 353.6667 332 325 329.3333 299.6667 
 
R. st. d 2.98317 3.86 4.94 1.02 2.82 
 
1.48 
 
1.26 
 
Content  100 93.4 % 102 % 95.76 % 93.74 % 
 
94.99 % 86.43 % 
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4.2.7.3 Microbiological Tests: 
The microbiological tests took place were tests for the total viable count before and 
after distribution of samples on different stations of the study. 
4.2.7.3.1 Initial count of bacteria: 
One gram powdered tablets was suspended in 10 ml sterile sodium chloride- peptone 
buffer solution B.P. Then 5 serial dilutions were made and used to prepare two sets of 
sterile Agar Medium B culture. After incubation at 33 °C, the arithmetic mean of the 
two sets could be presented as in table ( 86). 
 Control Test: 
Experiment Observation of set I Observation of set II Result 
Buffer + medium B No  c.f.u No  c.f.u Negative  
Buffer + Medium B + 
Staph. aureus 
Many c.f.u Many c.f.u Positive  
Table ( 86     )  Bacterial growth in different dilutions: 
Dilution 1×10¯¹ 1×10¯² 1×10¯³ 1×10¯4 1×10¯5 
Sample+ 
medium B 
No  c.f.u No  c.f.u No  c.f.u No  c.f.u No  c.f.u 
Sample + 
medium B + 
Staph.areus 
Many c.f.u Many c.f.u Many c.f.u Many c.f.u Many c.f.u 
Result: Total viable aerobic count for bacteria is < I0³/ gram of drugs. 
4.2.7.3.2 Initial count for fungi: 
One gram powdered tablets was suspended in 10 ml sterile sodium chloride- peptone 
buffer solution B.P. Then 5 serial dilutions were made and used to prepare two sets of 
sterile Medium C. After incubation at 23 °C, table ( 87 ).  
Control Test: 
Experiment Observation of set I Observation of set II Result 
Buffer + medium C No  c.f.u No  c.f.u Negative  
Buffer + Medium C + 
Candida Alb. 
Many c.f.u Many c.f.u Positive  
Table ( 87     )  Fungi growth in different dilutions: 
Dilution 1×10¯¹ 1×10¯² 1×10¯³ 1×10¯4 1×10¯5 
Sample+ 
medium C 
No  c.f.u No  c.f.u No  c.f.u No  c.f.u No  c.f.u 
Sample + 
medium C + 
Candida 
Many c.f.u Many c.f.u Many c.f.u Many c.f.u Many c.f.u 
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Result: Total viable aerobic count for Fungi is < I0²/ gram of tablets. 
4.2.7.3.3 Final bacterial count: 
Five serial dilutions of the powdered product were used for every station. 
Medium B was used and cultured at 33 °C for 30 hours and the results could be 
presented in table ( 88   ) 
Table ( 88  ) Bacterial Count for Product 5 At different stations 
Station  1×10¯¹ 1×10¯² 1×10¯³ Result  
Portsudan - 3- 0  c.f.u - 15×10¹/gram 
Juba - - - < I0³/ gram 
Dongola - - - < I0³/ gram 
Khartoum - - - < I0³/ gram 
Damazin - - - < I0³/ gram 
Fashir - - - < I0³/ gram 
Result: All samples pass the test. 
4.2.7.3.4 Final Fungal Count:  
Five serial dilutions of the powdered product were used for every station. 
Medium C was used and cultured at 23 °C for five days and the results could be 
presented in table (89   ) 
Table (89    ) Total Fungal Count for product 5 at different stations 
Station  1×10¯¹ 1×10¯² 1×10¯³ Result  
Portsudan - - - < I0²/ gram 
Juba 2 c.f.u 1 - 1×10²/gram 
Dongola - - - < I0²/ gram 
Khartoum 0.5 c.f.u - - 0.5×10¹/gram 
Damazin - - - < I0²/ gram 
Fashir - - - < I0²/ gram 
Result: All samples pass the test. 
4.2.8 Artemether 80mg/ml Injection – Indian brand: 
Tests were performed for artemether 80mg/ml  I.M injection from ….. – India, lot 
no;7000312, manufactured in 04/2006 with a labeled expiration date at 03/2008. Each 
8 ampoules were in a tray contained in carton box. The label clearly states storage 
below 25 °C 
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4.2.8.1 Physical tests: 
4.2.8.1.1 Appearance: It is a clear, colourless, oily solution in a colourless glass 
ampoule, with a break line at the neck of the ampoule and loosely adhesive label. 
4.2.8.1.2 Extractable volume: One ml ampoule. 
4.2.8.1.3 Particulate matter testing before and after Storage: 
Using filtration method, 10 ampoules of 1 ml were utilized; results could be presented 
in the following table (91). 
Table ( 91  ) Particulate matter testing before and after Storage for Product 1 
Station 25 µm 10 µm  
Initial blank 00 00 
Sample product 1 00 p/ ml 0.02 p/ml 
Final blank 00 00 
4 N  0/10 ml                            1/10 ml 
4 Th 0/10 ml                              1/10 ml                              
4 K 0/10 ml                             1/10 ml                             
4 G 1/10 ml                             2/10 ml                             
4 J 1/10 ml                              0/10 ml                              
4 B 0/10 ml                              0/10 ml                              
 
4.2.8.2 Chemical assay for Artemether contents: 
The following table shows the results of the assay which represents the results of zero 
time for all of the stations, the returned samples after distribution to different stations 
were subjected to test for content, samples of Indian Artemether injection were 
collected from all stations after storage of six months and assayed for Artemether 
contents, finally after the end of the storage period.. ( App. 21).  
Table ( 90  ) Content of Artemether in product 1 during 52 weeks ( Indian) 
Station 1B 1J 1G 1K 1Th 1N 
1 103.7 % 103.7% 103.7% 103.7% 103.7% 103.7% 
2 103.6% 103.6% 103.6% 103.6% 103.6% 103.6% 
3 103.6% 103.6% 103.6% 103.6% 103.6% 103.6% 
Mean  103.63% 103.63% 103.63% 103.63% 103.63% 103.63% 
STD 0.057735 0.057735 0.057735 0.057735 0.057735 0.057735 
Trans. A 9.6952 9.25037 9.48842 9.26507 9.48933 9.59888 
Trans. C 103.05% 98.33% 100.86% 98.48% 100.87% 102.03% 
6 months,A 8.97374 8.54636 8.49996 8.08013 8.68014 9.32729 
6 months, C 91.23% 86.88% 86.41% 82.14% 88.24% 94.82% 
52 weeks,A 9.41868 8.67109 8.2762 8.68624 8.16528 8.94962 
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52 weeks,A 9.36552 8.50595 8.53173 8.43527 8.82213 9.07455 
52 weeks,A 9.49218 8.32837 8.67852 7.81076 8.91586 9.14277 
52 weeks,A 9.64611 8.48286 8.62733 8.66295 8.8818 9.38046 
mean 9.480623 8.497068 8.528445 8.398805 8.696268 9.13685 
STD 0.121936 0.140266 0.178829 0.408051 0.356105 0.181032 
Percentage 91.8% 82.28% 82.59% 81.33% 84.21% 88.48% 
 
4.2.8.3 Microbiological Tests:  
Particulate matter, assay for total Endotoxins and sterility testing were performed 
initially before distribution, and then finally at the end of the storage period. 
4.2.8.3.1 Total Endotoxins testing before distribution: 
Samples were tested initially before distribution and results could be reported as 
follows: Number of samples : 2 ampoules. Incubation temperature: 37 °C.  
Lysate labeled sensitivity: 0.25 EU/ml. Dilution: No dilution. 
Table (92 ) Gel formation test for product 1 
No Sample  Observation  Set 1 Set 2 
1 L.S.E (positive test) Gel formation + + 
2 L.R.W(negative test) No gel formation _ _ 
3 Product 1 No gel formation _ _ 
 
Limit: Endotoxins in product 1 is< 0.25 EU/ml. 
4.2.8.3.2 Total Endotoxins testing after storage at different stations: 
The test was repeated for samples from different stations at the end of the storage 
period and none of the samples showed a clot formation and the total Endotoxins were 
below 0.25 EU/ml. 
4.2.8.3.3 Sterility testing before distribution: 
Using membrane filtration method, 20 mls of the product were utilized. Then dipping 
the membrane filter in a thioglycolate medium (Oxoid) and Soya bean Casein medium 
and incubate at 33 °C and 35°C respectively for 14 days. 
Observations: no change in the reddish-brown colour of thioglycolate medium and no 
turbidity or change in colour of Soya bean casein medium. 
Results: No evidence of microbial growth during entire 14 days of incubation. 
Comment: The product is complying with the requirements and passes the test for 
sterility. 
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4.2.8.3.4 Sterility testing for product 1 after storage at different stations:      
The test was repeated for samples from different stations at the end of the storage 
period and none of the samples showed a change in the reddish-brown colour of 
neither thioglycolate medium nor turbidity or change in colour of Soya bean casein 
medium. This indicates that, no evidence of disturbance in sterility of the product 1 
during storage at stations of the study. 
 
4.2.9 Artemether 80mg/ml Injection – Chinese brand: 
Tests were performed on artemether 80mg/ml  I.M injection from …… – China, lot 
no;060116, manufactured in Jan/2006 with a labeled expiration date at Jan/2009. Each 
8 ampoules were in a tray contained in carton box. The outer box did not direct the 
storage conditions, however, the enclosed leaflet states storage in cold place, 
protected from light. 
4.2.9.1 Physical tests: 
4.2.9.1.1 Appearance: It is a clear, colourless, oily solution in a colourless glass, 
printed ampoule, with a break line at the neck of the ampoule. 
4.2.9.1.2 Extractable volume: 1.2 ml. 
4.2.9.1.3 Particulate matter testing before distribution: 
Using filtration method, 10 ampoules of 1 ml were utilized; results could be presented 
in the following table.  
Table ( 99  ) Particulate matter testing for Product 2 before and after Storage 
Station 25 µm 10 µm  
Initial blank 00 00 
Sample product 4 00 p/ ml 0.3 p/ml 
Final blank 00 00 
4 N  0/10 ml                            1/10 ml 
4 Th 0/10 ml                              0/10 ml                              
4 K 0/10 ml                             0/10 ml                             
4 G 2/10 ml                             2/10 ml                             
4 J 1/10 ml                              0/20 ml                              
4 B 1/10 ml                              3/10 ml                              
 
4.2.9.2 Chemical assay for Artemether contents: 
4.2.9.2.1 Initial content: 
The following table shows the results of the assay which represents the results of zero 
time for all of the stations,  
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Table ( 93  ) Initial Content of Artemether in product 2 ( Chinese) 
Station 2B 2J 2G 2K 2Th 2N 
1 100.4 100.4 100.4 100.4 100.4 100.4 
2 100.9 100.9 100.9 100.9 100.9 100.9 
3 100.7 100.7 100.7 100.7 100.7 100.7 
Mean  100.6667 100.6667 100.6667 100.6667 100.6667 100.6667 
STD 0.251661 0.251661 0.251661 0.251661 0.251661 0.251661 
 
4.2.9.2.2 Contents of Artemether after transportation: 
The returned samples after distribution to different stations were subjected to test for 
content and the results are presented in table(94).. 
Table ( 94  ) Contents of Artemether in product 2 after transportation 
 RS 2B 2J 2G 2K 2Th 2N 
Area 9.40783 9.51785 9.81326 9.79266 9.83277 9.61611 9.46356 
Content% 100% 101.1695 104.3095 104.0905 104.5169 102.2139 100.5924 
4.2.9.2.3 Assay for Artemether content during storage: 
 Samples of Chinese Artemether injection were collected from all stations after 
storage of six months and assayed for Artemether contents. The results were 
presented in table (95   ). 
      Table ( 95  ) Contents of Artemether after 6 months storage 
 RS 2B 2J 2G 2K 2Th 2N 
1 9.85038 10.5952 10.0995 9.94664 10.2802 10.0601 10.4086 
2 9.8225 105.95% 103.60% 101.12% 104.51% 102.27% 105.81% 
3 9.83644 
std 0.019714 
 
4.2.9.2.4 Concentration of Artemether at the end of the storage period:  
Artemether injection has been assayed for its active contents after storage at different 
station for 52 weeks under the ambient conditions and the results were presented in 
table ( 96   ). ( App. 22). 
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Table (96) Assay for Artemether in product 2 concentration after 52 weeks  
  
RS 2B 2J 2G 2K 2Th 2N 
Peak area1 10.3207 10.9281 10.9582 11.3284 11.1651 10.8141 10.1397 
Peak area2 10.3867 10.9534 11.636 10.3852 11.6613 10.7649 9.45329 
Peak area3 10.3362 10.9036 11.6995 11.8228 11.5735 10.7876 10.2667 
Peak area4 10.2636 11.2604 11.2607 11.4421 10.5788 10.8657 9.46756 
Mean area 10.3268 11.01138 11.3886 11.24463 11.24468 10.80808 9.831813 
STD 0.050688 0.167257 0.346154 0.610713 0.493769 0.04336 0.432003 
percentage 100% 106.6291 110.282 108.8878 108.8883 104.6604 95.20677 
4.2.9.2.5 The overall chemical stability profile of Artemether in product 2: 
The following table represents the content percentage of Artemether in Artemether 
injection product 2 ( Chinese product ) when stored at different stations in their 
ambient conditions throughout 52 weeks. 
Table (97 ) Concentrations of Artemether at different stations during 52 weeks 
 Time 1B 1J 1G 1K 1Th 1N 
0 
100.66% 100.66% 100.66% 100.66% 100.66% 100.66% 
Transport 101.17% 104.31% 104.09% 104.52% 102.21% 100.59% 
6 months 105.95% 103.60% 101.12% 104.51% 102.27% 105.81% 
12 month 
106.63% 110.28% 108.89% 108.89% 104.66% 95.21% 
4.2.9.2.6 Profile of secondary peaks in the assay of artemether in product 2 
chromatogram: Table (98) 
 
4.2.9.3 Microbiological Tests:  
Particulate matter, assay for total Endotoxins and sterility testing were performed 
initially before distribution, and then finally at the end of the storage period. 
R.time 0.55 0.80 0.55 0.80 0.55 0.80 0.55 0.80 0.55 0.80 0.55 0.80 
6-Jul 3.767 5.734 9.002 9.8133 3.913 6.581 10.561 26.96 4.39 8.491 10.196 26.982 
             
2/11/2007 5.588 13.997 4.496 7.119 5.287 11.739 6.978 12.119 6.766 12.517 5.586 8.498 
             
15/05/2008 negligible 1.669 0.926 4.764 0.87 4.455 negligible negligible 1.786 3.316 0.838 4.098 
 negligible 1.738 0.893 4.916 0.938 4.498 negligible negligible 1.756 3.64 0.85 4.151 
 negligible 1.685 1.137 5.172 1.249 4.642 negligible negligible 1.68 2.915 0.9184 4.214 
 negligible 1.799 1.114 5.095 1.035 4.521 negligible negligible 1.579 3.375 0.852 4.32 
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4.2.9.3.1 Total Endotoxins testing before distribution: 
Samples were tested initially before distribution and results could be reported as 
follows:  
Number of samples: 2 ampoules. 
Incubation temperature: 37 °C. 
Lysate labeled sensitivity: 0.25 EU/ml. 
Dilution: No dilution. 
Table (100  ) Gel formation test for product 2 
No Sample  Observation  Set 1 Set 2 
1 L.S.E (positive test) Gel formation + + 
2 L.R.W(negative test) No gel formation _ _ 
3 Product 1 No gel formation _ _ 
Limit: Endotoxins in product 2 is < 0.25 EU/ml. 
4.2.9.3.2 Total Endotoxins testing at the end of the storage period at different 
stations: 
The test was repeated for samples from different stations at the end of the storage 
period and none of the samples showed a clot formation and the total Endotoxins were 
below 0.25 EU/ml. 
4.2.9.3.3 Sterility testing before distribution: 
Using membrane filtration method, whole volume of ampoule was utilized. Then 
dipping the membrane filter in a thioglycolate medium (Oxoid) and Soya bean Casein 
medium and incubate at 33 °C and 35°C respectively for 14 days. 
Observations: no change in the reddish-brown colour of thioglycolate medium and no 
turbidity or change in colour of Soya bean casein medium. 
Results: No evidence of microbial growth during entire 14 days of incubation. 
Comment: The product is complying with the requirements and passes the test for 
sterility. 
4.2.9.3.4 Sterility testing for product 2 after the storage period for all stations:      
The test was repeated for samples from different stations at the end of the storage 
period and none of the samples showed a change in the reddish-brown colour of 
neither thioglycolate medium nor turbidity or change in colour of Soya bean casein 
medium. This indicates that, no evidence of disturbance in sterility of product 2 
during storage at stations of the study. 
 167
5. Discussion 
5.1 Transportation and the Storage Conditions 
The Mean Kinetic Temperature and the Average Relative Humidity for the six 
Sudanese stations were calculated using data from different sources and compared 
with those obtained from the international records. 
5.1.1 Transportation Conditions: 
On transporting the samples of the study to the designated stations on different 
vehicles, the results obtained had been used to calculate the mean kinetic temperature 
and the average relative humidity for transportation conditions table ( 116 ). 
Table (101): The Transportation Conditions across Sudan 
Transportation conditions Station Vehicle 
MKT  °C % RH 
Damazin Truck 33.1 15.7 
Dongola Passenger's bus 34 16.6 
Fashir Airfreight 30.6 15.8 
Juba Airfreight 32.7 41 
Khartoum Private car 48.3 13 
Distribution truck 35.9 18.9 Portsudan  
Passenger's bus 45.2 26.3 
5.1.1.1 Transportation MKT 
From the above table it is clear that the transportation MKT for all of the six stations 
was > 30°C contradicting the EMRO stability guidelines instructions which states that 
the transportation conditions for Sudan should be < 30°C. These values were 
significantly different from 30°C with a significance value 0.033 and t-value 2.757. 
Transportation conditions via the usual routes and vehicles varies from 48.3°C which 
is the MKT of a private car in Khartoum to 30.6°C; the plane temperature. This result 
was in conformance with the result stated in the IDA field study which indicated that 
the temperature at the port may reach up to 45°C(Hogerzeil et.al,1991).  
The temperature inside a private car reached up to 50°C with an average of 48.3°C; 
which is harmful to medicinal products and this may take place inside doctors' cars 
especially the medical representatives who are always taking their samples in the car 
back or cabinet for many days during their daily work. It may also take place inside 
the distribution vehicles that are not conditioned.     
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The need for the DRA intervention may be of great importance to set regulations 
concerning transportation, distribution and promotion of drugs to preserve the 
EMRO's stability guidelines in order to maintain stability of drugs throughout their 
designated shelf lives. 
5.1.1.2 Transportation Humidity 
Five of the stations showed transportation humidity ranging from 13% to 26.5%; less 
than 35% indicating the dry conditions of transportation. The sixth station; Juba, 
transportation humidity was 41% due to the humid climate and the airfreight 
conditions. The EMRO stability guidelines stated that special testing for low humidity 
should be considered for liquids and aqueous preparations in permeable or 
semipermeable containers. 
5.1.1.3 Effects of Transportation on the stability of selected products: 
All products had been affected by transportation except Metronidazole I.V infusion in 
glass container, lumefantrine in product 5 and INH in product 8.  
Table (102) Changes in Potency of selected products after transportation 
Product 1 2 3 5a 6 7 8a 9a 9b mean 
Fashir -1.70%  × 3.60% -10.20% -11.50% -2.40%  × -12.40% -2% -7.20% 
Damazin -2.90% 1.50% 3.60% -6.30% -4.10% -5.10%  × -0.80% -6.80% -3.80% 
Khartoum -5.20% 3.80% 1.60%  × -1.90% -2.90% -7%   -5.40% -5.40% 
Dongola -2.90% 3.40% 4.20% -1.90%  ×  × -11.90% -8.70% -0.60% -4.65% 
Juba -5.40% 3.60% 3.60% -14.60% -5%  × -3.30%   -4.20% -4.20% 
Portsudan -0.70% 0.40% 4.60% -15.60% -8.30%  × -5.40% -1.30% -3.20% -2.25% 
mean -3.13% 2.54% 3.53% -9.72% -6.16% -3.47% -6.90% -5.80% -3.70% -3.65% 
Artemether in tablets and injection was greatly affected by transportation conditions 
which resulted in average loss of potency of 9.72% for tablets and 3.13% for 
injection. Artemether injection; product 2, the average increase in potency was 2.54%. 
Rifampicin and Amoxicillin trihydrate lost 6.9% and 6.16% from their potency as a 
result of transportation conditions. Metronidazole I.V infusion in plastic containers 
potency was increased by 3.53% on the average. 
5.1.2 Storage conditions: 
The MKT and the average relative humidity of the six stations constituting the storage 
condition for different sources of data were presented in table (103). (App. 1- 13).  
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Table 103  ) Calculated storage conditions of the six stations according to Dataloggers data    
Method Damazin station(1) Dongola station (2) Fashir station (3) Juba station (4) Khartoum station (5) Portsudan station (6) 
 MKT RH% MKT RH% MKT RH% MKT RH% MKT RH% MKT RH% 
Pooled 25.4 41.3 27.1 22.9 28.8 19.4 29.2 44 26.2 28.2 24.3 52.2 
USP 25.6 41.3 27.2 22.9 28.8 19.4 26.1 44 27 28.2 25.6 52.2 
FDA 25.6 41.3 27.6 22.9 28.8 19.4 26.1 44 27 28.2 25.6 52.2 
                          
 
Calculated storage conditions of the six stations according to the National 
records      
records Damazin station(1) Dongola station (2) Fashir station (3) Juba station (4) Khartoum station (5) Portsudan station (6) 
 MKT RH% MKT RH% MKT RH% MKT RH% MKT RH% MKT RH% 
Adopted 28.5 47.7 29.4 18 26.9 18 28.8 60.8 30.6 28 29.4 52.2 
parallel 31.7 50.4 33.8 23.1 27.8 26.2 28 55 31.6 37.8 30.8 39.1 
                          
 International Records on storage conditions of Sudan                                            
JTC WHO  EMRO  USP calculated USP derived 
WMO 
calculated  Grimm  
MKT MKT RH% MKT RH% MKT RH% MKT RH% MKT RH% MKT RH% 
32.5 30 35 30 65 27.1 35 30 35 33 35 32.5 35 
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5.1.2.1 MKT: 
There were three categories of results according to source of data: Table (118  ) 
1- MKT calculated from Dataloggers by three methods. 
2- MKT calculated from the adopted National Meteorological records and those 
nationally recorded for the same period of the study. 
3- Internationally published MKT for Sudan 
5.1.2.1.1 Comparison of MKT calculated from dataloggers records: 
Different Values of MKT, calculated from dataloggers at different stations, different 
facilities and conditions were introduced to SPSS software , one-way ANOVA 
analysis tool using level of significance 0.05 (App. 24) 
Comment: 
1- The MKT of different facilities at all stations were significantly different from 
each other having a significance value of (0.02) 
2- MKT of storage facilities at Damazin, Khartoum and Portsudan were 
insignificantly different having a significance value of (0.099 – 0.595). 
3- MKT of storage facilities at Dongola, Juba and Khartoum were insignificantly 
different having a significance values of (0.808 – 0.416). 
4- MKT obtained from Fashir was significantly different from all other stations. 
Conclusion: 
1- The in-house MKT depends mainly on the interventions to improve the 
storage conditions, so it was different from one facility to another. The MKT 
values of Damazin, Portsudan and Khartoum hospitals were insignificantly 
different (25.2, 27, 25.2 °C respectively, Juba also was insignificantly 
different because the mean value of the pooled, USP and FDA methods of 
calculation was 27.1°C). 
2-   The in-house MKT values for Dongola, Fashir, Juba and Khartoum were 
insignificantly different having values of (27.6, 28.8, 27.1, 27 °C 
respectively). 
3- The MKT of Fashir was some what higher because the temperature readings 
increases during the period from 3 PM to 11 PM and decrease during the 
working hours indicating that workers tend to switch off the conditioning 
equipments and close the pharmacy at 3 PM. 
4- It could be concluded that the controlled room temperature for the six stations 
was( 28.8°C - 25.2°C ) 
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5.1.2.1.2 Comparison between adopted and parallel meteorological records: 
On comparing the means of MKT values calculated from the adopted and recent 
records on the period April 2007- March 2008 for the six stations together, 
insignificant difference could be concluded having significance value of 0.148. 
5.1.2.1.3 Comparison between MKT calculated from the adopted and 
parallel National Meteorological records and WHO MKT for Sudan: 
On comparing the MKT values being calculated from both meteorological data and 
the MKT value defined by WHO for Sudan, it could be concluded that there was 
insignificant difference between the three results considering that, the MKT 
calculated from one source was for all stations taken as one group compared with the 
other sources. One-way ANOVA significance were (0.074, 0.243, 0.493) Thus it 
could be concluded that the calculations of WHO were based on the mean 
meteorological data. 
5.1.2.1.4 Comparison between MKT Calculated from dataloggers at different 
stations, adopted and parallel meteorological records for stations and 
WHO MKT for Sudan: 
The MKT values calculated for every individual station from datalogger records (1), 
past adopted meteorological records (2)and parallel period meteorological records(3) 
for the same station, and the MKT value defined by WHO(4), (30 °C), were compared 
with each other for every station. 
A- Damazin, Dongola, Fashir, Khartoum : 
There were significant differences between MKT calculated from datalogger records 
and that calculated from both meteorological records and WHO defined MKT having 
significance 0.00. The MKT calculated from recent and past National meteorological 
records for Damazin were significantly different from each other   and from that 
defined by WHO. This indicated that WHO MKT was significantly different from 
MKT calculated from both meteorological data for Damazin with a significance value 
0.00. (App 24) 
B- Juba, Portsudan : 
The calculated MKT from the adopted past meteorological records was insignificantly 
different from that defined by WHO having significance value 0.139 for Juba and 
0.086 for Portsudan. WHO defined MKT was significantly different from MKT 
calculated from datalogger records and from that calculated from meteorological data 
for the parallel period (0.004, 0.026 for Juba and 0.00, 0.031 for Portsudan)(App. S2). 
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5.1.2.1.5 Comparing the MKT from WMO report and that defined by JTC and 
Badawi and that defined by Grimm and that calculated from datalogger and 
meteorological records:  
1- There were significant differences between MKT obtained from WMO, defined by 
JTC and Grimm and MKT of all stations from all sources of data. 
2- The only insignificant difference was between JTC, Grimm and WMO with 
significance value (0.098 -0.562) 
3- There was insignificant difference between MKT calculated from Khartoum 
parallel meteorological data and that defined by JTC and Grimm (sign. 0.748). 
4- MKT calculated from meteorological data for Dongola the period of the study was 
still higher than that calculated from WMO records. 
5.1.2.1.6 Comparing the USP Calculated MKT; 27.9 °C: 
1-MKT calculated from dataloggers at all stations were compared with USP 
calculated MKT, the results were that there was insignificant differences between 
MKT of dataloggers for Dongola, Fashir, Juba and Khartoum; significances 0.351, 
0.161, 0.238, 0.82 respectively. 
2- Significant difference was obtained between USP calculated MKT and that of 
Damazin and Portsudan, However, the in-house MKT for these stations were below 
the USP calculated MKT.  
5.1.2.1.7 Comparing MKT for all stations calculated from different sources of 
data: (App. 24) 
The relationship between different sources and their adherence together irrespective 
of the station but orienting to the sources of results were given as follows: 
1- MKT obtained from the past meteorological data (1962-1991) was 
insignificantly different from that of WHO, EMRO and derived MKT of USP, but it is 
significantly different from the MKT calculated from the recent meteorological data 
(4/2007-3/2008) and from the MKT obtained from dataloggers readings calculated by 
pooled, USP and FDA methods. 
2- The MKT pointed out by WHO was only in conformance with the MKT 
calculated from the past and recent meteorological data (sig. 0.142, 0.392). 
3- There was insignificant difference between USP calculated MKT and that 
calculated from dataloggers using different methods and the past meteorological data, 
but it was significantly different from the recent meteorological data and WHO. 
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The MKT obtained by utilizing dataloggers data was significantly different from both 
meteorological data. The average mean of MKT of the open air is 3.8 °C above the in-
house MKT and it was contrary to the international records which pointed that the 
measured room temperature was 7.8, 4.1, 1.6 and 1.9 above the open air temperature 
for zone I, II, III, IV. 
5.1.2.2 Average Relative Humidity: 
The average relative humidity of the stations was significantly different as shown by 
One-way ANOVA having significance value (0.00) (App. S4). 
 The multiple comparisons (App. 24) show the following results: 
1- There was insignificant difference in the average relative humidity between 
Portsudan, Damazin and Juba (sig. 0.065, 0.714) but there was a significant difference 
in the average relative humidity of these station and the other three stations (sig.0.00). 
2- There was insignificant difference in the average relative humidity between 
Dongola and Fashir with significance value 0.838. 
2- On comparing the average relative humidity obtained from different sources of data 
and the internationally published data, all results were insignificantly different from 
each other except the result pointed out by EMRO2 which is significantly different 
from all results with sig. value 0.001. 
3- There was insignificant difference in average relative humidity obtained from 
dataloggers data, past and recent meteorological records for Juba, Damazin and 
Portsudan and that pointed out by EMRO with a level of significance 0.104, but they 
were significantly different from WHO % RH (35%) sig. 0.001 ( App. S6). 
4- The average room relative humidity was 6% and 6.4% lower than that measured in 
the open air as recorded by the adopted meteorological records for Portsudan and 
Damazin respectively.  
It could be concluded that by application of this method on the Asian countries, new 
real results could be obtained and new storage conditions may take place.  
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5.1.3 Effects of Storage conditions on potency of selected products 
Changes in potency with time for all products at all stations could be concluded as in 
table (104). 
Table ( 104 ) Changes in potency with time for all products at all stations 
Table (    ) Change in Potency of Selected Product after the Storage  
Product Fashir Damazin Khartoum Dongola Juba Portsudan 
Art. India 15.10% 19.40% 22.30% 21.00% 21.30% 11.80% 
Art. China 5.50% +4.00% +8.20% +8.20% +9.50% +5.90% 
Met. Plastic +2.40% +1.90% +1.40% +2.20% +2.60% +3.53% 
Met. Glass 1.80% 1.20% 1.20% 1.50% 1.70% 0.50% 
Lum.Product5 +2.60% -2.50% +3.80% +3.00% +2.90% 1.40% 
Art.product5 15.80% 7.20% 8.50% 6.50% 0.20% 8.80% 
Amox.SD 8.90% 11.80% 10.00% 11.10% 10.80% 11.70% 
Amox.IND 1.40% 2.40% 3.10% 0.50% 0.70% 0.30% 
Rif.SD 40.20% 41.70% 42.00% 40.80% 42.10% 41.00% 
INH SD 29.30% 31.20% 31.60% 31.10% 31.40% 31.90% 
Rif.IND +0.70% +1.70% +1.30% +1.50% 18.30% 18.90% 
INH.IND 3.00% 4.10% 5.10% 4.00% 36.10% 36.70% 
 
From the table above it is obvious that all products were affected by storage 
conditions which were almost above 25 °C 
5.1.4 Thermal Exposure Periods: 
Table (105) Thermal Exposure Periods for the Six Stations 
 Station Total Exposure Hours Period Over 25°C % Period Over 30°C % 
1 Damazin 9003 hours 65% 0.4% 
2 Dongola 5869.5 hours 55% 19.5% 
3 Fashir 7927.5 hours 60.9% 25.2% 
4 Juba 7563 hours 71.2% 48.7% 
5 Khartoum 7773.5 hours 51% 10.2% 
6 Portsudan 8700 hours 57% 3% 
From the above table, it could be concluded that all samples were expoesd at all 
stations to temperature more than 25°C % for the most period of storage with a considerable 
excursions over 30°C % and this was contradicting to the labeled storage instructions for 
most products. The FDA specifies two excursions up to 30°C % after which the 
storage facility will be disqualified.  
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5.2 Stability of Selected Products: 
5.2.1 Metronidazole IV Infusion in Glass Container (product 4): 
5.2.1.1 Physical Stability: 
There were no significant changes in appearance, colour, calirity and PH. 
The harmonized test for particulate material specifies that 100 ml should not contain 
more than 300 sub- visible particles of size 25 µm and 3000 particles for size 10 µm. 
Since the product contains less than the specified limits, it passes the test and so no 
evidence of generation of particulate matter from the container or the closure during 
storage. The product could be considered physicaly stable when stored at the 
conditions of the six sudanese stations. 
5.2.1.2 Chemical Stability: 
The B.P allows the range of required content from 95%  to 110% and the USP 
specifies the range from 90% to 110%. The samples were tested on the B.P method. 
The date of manufacture for the tested batch of samples was 12/2005, having a shelf-
life of three years. 
The results obtained at 5/2008 show no significant change in the content of 
metronidazole. The lowest concentration obtained was 99.6% for the samples stored 
at Juba and Fashir. 
Determination of Reaction order and Rate constant of Metronidazole I.V solution 
Degradation Reaction: 
Using the substitution method, results were substituted in the integral equation of 
zero, first and second order of reaction to get the rate constant values. Considering 
Portsudan station excluding the transportation results the K rate constat for different 
orders could be calculated ( table 106 ) 
Table (106) Rate constant values for Product 4B 
K2 K1 Ko 1/at (2.303/t Co-Ct(x) log(Co/Ct) Ct Co T 
        507 0 
0.00000283 0.00143088 0.722222 0.000329 0.383833 4.333333 0.003728 502.6667 507 6 
0.00000239 0.00120995 0.611111 0.000329 0.383833 3.666667 0.003152 503.3333 507 6 
0.00000252 0.00126999 0.638889 0.000164 0.191917 7.666667 0.006617 499.3333 507 12 
0.00000252 0.00126999 0.638889 0.000164 0.191917 7.666667 0.006617 499.3333 507 12 
0.00000257 0.00129520 0.652778 mean       
0.00000019 0.00009478 0.048113 St.d       
7.27031511 7.31769015 7.370429 CV       
From the above tables, the reaction order of product 4B seemed to accept first and 
second orders of kinetics, thus the reaction could be considered pseudo-first order 
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with K1 1.4×10¯³ to 1.2×10¯³ month¯¹ with standard deviation of 0.000095. Values 
obtained were insignificantly different from each other given by ANOVA analysis 
tool with F value of 0.86 and significance value 0.451 ( App. 24). 
5.2.1.2.1 Chemical Stability Profile: 
Considering the results obtained from the samples stored at Juba station( App. 14), the 
following table could be obtained. Table ( 107  )  
metronidazole 4   Y lnC   Y Y2 (Y-y)2 time X X2 (X-x)2 XY 
101.6% 508 6.230481448 38.81889907 0.000132744 0 0 34.2225 0 
101.6% 508 6.230481448 38.81889907 0.000132744 0 0 34.2225 0 
101.6% 508 6.230481448 38.81889907 0.000132744 0 0 34.2225 0 
101.2% 506 6.226536669 38.76975889 5.74059E-05 0 0 34.2225 0 
101.2% 506 6.226536669 38.76975889 5.74059E-05 0 0 34.2225 0 
101.333% 506.667 6.227853325 38.78615704 7.90912E-05 0 0 34.2225 0 
101.333% 506.667 6.227853325 38.78615704 7.90912E-05 1 1 23.5225 6.227853 
101.333% 506.667 6.227853325 38.78615704 7.90912E-05 1 1 23.5225 6.227853 
101.467% 507.333 6.22916825 38.80253708 0.000104208 1 1 23.5225 6.229168 
99.8667% 499.333 6.213273875 38.60477225 3.2332E-05 6 36 0.0225 37.27964 
99.8667% 499.333 6.213273875 38.60477225 3.2332E-05 6 36 0.0225 37.27964 
99.6% 498 6.210600077 38.57155332 6.98883E-05 6 36 0.0225 37.2636 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
99.6% 498 6.210600077 38.57155332 6.98883E-05 12 144 37.8225 74.5272 
  sum 124.3791944 773.5107475 0.001548184 117 1263 578.55 726.7254 
 mean 6.218959718   5.85    
On plotting potency versus time using Statistica program, Least Square Linear 
Regression Tool, the following graph was obtained. 
Graph (1) Stability Profile of Product 4 J 
Metronidazole I.v in Glass Container
Product 4
content = 101.3492-0.1553*x
0 10 20 30 40 50 60 70
time ( months)
90
92
94
96
98
100
co
nt
en
t%
 
 177
The regression equation was: 
C = 101.3492 – 0.1553 × t. 
The 5% lower confedence interval band intercept the 90% potency at 62 months. 
But the rate of degradation reaction was supposed to be pseudo-first order,however, if 
the variance is small, and the concentrations measured are in a narrow range ( as 
might occur in short- term stability study to 10% decomposition) the log 
transformation will result in data that are close to normal with homogeneous variance. 
Prediction for stability during short- term based on the least squares fit will be 
approximately correct under these conditions ( Bulton S,2004). Thus, the ln contents 
were plotted versus time and the following graph could be obtained. 
Graph (2) Stability Profile of Product 4 B Ln Transformation 
Metronidazole I.V in glass container product 4
Ln transformation
ln content = 6.228-0.0015*x
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The regression equation is: 
Ln content = 6.228 – 0.0015434 × t.     Representing;  lnC = ln C° - k t. 
The FDA suggested that a one-sided interval may be more appropriate than two-sided 
interval to estimate the expiration date. For most drug products, drug potency can 
only decrease with time and only the lower confidence band of potency versus time 
curve may be considered relevant. An exception may occur in the case of liquid 
products where evaporation of the solvent could result in an increased potency with 
time. 
5.2.1.2.2 Estimation of Expiration Date: 
According to the B.P.: 
From the regression equation lnC= 6.228 – 0.0015434 × t 
t (95) = (6.228- 6.163)/ 0.0015434 = 42.1 months 
                                                  .  
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By application of Woolf's equation for one sided confidence interval for X at a given 
Y , the expiration date could be estimated. 
(X-gx¯ )±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
                                                                1-g 
g is the inverse prediction factor which could be obtained by the equation: 
g =    t²( S²yx) 
            b²∑(x-x¯)² 
Where S²yx is the variance estimate and could be given by the equation: 
S²yx = ∑y² - (∑y)²/N - b²∑(x-x¯)² 
N- 2 
By substitution in Woolf's equation 
[42.1- (0.0750243×5.85)] – [1.73×0.00587766765/0.0015434] [ √(0.04625+2.2713) 
                                                               0.924957 
                                                                                                               = 34.21 months 
Because the study had begun at March 2007, this product may still be valid up to 
January 2010, that means it could be given expiration date 12/2009. This makes the 
shelf life of product 4 years which conforms the B.P.C which states that 
metronidazole is stable for more than 5 years.  
5.2.1.2.3 Related Substances: 
2- methyl-5-nitroimazole and nitrite contents were within the B.P limits, so the 
product fulfills the requirements.  
5.2.1.3 Microbiological stability: 
5.2.1.3.1 Sterility testing: 
Since the sterility of the product was not altered during storage, this indicates that no 
evidence of microbial contamination during storage. The product had been 
manufactured under GMP measures and the packaging container and the closure 
system were efficient enough to keep the product microbiologically stable throughout 
its shelf-life. 
5.2.1.3.2 Total Endotoxin Testing: 
The harmonized total endotoxin test specifies that the solution should contain not 
more than 0.35 endotoxin units per mg of metronidazole. The lysate labeled 
sensitivity was 0.25 EU/ ml. The test resulted in no gel formation, thus the total 
endotoxin was less than0.25 EU/ml and so the product passes the test indicating GMP 
compliance.    
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5.2.1.4 Comment: 
Metronidazole I.V infusion contained in glass container seems to exhibit a marked 
stability when stored at various conditions of Sudan. It is supposed to be stable 
beyond its labeled expiration date and its shelf life could be extended for another one 
year. 
This may be due to the stability properties of metronidazole, the GMP measures of the 
manufacturer and the addition of overage which was 2-3%. 
5.2.2 Metronidazole I.V. in Plastic container ( Product 3): 
5.2.2.1 Physical Stability: 
There were no significant changes in appearance, colour or PH. The harmonized test  
for particulate materials specifies that 100 ml should not contain more than 300 sub- 
visible particles of size 25 µm and 3000 particles for size 10 µm. Since the product 
contains less than the specified limits, it passes the test and so no evidence of 
generation of particulate matter from the container or the closure during storage at the 
specified conditions.  But there was a marked decrease in the deliverable volume of 
samples stored at three stations out of six. 
The initial volume was found to be 100.1 ml, and at the end of the study the following 
results were obtained: 
1- Samples stored at Fashir   : 94 ml 
2- Samples stored at Juba       : 96 ml 
3- Samples stored at Damazin: 97.5 ml.  
 The mass or volume of one container is not less than the amount stated in the label 
(B.P 2007). Since the quantity stated in the label was 100 ml, thus the samples at the 
above stations failed the test. This may be due to either leakage of solution out of the 
container or evaporation of solvent and as there was no visible container damage, this 
loss may be due to evaporation of solvent which could be confirmed by the chemical 
stability findings. This result was in conformance with that stated in B.P.C which 
states that metrondiazole solution in plastic container can leach out some chemical 
components up to 5 ppm. This range was increased due to the hot dry conditions. 
5.2.2.2 Chemical Stability: 
The B.P allows the range of required content from 95%  to 110% and the USP 
specifies the range from 90% to 110%. The samples were tested on the B.P method. 
The date of manufacture for the tested batch of samples was 12/2005, having a shelf-
life of three years with a labeled expiration date 11/2008. 
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1- Effect of transportation: The mean initial content was 102.82% with STD of 0.85. 
The samples had been transported from Khartoum to various stations and the back to 
Khartoum in summer 2007. The results could be concluded in the following table: 
Station Fashir Damazin Khartoum Dongola Juba Portsudan 
Content 106.4% 106.35 104.4% 106.98% 106.4% 107.4% 
This indicates the marked increase in the active content of the solution. 
2- The potency after six months of storage at different stations showed increase in 
manner lower than that caused by transportation but more than that tested initially. 
After another six months another increase in potency resulted. The increase was 
markedly noted in samples stored at Portsudan, Juba and Fashir. 
5.2.2.2.1 Chemical Stability Profile: 
Treating the results obtained from Portsudan (App.15), the following table was 
obtained: 
Table (108) Analysis of Results of Product 3 B 
content % content ln conc Y Y² (Y-y)² 
time 
X X² (X-x)² XY 
102.133 510.67 6.235717 38.884167 0.000855 0 0 34.2225 0 
102 510 6.234411 38.867877 0.000934 0 0 34.2225 0 
102 510 6.234411 38.867877 0.000934 0 0 34.2225 0 
103.6 518 6.249975 39.062191 0.000225 0 0 34.2225 0 
103.6 518 6.249975 39.062191 0.000225 0 0 34.2225 0 
103.6 518 6.249975 39.062191 0.000225 0 0 34.2225 0 
107.333 536.67 6.285377 39.505966 0.000417 1 1 23.5225 6.285377 
107.467 537.33 6.286619 39.521574 0.000469 1 1 23.5225 6.286619 
107.467 537.33 6.286619 39.521574 0.000469 1 1 23.5225 6.286619 
104.533 522.67 6.258944 39.174379 3.63E-05 6 36 0.0225 37.55366 
104.533 522.67 6.258944 39.174379 3.63E-05 6 36 0.0225 37.55366 
104.533 522.67 6.258944 39.174379 3.63E-05 6 36 0.0225 37.55366 
106.267 531.33 6.27539 39.380514 0.000109 12 144 37.8225 75.30467 
106.267 531.33 6.27539 39.380514 0.000109 12 144 37.8225 75.30467 
106.267 531.33 6.27539 39.380514 0.000109 12 144 37.8225 75.30467 
106.4 532 6.276643 39.396253 0.000136 12 144 37.8225 75.31972 
106.4 532 6.276643 39.396253 0.000136 12 144 37.8225 75.31972 
106.4 532 6.276643 39.396253 0.000136 12 144 37.8225 75.31972 
106.4 532 6.276643 39.396253 0.000136 12 144 37.8225 75.31972 
106.4 532 6.276643 39.396253 0.000136 12 144 37.8225 75.31972 
 mean 6.264965     5.85    
  ∑ sum 125.2993 785.00155 0.005868 117 1263 578.55 734.0322 
On plotting potency versus time using Statistica program, Least Square Linear 
Regression Tool, the following graph was obtained. 
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Graph(3) Stability Profile of Product 3B  
Metronidazole I.V in Plastic Container 3B
lnC = 6.2545+0.0018*x
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The regression equation was: 
Ln C = 6.25453631 + 0.001783 × t 
The FDA suggested the one sided confidence interval to estimate the expiration date. 
It suggested using the upper one sided confidence interval for liquid products where 
evaporation could result in an increased potency with time. The upper limit for 
metronidazole I.V infusion according to both USP and B.P is 110%.  
Graphically the regression line intercept 6.3099, ( ln 550 ), at about 30 months and the 
two-sided confidence interval upper band intercept the X axis at about 20 months. 
5.2.2.2.2 Estimation of the expiration date for product 3B: 
Both USP and B.P specify 110% as the upper limit for the product which is 550 mg 
/100ml. ln 550 is 6.3099182782265, from the equation: 
Ln C = 6.25453631 + 0.001783 × t 
The time for concentration to reach 550 mg/ 100 ml is 31.06 months. 
By applying Woolf's equation to obtain the one-sided confidence interval for 31.06 
months at a given ln concentration, the expiration date could be obtained.  
(X-gx¯ )±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
g is the inverse prediction factor which could be obtained by the equation: 
g =   t²( S²yx) 
          b²∑(x-x¯) ² 
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Where S²yx is the variance estimate and could be given by the equation: 
S²yx = ∑y² - (∑y)²/N - b²∑(x-x¯)² 
                             N- 2 
Using N = 20, d.f will be 18, the t value for 5% one sided confidence interval at d,f 18 
is 1.73. 
S²yx = 785.00155-(15699.91458) /20 – (0.001783 )² × 578.55 = 0.000221247458 
                                               18 
g = ( 1.73)² × 0.000221247458  = 0.3601605 
         (0.00178265288)² × 578.55 
One-sided confidence interval: 
31.06-(0.3601605×5.85)-
[1.73×0.014874389332/0.001783][√0.6398395/20+586.1241/578.55] 
              0.6398395 
 = 21.5 months  
Since the first analysis was in March 2007, the expiration date could be November 
2008 which is identical to the labeled expiration date without conservative period. 
Inspite of the acceptable MKT of Portsudan warehouse which is 24.3 °C  and high 
relative humidity; 52.2 %. This decline in the shelf life may be due to the higher 
transportation MKT and this could be confirmed by the higher results obtained after 
transportation which reached up to 107%.  
3- Considering samples stored at Fashir with a warehouse MKT 28.8 °C and %RH 
19.4 %. On plotting ln C versus time, the following graph could be obtained: 
Graph (4) Stability Profile of Product 3 F 
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The regression equation is as follows: 
Ln C = 6.25250769 + 0.0010972255. 
5.2.2.2.3 Estimation of the expiration date for samples stored at Fashir: 
From the regression equation:  
Ln C = 6.25250769 + 0.0010972255. Then ln 550 is 6.3099182782265, so, the 
time required for the product to reach 110% is 52.3 months. 
The results could be treated as in the following table. 
Table (109) Analysis of Results of Product 3N 
content ln conc Y Y² (Y-y)² time X X² (X-x)² XY 
510.67 6.235717 38.884167 0.000539 0 0 34.2225 0 
510 6.234411 38.867877 0.000601 0 0 34.2225 0 
510 6.234411 38.867877 0.000601 0 0 34.2225 0 
518 6.249975 39.062191 8.01E-05 0 0 34.2225 0 
518 6.249975 39.062191 8.01E-05 0 0 34.2225 0 
518 6.249975 39.062191 8.01E-05 0 0 34.2225 0 
532 6.276643 39.396253 0.000314 1 1 23.5225 6.276643 
532 6.276643 39.396253 0.000314 1 1 23.5225 6.276643 
532 6.276643 39.396253 0.000314 1 1 23.5225 6.276643 
522 6.257668 39.158404 1.58E-06 6 36 0.0225 37.54601 
522 6.257668 39.158404 1.58E-06 6 36 0.0225 37.54601 
521.33 6.25639 39.142411 6.43E-06 6 36 0.0225 37.53834 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
526 6.265301 39.253999 4.06E-05 12 144 37.8225 75.18361 
mean 6.258926 39.17416      
sum  125.1785 822.66063 0.003257 117 1263 578.55 732.9292 
The first step is to calculate the variance estimate:  
  S²yx = ∑y² - (∑y)²/N - b²∑(x-x¯)²  
                             N- 2                                                       
= 783.48647-15669.686225/20-0.0000012039×578.55 = 0.0001627982785 
                                    18 
Then to obtain the confidence estimate factor ( g ):      g =   t²( S²yx) 
                                                                                               b²∑(x-x¯) ² 
 184
(1.73)²(0.0001627982785)/0.0000012039037×578.55 = 0.6995348691367 
To obtain the 5% one-sided confidence interval for 52.3 months, Woolf's equation 
could be used:  
(X-gx¯ )±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
48.2 – [20.117551184615] [√ (0.304651308633/20)+(46.45)²/578.55] 
                                       0.304651308633                                                = 30.4 months   
This conformance period could be derived to a shelf life period of two years from 
March 2007 to Feb.2009 which is three months more than the labeled expiration date. 
2- Estimation of Expiry date for samples stored at Juba: 
Graph (5) Stability Profile of Product 3 J 
Metronidazole I.V Fluid in Plastic container 
Juba Station
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The Least Square Regression equation is: 
Ln C = 6.25321796 + 0.00129057595 × t 
From the equation time for the ln concentration to reach 6.3099182782265 is: 
 43.9 months, the upper 5% two-sided confidence interval band intercepts the time 
axis at about 26.5 months. The upper one-sided confidence interval band intercepts 
the time axis at 29.7 months which is the conformance period. Thus, the product 
could be given 24 months as shelf life from March 2007 to Feb.2009. 
This result confirm the conclusion obtained from samples stored at Fashir. 
5.2.2.2.4 Tests for related substances: 
2- methyl-5 nitroimdazole was within the limits, also the nitrite content was within the 
limits. 
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5.2.2.3 Microbiological stability of Product 3:         
5.2.2.3.1 Sterility testing: 
The product passes the initial sterility testing before distribution but the final sterility 
testing at the end of the storage period, samples from Portsudan and Juba show a 
distinct mold growth in the Soya bean-Casein Digest broth. Since it is one batch and 
initially it was free from fungi growth and as it is unlikely for the organism to 
penetrate the container walls, it could be suggested that this growth may be due to 
contamination at the outer wall of the site for the connection of the infusion set.    
 
5.2.2.3.2 Total Endotoxin Testing: 
The harmonized total endotoxin test specifies that the solution should contain not 
more than 0.35 endotoxin units per mg of metronidazole. The lysate labeled 
sensitivity was 0.25 EU/ ml. The test resulted in no gel formation, thus the total 
endotoxin was less than0.25 EU/ml and so the product passes the test. 
 
5.2.2.4 Comment: 
1- The manufacturer instructed on overwrap not to remove the bottle from the 
overwrap and described it as moisture barrier, but it was a thin cellophane sheet which 
was known to be vapour permeable and even it was not well sealed. 
2- The manufacturer instructed storage below 25 °C, but the moisture conditions were 
not considered.  
3- The manufacturer advised squeezing the bottle before use to check the minute leak 
and not to use if leakage was detected, but evapouration could not be detected by such 
manner. 
4- The concentration of the active ingredient increased due to the drastic conditions of 
double transportation in one summer month, this increment exceeds the limit for 
significant changes, 5%, described by WHO, ICH, FDA and EMRO. This significant 
change occurred in samples transported to and from Portsudan and Dongola where the 
concentration exceeds 107 %. 
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5- The concentration increased over time in all stations and storage conditions 
indicating the loss in solvent, this conclusion could be supported by the decrease in 
volume in the physical stability testing which was reached in Fashir down to 94 ml. 
6- Inspite of the lower MKT and more humid conditions than Fashir , the 
concentration of the AI was much higher. This could be attributed to the drastic 
conditions of transportation to Portsudan via unconditioned distribution truck for a 
journey of many days, while transportation to Fashir was in conditions less severe and 
in a short duration of time via air plane. 
7- The results were in conformance with the EMRO guidelines which necessitated the 
test in lower humidity conditions for liquids in semipermeable containers. However, 
the dry conditions of Sudan are much severe than those defined by EMRO for long-
term and intermediate stability testing; 35±5%. 
5.2.3 Domestic Amoxicillin Trihydrate Powder for 125mg/5ml Oral Suspension:   
5.2.3.1 Physical stability: 
There were no significant changes in appearance, odour or colour. Samples collected 
from the different stations showed no significant deviation from 75 ml with standard 
deviation of 0.52. The deliverable volume was 76 ml and the sedimentation volume 
was 68/76 ml, PH ranging from 5.9- 5.96 and the reconstitution time was 2-3 shakes 
and there was no significant variation in the powder weight, four bottles contain 
between 95-100% of the required weight out of 10 bottle, six bottles contain between 
100%-105%. Thus, the product could be defined as physically stable. 
5.2.3.2 Chemical Stability: 
Samples transported from Fashir and Portsudan to Khartoum were greatly affected by 
transportation, that potency decline down to 89.93472% and 93.1% respectively. 
At the end of the storage period, samples being stored at Damazin and Portsudan yield 
a potency of 89.7% and 89.8% respectively. 
Determination of Reaction order and Rate Constant of the powder: 
Table ( 110 ) Determination of Rate Constant Values of product 6 powder 
Time station Ko K1 
6 Juba 1.48333333 0.01211636 
6 Portsudan 1.32708333 0.01079776 
12 Juba 1.13281250 0.00943985 
12 Portsudan 1.22500000 0.01025725 
 mean 1.29205729 0.01065280 
 St.d 0.15018758 0.00112409 
 CV 11.62391061 10.55203990 
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The degradation reaction for the dry powder was supposed to follow zero and first 
order of kinetics as values were with acceptable standard deviation and best fit  
 CV, so the reaction could be pseudo-zero order of 1.3 mg.month¯¹ value.    
5.2.3.2.1 Chemical Stability Profile for Samples from Portsudan: 
Results obtained from the analysis of samples stored at Portsudan were treated to 
yield table ( 111 ). As the powder was in the solid state, the rate of degradation may 
be zero or pseudo- zero order, thus the contents in mg/ 5 ml was plotted versus time 
and graph (6 ) was obtained.   
Table (111) Analysis of results of Product 6 B 
 Time   X content% C mg/5 ml Y X² y² (X-x)² ( Y-y)² 
1 0 101.41 126.7625 0 16068.73140625 47.26563 76.63776849 
2 0 101.56 126.95 0 16116.30250000 47.26563 79.95578724 
3 1 93.10463 116.3808 1 13544.48769912 34.51563 2.64847145 
4 6 95.19149 118.9894 36 14158.46838816 0.765625 0.96267985 
5 12 88.32 110.4 144 12188.16000000 26.26563 57.88470724 
6 12 90.79 113.4875 144 12879.41265625 26.26563 20.43672849 
7 12 90.47 113.0875 144 12788.78265625 26.26563 24.21328849 
8 12 89.63 112.0375 144 12552.40140625 26.26563 35.64925849 
∑ 55  938.0952 613 110296.74671228 234.875 298.38868974 
AV 6.875  118.0082         
 
Graph ( 6  ) Stability profile of Product 6 B 
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 time:C B:   y = 124.021631 - 0.98323446*x
The least squares regression equation is: 
C = 124.021631 - 0.98323446 × t 
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From the graph, the only point out of the 5% confidence interval bands, was at 
month 1 which is the after transportation point. 
Graphically the true line at 90% content intercepts the time axis at about 12 
months and the lower 5% confidence interval band intercepts the time axis at 9 
months. From the equation, time required for the content to reach 90% is: 
(124.021631 – 112.5) / 0.98323446 = 11.7 months. 
5.2.3.2.2 Estimation of the Expiration Date for product 6 B: 
The 5% one sided confidence interval for X at a givenY could be calculated by 
Woolf's equation   (X-gx¯ )±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where,  Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
= √  110296.74671228-880022.60426304/8 – 0.966750× 234.875  = 3.33805765 
                                                          6 
And g =   t²( S²yx)      = (1.94)² (3.33805765)²   = 0.184688626568 
              b²∑(x-x¯) ²       0.966750 ×234.875 
1.94 is the t value for 5% one- sided confidence interval at degree of freedom 6. 
Thus, the one-sided confidence interval for 11.7 is: 
11.7 - (0.184688626568 × 6.875-1.94 × 3.33805765 / 0.98323446  
√ ( 0.815311373432/8 + 23.280625 ) / 234.875 
                     0.815311373432                                             =10.2 months 
 The one-sided lower confidence interval for 90 % content of product 6 transported 
from Khartoum and stored at Portsudan for 52 weeks was 10.2 months, this is the 
conformance period. As this period started from March 2007and ended February 
2008.  
5.2.3.2.3 Chemical stability profile of product 6 stored at Damazin: 
At May 2008, the potency decreased down to 89.7%, in one month the potency 
decreased from 101.4 % to 97.3 % due to transportation conditions. 
Data from stability testing for product 6 stored at Damazin ( App. 16). could be 
treated as in table( 112  ).       
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 Table (112   ) Analysis of results of product 6 at Damazin 
 On plotting C mg/ 5ml versus time using Statistica linear least square regression 
graph (  7  ) could be obtained.    
Graph ( 7)Stability profile of product 6 stored at Damazin 
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Graphically the true regression line intercept the time axis at the point of 112.5 mg/5 
ml at about 12 months giving a decline in the shelf live of 3 months. It is clear that the 
result obtained after transportation was below the lower confidence interval band of 
the regression line. 
The regression equation is: 
C = 126.164078 – 1.139 × t 
Time at 112.5 mg/ 5 ml concentration is 12 months. 
 
 
 Tme  X content% C  mg/5ml (Y) X² (X-x)² Y² ( Y-y)² 
1 0 101.41 126.7625 0 47.26563 16068.73140625 71.04788287 
2 0 101.56 126.95 0 47.26563 16116.30250000 74.24391060 
3 1 97.32578 121.657225 1 34.51563 14800.48039470 11.04708552 
4 6 98.18868 122.73585 36 0.765625 15064.08887522 19.38060293 
5 12 90.85 113.5625 144 26.26563 12896.44140625 22.76253050 
6 12 90.39 112.9875 144 26.26563 12766.17515625 28.57981629 
7 12 89.43 111.7875 144 26.26563 12496.44515625 42.85023880 
8 12 88.18 110.225 144 26.26563 12149.55062500 65.74792437 
∑ 55   946.66807500 613 234.875 112358.21551992 335.65999190 
mean 6.875   118.33350938         
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5.2.3.2.4 Estimation of Expiration Date for product 6 Th: 
The 5% lower one-sided confidence interval for the time at the concentration of  
112.5 mg/ 5m; 90%, could be given by Wool's equation:   
        X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
12-0.439968942174984-1.94×2.2712596363767/1.139 √ .936/8+(12-6.875)²/234.875 
                                                      0.936 
= 10.965  months. 
This confirms the previous result of product 6B, indicating that the product lost about 
six months of its declared shelf life due to the improper transportation and storage. 
  5.2.3.3 Microbiological Stability:  
The total microbial count results indicated that either the product was free of bacterial 
contamination and no contamination took place during storage or the microbial 
activity of amoxicillin was not affected by the inactivating agent and dilution. The 
fungal count yielded results that were within the B.P limits. Thus the product could be 
considered microbiologically stable. 
Stability of the constituted Suspension: 
Calculating the results obtained at zero time and after 7 days, table (113 ) could be 
presented.  
Table (113 ) Analysis of results of the constituted suspension. 
Days content% C mg/5ml ln C Days Content% C mg/5ml Ln C 
0 103.4107 129.2634 4.861852 7 87.43471 109.2934 4.694036 
0 101.2917 126.6146 4.841148 7 88.00876 110.011 4.70058 
0 100.2513 125.3141 4.830823 7 86.77688 108.4711 4.686484 
0 101.1841 126.4801 4.840085 7 87.0734 108.8418 4.689895 
0 101.7131 127.1414 4.8453 7 91.41859 114.2732 4.738592 
0 98.39123 122.989 4.812095 7 95.42159 119.277 4.781448 
0 99.84717 124.809 4.826784 7 94.85182 118.5648 4.775459 
0 106.9004 133.6256 4.895042 7 97.12965 121.4121 4.79919 
0 99.16417 123.9552 4.81992 7 99.54914 124.4364 4.823795 
0 100.0083 125.0104 4.828397 7 103.2905 129.1131 4.860689 
0 100.5005 125.6256 4.833306 7 95.51217 119.3902 4.782397 
0 98.39135 122.9892 4.812096 7 92.82711 116.0339 4.753882 
The reaction was supposed to follow pseudo-first order of kinetic, so ln C was plotted 
versus time. Thus graph ( 8 ) could be obtained by using the least squares line of 
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linear regression analysis. The regression equation is: Ln C = 4.83723743 – 
0.0114333454 × t   
The time required for the potency to reach 80%; 100 mg/5ml was: 20 days.  
The 5% lower one-sided confidence interval intercepts the ln 100 mg/ml( 4.605) at 
about 15 days. The 5% lower one –sided confidence interval of Ln 100 mg/ 5 ml was 
calculated according to Woolf's equation resulting in 15.3 days as a conformance 
period and so the suspension may have a shelf life of 15 days and 7 days to reach 90% 
when stored at an air-conditioned room temperature (MKT 29.7°C and %RH 31.4%) . 
Graph (8 ) Stability Profile of product 6 constituted suspension 
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Determination of reaction order: 
On substitution on the zero and first order equations, Ko was found to be 1.365 
mg.month¯¹ and that of K1 was 0.011258, that is to say the value of Ko was 
insignificantly different from that of the dry powder. And value of K1 was 
insignificantly different from that obtained by graph (8), so the reaction follows first 
order kinetics with a rate constant K1 = 1.1 × 10¯² month¯¹.   
5.2.3.4 Comment: 
The product exhibited a considerable chemical instability when stored at Portsudan 
and Damazin. This may be due to: 
1- The drastic transportation conditions. 
2- The higher ambient humidity of the warehouses that may get in the container 
through the cap. 
3-   The insufficient overage.                                          
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5.2.4 Indian Amoxicillin Trihydrate Powder for 125mg/5m Oral Suspension: 
The labeled expiration date is 5/2007 and the study continued up to 4/2008. 
5.2.4.1 Physical stability: 
Samples lost their flavours and so they lost their odour and acceptable taste. The 
powder get yellowish colour. There were no changes in PH, deliverable volume or 
weight of powder. However the sedimentation volume was 9/74 and the reconstitution 
time was 4-5 shakes indicating partial loss of suspending  properties of the additives. 
5.2.4.2 Chemical stability: 
The product showed marked chemical stability. All samples at all stations contained 
more than 100 % of the active ingredient constituents at the end of the storage period 
inspite of exceeding the labeled shelf life by 12 months. ( App. 17). 
Treating results of samples being stored at Damazin, table (114   ) could be presented. 
Table (114   ) Analysis of Product 7 Th  results. 
Time  X content % C mg/5ml (Y) Y² (Y-y)² (X-x)² 
0 103.67000 129.58750000 16792.92015625 277760546.70811600 47.265625 
0 104.68000 130.85000000 17121.72250000 288828395.87213400 47.265625 
1 99.05007 123.81258750 15329.55682345 231124714.13414700 34.515625 
6 96.84068 121.05085000 14653.30828572 211020302.08274500 0.765625 
12 101.93000 127.41250000 16233.94515625 259441077.67193300 26.265625 
12 102.14000 127.67500000 16300.90562500 261602649.31616600 26.265625 
12 101.45000 126.81250000 16081.41015625 254550528.80432700 26.265625 
12 101.57000 126.96250000 16119.47640625 255766644.45269800 26.265625 
55.   128633.24510917 2040094859.04227000 234.8750 
6.875  126.77042969    
On plotting content versus time, the LSRL was obtained graph (9 ) 
Graph ( 9   ) Stability Profile of product 7 Th 
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The regression equation is:   C = 127.236 – 0.0677 × t 
                               t(90) = ( 127.236 – 112.5) /    0.0677=  217 months 
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The 5% lower two-sided confidence interval band of 112.5 mg/ 5ml intercepts the 
time axis at about 32 months. 
Estimation of expiration date: 
According to ICH and FDA guidelines the 5% one-sided confidence interval 
represents the conformance period. 
                            X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
                                                                                                                = 33.5 month.  
Depending on the degradation of the active ingredient the product could be given an 
expiration date September 2009. That is to say the shelf life could be extended for 24 
months. 
Stability of the constituted Suspension: 
The results obtained at day zero; at the constitution time, were compared to results at 
day 7 when the products kept at room temperature (29.7°C /31.4% RH). 
Table (115) Analysis of Results of the Constituted Suspension of Product 7 TH 
product 7 content% C mg/5ml ln C 
product 
7 content% C mg/5ml ln C 
0 106.8788 133.5985 4.894839 7 90.98507 113.7313 4.733839 
0 106.4985 133.1231 4.891274 7 95.7585 119.6981 4.784973 
0 106.7931 133.4914 4.894037 7 96.26335 120.3292 4.790231 
0 108.8304 136.038 4.912935 7 96.1149 120.1436 4.788688 
0 106.7338 133.4172 4.893481 7 93.29548 116.6194 4.758915 
0 107.0591 133.8239 4.896524 7 94.48384 118.1048 4.771572 
0 107.5097 134.3872 4.900725 7 93.14917 116.4365 4.757346 
0 106.8183 133.5229 4.894273 7 92.91417 116.1427 4.75482 
0 109.1151 136.3939 4.915547 7 94.95171 118.6896 4.776512 
0 107.3228 134.1535 4.898984 7 96.06119 120.0765 4.788129 
0 107.8665 134.8331 4.904038 7 93.455 116.8188 4.760624 
0 106.869 133.5862 4.894747 7 91.31556 114.1444 4.737465 
Determination of the Rate constant and the reaction order: 
The calculated K1 was compared with that obtained graphically from the regression 
line when plotting ln C against time. 
The calculated first order rate constant from the first order equation: 
K1 = 2.303/ t × log (Co/Ct ) = 0.01889 and this was the same value obtained from 
graph (10   ). 
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So, the suspension followed first order reaction of kinetics with a K1 value of 
1.89×10¯² when stored for 7 days at room temperature (29.7°C /31.4% RH).   
Graph (10) Stability Profile of the Constituted Suspension of Product 7 
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The regression equation is: Ln C =4.89928377 – 0.018908238 × t 
The time at which the concentration reaches ln 100 ;4.6051701859881 equals to 15.5 
days. Graphically the lower 5% two-sided confidence interval band intercepts the time 
axis of point 4.60 at about 14 days. The 5% lower one sided confidence interval band 
which represents the conformance period, could be calculated by Woolf's equation. It 
was 14.6 days. Thus, the shelf life of the reconstituted suspension could be 14 days at 
an air-conditioned room temperature and 6 days to reach 90%. 
5.2.4.3 Microbiological Stability: 
The results of the total viable count for the product of Amoxicillin trihydrate for oral 
suspension show an adequate quality. The product was free from bacterial 
contamination and the fungi counts were within the B.P limits. The microbiological 
quality had not been affected by storage at all sites.  
5.2.5 Rifampicin 300 mg + INH 150 mg (Product 8): 
 5.2.5.1 Physical Stability Testing: 
5.2.5.1.1 Appearance: 
There were no significant changes in colour and appearance, however, samples stored 
at Fashir became dirty and the outer carton boxes were affected by water but tablets 
inside the blister were not affected. 
5.2.5.1.2 Uniformity of weight: 
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The B.P Appendix XII G (Ph. Eur. Method 2.9.5)  specifies that for tablets containing 
more than 250 mg, not more than two tablets deviate from the average weight of 20 
tablets by more than 5% and none deviates by more than 10%. 
All samples pass the test initially and at the end of the storage period at all stations. 
5.2.5.1.2 Hardness testing: 
The results of minimum, maximum and mean showed a marked variation initially and 
at the end of the storage period at all stations. This indicates the irregular force being 
applied to tablets during compression. 
5.2.5.1.3 Loss on drying: 
The initial moisture content was 1.67%, finally it increased notably in samples stored 
at Portsudan and Juba giving values of 2.93% and 2.66% but still these values were 
within the pharmacopoeial limit which is 3.3%. This indicates the gain of moisture by 
tablets and penetration of water vapour through the PVC blister especially at higher 
relative humidity conditions of Juba and Portsudan. 
5.2.5.1.4 Disintegration Time: 
 The harmonized USP, B.P and Ph. Eur  method specifies 30 minutes as limit for 
disintegration failure. According to this criterion the results obtained indicated that the 
product passes the disintegration test at the beginning and at the end of the storage 
period. 
5.2.5.2 Chemical Stability of Rifampicin component:  
The content of Rifampicin declined with time till the designated expiration date. The 
results of assays for Rifamicin show no deviations under 90% of the labeled contents. 
USP and B.P considered Rifampicin and INH in capsules and both with pyrazinamide 
in tablets. However, the lower limit for Rifampicin in tablet and capsules combination 
was 90% of the labeled contents. 
Results obtained from the assays of Rifampicin in samples stored at Portsudan and 
Dongola were used to study the stability profile of the product and to estimate the 
shelf-life according to ICH guidelines. 
5.2.5.2.1 Stability Profile of Rifampicin in Product 8 being stored at Portsudan:  
The study was continued after the labeled expiration date. The results obtained were 
treated to obtain the tablet content of Rifampicin in mg. 
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Table ( 116 ) Analysis of results of Product 8 B 
 Then, the contents in mg were plotted versus time, Graph ( 11 ) was obtained. 
Graph   (11 ) Stability Profile of Rifampicin In Product 8 B 
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The regression equation: 
C = 305.763864 – 9.036562 × t  
t( 90) = 3.96 months 
Graphically, the true line at CB 270 mg which 90% 0f the labeled content intercepts 
the time axis at 4 months. 
5.2.5.2.2 Estimation of the Expiration date of Rifampicin in Product 8 B: 
According to the ICH, FDA and EMRO guidelines the 5% lower one-sided 
confidence interval represents the conformance period which was then drawn down to 
state the expiration date. 
Product 8 B content% 
content 
mg X² Y² ( X-x)² (∑Y)² 
0.000 95.100 285.300 0.000 81396.090 47.266  
0.000 99.900 299.700 0.000 89820.090 47.266  
1.000 99.200 297.600 1.000 88565.760 34.516  
6.000 101.000 303.000 36.000 91809.000 0.766  
12.000 64.500 193.500 144.000 37442.250 26.266  
12.000 63.300 189.900 144.000 36062.010 26.266  
12.000 63.700 191.100 144.000 36519.210 26.266  
12.000 63.000 189.000 144.000 35721.000 26.266  
55.000 649.700 1949.100 613.000 497335.410 234.875 3798990.810 
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By application of Woolf's equation the 5% lower confidence interval could be 
calculated. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²]  ,   Syx = 23.388 
 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx)       and t value of 5% one sided CI at d.f 6 
        b²∑(x-x¯) ² 
g     = 0.1073304475945.  Thus, the 5% one-sided CI was 2.53 months. So, this 
product will have an expiration date June 2007 instead of October 2007 if treated 
according to ICH, FDA and EMRO guidelines. 
5.2.5.2.3 Stability Profile of INH in Product 8 being stored at Portsudan:  
Table ( 117  ) Analysis of results of INH in Product  8 B 
Product 8 B content% content mg X² Y² ( X-x)² 
0.000 95.800 143.700 0.000 20649.690 47.266 
0.000 94.800 142.200 0.000 20220.840 47.266 
1.000 99.400 149.100 1.000 22230.810 34.516 
6.000 97.700 146.550 36.000 21476.903 0.766 
12.000 63.000 94.500 144.000 8930.250 26.266 
12.000 64.300 96.450 144.000 9302.603 26.266 
12.000 64.400 96.600 144.000 9331.560 26.266 
12.000 63.500 95.250 144.000 9072.563 26.266 
55.000 642.900 964.350 613.000 121215.218 234.875 
When plotting contents against time graph (12   ) was obtained. 
5.2.5.2.4   Estimation of the Expiration date of INH in Product 8 B: 
Graph (12 ) Stability profile of INH in Product 8 B 
C B = 150.0461-4.2912*x
-2 0 2 4 6 8 10 12 14
time
95
100
105
110
115
120
125
130
135
140
145
150
C
 B
 time:C B:   y = 150.046062 - 4.29124534*x
  
 198
The regression equation is : C = 150.0461- 4.2912 × t. 
t( 90) = 3.5 months 
The 5% lower one- sided CI is 1.52 months. This result was one month less than that 
for Rifampicin. Based on these calculations the product might have an expiration date 
of June 2007 instead of October 2007 when stored at Portsudan. 
5.2.5.2.5 Stability Profile of Rifampicin in Product 8 G: ( App. 18). 
Samples were markedly affected by the double transportation in summer 2007, 
because stored samples gave higher results when transported in winter. At the same 
time   
The potency decline to about 63.8% due to inappropriate storage conditions, 
transported again in summer 2008 and assay took place after 6 months from the 
labeled expiration date. 
Table ( 118 ) Analysis of results of Rifampicin in Product 8 G 
Product 8 G content% content mg X² Y² ( X-x)² 
0.000 95.100 285.300 0.000 81396.090 47.266 
0.000 99.900 299.700 0.000 89820.090 47.266 
1.000 92.700 278.100 1.000 77339.610 34.516 
6.000 94.600 283.800 36.000 80542.440 0.766 
12.000 64.200 192.600 144.000 37094.760 26.266 
12.000 63.200 189.600 144.000 35948.160 26.266 
12.000 63.500 190.500 144.000 36290.250 26.266 
12.000 64.300 192.900 144.000 37210.410 26.266 
55.000 637.500 1912.500 613.000 475641.810 234.875 
On plotting content against time graph (13 ) could be obtained 
Graph (13   ) Stability profile Rifampicin of Product 8G 
C mg = 297.0287-8.4315*x
-2 0 2 4 6 8 10 12 14
                    Time(months)
180
190
200
210
220
230
240
250
260
270
280
290
300
310
320
8 
G
 C
 m
g
e:8 C G mg/5ml:   y = 297.028739 - 8.4314529*x
 
 199
 
The regression equation is C = 297.0287 -8.4315 × t 
From the equation, the time required for the concentration to reach 270 mg was, 
t(90) = 3.2 months 
Estimation of the Expiration date based in Rifampicin in product 8 G: 
The 5% lower one-sided CI given by Woolfs equation was 1.93 months. 
According to the ICH guidelines and based on the Rifampicin components, product  
8 G might have an expiration date not more than May 2007 instead of October 2007. 
 5.2.5.2.6 Stability Profile of INH in Product 8 G: 
Table (119) Analysis of results treatment for INH in product 8 G. 
Product 8 G content% content mg X² Y² ( X-x)² 
0.000 95.800 143.700 0.000 82598.760 47.266 
0.000 94.800 142.200 0.000 80883.360 47.266 
1.000 95.800 143.700 1.000 82598.760 34.516 
6.000 92.100 138.150 36.000 76341.690 0.766 
12.000 65.000 97.500 144.000 38025.000 26.266 
12.000 64.500 96.750 144.000 37442.250 26.266 
12.000 64.700 97.050 144.000 37674.810 26.266 
12.000 64.400 96.600 144.000 37326.240 26.266 
55.000 637.100  613.000 472890.870 234.875 
On plotting content against time, graph (14   ) could be obtained 
Graph ( 14   ) Stability Profile of INH in Product 8 G 
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The regression equation: C = 147.049734 – 4.01359766 × t 
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Thus, t (90) = (147.049734 -135)/ 4.01359766 = 3 months. 
The lower 5% two-sided confidence interval for 135 mg concentration intercepts the 
time axis at 1.2 months, but the ICH, FDA and EMRO state that 5% one- sided lower 
CI was appropriate enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for 135 mg intercepts the time axis could 
be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx)  /   b²∑(x-x¯) ² 
   and t value of 5% one sided CI at d.f 6 
= 2.12 months. So, the product might be given an expiration date at May 2007 when 
stored at Dongola conditions and this was the same result as obtained from 
Rifampicin component.  
5.2.5.3 Microbiological Stability: 
No bacterial contamination was detected in the total viable count and the fungi count 
was less than 10² initially and finally indicating appropriate microbiological quality of 
the product and no microbial contamination took place during the storage period at 
the selected stations which may be due to appropriate packaging of tablets that the 
blisters and blisters packs were sufficient enough to preserve tablets from 
contamination. 
 
5.2.6 Rifampicin 150 mg + INH 100 mg Tablets (Product 9): 
5.2.6.1 Physical Stability: 
5.2.6.1.1 Appearance: 
The black spots observed on the surface of tablets might be due to a manufacturing 
error, that the lubricating wax that was usually used to lubricate the movement of 
punches and if the rubber seal was loose or ruptured, oil and wax that gained the black 
colour might run around the punch and reaches the powder while the punch was 
compressing the powder to form the tablet. This postulation may be supported by the 
coarse touch of the tablets meaning that the punch surface was not perfect. However, 
this test disqualifies the product.   
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5.2.6.1.2 Uniformity of weight: 
The B.P Appendix XII G (Ph. Eur. Method 2.9.5) specifies that for tablets containing 
more than 250 mg, not more than two tablets deviate from the average weight of 20 
tablets by more than 5% and none deviates by more than 10%. 
All samples pass the test initially and at the end of the storage period at all stations. 
5.2.6.1.2 Hardness testing: 
The results of minimum, maximum and mean showed a marked variation initially and 
at the end of the storage period at all stations. This indicates the irregular force being 
applied to tablets during compression. 
5.2.6.1.3 Loss on drying: 
The initial moisture content was 1.67%, finally it increased notably in samples stored 
at Damazin, Portsudan and Juba giving values of 2.81%, 2.66% and 2.66% but still 
these values were within the pharmacopoeial limit which is 3.3%. This indicates the 
gain of moisture by tablets especially at higher relative humidity conditions of 
Damazin, Juba and Portsudan. 
5.2.6.1.4 Disintegration Time: 
 The harmonized USP, B.P and Ph. Eur  method specifies 30 minutes as limit for 
disintegration failure. According to this criterion the results obtained indicate that the 
product passes the disintegration test at the beginning and at the end of the storage 
period having a short disintegration time (2-3 minutes). 
5.2.6.2 Chemical Stability of Rifampicin component:  
Samples at all stations yielded results that were over 90 % potency, although the 
labeled expiration date had been passed four months ago from the end of the storage 
period, except samples stored at Juba and Portsudan. However, results obtained after 
transportation to and from Dongola and Fashir indicated a marked decrease in potency 
reaching 86.6% and 82.9% respectively. Because the results of the third point of 
analysis were higher than those of the second point results, the only difference is that, 
samples were transported back to Khartoum in summer 2007, and those for the third 
point were transported in winter. 
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Determination of Rate and order of reaction: 
Considering product 9B, results were used to calculate rate constant for zero, first and 
second reaction orders.( table 120    ). 
Table ( 120  ) Comparison of reaction rate constant Values 
 
The degradation reaction can behave as zero or first order as standard deviation and 
the variation coefficient values were more close, but as the product was in the solid 
state it is likely to be pseudo-zero order reaction with a Ko 1.66 mg.month¯¹. 
5.2.6.2.1 Stability Profile of Rifampicin in Product 9 B: ( App. 19). 
Table (121) Analysis of results of Rifampicin in Product 9B 
Product 9 B content% content mg X² Y² ( X-x)² 
0.000 94.100 141.150 0.000 19923.323 47.266 
0.000 95.300 142.950 0.000 20434.703 47.266 
1.000 93.400 140.100 1.000 19628.010 34.516 
6.000 86.000 129.000 36.000 16641.000 0.766 
12.000 74.500 111.750 144.000 12488.063 26.266 
12.000 73.300 109.950 144.000 12089.003 26.266 
12.000 78.000 117.000 144.000 13689.000 26.266 
12.000 77.400 116.100 144.000 13479.210 26.266 
55.000 672.000 1008.000 613.000 128372.310 234.875 
On plotting the contents versus time graph (15   ) could be obtained. 
 
 
 
Rif 9 
B          
t Co Ct x log(Co/Ct) 2.303/t 1/at x/a-x ko ki Kii 
1 95.3 93.4 1.9 0.008746 2.303 0.010493 0.020343 1.9 0.020142 0.00021346 
6 95.3 86 9.3 0.044594 0.383833 0.001749 0.10814 1.55 0.017117 0.00018912 
12 95.3 74.5 20.8 0.106937 0.191917 0.000874 0.279195 1.733333 0.020523 0.00024414 
12 95.3 73.3 22 0.113989 0.191917 0.000874 0.300136 1.833333 0.021876 0.00026245 
12 95.3 78 17.3 0.086998 0.191917 0.000874 0.221795 1.441667 0.016696 0.00019394 
12 95.3 77.4 17.9 0.090352 0.191917 0.000874 0.231266 1.491667 0.01734 0.00020223 
       mean 1.658333 0.018949 0.00021756 
       St.d 0.190321 0.002167 0.00002946 
       CV 11.47667 11.43843 13.54173874 
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Graph ( 15  ) Stability Profile of Rifampicin in Product 9 B 
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The LSR line equation is : C =142.341937- 2.377 × t. 
So, t (90) = 3.1 months. 
The 5% lower two-sided CI for 90% concentration (135 mg) intercepts the time axis 
at 2 months. 
Estimation of the expiration date: 
 The  ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for 270 mg intercepts the time axis could 
be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx) /     b²∑(x-x¯) ² ,     and t value of 5% one sided CI at d.f 6 is 1.94 
LCI for t (90) = 2.09 months. So, the product might be given an expiration date at 
May 2007 when stored at Portsudan conditions.  
5.2.6.1.5 Stability Profile of INH in Product 9 B: 
The rate of reaction seemed to be pseudo-zero order, with a Ko 3.147 mg.month¯¹ 
having a standard deviation 0.15 and CV 4.7. 
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Table (122) Analysis of Results of INH in Product 9 B 
Product 9 B content% content mg X² Y² ( X-x)² 
0.000 103.600 103.600 0.000 10732.960 47.266 
0.000 102.800 102.800 0.000 10567.840 47.266 
1.000 100.200 100.200 1.000 10040.040 34.516 
6.000 100.500 100.500 36.000 10100.250 0.766 
12.000 65.800 65.800 144.000 4329.640 26.266 
12.000 66.300 66.300 144.000 4395.690 26.266 
12.000 67.400 67.400 144.000 4542.760 26.266 
12.000 66.900 66.900 144.000 4475.610 26.266 
55.000 673.500 673.500 613.000 59184.790 234.875 
On plotting the contents versus time graph (16   ) could be obtained. 
Graph (16   ) Stability Profile of INH in Product 9 B 
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The LSR line equation is : C =105.5644 – 3.1094 × t. 
So, t (90) = 8.22 months. 
The 5% lower two-sided CI for 90% concentration (80 mg) intercepts the time axis at 
6.8  months. 
Estimation of the expiration date of INH component in product 9 B: 
 The  ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for 80 mg intercepts the time axis could 
be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
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Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx)  /      b²∑(x-x¯) ² 
       and t value of 5% one sided CI at d.f 6 is 1.94 
LCI for t (90) = 8.07 months. So, the product might be matching to its labeled 
expiration date, but the component of Rifampicin was less stable and can govern the 
shelf life of the product. 
5.2.6.2.3 Stability Profile of Rifampicin in Product 9 J: 
Table ( 123  ) Analysis of results of Rifampicin in Product 9 J 
Table ( Analysis 
of Results of 
Product 9 J content% content mg X² Y² ( X-x)² 
0.000 94.100 141.150 0.000 19923.323 47.266 
0.000 95.300 142.950 0.000 20434.703 47.266 
1.000 96.000 144.000 1.000 20736.000 34.516 
6.000 95.200 142.800 36.000 20391.840 0.766 
12.000 79.900 119.850 144.000 14364.023 26.266 
12.000 76.700 115.050 144.000 13236.503 26.266 
12.000 74.000 111.000 144.000 12321.000 26.266 
12.000 74.900 112.350 144.000 12622.523 26.266 
55.000 686.100 1029.150 613.000 134029.913 234.875 
On plotting the contents versus time graph (17   ) could be obtained. 
The LSR line equation is : C =145.4923 – 2.4507 × t. So, t (90) = 4.3 months.  The 
5% lower two-sided CI for 90% concentration (80 mg) intercepts the time axis at 0.3  
months.      Graph (17  ) Stability Profile of Rifampicin in Product 9 J 
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Estimation of the expiration date: 
The  ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for 80 mg intercepts the time axis could 
be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx)  /      b²∑(x-x¯) ² ,and t value of 5% one sided CI at d.f 6 is 1.94 
LCI for t (90) = 2.8 months. So, based on Rifampicin contents the product might be 
given an expiration date June 2007 when stored at Juba conditions.  
5.2.6.2.4 Stability Profile of INH in Product 9 J: 
Table (124) Analysis of Results of INH in Product 9 J 
Product 9 J content% content mg X² Y² ( X-x)² 
0.000 103.600 103.600 0.000 10732.960 47.266 
0.000 102.800 102.800 0.000 10567.840 47.266 
1.000 99.200 99.200 1.000 9840.640 34.516 
6.000 99.700 99.700 36.000 9940.090 0.766 
12.000 67.300 67.300 144.000 4529.290 26.266 
12.000 68.200 68.200 144.000 4651.240 26.266 
12.000 67.800 67.800 144.000 4596.840 26.266 
12.000 65.800 65.800 144.000 4329.640 26.266 
55.000 674.400 674.400 613.000 59188.540 234.875 
On plotting the contents versus time graph (18) could be obtained. 
Graph (18) Stability Profile of INH in Product 9 J 
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The LSR line equation is : C =105.07904 – 3.022458 × t. 
So, t (90) = 8.3 months. 
The 5% lower two-sided CI for 90% concentration (80 mg) intercepts the time axis at 
about 6.6  months. 
Estimation of the expiration date: 
The  ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for 80 mg intercepts the time axis could 
be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
g =   t²( S²yx)  /      b²∑(x-x¯) ², and t value of 5% one sided CI at d.f 6 is 1.94 
LCI for t (90) = 8.02 months. So, the product might be matching to its labeled 
expiration date, but the component of Rifampicin was less stable and can govern the 
shelf life of the product. This conclusion was the same as that obtained for the same 
product at Portsudan. 
5.2.6.3 Microbiological stability of Product 9: 
The total microbial count results indicated that either the product was free of bacterial 
contamination and no contamination took place during storage or the microbial 
activity of the product was not affected by the inactivating agent and dilution. The 
fungal count yielded results that were within the B.P limits for all the stations except 
samples stored at Dongola, ( App.23), and this may be either to contamination during 
storage or during handling because the product was in a hospital pack of 1000 tablets 
without blisters or strips. 
5.2.7 Lumefantrine 120 mg + Artemether 20 mg Tablets ( Product 5): 
5.2.7.1 Physical Stability: 
5.2.7.1.1 Appearance: 
There were no significant changes in shape, colour or appearance. 
5.2.7.1.2 Uniformity of weight: The B.P Appendix XII G (Ph. Eur. Method 2.9.5) 
specifies that for tablets containing more than 80 mg and less than 250 mg, not more 
than two tablets deviate from the average weight of 20 tablets by more than 5% and 
none deviates by more than 10%. 
 208
All samples pass the test initially and at the end of the storage period at all stations 
with standard deviation of about 0.001. This indicates GMP measures and accurate 
and precise machinery systems. 
5.2.7.1.3         Hardness testing: 
The results of minimum, maximum and mean showed a little variation initially and 
increased at the end of the storage period at all stations. This indicates the regular 
force being applied to tablets during compression to give uniform tablet hardness. 
5.2.7.1.4 Loss on drying: 
The initial moisture content was 3.85%, finally it decreased in samples stored at all 
stations to 1.67% except samples stored at Portsudan and Juba giving values of 
2.87%, 2.17%  respectively. 
5.2.7.1.5 Disintegration Time: 
 The harmonized USP, B.P and Ph. Eur  method specifies 30 minutes as limit for 
disintegration failure. According to this criterion the results obtained indicated that the 
product passes the disintegration test at the beginning and at the end of the storage 
period having a short uniformed disintegration time (4: 10 - 4:55 minutes). 
5.2.7.2 Chemical Stability of Lumefanterine component:  
Samples at all stations yielded results that were over 90 % potency, although the 
labeled expiration date had been passed four months ago from the end of the storage 
period.  
5.2.7.2.1 Stability Profile of Lumefantrine in Product 5: 
Table ( 125 ) Analysis of results of Lumefantrine in Product 5 
time B J G K TH N 
0 100.3 100.3 100.3 100.3 100.3 100.3 
0 100.3 100.3 100.3 100.3 100.3 100.3 
1 102.7 100.6 100.3 100.8 99.9 101.5 
6 104.15 101.8 106.93 99.89 103.59 99.67 
12 96.4014 104.884 102.7959 101.1961 101.7449 103.5912 
12 99.26614 100.4102 103.0052 105.0607 103.3633 101.6426 
12 101.2008 104.5073 104.1771 106.1304 103.2703 103.6656 
12 98.95609 103.2672 103.3261 104.1291 102.7928 102.9665 
 
There were insignificant differences between concentrations obtained from different 
stations, sign. 0.087. 
Stability Profile of Lumefantrine in Product 5: ( App. 20). 
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Graph (19   ) Stability Profile of lumefantrine in Product 5B 
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The LS regression equation is: C = 122.072445 – 0.230004955 × t 
Thus, t (90) = 61.18 months. 
5.2.7.2.2 Estimation of expiration date based on Lumefantrine content: 
 The  ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for 108 mg intercepts the time axis could 
be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
g =   t²( S²yx)  /   b²∑(x-x¯) ², and t value of 5% one sided CI at d.f 6 is 1.94 
LCI for t (90) = 26.13 months. So, the product could be given a shelf life of two years 
from April 2007. Thus, based on lumefantrine the expiration date could be labeled as 
March 2009 which is 15 months more than its labeled expiration date.  
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5.2.7.3 Stability Profile of Artemether in Product 5: ( App. 20). 
Table (126) Stability Profile of Artemether in Product 5 
contents of Artemether in mg in Product 5    
Time/months 5 B 5 J 5 G 5 K 5 TH 5 N 
0.000 20.432 20.432 20.432 20.432 20.432 20.432 
0.000 20.482 20.482 20.482 20.482 20.482 20.482 
0.000 20.432 20.432 20.432 20.432 20.432 20.432 
1.000 17.360 17.520 20.060 21.740 19.220 18.480 
6.000 22.130 19.620 19.590 20.214 18.824 17.258 
12.000 17.940 21.400 19.036 18.864 18.806 17.132 
12.000 18.690 19.200 19.036 19.208 19.326 17.190 
12.000 19.382 20.400 19.382 18.170 18.864 17.536 
 
1- Product transported to and from Portsudan and Juba had been severely affected 
by transportation, that the concentration decline to less than 90% ( 18 mg). 
2- Samples at Fashir showed a marked decline in potency after 6 months only and 
continued to decline throughout the storage period. 
3- All concentrations at the end of the storage period were above 90% for all 
stations except Fashir.  
4- Reaction rate constant;  
5- Results were used to calculate and compare reaction rate constant to define the 
order of reaction table (127 ) 
Table ( 127 ) comparison of the rate constant values 
t ko ki Kii 
6 0.0365 0.001796 0.76103501 
12 0.130833 0.006663 0.05307856 
12 0.10225 0.005161 0.06791633 
12 0.188833 0.009796 0.03677552 
    
mean 0.114604 0.005854 0.22970135 
St.d 0.063315 0.003323 0.35445067 
CV 55.24639 56.77188 154.30935275 
The order of reaction seemed to be pseudo-zero order with a Ko = 1.14× 10¯¹. 
On plotting content against time for product 5 N, using Statistica LSR analysis 
graph (20 ) was obtained. 
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Graph (20 ) Stability Profile of Product 5 N 
Artemether in Product 5 N
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The LSR line equation is: 
C = 19.8885265 – 0.236423542 × t 
Thus, t (90) = 7.99 months 
5.2.7.3.4 Estimation of expiration date of Artemether in product 5 N: 
Table (128) Analysis of Results of Artemether in Product 5N 
Product 5 N content% content mg X² Y² ( X-x)² (∑Y)² 
0.000 103.600 20.432 0.000 417.467 28.891  
0.000 102.800 20.482 0.000 419.512 28.891  
0.000 99.200 20.432 0.000 417.467 28.891  
1.000 99.700 18.480 1.000 341.510 19.141  
6.000 67.300 17.258 36.000 297.839 0.391  
12.000 68.200 17.132 144.000 293.505 43.891  
12.000 67.800 17.190 144.000 295.496 43.891  
12.000 65.800 17.536 144.000 307.511 43.891  
43.000 674.400 148.942 469.000 2790.307 237.875 22183.719 
 
The  ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for 18 mg intercepts the time axis could 
be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
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 g =   t²( S²yx)  /   b²∑(x-x¯) ²,  and t value of 5% one sided CI at d.f 6 is 1.94 
(8-0.19088168×5.373)-1.94×0.80911832/0.2364235 √ .80911832/8+6.89/234.875 
                                                      0.80911832 
LCI for t (90) = 7.19148488 months.  
So, the product could be given a shelf life of 7 months from April 2007. Thus,  the 
expiration date could be labeled as November 2007 which was 2 months less than its 
labeled expiration date.  
5.2.7.3.5 Estimation of expiration date of Artemether in product 5 B: 
Table (129) Analysis of Results of Artemether in Product 5 B 
Product 5 B content mg X² Y² ( X-x)² 
0.000 20.432 0.000 417.467 28.891 
0.000 20.482 0.000 419.512 28.891 
0.000 20.432 0.000 417.467 28.891 
1.000 18.480 1.000 341.510 19.141 
6.000 17.258 36.000 297.839 0.391 
12.000 17.132 144.000 293.505 43.891 
12.000 17.190 144.000 295.496 43.891 
12.000 17.536 144.000 307.511 43.891 
43.000 148.942 469.000 2790.307 237.875 
On plotting contents content versus time , graph ( 21  ) could be obtained.  
Graph ( 21 ) Stability Profile of Product 5 B 
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The LSR line equation is: 
C = 20.8159 – 0.1482 × t  
From the equation, the time required for concentration to reach 18 mg=19 months. 
The 5% lower band of the two-sided CI intercept the content of 18 mg at about 10 
months. But, the  ICH, FDA and EMRO stated that 5% one- sided lower CI was 
appropriate enough for drugs known to decrease with time. The 5% lower one-sided 
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confidence interval for 18 mg intercepts the time axis could be given by Woolf's 
equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
Thus, t(90) =   7.54729887 months and this was almost similar to that of Fashir. 
5.2.7.3.4 Estimation of expiration date of Artemether content in product 5 G:   
Table ( 130 ) Analysis of Results of Product 5 G 
Product 5 G content mg X² Y² ( X-x)² 
0.000 20.432 0.000 417.467 28.891 
0.000 20.482 0.000 419.512 28.891 
0.000 20.432 0.000 417.467 28.891 
1.000 20.060 1.000 402.404 19.141 
6.000 17.258 36.000 297.839 0.391 
12.000 17.132 144.000 293.505 43.891 
12.000 17.190 144.000 295.496 43.891 
12.000 17.536 144.000 307.511 43.891 
43.000 130.462 469.000 2448.797 237.875 
On plotting contents content versus time , graph 22   ) could be obtained.  
Graph ( 22  ) Stability Profile of Product 5 G 
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The LSER line equation is: C = 20.362578 – 0.103502289 × t 
So, the time required for the concentration to reach 18 mg was 22.8 months. The 5% 
lower two-sided CI incepts content 18 mg at 19 months, but the  ICH, FDA and 
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EMRO stated that 5% one- sided lower CI was appropriate enough for drugs known 
to decrease with time. The 5% lower one-sided confidence interval for 18 mg 
intercepts the time axis could be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
Thus, t (90) =   19.84598868 months. So, it could be given 18 months from April 2007 
to September 2008 with an additional eight months from the labeled expiration date. 
5.2.7.4 Microbiological stability of Product 5: 
The total viable count was within the B.P limits which are 10³ for aerobic bacteria and 
10² for fungi. As no bacterial contamination was detected, so no evidence of presence 
of specific organism. These results indicate the adherence to GMP measures of the 
manufacturer and the packaging system of the product was efficient enough to prevent 
microbiological contamination during storage. 
5.2.8. Artemether 80mg/ml Injection- Indian brand ( Product 1): 
5.2.8.1 Physical Stability: 
The product retained its appearance, clarity colour and the extractable volume but the 
adhesive label was getting loosely attached to the glass ampoules surface. Some labels 
were completely detached.  
Particulate materials were within the harmonized test limits. 
5.2.8.2 Chemical Stability: 
The International Pharmacopoeia specifies the limits for Atemether injection 95%- 
105%. Table (131  ) shows the stability profile of Product 1 in different stations. 
Table (    ) Content % of Product 1 at different stations during the storage period 
               1B 1 J 1 G 1 K 1 Th 1 N 
0             103.7 103.7 103.7 103.7 103.7 103.7 
0             103.6 103.6 103.6 103.6 103.6 103.6 
0             103.6 103.6 103.6 103.6 103.6 103.6 
1       103.0546 98.32629 100.8566 98.48254 100.8663 102.0308 
6       91.22955 86.88469 86.41297 82.14486 88.24473 94.82384 
12     91.20618 83.96686 80.14293 84.11357 79.06883 86.66402 
12     90.69140 82.36772 82.61736 81.68329 85.42947 87.87378 
12     91.91792 80.64812 84.03881 75.63582 86.3371 88.5344 
12     93.40851 82.14413 83.54311 83.88804 86.00728 90.83608 
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From the table it is clear that the potency of the product declined below the specified 
limit within the first six months of storage at all stations. It was below 90% in 
products at all the stations except Portsudan. That is because the product was in glass 
ampoules, so the humidity has no rule in assessing the effects of storage conditions.  
5.2.8.2.1 Stability Profile of Product 1B: 
To analyze the results of potency against time and to estimate the expiration date, 
table ( 132) was prepared. 
Table (132) Analysis of Results of Product 1B 
Product 1 B  C% Content  Y Y² X² ( X- x)² 
0.00 103.70000000 82.96000000 6882.36160000 0.00 37.33210000 
0.00 103.60000000 82.88000000 6869.09440000 0.00 37.33210000 
0.00 103.60000000 82.88000000 6869.09440000 0.00 37.33210000 
1.00 103.05000000 82.44000000 6796.35360000 1.00 26.11210000 
6.00 91.23000000 72.98400000 5326.66425600 36.00 0.01210000 
12.00 91.20618197 72.96494558 5323.88328327 144.00 34.69210000 
12.00 90.69140489 72.55312391 5263.95578919 144.00 34.69210000 
12.00 91.91792230 73.53433784 5407.29884148 144.00 34.69210000 
12.00 93.40850990 74.72680792 5584.09582150 144.00 34.69210000 
55.00  697.92321525 54322.80199144 613.00 276.88890000 
The plotting Ln content versus time, graph (23   ) was obtained. 
Graph ( 23   ) LSR analysis of Product 1B 
Artemether Ln Content in 1B = 4.4111-0.0102*x
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The LSR line equation is: C = 4.41112168 – 0.0101590633 × t , Thus time required 
for the concentration to reach 95%, which is Ln 76 mg,  is 7.9 months. 
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The ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for Ln 76 mg intercepts the time axis 
could be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx)  /  b²∑(x-x¯) ²,     and t value of 5% one sided CI at d.f 7 is 1.89 
The 5% lower one-sided CI is 7.5 months. 
Thus, the product could be given an expiration date October 2007 instead of 3/2008 
with a shortage of 5 months. 
The worst results obtained for the product were those samples stored at Khartoum 
where the concentration of the active ingredient reached 81.33% in 12 months. 
5.2.8.2.2 Stability Profile of Product 1K: ( App. 21). 
Table ( 133) Analysis of Results of Product 1 K 
Product 
1K Content % 
Content in mg 
Ln content Y² X² ( X- x)² 
0.00 103.7 82.96000000 4.41835856 19.52189240 0.00 37.3321 
0.00 103.6 82.88000000 4.41739378 19.51336779 0.00 37.3321 
0.00 103.6 82.88000000 4.41739378 19.51336779 0.00 37.3321 
1.00 98.48254 78.78603200 4.36673572 19.06838087 1.00 26.1121 
6.00 82.14486 65.71588800 4.18534072 17.51707697 36.00 0.0121 
12.00 84.11356858 67.29085486 4.20902434 17.71588591 144.00 34.6921 
12.00 81.68329008 65.34663206 4.17970590 17.46994143 144.00 34.6921 
12.00 75.63582136 60.50865709 4.10278645 16.83285663 144.00 34.6921 
12.00 83.88803889 67.11043111 4.20633949 17.69329189 144.00 34.6921 
55.00  697.92321525 38.50307874 164.84606167 613.00 276.8889 
 
On plotting Ln content against time using LSR analysis graph (24 ). 
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Graph (24) Stability Profile of Product 1 K 
Artemether Ln Content in 1K = 4.3983-0.0197*x
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The LSR line equation was: Ln C = 4.9826215 – 0.0196596481 × t 
Thus, t( 95) = 3.43 months. 
The  ICH, FDA and EMRO stated that 5% one- sided lower CI was appropriate 
enough for drugs known to decrease with time. 
The 5% lower one-sided confidence interval for Ln 76 mg intercepts the time axis 
could be given by Woolf's equation. 
X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx)  /  b²∑(x-x¯) ², and t value of 5% one sided CI at d.f 7 is 1.89 
The 5% lower one-sided CI of Ln 76 mg intercepts the time axis at 2.3 months. 
The product might be given an expiration date June 2007 instead of March 2008. 
This may be due to transportation and storage conditions that were below the labeled 
storage directions. 
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5.2.8.3 Microbiological Stability: 
5.2.8.3.1 Sterility testing: 
Since the sterility of the product was not altered during storage, this indicates that no 
evidence of microbial contamination during storage. The product had been 
manufactured under GMP measures and the packaging container and the closure 
system were efficient enough to keep the product microbiologically stable throughout 
its shelf-life. 
5.2.8.3.2 Total Endotoxin Testing: 
The harmonized total endotoxin test specifies that the solution should contain not 
more than 0.35 endotoxin units per mg of artemether. The lysate labeled sensitivity 
was 0.25 EU/ ml. The test resulted in no gel formation, thus the total endotoxin was 
less than0.25 EU/ml and so the product passes the test indicating GMP compliance. 
5.2.9.    Artemether 80mg/ml Injection- Chinese brand ( Product 2): 
5.2.9.1 Physical Stability: 
The product retained its physical characters. The extractable volume was 1.2 ml 
meaning that there was 0.2 ml overage constituting 20%, so, if the concentration of 
artemether initially was 100%, the content of the ampoule will be 120% which is 
above the International Pharmacopoeia limits. Particulate materials were within the  
harmonized test limits. 
5.2.9.2 Chemical Stability: 
The concentration of Artemether in product 2 increased with time at all stations 
except those samples stored at Fashir ( table 134). 
 Table (      ) Content % of Product 2 During the Storage Period at Different Stations 
Time 2 B 2 J 2 G 2 K 2 Th 2 N 
0 100.4 100.4 100.4 100.4 100.4 100.4 
0 100.9 100.9 100.9 100.9 100.9 100.9 
0 100.7 100.7 100.7 100.7 100.7 100.7 
1 101.1695 104.4226 104.095 104.5169 102.2139 100.5924 
6 105.9586 103.6096 101.1203 104.5114 102.2738 105.8167 
12 105.8227 106.1142 109.699 108.1177 104.7188 98.18821 
12 106.0677 112.6777 100.5655 112.9227 104.2424 91.54133 
12 105.5855 113.2926 114.4866 112.0725 104.4622 99.41802 
12 109.0406 109.0435 110.8001 102.4403 105.2185 91.67951 
Concentrations of Artemether increased above 105% in product 2 at all stations after 
six months of storage. 
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On plotting content against time and Ln content against time, the same curve 
characters were obtained. Hence, contents were plotted against time using Statistica 
LSR linear analysis and then the following stability Profile of product 2 was obtained. 
5.2.9.2.1 Stability Profile of Product 2 being stored at Portsudan: 
To analyze the results of potency against time and to estimate the expiration date, 
table (135) was prepared. 
Table (135) Analysis of Results of Product 2 B 
Product 2 B Content % Content Y² X² ( X- x)² 
0.00 100.4 80.32000000 6451.30240000 0.00 37.33210000 
0.00 100.9 80.72000000 6515.71840000 0.00 37.33210000 
0.00 100.7 80.56000000 6489.91360000 0.00 37.33210000 
1.00 101.1695 80.93560000 6550.57134736 1.00 26.11210000 
6.00 105.9586 84.76688000 7185.42394493 36.00 0.01210000 
12.00 105.8227 84.65816000 7167.00405459 144.00 34.69210000 
12.00 106.0677 84.85416000 7200.22846931 144.00 34.69210000 
12.00 105.5855 84.46840000 7134.91059856 144.00 34.69210000 
12.00 109.0406 87.23248000 7609.50556695 144.00 34.69210000 
55.00  748.51568000 62304.57838170 613.00 276.88890000 
The LSRL obtained (graph 25 ) was used to estimate the expiration date. 
Graph ( 25   ) Stability Profile of Artemether in product 2B 
 
Stability Profile of Artemether in product 2 B
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The LSRL equation was  C 2B = 80.7443304 + 0.396667384 × t  
105% concentration equals 84 mg, thus the time required for concentration to reach 
84 mg was: t(105) = 8.207 months. 
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As the potency may decrease or increase, the 5% two-sided confidence intervals were 
considered to demonstrate the product shelf life. 
The 5 % two-sided confidence interval for X at a given Y could be given by Woolf's 
inverse prediction equation. 
 X-gx¯ ±[t(Syx)/b] [ √(1-g)/N+(X-x¯)²/∑(x-x¯)²] 
1-g 
Where, Syx =√ ∑y² - (∑y)²/N - b²∑(x-x¯)²     
                                       N- 2 
 g =   t²( S²yx)  /  b²∑(x-x¯) ² 
and t value of 5% two- sided CI at d.f 7 is 2.36 
The 84 mg content line intercepts the upper band of the two-sided confidence interval 
at 6.1 months .One-sided CI at t-value 1.89 for the d.f. 7, is 6.5 months.  
Thus, the conformance period of this product at Portsudan will be 6.5  months and the 
expiration date might be stated as October 2007 instead of January 2009 losing 3 
months due to improper transportation and storage and to the quality of the product. 
5.2.9.2.2 Stability Profile of Product 2 being stored at Dongola (product 2 G):  
To analyze the results of potency against time and to estimate the expiration date, 
table ( 136 ) was prepared. 
Table (136 ) Analysis of results of product 2 G 
Product 2 G Content % Content Y² X² ( X- x)² 
0.00 100.4 80.32000000 6451.30240000 0.00 37.33210000 
0.00 100.9 80.72000000 6515.71840000 0.00 37.33210000 
0.00 100.7 80.56000000 6489.91360000 0.00 37.33210000 
1.00 104.095 83.27600000 6934.89217600 1.00 26.11210000 
6.00 101.1203 80.89624000 6544.20164614 36.00 0.01210000 
12.00 109.699 87.75920000 7701.67718464 144.00 34.69210000 
12.00 100.5655 80.45240000 6472.58866576 144.00 34.69210000 
12.00 114.4866 91.58928000 8388.59621092 144.00 34.69210000 
12.00 110.8001 88.64008000 7857.06378241 144.00 34.69210000 
55.00  754.21320000 63355.95406586 613.00 276.88890000 
 
The LSRL obtained (graph 26) was used to estimate the expiration date. 
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Graph ( 26 ) Stability Profile of Artemether in product 2G 
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The LSRL equation was C= 80.6925035 + 0.508739422 × t 
Thus, t(105) = 6.5 months. 
 The upper confidence interval of results at time zero exceeded the International 
Pharmacopoeia limits.  By application of calculations of the inverse prediction, the 
upper band of the 5% one-sided confidence interval intercepts the line of 84 mg at 0.6 
months. This finding was in conformance with the results of the extractable volume, 
that the addition of 0.2 ml overage constituted 20% of the required potency. 
5.2.9.2.3 Stability Profile of Product 2 being stored at Khartoum (product 2 K):  
To analyze the results of potency against time and to estimate the expiration date, 
table ( 137   ) was prepared. Table ( 137   ) Analysis of results of product 2 K 
Product 2K Content % Content Y² X² ( X- x)² 
0.00 100.4 80.32000000 6451.30240000 0.00 37.33210000 
0.00 100.9 80.72000000 6515.71840000 0.00 37.33210000 
0.00 100.7 80.56000000 6489.91360000 0.00 37.33210000 
1.00 104.5169 83.61352000 6991.22072679 1.00 26.11210000 
6.00 104.5114 83.60912000 6990.48494717 36.00 0.01210000 
12.00 108.1177 86.49416000 7481.23971411 144.00 34.69210000 
12.00 112.9227 90.33816000 8160.98315219 144.00 34.69210000 
12.00 112.0725 89.65800000 8038.55696400 144.00 34.69210000 
12.00 102.4403 81.95224000 6716.16964102 144.00 34.69210000 
55.00  757.26520000 63835.58954527 613.00 276.88890000 
The LSRL obtained (graph 27  ) was used to estimate the expiration date. 
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Graph ( 27  ) Stability Profile of Artemether in product 2K 
Artemether Content mg in 2 K = 81.0761+0.5015*x
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The LSRL equation was: C= 81.0761335 + 0.5014541 × t 
Thus, t(105) = 5.8 months. 
The upper confidence interval of results at time zero exceeded the International 
Pharmacopoeia limits.  By application of calculations of the ICH and EMRO, the 
upper band of the 5% two sided confidence interval intercepts the line of 84 mg one 
month before commencing of the study and the one-sided CI at 1.5 months. This 
finding was in conformance with the findings obtained from the same product being 
stored at Dongola and those of the extractable volume, that the addition of 0.2 ml 
overage constituted 20% of the required potency. 
5.2.9.2.4 Stability Profile of Product 2 being stored at Damazin (product 2 Th):  
To analyze the results of potency against time and to estimate the expiration date ( 
App. 22)., table (138) was prepared. 
Table ( 138 ) Analysis of results of product 2 Th 
Product 2 
Th Content % Content Y² X² ( X- x)² 
0.00 100.4 80.32000000 6451.30240000 0.00 37.33210000 
0.00 100.9 80.72000000 6515.71840000 0.00 37.33210000 
0.00 100.7 80.56000000 6489.91360000 0.00 37.33210000 
1.00 102.2139 81.77112000 6686.51606605 1.00 26.11210000 
6.00 102.2738 81.81904000 6694.35530652 36.00 0.01210000 
12.00 104.7188 83.77504000 7018.25732700 144.00 34.69210000 
12.00 104.2424 83.39392000 6954.54589297 144.00 34.69210000 
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12.00 104.4622 83.56976000 6983.90478646 144.00 34.69210000 
12.00 105.2185 84.17480000 7085.39695504 144.00 34.69210000 
55.00  740.10368000 60879.91073404 613.00 276.88890000 
 
The LSRL obtained (graph 28  ) was used to estimate the expiration date. 
Graph ( 28 ) Stability Profile of Artemether in product 2Th 
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The LSRL equation:                              C = 80.7154646 + 0.248445425 × t 
Thus t(105) = 13.2 months. 
The 84 mg content line intercepts the upper band of the two-sided confidence interval 
at 12 months. From Woolf's equation at t value 2.36 the upper band of the two-sided 
confidence interval at 11.3 months and the One-sided CI at 11.6 months.  
Thus, the conformance period of this product at Damazin will be 12 months and the 
expiration date might be stated as April 2008 instead of January 2009 with a loss of 
8months from the labeled shelf life.. 
5.2.9.2.6 Stability Profile of Product 2 being stored at Fashir (product 2 N):  
To analyze the results of potency against time and to estimate the expiration date, 
table (139 ) was prepared. 
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Table (139 ) Analysis of results of product 2 N 
Product 2N Content % Content Y² X² ( X- x)² 
0.00 100.4 80.32000000 6451.30240000 0.00 37.33210000 
0.00 100.9 80.72000000 6515.71840000 0.00 37.33210000 
0.00 100.7 80.56000000 6489.91360000 0.00 37.33210000 
1.00 100.5924 80.47392000 6476.05180017 1.00 26.11210000 
6.00 105.8167 84.65336000 7166.19135929 36.00 0.01210000 
12.00 98.18821 78.55056800 6170.19173312 144.00 34.69210000 
12.00 91.54133 73.23306400 5363.08166283 144.00 34.69210000 
12.00 99.41802 79.53441600 6325.72332846 144.00 34.69210000 
12.00 91.67951 73.34360800 5379.28483446 144.00 34.69210000 
55.00  711.38893600 56337.45911833 613.00 276.88890000 
The LSRL obtained (graph 29 ) was used to estimate the expiration date. 
Graph ( 29  ) Stability Profile of Artemether in product 2N 
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The LSRL equation was: 
C = 81.317436 – 0.37214532 × t 
Thus, t(95) = 14.3 months 
The 5% two-sided confidence interval at 76 mg concentration intercepts the time axis 
at 7.5 months and the one-sided CI at 8.5 months. It could be given an expiration date 
February 2008 instead of Jan.2009.so, the product might acquire a shelf life of two 
years instead of three years. 
5.2.9.3 Comment on the Chemical Stability Profile of Product 2:   
1- There was no significant difference between the graphical and calculated intercepts 
for all stations and between the stations. 
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Using Statistica software, one sample t test for the intercepts obtained from the LSRL 
equations and the measured values at zero time, the following table of analysis was 
obtained. 
Reference value d.f mean St.d. St.error CI - 95% CI+95% t- value P 
80.6 5 81.037 0.4046 0.16518 80.6 81.5 2.64 0.05 
Using Statistica soft ware , t-sample test tool to compare the slopes of LSRL with zero 
Ref.value d.f mean St.d St.error CI-95% CI+95% t-value P 
00 5 0.4431 0.133 0.054194 0.303 0.582 3.17 0.0004 
The slopes of the LSRL of different stations were significantly different from zero.  
2- All the slopes are positive except that of Fashir station which was negative. 
3-         Although glass ampoules were used, the Artemether contents increased with 
time for five stations. This could be correlated with areas of the secondary peaks in 
the chromatogram (table 98). 
Using Stastica Software, Matrix correlation tool, the area of the main peak, secondary 
peak 1 and secondary peak 2 were correlated, resulting in table (140 ).  
Table (  140  ) Correlation Analysis 
 Station main Peak and secondary 1 main Peak and secondary 2 
1 B - 0.73 - 0.49 
2 J - 0.9 - 0.88 
3 G - 0.65 - 0.93 
4 K - 0.85 - 0.84 
5 TH - 0.81 - 0.82 
6 N - 0.13 - 0.34 
From the above table there was a marked significant negative correlation between the 
Artemether peak area and the other two secondary peaks. As the secondary peaks 
decrease, the main peak increases. Knowing that the related substances supposed to be 
present were α-artemether and dihydroartemisine, it is likely to suppose that 
transformation took place between the two isomers, α-artemether and β-artemether where 
the α-isomers was known to be less effective. Also dihydroartemisine was the 
intermediate substance in synthesizing artemether. Artemether is the methyl ether of 
dihydroartemisine, so it likely to suggest that dihydroartemisine was transformed to 
artemether during the inappropriate conditions of transportation and storage. These 
related substances were supposed to increase with time but it had been found to decrease 
with time. 
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4- Samples being stored at Fashir showed a negative slope inspite of the negative 
correlation between peaks, but it could be shown in graph (29  ) that the mid point after 6 
months of storage was above 84 mg constituting the peak then the results of the last point 
were responsible for the negative slope. This could be attributed to the severe 
transportation conditions during transportation from Fashir to Khartoum in summer 
2008, in the blazing sun on the ground at the airport, where the true decomposition might 
have taken place.  
5- The excessive overage had been added to compensate the extension of the shelf life 
to three years but it did not regard the upper Pharmacopoeial limits.  
5.2.9.4 Microbiological Stability: 
5.2.9.4.1 Sterility testing: 
Since the sterility of the product was not altered during storage, this indicates that no 
evidence of microbial contamination during storage. The product had been 
manufactured under GMP measures and the packaging container and the closure 
system were efficient enough to keep the product microbiologically stable throughout 
its shelf-life. 
5.2.9.4.2 Total Endotoxin Testing: 
The harmonized total endotoxin test specifies that the solution should contain not 
more than 0.35 endotoxin units per mg of artemether. The lysate labeled sensitivity 
was 0.25 EU/ ml. The test resulted in no gel formation, thus the total endotoxin was 
less than0.25 EU/ml and so the product passes the test indicating GMP compliance. 
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Determination of Reaction order and Rate constant of Artemether Degradation 
Reaction in Product 1: 
Using the substitution method, results were substituted in the integral equation of zero, 
first and second order of reaction to get the rate constant values 
Table (141) Analysis of Rate constant Values: 
 Product 1 C (a) Ct(a-x) C-Ct(x) log(c/ct) K° K¹ K¹¹ 
 103.6333 82.90667       
1 103.0546   82.44367 0.456333 0.002397 0.456333 0.005521 0.00006677 
6 91.22955  72.98364 9.91636 0.055329 0.009222 0.021237 0.00027316 
12 91.806   73.4448 9.455196 0.052593 0.004383 0.010094 0.00012941 
1 98.32629   78.66103 4.23897 0.022795 4.23897 0.052497 0.00065005 
6 86.88469  69.50775 13.39225 0.076521 0.012754 0.029371 0.00038736 
12 82.28171   65.82537 17.07463 0.100161 0.008347 0.019223 0.00026075 
1 100.8566   80.6853 2.214699 0.01176 2.214699 0.027084 0.00033110 
6 86.41297  69.13038 13.76962 0.078886 0.013148 0.030279 0.00040045 
12 82.58555   66.06844 16.83156 0.09856 0.008213 0.018915 0.00025609 
1 98.48254   78.78603 4.113968 0.022105 4.113968 0.050909 0.00062988 
6 82.14486  65.71589 17.18411 0.100884 0.016814 0.038723 0.00052572 
12 81.33018   65.06414 17.83586 0.105213 0.008768 0.020192 0.00027556 
1 100.8663   80.69304 2.20696 0.011718 2.20696 0.026988 0.00032992 
6 88.24473  70.59578 12.30422 0.069776 0.011629 0.026782 0.00035040 
12 84.21067   67.36854 15.53146 0.090097 0.007508 0.017291 0.00023175 
1 102.0308   81.6246 1.275396 0.006733 1.275396 0.015507 0.00018848 
6 94.82384  75.85907 7.040929 0.038547 0.006425 0.014796 0.00018660 
12 88.47707   70.78166 12.11834 0.068634 0.005719 0.013172 0.00017210 
     mean 0.812181 0.024366 0.000313642 
     St.d 1.427292 0.012764 0.000160087 
     CV 175.7357 52.38629 51.0412156 
K2 values: there was no significant difference between values (sign. 0.229). 
K1 values: there was no significant difference between values (sign. 0.169). 
K0 values: there significant difference between values (sign. 0.00). 
For the zero order: There was significant difference in values with sig value 0.00 
between the groups and within the groups. 
For the first and second order: There were insignificant differences in K1 and K2 
values between groups and within the groups, so the reaction behaved as second order 
as well as first order. Thus, it could be assumed to be pseudo-first order with K1 value 
2.4 × 10¯²mg.month¯¹.   
 228
Determination of rate constant of degradation of Artemether in Product 2: 
Artemether in Product1 increased with time, marked significant negative correlation was 
found to take place between the main and secondary peaks, indicating the conversion of 
α-artemether and dihydroartemesinine , the related substances, into artemether by time at 
tropical conditions. 
Table (142)Determination of rate constant of degradation of Artemether Product 2: 
time Percentage C (a) Ct(a-x) C-Ct(x) log(C/Ct) K0 K1 K2 
0 100.6667 80.53333       
1B 101.1695  80.93556 -0.40556 -0.00218 -0.40556 -0.00502442 -0.00006222 
6B 105.9586  84.76685 -4.23685 -0.02227 -0.70614 -0.00854733 -0.00010344 
12B 106.6291  85.30329 -4.77329 -0.02501 -0.39777 -0.00479947 -0.00005790 
1J 104.3095  83.4476 -2.9176 -0.01546 -2.9176 -0.03559547 -0.00043416 
6J 103.6096  82.88771 -2.35771 -0.01253 -0.39295 -0.00481037 -0.00005887 
12J 110.282  88.22559 -7.69559 -0.03964 -0.6413 -0.00760697 -0.00009026 
1G 104.0905  83.27242 -2.74242 -0.01454 -2.74242 -0.03349369 -0.00040896 
6G 101.1203  80.89626 -0.36626 -0.00197 -0.06104 -0.00075644 -0.00000937 
12G 108.8878  87.11024 -6.58024 -0.03411 -0.54835 -0.00654657 -0.00007817 
1K 104.5169  83.6135 -3.0835 -0.01632 -3.0835 -0.03758198 -0.00045794 
6K 104.5114  83.60911 -3.07911 -0.0163 -0.51319 -0.00625491 -0.00007622 
12K 108.8883  87.11062 -6.58062 -0.03411 -0.54839 -0.00654694 -0.00007817 
1TH 102.2139  81.77112 -1.24112 -0.00664 -1.24112 -0.01529710 -0.00018848 
6TH 102.2738  81.81903 -1.28903 -0.0069 -0.21484 -0.00264716 -0.00003261 
12TH 104.6604  83.72836 -3.19836 -0.01691 -0.26653 -0.00324625 -0.00003953 
1N 100.5924  80.4739 0.056097 0.000303 0.056097 0.00069696 0.00000866 
6N 105.8167  84.65339 -4.12339 -0.02169 -0.68723 -0.00832406 -0.00010081 
12N 95.20677  76.16541 4.364586 0.0242 0.363715 0.00464436 0.00005930 
     mean -0.83045 -0.01009654 -0.000122731 
     St.d 1.018891 0.01245462 0.000152215 
     CV -122.691 -123.355259 -124.0229152 
The values of K2 were insignificantly different with sign. value 0.312. 
Values of K1 were insignificantly different with sign. value 0.309. 
K0 values were insignificantly different with sign. value 0.305.  
The reaction order was indefinite that the reaction might be second, first or zero order, 
the difference in CV was only 0.7%. All orders may take place because there might be 
conversion of α and β- artemether and dihydroartemesinine to artemether and the 
degradation of artemether. 
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6. Conclusion and Recommendations: 
6.1 Transportation Conditions: 
Transportation conditions were the most drastic conditions faced drugs along their 
distribution chain.. Temperature reached up to 48.3 °C during transportation at the in-
town streets and the lowest temperature was 30.6 °C. Thus it could be concluded that 
all transportation MKT values across Sudan to all station were above 30°C; the 
specified limit of EMRO. On comparing the transportation MKT of various cities 
using statistica one sample test, it was found to be significantly different, of 
significance 0.033 and t-value 2.757 from the EMRO limits. 
Artemether in tablets and injection was greatly affected by transportation conditions 
which resulted in average loss of potency of 9.72% for tablets and 3.13% for 
injection. Artemether injection; product 2, the average increase in potency was 2.54%. 
Rifampicin and Amoxicillin trihydrate lost 6.9% and 6.16% from their potency as a 
result of transportation conditions. Metronidazole I.V infusion in plastic containers 
potency was increased by 3.53% on the average. 
6.2 Storage conditions: 
6.2.1 MKT for Sudan: 
The concept of the MKT  was adopted world wide.It is a single derived temperature 
reflecting the effects of a range of temperature fluctuating over agiven time. There are 
three basic principles regarding determination of the storage conditions: 
1- WHO recommended that when two or more climatic zones were situated at one 
country, the storage conditions should be based on the worst condition.   
2- The main disadvantage of WHO calculations is that, it utilized the meteorological 
data which was taken from the shade at the open air where drugs were not stored in. 
3-USP and FDA recommended that storage conditions should be calculated from 
drugs warehouses, hospitals and pharmacies where drugs are usually stored in. 
The principle of encoutering the worst conditions in the countery was quite justicious, 
so the wost storage conditions of the six stations utilizing different sources of data 
could be concluded as in table ( 143). 
Table ( 143 ) The Worst Storage Conditions 
source of date MKT  Station 
worst 
humid station 
Worst 
dry Station 
1962-1991 meteorological 30.6 °C Khartoum 60.80% Juba 18% Dongola 
parallel period 
meteorological 33.8°C Dongola 55% Juba 23.10% Dongola 
datalogger 28.8°C Fashir 52.20% Portsudan 19.40% Fashir 
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  All international records on the MKT of Sudan correctely defined it, but they did not 
refelect the true value for the whole country because each record calculated the MKT 
from different sources of data that were truly existing and differing. 
1- MKT defined by WHO was based on the past adopted meteorological data (1962-
1991) which had been adopted by the National Meteorological Authority. WHO 
pointed 30°C as the MKT for Sudan taking the mean of MKT for the whole 
country disregarding the principle of encountering the worst conditions which was 
Khartoum 30.6 °C and those locations having more than the MKT value as 
reported by the pararell records for Dongola ( 33.8°C). 
2- The MKT calculated from dataloggers, adopted and pararelled meteorological 
data for Khartoum, Damazin, Dongola and Fashir which were significantly 
different from that defined by WHO. Where those for Juba and Portsudan adopted 
meteorological data were insignificantly different from WHO defined MKT, but 
still different from meteorological data of the parallel period of the study. 
3- The MKT calculated using one source of data for one station was insignificantly 
different from the MKT obtained using the same source of data for another 
station. 
4- JTC and Grimm defined MKT for Sudan 32.5°C that was approved to be in 
conformance with that calculated from WMO records which was found to be 
insignificantly different from the Khartoum conditions of meteorological records 
for the period of the study. 
5- USP calculated MKT (27.9°C) was insignificantly different from that obtained by 
calculating dataloggers records for the in-house conditions except MKT of 
Damazin, Khartoum and Portsudan which were lower than USP calculated MKT. 
Although USP derived value was 30°C making 2.1°C as conservative value.  
6- The controlled room temperature of the six station was ranging from 25.2°C to 
28.8°C. The highest MKT was reported for Fashir Hospital where they use to 
switch off the air conditioner  after the working hours. 
7- The difference in means of in-house daily MKT and that of the shaded open air 
MKT was 3.89 °C. 
8- All of the above conditions considered the relative humidity as 35% which 
represents the mean of the higher and lower humidity, but this was incorrect because 
it had been approved that some areas were more humid throughout the year while 
others were very dry. 
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9- The EMRO considered the MKT value as 30°C, and made attention to the 
humid areas by defining zone IVa for Sudan pointing 65% as a relative humidity . Dry 
areas were considered by EMRO guidelines by recommending that special dry 
conditions should be considered for liquids in semipermeable containers. 
10- All records disregarded the transportation conditions except EMRO which 
stated that transportation MKT should not be more than 30°C. 
11- WHO defined MKT was based on the open air readings where drugs were not 
stored in, while USP relied upon the in-house readings and neglected the effects of 
transportation conditions. 
12-  The mean of stations MKT  being calculated from the pararell meteorological 
open air data was 3.89°C above the mean of stations MKT being calculated from 
dataloggers in-house data. That was due to man intervention by using air conditioning 
and cooling devices at facilities were drugs were stored. 
13-  Using Dataloggers facilitated adherence to the most probably true conditions, 
they provided readings for the true transportation conditions in the open air, on the 
blazzy sun and on the back of trucks. They provided readings on the true conditions 
where drugs were stored. Based on this concept, the worst transportation MKT was 
48.3°C obtained at Khartoum streets and the worst storage MKT was 28.8°C obtained 
at Fashir. 
14- Using Dataloggers method in calculating MKT of both transportation and 
storage conditions for all over the world was justiceous and greatly support the 
thought of globalization of drug stability guidelines. 
6.2.2 Humidity: 
1- Average relative humidity defined by EMRO (65%) was insignificantly 
different from that recorded by dataloggers and meteorological records for Damazin, 
Juba and Portsudan. 
2- Dry conditions reported by both dataloggers and meteorological records on 
Khartoum (35%) and the very dry conditions of Dongola and Fashir ( 18% and 19%) 
requires special regulations for liquid preparations in semipermeable containers and 
this was on conformance with that stated by EMRO guidelines. The room relative 
humidity was 6 to 7 % lower than open air relative humidity. 
Conditions defined by EMRO might be accepted as an in-house coditions and this 
method might be generalized all over the world. Then global conditions may results. 
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DRA in all countries may set regulations concerning conditioning of drug storage 
facilities to preserve the specified conditions. 
DRA should have to take regultory quick actions concerning drug transportation, 
distribution and handling vehicles environmental conditions. That, specially 
designed vehicles were required  with an air conditioning systems to maintain 
fluctuation of temperature not exceeding 30°C. 
6.3 Pharmaceutical Stability of the Selected Products: 
6.3.1 Metronidazole I.V infusion 500 mg/100 ml in Glass container ( product 4): 
The product showed a markedly stability profile during transportation and storage at 
different cities in Sudan. The lowest concentration of metronidazole obtained at the 
end of 52 weeks at Fashir was 99.6%. 
The degradation reaction followed pseudo-first order reaction of kinetics with a rate 
constant K1= 1.5× 10¯³ month¯¹, with standard deviation of 0.0005 for Juba and rate 
constant K1= 1.3× 10¯³ month¯¹, with standard deviation 0.00009 for samples at 
Portsudan. The two values were insignificantly different (sig. 0.45) 
The LSRL equation for samples at Juba was: 
Ln C =6.228 – 0.0015434 × t and the calculated t(90) according to B.P was four years 
from the date of manufacture but on application of ICH and EMRO guidelines, t(90)  
Was 34 months from April2007 till December 2009. Thus the shelf life of the product 
could be extended for another one year. The microbiological and physical stability 
were not altered during transportation and storage. 
This marked stability may be due to the inherited stability of the active substance, due 
to GMP measures of the manufacturer and to adequate overage (2 -3%) and 
appropriate packaging.  
6.3.2 Metronidazole I.V infusion 500 mg/100 ml in plastic container ( product 3): 
The product exhibited an instability problem in the hot and dry conditions. It was 
markedly affected by transportation and storage conditions of higher temperature and 
lower humidity. The volume of the solution decreased by up to 6 ml in samples 
returned from Fashir. The concentration of metronidazole reached up to 107.4% after 
the long trip to Portsudan. Increase in concentration continued with time due to loss of 
moisture through the container walls. 
The B.P harmonized test specified that none of the container should contain less than 
the labeled volume, this physical test for volume disqualifies the product. 
The LSRL equation was: Ln C = 6.2545361 + 0.00178265285 × t 
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t (110) = 31 months from 4/2007 till 10/2009. But on applying ICH and EMRO 
guidelines considering the 5% one-sided upper confidence interval the shelf life was 
21 months ended at December 2008 and this was identical to the labeled expiration 
date although the labeled storage conditions had not been met. At Portsudan it lost 
three months of its shelf life due to the long trip of transportation. On these bases 
liquid preparations for parenteral use in plastic containers should better be prohibited. 
6.3.3 Amoxicillin trihydrate for 125mg/5ml suspension, SD ( Product 6):  
   The product was greatly affected by transportation that the amoxicillin contents 
declined below 90% after the long trip to and from Portsudan. The degradation of the 
powder followed pseudo-zero order reaction of kinetics with a K0 1.3mg.month¯¹. 
The regression equation for samples returned from Portsudan was: 
C = 124.0216 – 0.9832 × t , the shelf life from the true LSRL was 12 months and 
having an expiration date 4/2008 losing 3 months from its labeled expiration date. 
On applying ICH guidelines using the 5% lower one sided confidence interval, the 
shelf life was 10.2 months and it will be expired at 2/2008 losing four months from its 
labeled expiration date. Samples returned from Damazin lost 3 months from their 
labeled shelf life. 
This could be attributed to lack of adequate overage, inappropriate transportation and 
storage conditions and the concept of confidence intervals were not applied. 
The reconstituted suspension degradation reaction followed first order reaction with a 
rate constant K1 = 1.1× 10¯² month¯¹. The LSRL equation was: 
Ln C = 4.8372743 – 0.0114333454 × t and the concentration reached 80% after 15 
days at ambient conditions (29.7 °C /31.4% RH) and 90% after 7 days.  
6.3.4 Amoxicillin trihydrate for 125mg/5ml suspension, INDIA ( Product 7):  
Quality wise the product lost its organoleptic properties beyond its expiration date and 
should no longer be used inspite of its chemical stability. 
The product showed a markedly stability profile withstanding the drastic 
transportation and storage conditions and this could be attributed to the adequate 
overage and the efficient closure system. 
The LSRL equation was: C = 127.236 – 0.677 × t 
The expiration date according to ICH guidelines utilizing the 5% lower one sided 
confidence interval was 33 months from 4/2007 to September 2009 if it retained its 
physical properties. 
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The reconstituted suspension degradation reaction followed first order reaction  with a 
rate constant K1 = 1.89× 10¯² month¯¹ at conditions(29.7 °C /31.4% RH). It reached 
80% after 14 days and 90% after 6 days 
6.3.5 Rifampicin 300 mg + INH 150 mg tablets SD ( Product 8): 
The regression equation for samples returned from Portsudan was; 
C = 305.763864 – 9.036562 × t 
t(90) was four months from 4/2007, and it was 2.5 months on applying ICH guidelines 
that its expiration date would be June 2007 instead of October 2007, losing 5 months 
due to inappropriate conditions of transportation and storage, that the manufacturer 
specified 25°C as higher limits for storage. 
The LSRL equation for INH components was: 
C = 150.0461 – 4.2912 × t  , t(90) = 3.5 months that the expiration date might be 
August 2007 and so the product lost two months from its shelf life. However on 
application of ICH guidelines, the expiration date might be June 2007, losing five 
months from its labeled expiration date and was typical to that obtained for 
Rifampicin component. Results obtained from samples returned from Dongola 
yielded almost the same results. 
6.3.6 Rifampicin 150 mg + INH 100 mg tablets INDIA ( Product 9): 
This product failed the quality control tests from the physical examination, that it 
contains black spots on the coarse notched surface of tablets. This was attributed to 
inadequate machinery system, specially the punches sites where the lubrication wax 
and oil may run along the punch stem if it was improper punch and loose sealing, 
down to the powder in the die during the compression process. 
However, chemically the degradation reaction follows pseudo-zero order of kinetics 
with a rate constant Ko = 1.66 mg/month. 
Rifampicin in samples returned from Portsudan yielded LSRL equation;  
C = 142.34193 – 2.377 × t , t(90) = 3.1 months and it was only two months on applying 
ICH guidelines. That it lost 6 months from its labeled expiration date and this was 
attributed to lack of overage, drastic transportation conditions, nonconformance of 
storage conditions to the label instructions and the product was in a hospital packs 
1000 tablets/bottle. 
The INH component follows pseudo zero order reaction with Ko = 3.147 mg/month. 
The LSRL yielded expiration date t(90) = 8.2 months and 8.1 months on applying ICH 
guidelines , but the expiration date here was governed by Rifampicin component. 
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Samples returned from Dongola showed fungal contamination and this may be due to 
contamination during storage or handling because of lack of packaging.    
6.3.7 Lumefantrine 120mg + Artemether 20 mg tablets (Product 5): 
Lumefantrine was thermally stable; there was some increase and decrease in 
concentration by time of insignificant differences. The LSRL equation was: 
C = 122.07 – 0.23 × t, t(90) = 61 months; but it was 26 months on application of the 
ICH guidelines, the expiration date might be January 2009. Thus on the basis of 
lumefanterine the shelf life of the product could be extended for one year more. 
But the Artemether component showed different profile, being transported to and 
from Juba and Portsudan in summer 2007, the contents of Artemether declined down 
to less than 90%. It showed a marked instability during storage at Fashir. At the end 
of the storage period, samples returned from all stations were above 90% except 
Fashir that of MKT 28.8 °C and was affected by the rainfall in the pharmacy, that the 
outer carton and the inner boxes had been wetted for a long time. 
The degradation reaction followed pseudo-zero order with Ko 1.14 ×  10¯¹ month¯¹.   
The LSRL zero order reaction was: C = 19.89 – 0.236423542 × t 
  t(90) = 8 months; expiration would be December 2007 which was close  to the labeled 
expiration date, but on applying ICH guidelines the shelf life was 7 months and the 
expiration date would be November 2007 with two months less than the labeled 
expiration date. 
Samples returned from Portsudan might be expired at December 2007 when applying 
ICH guidelines which was close enough to the labeled expiration date. 
Samples returned from Dongola, the LSRL equation was: 
20.36 – 0.103502289 × t , t(90) = 22.8 months, on applying ICH guidelines it might 
gain additional nine months in their shelf life the expiration might be 9/2008 instead 
of January 2008. The stability of the artemether component might be influenced by 
moisture.  
There were no changes in the physical and microbiological properties during storage.   
6.3.8 Artemether 80 mg/1 ml injection – INDIA (product 1): 
This product exhibited a marked instability profile, although the manufacturer 
instructed storage conditions below 25°C which had not been fulfilled and the product 
was exposed to the inappropriate conditions of transportation. 
Samples returned from all stations were of potency less than 90% except Portsudan, 
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The international Pharmacopoeia specified that the lower limit for artemether 
injection was 95%. Thus, the product failed stability testing from the first six months.  
The best results obtained from Portsudan yielded LSRL first order equation: 
Ln C = 4.41112168 – 0.0101590633 × t, t(95) = 7.9 months and that obtained on 
applying ICH guidelines was 7.5 months. The expiration date would be 10/2007 
instead of 3/2008 with a loss of 5 months in the shelf life. The reaction follows 
pseudo- first order reaction of kinetics of rate constant K1 = 2.4 × 10¯² mg.month¯¹.  
The worst results obtained from samples at Khartoum where the LSRL first order 
equation was Ln C = 4.9826215 – 0.0196596481 × t, , t(95) = 3.43 months. On 
applying ICH guidelines, t(95) = 2.3 months, that the expiration date would be June 
2007 instead of March 2008 with a loss in shelf life of nine months. 
This might be attributed to artemether inherited properties and quality, lack of 
adequate overage, the non-complying transportation and storage conditions with those 
specified by the manufacturer and the narrow range specified by the Int. Ph. 
 6.3.9 Artemether 80 mg/1ml injection – CHINA ( product 2): 
The product contains excessive overage which constituting 20% of the labeled 
potency and volume pointing to that at the manufacturing date the potency was above 
the International Ph. Limits which was 105%. Only after six months the artemether 
contents of samples at Portsudan were above the pharmacopoeial limits. The reaction 
order was indefinite that the reaction might be second, first or zero order, the 
difference in CV was only 0.7%. All orders may take place because there might be 
conversion of α and β- artemether and dihydroartemesinine to artemether and the 
degradation of artemether. Samples returned from Portsudan yielded the zero order 
equation: C = 80.74 +0.39667384 × t, t(105) = 8.2 months and in accordance to ICH 
guidelines t(105) was 6.5 months and the expiration date would be October 2007 
instead of January 2009, with a loss in shelf life of 14 months out of 36 months.    
Samples returned from Juba yielded the zero order equation: C = 81.68 + 0.631 × t, 
t(105) = 3.7 months and in accordance to ICH guidelines t(105) was 1.7 months and the 
expiration date would be June 2007 instead of January 2009, with a loss in shelf life 
of 18 months out of 36 months. Samples returned from Dongola yielded the zero 
order equation: C = 81.07 + 0.508739 × t, t(105) = 6.5 months and in accordance to 
ICH guidelines t(105) was 0.6 months and the expiration date would be May 2007 
instead of January 2009, with a loss in shelf life of 19 months out of 36 months. 
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Samples at Khartoum yielded the zero order equation: C = 81.07 + 0.5014541 × t, 
t(105) = 5.8 months and in accordance to ICH guidelines t(105) was 1.5 months and the 
expiration date would be June 2007 instead of January 2009, with a loss in shelf life 
of 18 months out of 36 months. Samples returned from Damazin yielded the zero 
order equation: C = 80.71 + 0.248445 × t, t(105) = 13.2 months and in accordance to 
ICH guidelines t(105) was 11.6 months and the expiration date would be April 2008 
instead of January 2009, with a loss in shelf life of 8 months out of 36 months.  
Samples returned from Fashir yielded the zero order equation: 
                            C = 81.31 – 0.37214532 × t, t(95) = 14.3 months and in accordance to 
ICH guidelines t(95) was 8.5 months for one-sided CI and 7.5 months for the two-sided 
CI and the expiration date would be January 2008 instead of January 2009, with a loss 
in shelf life of 12 months out of 36 months.    
 There was a markedly significant negative correlation between the two secondary 
peaks of α-artemether and dihydroartemesinine and the main peak of artemether in 
samples from all stations. It was suggested that during storage α-artemether and 
dihydroartemesinine undergo degradation to artemether resulting in increased 
potency. The manufacturer added excessive overage to achieve 36 months shelf life 
disregarding this phenomenon and the specified upper confidence interval limits. 
The product contains excessive amount of related substances. 
6.4 General Recommendation:            
  1- The use of controlled storage conditions with definite allowable excursions in 
zoning different countries of different climates may be more perfect than the open air 
meteorological information. The use of dataloggers during transportation and storage 
period for 52 weeks method is recommended to be used worldwide to set the global 
conditions that, it provides a true pictures of actual conditions which could be 
maintained. 
2- If the in-house method is adopted worldwide the conditions for Sudan could be 
30°C / 65% ± 5% with prohibiting liquid preparation in semipermeable containers.  
3- If the meteorological information method is continued as the adopted method, the 
conditions for Sudan is recommended to be changed to 34°C / 65% ± 5% with 
prohibiting liquid preparation in semipermeable containers. 
4- DRA should set regulations for transportation of medicines throughout the country. 
It is recommended to transport, distribute and handle medicinal products in controlled 
conditioned vehicles of temperature not exceeding 30°C. Medical representative 
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should carry their products only in the conditioned cabinet of their cars and they 
should not be allowed to carry drugs in the back. 
5- Parentral liquid preparations in plastic containers should be prohibited. 
6- It is high time for hospital packs to be replaced by individual blister package, 
especially for anti-infectious drugs. 
7- Great care should be given to Artemether quality and its isomer and precursor. It 
could be given a shelf life of one year unless the storage conditions were improved. 
8- Adequate but not so excessive overage should be added to compensate the loss of 
active ingredient during the manufacturing process and during transportation. 
9- ICH guidelines which was adopted by EMRO was more conservative and targeting 
the patient welfare, so expiration date calculations are recommended to be based on it, 
and so , shelf life reevaluation is recommended to take place for every registered 
product. 
10- The expression of "store below 25°C" should disappear and replaced by 30°C 
with scientifically estimated shelf life. 
11-DRA reference laboratory should be rehabilitated and perfectly equipped with 
appropriate materials and literature to achieve evaluations of stability of drugs and to 
issue proper expiration dates and shelf lives for every registered pharmaceutical 
product on the bases of the lower one-sided confidence interval and the upper when 
indicated of the LSRL of drug degradation. With three cycles of one month stress 
testing of 50°C to assure that the product can withstand transportation errors.  
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           Appendix 1: Damazin MKT calculated from Datalogger Records 
 
 
Appendix 2: Dongola MKT Calculated from Datalogger Records 
 
 
Appendix 3: Dongola MKT calculated from Meteorological Records (4/2007 – 3/2008) 
 
 
Appendix 4: Fashir MKT calculated from Datalogger Records 
 
 
 
Appendix 6: Juba MKT calculated from Datalogger Records 
 
 
Appendix 7: Juba MKT using USP method of calculation 
 
 
Appendix 8: Khartoum MKT calculated from Datalogger Records 
 
 
 
Appendix 9: Khartoum MKT calculated from WMO Records 
 
 
 
Appendix 10: Khartoum MKT calculated from Meteorological Records (1962 – 1991) 
 
 
 
 
Appendix 11: Khartoum MKT calculated from Meteorological Records (4/2007 – 3/2008) 
 
 
 
 
Appendix 12: Portsudan MKT calculated from Datalogger Records 
 
 
 











Multiple Comparisons
Dependent Variable: dataloggers
LSD
-1.76667* .67192 .022 -3.2307 -.3027
-3.26667* .67192 .000 -4.7307 -1.8027
-1.60000* .67192 .035 -3.0640 -.1360
-1.20000 .67192 .099 -2.6640 .2640
.36667 .67192 .595 -1.0973 1.8307
1.76667* .67192 .022 .3027 3.2307
-1.50000* .67192 .045 -2.9640 -.0360
.16667 .67192 .808 -1.2973 1.6307
.56667 .67192 .416 -.8973 2.0307
2.13333* .67192 .008 .6693 3.5973
3.26667* .67192 .000 1.8027 4.7307
1.50000* .67192 .045 .0360 2.9640
1.66667* .67192 .029 .2027 3.1307
2.06667* .67192 .010 .6027 3.5307
3.63333* .67192 .000 2.1693 5.0973
1.60000* .67192 .035 .1360 3.0640
-.16667 .67192 .808 -1.6307 1.2973
-1.66667* .67192 .029 -3.1307 -.2027
.40000 .67192 .563 -1.0640 1.8640
1.96667* .67192 .013 .5027 3.4307
1.20000 .67192 .099 -.2640 2.6640
-.56667 .67192 .416 -2.0307 .8973
-2.06667* .67192 .010 -3.5307 -.6027
-.40000 .67192 .563 -1.8640 1.0640
1.56667* .67192 .038 .1027 3.0307
-.36667 .67192 .595 -1.8307 1.0973
-2.13333* .67192 .008 -3.5973 -.6693
-3.63333* .67192 .000 -5.0973 -2.1693
-1.96667* .67192 .013 -3.4307 -.5027
-1.56667* .67192 .038 -3.0307 -.1027
(J) Stations
2.00
3.00
4.00
5.00
6.00
1.00
3.00
4.00
5.00
6.00
1.00
2.00
4.00
5.00
6.00
1.00
2.00
3.00
5.00
6.00
1.00
2.00
3.00
4.00
6.00
1.00
2.00
3.00
4.00
5.00
(I) Stations
1.00
2.00
3.00
4.00
5.00
6.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*.  
Multiple Comparisons
Dependent Variable: Damazin
LSD
-2.96667* .04714 .000 -3.0754 -2.8580
-6.16667* .04714 .000 -6.2754 -6.0580
-4.46667* .04714 .000 -4.5754 -4.3580
2.96667* .04714 .000 2.8580 3.0754
-3.20000* .04714 .000 -3.3087 -3.0913
-1.50000* .04714 .000 -1.6087 -1.3913
6.16667* .04714 .000 6.0580 6.2754
3.20000* .04714 .000 3.0913 3.3087
1.70000* .04714 .000 1.5913 1.8087
4.46667* .04714 .000 4.3580 4.5754
1.50000* .04714 .000 1.3913 1.6087
-1.70000* .04714 .000 -1.8087 -1.5913
(J) source
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00
(I) source
1.00
2.00
3.00
4.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
 
 
 
Appendix: 24 SPSS Results  
Multiple Comparisons
Dependent Variable: Dongola
LSD
-2.10000* .10801 .000 -2.3491 -1.8509
-6.50000* .10801 .000 -6.7491 -6.2509
-2.70000* .10801 .000 -2.9491 -2.4509
2.10000* .10801 .000 1.8509 2.3491
-4.40000* .10801 .000 -4.6491 -4.1509
-.60000* .10801 .001 -.8491 -.3509
6.50000* .10801 .000 6.2509 6.7491
4.40000* .10801 .000 4.1509 4.6491
3.80000* .10801 .000 3.5509 4.0491
2.70000* .10801 .000 2.4509 2.9491
.60000* .10801 .001 .3509 .8491
-3.80000* .10801 .000 -4.0491 -3.5509
(J) source
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00
(I) source
1.00
2.00
3.00
4.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
 
 
Multiple Comparisons
Dependent Variable: Fashir
LSD
1.89333* .00782 .000 1.8753 1.9114
.99667* .00782 .000 .9786 1.0147
-1.19667* .00782 .000 -1.2147 -1.1786
-1.89333* .00782 .000 -1.9114 -1.8753
-.89667* .00782 .000 -.9147 -.8786
-3.09000* .00782 .000 -3.1080 -3.0720
-.99667* .00782 .000 -1.0147 -.9786
.89667* .00782 .000 .8786 .9147
-2.19333* .00782 .000 -2.2114 -2.1753
1.19667* .00782 .000 1.1786 1.2147
3.09000* .00782 .000 3.0720 3.1080
2.19333* .00782 .000 2.1753 2.2114
(J) source
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00
(I) source
1.00
2.00
3.00
4.00
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
 
Multiple Comparisons
LSD
-1.66667 .73068 .052 -3.352 .0183
-.86667 .73068 .270 -2.552 .8183
-2.86667* .73068 .004 -4.552 -1.18
1.66667 .73068 .052 -.0183 3.352
.80000 .73068 .305 -.8849 2.485
-1.20000 .73068 .139 -2.885 .4849
.86667 .73068 .270 -.8183 2.552
-.80000 .73068 .305 -2.485 .8849
-2.00000* .73068 .026 -3.685 -.3151
2.86667* .73068 .004 1.1817 4.552
1.20000 .73068 .139 -.4849 2.885
2.00000* .73068 .026 .3151 3.685
-3.86667* .18856 .000 -4.301 -3.43
-4.86667* .18856 .000 -5.301 -4.43
-3.26667* .18856 .000 -3.701 -2.83
3.86667* .18856 .000 3.4318 4.301
-1.00000* .18856 .001 -1.435 -.5652
.60000* .18856 .013 .1652 1.035
4.86667* .18856 .000 4.4318 5.301
1.00000* .18856 .001 .5652 1.435
1.60000* .18856 .000 1.1652 2.035
3.26667* .18856 .000 2.8318 3.701
-.60000* .18856 .013 -1.035 -.1652
-1.60000* .18856 .000 -2.035 -1.17
-4.23333* .30641 .000 -4.940 -3.53
-5.63333* .30641 .000 -6.340 -4.93
-4.83333* .30641 .000 -5.540 -4.13
4.23333* .30641 .000 3.5267 4.940
-1.40000* .30641 .002 -2.107 -.6934
-.60000 .30641 .086 -1.307 .1066
5.63333* .30641 .000 4.9267 6.340
1.40000* .30641 .002 .6934 2.107
.80000* .30641 .031 .0934 1.507
4.83333* .30641 .000 4.1267 5.540
.60000 .30641 .086 -.1066 1.307
-.80000* .30641 .031 -1.507 -.0934
(J)
source
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00
2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00
(I) source
1.00
2.00
3.00
4.00
1.00
2.00
3.00
4.00
1.00
2.00
3.00
4.00
Dependent Variable
Juba
Khartoum
Portsudan
Mean
Difference
(I-J)
Std.
Error Sig.
Lower
Bound
Uppe
r
Boun
d
95%
Confidence
Interval
The mean difference is significant at the .05 level.*.  
 
Multiple Comparisons
Dependent Variable: humidity
LSD
22.44000* 3.29497 .000 15.6395 29.2405
23.12000* 3.29497 .000 16.3195 29.9205
-5.16000 3.29497 .130 -11.9605 1.6405
14.32000* 3.29497 .000 7.5195 21.1205
-6.38000 3.29497 .065 -13.1805 .4205
-22.44000* 3.29497 .000 -29.2405 -15.6395
.68000 3.29497 .838 -6.1205 7.4805
-27.60000* 3.29497 .000 -34.4005 -20.7995
-8.12000* 3.29497 .021 -14.9205 -1.3195
-28.82000* 3.29497 .000 -35.6205 -22.0195
-23.12000* 3.29497 .000 -29.9205 -16.3195
-.68000 3.29497 .838 -7.4805 6.1205
-28.28000* 3.29497 .000 -35.0805 -21.4795
-8.80000* 3.29497 .013 -15.6005 -1.9995
-29.50000* 3.29497 .000 -36.3005 -22.6995
5.16000 3.29497 .130 -1.6405 11.9605
27.60000* 3.29497 .000 20.7995 34.4005
28.28000* 3.29497 .000 21.4795 35.0805
19.48000* 3.29497 .000 12.6795 26.2805
-1.22000 3.29497 .714 -8.0205 5.5805
-14.32000* 3.29497 .000 -21.1205 -7.5195
8.12000* 3.29497 .021 1.3195 14.9205
8.80000* 3.29497 .013 1.9995 15.6005
-19.48000* 3.29497 .000 -26.2805 -12.6795
-20.70000* 3.29497 .000 -27.5005 -13.8995
6.38000 3.29497 .065 -.4205 13.1805
28.82000* 3.29497 .000 22.0195 35.6205
29.50000* 3.29497 .000 22.6995 36.3005
1.22000 3.29497 .714 -5.5805 8.0205
20.70000* 3.29497 .000 13.8995 27.5005
(J) group
2
3
4
5
6
1
3
4
5
6
1
2
4
5
6
1
2
3
5
6
1
2
3
4
6
1
2
3
4
5
(I) group
1
2
3
4
5
6
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant  at the .05 level.*.  
 
